

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/85, C07K 14/075, C12N 5/10, 15/34, A61K 48/00	A1	(11) International Publication Number: WO 00/42208 (43) International Publication Date: 20 July 2000 (20.07.00)
(21) International Application Number: PCT/EP00/00265 (22) International Filing Date: 14 January 2000 (14.01.00) (30) Priority Data: 60/115,920 14 January 1999 (14.01.99) US (71) Applicant (for all designated States except AT): NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH). (71) Applicants (for AT only): NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H. [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT). THE SCRIPPS RESEARCH INSTITUTE [US/US]; 10550 North Torrey Pines Road, La Jolla, CA 92037 (US). (72) Inventors: NEMEROW, Glen, Robert; 462 Cerro Street, Encinitas, CA 92024 (US). VON SEGGERN, Daniel, J.; 5175 Luigi Terrace, Apt. 30, San Diego, CA 92122 (US). HALLENBECK, Paul, L.; 7461 Rosewood Manor Lane, Gaithersburg, MD 20882 (US). STEVENSON, Susan, C.; 10974 Horseshoe Drive, Frederick, MD 21701 (US). SKRIPCHENKO, Yelena; 17708 Stoneridge Drive, Gaithersburg, MD 20878 (US).		(74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Dept., CH-4002 Basel (CH). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: ADENOVIRUS VECTORS, PACKAGING CELL LINES, COMPOSITIONS, AND METHODS FOR PREPARATION AND USE		
(57) Abstract <p>The present invention relates to methods for gene therapy, especially to adenovirus-based gene therapy, and related cell lines and compositions. In particular, novel nucleic acid constructs and packaging cell lines are disclosed, for use in facilitating the development of high-capacity and targeted vectors. The invention also discloses a variety of high-capacity adenovirus vectors and related compositions and kits including the disclosed cell lines and vectors. Finally, the invention discloses methods of preparing and using the disclosed vectors, cell lines and kits.</p>		

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Adenovirus Vectors, Packaging Cell Lines, Compositions, and Methods for
Preparation and Use

This application is a continuation-in-part of U.S. Application 09/423,783 filed November 12, 1999 and claims the benefit of the filing date of U.S. Provisional Application 60/115,920 filed January 14, 1999.

This invention was made with U.S. government support under NIH Grant No. HL 54352. The government has certain rights in the invention.

The present invention relates to gene therapy, especially to adenovirus-based gene therapy. In particular, novel packaging cell lines are disclosed, for use in facilitating the development of high-capacity and targeted vectors. High-capacity adenovirus vectors are also disclosed herein, as are related compositions, kits, and methods of preparation and use of the disclosed vectors, cell lines and kits.

Enhanced transfer of DNA conjugates into cells has been achieved with adenovirus, a human DNA virus which readily infects epithelial cells (Horwitz, "Adenoviridae and Their Replication", in *Virology*, Fields and Knipe, eds., Raven Press, NY (1990) pp. 1679-1740).

There is a need in the art to obtain Adenovirus vectors capable of incorporating large segments of foreign DNA and capable of being targeted to specific cells, as well as to obtain cell lines which can package such adenovirus-gene deficient vectors or targeted vectors. These needs, as well as others, are met by the invention.

This invention utilizes recombinant adenovirus constructs which duplicate the cell receptor binding and DNA delivery properties of intact adenovirus virions and thus represents an improved method for gene therapy and cell targeting as well as for antisense-based antiviral therapy.

In contrast to the disadvantages of using intact adenovirus, modified adenovirus vectors requiring a helper-plasmid or virus, or so-called replication-deficient adenovirus in the art, the use of recombinant adenovirus-derived vectors according to one aspect of the present invention provides certain advantages for gene delivery. First, the Ad-derived vectors of the present invention possess all of the functional properties required for gene therapy including binding to epithelial cell receptors and penetration of endocytic vesicles. Therapeutic viral vectors of the present invention may also be engineered to target the receptors of and

- 2 -

achieve penetration of non-epithelial cells; means of engineering viral vectors to accomplish these ends are described in detail herein below.

Second, the vectors of the present invention have deletions of substantial portions of the Ad genome, which not only limits the ability of the Ad-derived vectors to "spread" to other host cells or tissues, but allows significant amounts of "foreign" (or non-native) nucleic acids to be incorporated into the viral genome without interfering with the reproduction and packaging of the viral genome. Therefore, the vectors of the present invention are ideal for use in a wide variety of therapeutic applications.

Third, while the vectors disclosed herein are safe for use as therapeutic agents in the treatment of a variety of human afflictions, some of these vectors do not require the presence of any "helpers" for propagation and packaging, largely because of the novel cell lines in which they are reproduced. Such cell lines -- referred to herein as packaging cell lines -- comprise yet another aspect of the invention.

To reduce the frequency of contamination with wild-type adenovirus, it is desirable to improve either the viral vector or the cell line to reduce the probability of recombination. For example, an adenovirus from a group with less homology to the group C viruses may be used to engineer recombinant viruses with little propensity for recombination with the Ad5 sequence contained in the packaging lines. The invention describes the preparation of packaging cell lines which stably expresses adenovirus proteins or polypeptides. These cell lines are useful for complementing viral vectors bearing deletions of regulatory and/or structural genes, irrespective of the serotype from which such a vector was derived.

It is also contemplated that the constructs and methods of the present invention will support the design and engineering of chimeric viral vectors which express amino acid residue sequences derived from two or more Ad serotypes. Thus, unlike methods and constructs available prior to the advent of the present disclosure, this invention allows the greatest possible flexibility in the design and preparation of useful viral vectors and cell lines which support their construction and propagation -- all with a decreased risk of recombining with wild-type Ad to produce potentially-harmful recombinants.

In part, the present invention discloses a simpler, alternative means of reducing the recombination between viral and cellular sequences than those discussed in the art. One such means is to increase the size of the deletion in the recombinant virus and thereby reduce the extent of shared sequences between

- 3 -

that virus and any Ad genes present in a packaging cell line *e.g.*, the Ad5 genes in 293 cells, or the various Ad genes in the novel cell lines of the present invention.

Deletions of all or portions of structural genes of the adenovirus have been considered undesirable because of the anticipated deleterious effects such deletions would have on viral reproduction and packaging. Indeed, the use of "helper" viruses or plasmids has often been recommended when using Ad-derived vectors containing large deletions in structural protein sequences precisely for this reason.

Contrary to what has been suggested in the art, however, this invention discloses the preparation, propagation and use of recombinant Ad-derived vectors having deletions of all or part of various gene sequences encoding Ad structural proteins, both as a way of reducing the risk of wild-type adenovirus contamination in virus preparations, as a way of allowing foreign DNA to be packaged in such vectors for a variety of diagnostic and therapeutic applications and as a way of targeting an adenovirus vector to a specific cell type.

The invention further discloses a wide variety of nucleic acid sequences and viral vectors. Thus, in one embodiment, the invention discloses a nucleic acid sequence encoding any one of the adenovirus fiber proteins mentioned in the specification, polypeptides or fragments thereof -- including, without limitation, those that include deletions or other mutations; those that are chimeric; and those that have linkers, foreign amino acid residues, or other molecules attached for various purposes as disclosed herein. Nucleic acid sequences encoding various other adenovirus structural and/or regulatory proteins or polypeptides are also within the scope of the present invention.

In various embodiments, the adenovirus is a Group C adenovirus selected from serotypes 1, 2, 5 or 6; while in other embodiments, adenovirus selected from other serotypes, such as for example Ad37 (subgroup D) are useful as disclosed herein.

The invention is also directed to an isolated nucleic acid molecule comprising an adenovirus tripartite leader (TPL) nucleotide sequence, said TPL nucleotide sequence comprising (a) first and second different TPL exons or (b) first, second and third same or different TPL exons, said TPL exons selected from the group consisting of complete TPL exon 1, partial TPL exon 1, complete TPL exon 2 and complete TPL exon 3, wherein said isolated nucleic acid molecule may not comprise the nucleic acid sequence consisting of partial TPL exon 1, complete TPL exon 2 and complete TPL exon 3. A preferable embodiment of the invention may further comprise an intron operatively linked to the TPL, wherein said intron also

- 4 -

contains requisite processing signals for the intron's removal. Another preferable embodiment of the invention is directed to the isolated nucleic acid molecule wherein said TPL nucleotide sequence consists essentially of complete TPL exon 1 operatively linked to complete TPL exon 2 operatively linked to complete TPL exon 3. A related embodiment may further include an intron and appropriate processing signals. Additional embodiments of the invention are directed to nucleic acid molecules contained in plasmids selected from the group; consisting of pCLF, pDV60, pDV67, pDV69, pDV80 and PDV90. Packaging cell lines and adenovirus particles containing the nucleic acids described above are also included in the invention.

The invention is further directed to methods for producing an adenovirus vector particle containing a helper-independent fiberless recombinant adenovirus vector genome comprising providing a) a packaging cell line which complements replication and packaging of said genome and b) a helper-independent fiberless recombinant adenovirus vector genome which is deficient in expressing sufficient functional fiber protein to support assembly of fiber-containing particles. The genome is introduced into the cell line. Additional embodiments of the invention may also include the following steps; a) growing the cell line produced under conditions for producing particles; and/or b) harvesting an adenovirus vector particle containing said helper-independent fiberless recombinant adenovirus vector genome. The method may also include a cell line that expresses a fiber protein and complements a fiber mutation in the vector.

The invention is also directed to an adenovirus vector packaging cell line comprising a stably integrated nucleic acid molecule as described above, an operatively-linked promoter and a nucleic acid sequence which encodes an adenovirus structural protein, wherein said TPL sequence consists essentially of a first TPL exon operatively linked to a complete second TPL exon operatively linked to a complete third TPL exon, wherein said packaging cell comprises an isolated nucleic acid molecule comprising an adenovirus tripartite leader (TPL) nucleotide, said TPL nucleotide sequence comprising (a) first and second different TPL exons or (b) first, second and third different TPL exons, said TPL exons selected from the group consisting of complete TPL exon 1, partial TPL exon 1, complete TPL exon 2 and complete TPL exon 3 and, wherein said isolated nucleic acid molecule may not comprise the nucleic acid sequence consisting of partial TPL exon 1, complete TPL exon 2 and complete TPL exon 3. Preferably, the cell line may have a complete first TPL exon. Another embodiment of the invention comprises adenovirus

- 5 -

structural protein, such as adenovirus fiber protein or a chimeric protein which includes an adenovirus fiber protein tail domain.

The invention is further directed to a recombinant adenovirus particle comprising a recombinant adenovirus vector genome wherein said genome: (a) does not encode or does not express sufficient adenovirus fiber protein to support packaging of a fiber-containing adenovirus particle without complementation of said fiber gene, and (b) encodes an adenovirus packaging signal and inverted terminal repeats containing adenovirus origin of replication. The invention is also directed to a helper-independent fiberless recombinant adenovirus vector genome comprising genes which (a) encode all adenovirus structural gene products but do not express sufficient adenovirus fiber protein to package a fiber-containing adenovirus particle without complementation of said fiber gene or said genome lacks at least the fibre gene and (b) encodes an exogenous protein. Either of the above embodiments may substitute a helper-dependent for a helper-independent recombinant adenovirus vector genome. In a preferable embodiment, no fiber protein is expressed. In yet another embodiment of the invention, the recombinant adenovirus particle fails to express sufficient fiber protein to allow fiber incorporation into the particle such that the particle can use the fiber pathway for infection.

The invention is further directed to a method for producing an adenovirus vector particle containing a helper-independent fiberless recombinant adenovirus vector genome, said method comprising providing a packaging cell line which complements replication and packaging of said genome and a helper-independent fiberless recombinant adenovirus vector genome which is deficient in expressing sufficient functional fiber protein to support assembly of fiber-containing particles, wherein said packaging cell comprises an isolated nucleic acid molecule comprising an adenovirus tripartite leader (TPL) nucleotide, said TPL nucleotide sequence comprising (a) first and second different TPL exons or (b) first, second and third different TPL exons, said TPL exons selected from the group consisting of complete TPL exon 1, partial TPL exon 1, complete TPL exon 2 and complete TPL exon 3 and, wherein said isolated nucleic acid molecule may not comprise the nucleic acid sequence consisting of partial TPL exon 1, complete TPL exon 2 and complete TPL exon and harvesting said adenovirus particles produced by said cell line.. In a preferable embodiment the adenovirus particle further comprises an exogenous protein or a modified fiber protein. The method may also comprise a step of coating a particle (i.e. providing fiber protein in any way) with an adenovirus fiber protein.

- 6 -

Another aspect of the invention is directed to a method for pseudotyping recombinant viral vectors comprising complementing a missing fiber gene of a helper-independent fiberless recombinant adenovirus vector genome by expressing in packaging cells a fiber gene from a different adenoviral serotype than said recombinant adenovirus vector, thereby pseudotyping said vector. An additional embodiment of the invention is directed to the method for pseudotyping recombinant viral vectors comprising: a) providing a packaging cell line for propagating a fiber gene deleted recombinant adenovirus vector, b) introducing into said cell line a helper-independent fiberless recombinant adenovirus vector genome, and c) complementing the missing fiber gene by expression in the cells of a fiber gene from a different adenoviral serotype thereby pseudotyping the vector.

The invention is further directed to a method for specifically targeting an adenovirus vector to a cell of choice comprising introducing a helper-independent or helper-dependent fiberless recombinant adenovirus vector genome into a packaging cell line for producing a fiber gene-deleted adenovirus vector and providing, wherein said gene for a missing fiber protein is complemented with a gene for a desired modification for targeting the vector to a cell of choice

The invention is further directed to a method for producing a modified adenovirus comprising providing *in vitro* an exogenous fiber protein to a fiberless adenovirus. Additional embodiments of the invention may provide any combination of all of the following steps such that the invention be directed to a method for producing a modified adenovirus comprising: a) providing a packaging cell line for producing a fiberless adenovirus vector, b) introducing into said cell line a helper-independent fiberless or helper-dependent fiberless recombinant adenovirus vector genome, c) growing and harvesting a fiberless adenovirus, d) maintaining the fiberless adenovirus in any suitable buffer, and e) providing exogenous fiber, wherein said fiber may be a modified fiber, to the fiberless adenovirus by adding conditioned media or a soluble fiber preparation or a fiber in any suitable buffer to a virus preparation thereby producing the modified adenovirus.

The invention is further directed to a method for producing a modified adenovirus comprising providing a packaging cell line for producing a helper-dependent fiberless adenovirus vector genome and providing a helper virus vector, wherein said cell line complements at least a deficient fiber protein gene, thereby producing the modified adenovirus. Another aspect of the invention is directed to a method for producing a modified adenovirus comprising: a) providing a packaging cell line for producing a fiberless adenovirus vector, b) introducing into said cell line a helper dependent fiberless recombinant adenovirus vector genome

- 7 -

and a fiberless helper virus vector, c) growing and harvesting a fiberless adenovirus, and d) maintaining the fiberless adenovirus in infectious media, and e) providing exogenous fiber to the fiberless adenovirus by adding conditioned media or a soluble fiber preparation to a virus preparation thereby producing the modified adenovirus.

Additional aspects of the invention are directed to hybrid Ad/AAV vectors and to new helper-dependent vectors used with fiberless adenovirus vectors.

The invention is also directed to a method for delivering a heterologous gene to an EBV-infected B cells comprising infecting said B cells with a pseudotyped Ad5 β gal. Δ F particle or other fiber-deleted adenovirus particle, said particle having a chimeric fiber with the receptor-binding knob domain of the adenovirus type 3 fiber.

The invention is also directed to an isolated nucleic acid comprising a post-transcriptional regulatory element (PRE) and a TPL. Preferably the PRE is the woodchuck hepatitis virus PRE (WPRE).

The invention is further directed to a composition for preparing a therapeutic vector, said composition comprising a plasmid comprising an adenovirus genome lacking a nucleotide sequence encoding a fiber protein or a genome that is incapable of expressing sufficient fiber to result in packaging.

Another aspect of the invention is directed to a method of delivering a heterologous gene to a human or any animal comprising providing an exogenous gene to a target cell comprising contacting said cell *in vivo* or *ex vivo* with an amount of a recombinant adenovirus particle sufficient to infect said cell.

The invention is also directed to A method for producing a gutless adenoviral vector particle comprising: a) delivering a helper adenovirus vector genome to an adenovirus vector packaging cell, wherein said helper adenovirus vector genome lacks any gene encoding adenovirus fiber protein or lacks the ability to encode sufficient adenovirus fiber protein to produce an adenoviral vector comprising fiber protein in the absence of complementation by said packing cell and wherein said packaging cell comprises the nucleic acid molecule of claim 2 operably linked to a promoter and to an adenoviral fiber protein or to a chimeric protein that includes an adenovirus fiber protein tail domain; (b) delivering a gutless adenovirus vector genome to said packaging cell; and (c) recovering the gutless adenoviral vector particle produced by said cell.

Another aspect of the invention is directed to a helper adenovirus particle comprising an adenovirus vector genome that does not encode or does not express sufficient adenovirus fiber protein to support packaging of a fiber-

- 8 -

containing adenovirus particle without complementation of said fiber gene, wherein said genome has a mutation in its packaging sequence that renders said genome substantially incapable of being packaged. Packaging sequence are those sequences are those sequences involved in packaging the viral particle.

The invention is further directed to a helper adenovirus particle comprising an adenovirus vector genome with recombinase sites flanking its packaging sequence, wherein said vector genome does not encode or does not express sufficient adenovirus fiber protein to support packaging of a fiber-containing adenovirus particle without complementation of said fiber gene.

The invention is also directed to an adenovirus particle comprising a gutless adenoviral vector genome and a fiberless capsid, as well as an adenovirus particle comprising a gutless adenoviral vector genome and a capsid comprising a modified fiber protein.

Another aspect of the invention is directed to a packaging cell for the production of a fiberless or fiber-modified gutless adenovirus particle comprising an adenovirus vector complementing plasmid and a nucleotide sequence encoding a recombinase, wherein said complementing plasmid comprises the nucleic acid molecule of claim 2 operably linked to a promoter and to a nucleotide sequence encoding an adenoviral fiber protein or a chimeric adenoviral fiber protein. Preferably the cell line may comprise a recombinase. In an embodiment of the invention the recombinase may be Cre.

In another embodiment of the invention, the fiber-deleted adenovirus vectors of the invention and the fiber-complementing adenovirus packaging cells of the invention are used to produce a gutless adenovirus vector particle. Such particle comprises a gutless adenoviral vector genome in an adenoviral capsid. The fiber proteins of the capsid may be wild-type fiber, or the modified fiber proteins disclosed herein. Alternatively, such particle may have a fiberless capsid as disclosed herein. Preferably, the gutless genome contains at least one heterologous gene as described herein. As used herein, the term "gutless adenoviral vector genome" means an adenoviral vector genome from which all of the viral genes have been deleted..

The invention also discloses systems or kits for use in any of the aforementioned methods. The systems or kits may contain any appropriate combination of the within-described vectors, plasmids, cell lines, virus particles and additional therapeutic agents as disclosed. Preferably, each such kit or system includes a quantity of the appropriate therapeutic substance or sequence sufficient for at least one administration, and instructions for administration and use. Thus,

- 9 -

one system further comprises an effective amount of a therapeutic agent which enhances the therapeutic effect of the therapeutic viral vector-containing composition. Another variation discloses that the composition and the therapeutic agent are each included in a separate receptacle or container.

It will also be appreciated that any combination of the preceding elements may also be efficacious as described herein, and that all related methods are also within the scope of the present invention.

< Figure 1 is a schematic diagram of the entire adenoviral E4 transcriptional unit with the open reading frames (ORF) indicated by blocked segments along with the promoter and terminator sequences. The location of primers for amplifying specific portions of E4 are also indicated as further described in Example 1A.

Figure 2 is a schematic map of plasmid pE4/Hygro as further described in Example 1B.

Figure 3 is a schematic map of plasmid pCDNA3/Fiber as further described in Example 1B.

Figure 4 is a schematic map of plasmid pCLF as further described in Example 1B.

Figure 5 is a photograph of a Southern blot showing the presence of intact adenovirus E4 3.1 kilobase (kb) insert in the 211 cell line as further described in Example 1C.

Figure 6 is an autoradiograph showing labeled fiber protein immunoprecipitated from cells and electrophoresed under native and denaturing electrophoresis conditions as described in Example 1C. The 293 cells lack fiber while the sublines 211A, 211B and 211R contain fiber protein detectable in functional trimerized form and denatured monomeric form.

Figure 7 is a schematic map of plasmid pDEX/E1 as further described in Example 1D.

Figure 8 is a schematic map of plasmid pE1/Fiber as further described in Example 1F1.

Figure 9 is a schematic map of plasmid pE4/Fiber as further described in Example 1F2).

Figure 10 is a schematic illustration of linearized pD E1Bb gal delivery plasmids for use in cotransfection and recombination to form a recombinant adenoviral vector having multiple adenoviral gene deletions. The plasmids and recombination event are more fully described in Example 2A.

- 10 -

Figure 11 is a schematic of plasmid p11.3 as further described in Example 2A used in the construction of pDV44 delivery plasmid.

Figure 12 is a schematic of plasmid 8.2.

Figure 13 shows the trimeric structure of the recombinant fiber. 293, 211A, 211B, or 211R cells as indicated were metabolically labeled with [³⁵S]methionine, soluble protein extracts prepared, and fiber was immunoprecipitated. A portion of the precipitated protein was electrophoresed on an 8% SDS-PAGE gel under either semi-native or denaturing conditions. The positions of trimeric (T) and monomeric (M) fiber are indicated. As a control for electrophoretic conditions, recombinant Ad2 fiber produced in baculovirus-infected cells was run under identical conditions and stained with Coomassie blue.

Figure 14 shows the complementation of a fiber mutant adenovirus by fiber-producing cells. The cell lines indicated (2×10^6 cells per sample) were infected with the temperature-sensitive fiber mutant adenovirus H5ts142 at 10 PFU/cell and incubated at either the permissive (32.5°C, stippled bars) or the restrictive (39.5°C, solid bars) temperature. 48 hours post-infection, virus was isolated by freeze-thaw lysis and yields determined by fluorescent focus assay on SW480 cells. Each value represents the mean of duplicate samples, and the data shown is representative of multiple experiments.

Figure 15 shows the incorporation of the recombinant Ad5 fiber into Ad3 particles. In Figure 15A, the alignment of the N-terminal (penton base-binding) domains of fiber proteins from several different adenovirus serotypes is shown. From top to bottom, the five different serotypes are listed as SEQ ID NOs 21-25. In Figure 15B, type 3 adenovirus was propagated in 293, 211B, or 211R cells as indicated and purified by two sequential CsCl centrifugations. 10 µg of the purified viral particles was then electrophoresed under denaturing conditions and transferred to a PVDF membrane. Ad5 fiber was detected with a polyclonal rabbit antibody raised against recombinant Ad2 fiber. As a positive control for detection, 400 ng of wild-type Ad2 was run in the lane marked "Ad2". Under these conditions, the mobilities of the Ad2 and Ad5 fibers are indistinguishable and the antibody reacts with both proteins.

Figure 16 shows the fiber deletion in pDV44 and the genomic structures of the Ad5.βgal.ΔF and Ad5.βgal.wt vectors: Figure 16A shows pDV44 that was constructed by removing the fiber gene and residual E3 sequences (nt 30819:32743 of AD5) from pBHG10. Figure 16B shows viruses constructed by cotransfection of either pBHG10 or pDV44 with pΔE1Bβgal. Both are E1/E3 deleted Ad5 vectors, and Ad5.βgal.ΔF has the additional fiber (L5) deletion as in pDV44.

- 11 -

Figure 17 shows the analysis of the viral chromosomes. Figure 17A shows the predicted EcoRI restriction maps of Ad5. β gal.wt and Ad5. β gal. Δ F. The 5.9 kb fragment at the right end of the Ad5. β gal.wt genome is reduced to 4.0 kb by the deletion of fiber sequences in Ad5. β gal. Δ F. Figure 17B shows an ethidium bromide-stained gel of EcoRI-digested viral DNA. Figure 17C shows a Southern blot of the gel as described in Example 2 probed either with labeled fiber or E4 sequences.

Figure 18 shows the analysis of vertex proteins in the viral particles. 293 (non-fiber expressing) or 211B (fiber-expressing) cells were infected with Ad5. β gal.wt ('wt') or with Ad5. β gal. Δ F (' Δ F') and the resulting viral particles were purified on CsCl gradients. 10 μ g of purified virions was then electrophoresed on 5-16% gradient gels and Western blotted. Proteins were detected with polyclonal anti-fiber or anti-penton base antibodies.

Figure 19 shows the infectivity of Ad particles on THP-1 monocytic cells. Figure 19A shows THP-1 cells that were infected with Ad5. β gal.wt or with fiberless Ad5. β gal. Δ F at 100,000 particles/cell. Forty-eight hours after infection, cells were fixed and stained with X-gal and the fraction of infected cells was determined by light microscopy. Figure 19B shows cells that were infected with 1000 particles per cell of Ad5. β gal.wt or with 100,000 particles/cell of Ad5. β gal. Δ F. As indicated, cells were pretreated with 100 μ g/ml of recombinant penton base or with 20 μ g/ml of recombinant Ad2 fiber.

Figure 20 shows a schematic of improved fiber-complementing cell lines, 633 and 644 as further described in the Examples.

Figures 21 and 22 illustrates pseudotyping of fiberless particles with fiber proteins and infectivity data as further described in the Examples.

Figure 23 shows the ClaI to BglII fragment of Ad5.

Figure 24 shows the plasmid pGRE5-2/EBV

Figure 25 shows the plasmid pGRE5-E1.

Figure 26 shows the plasmid pSE280-E2 BamHI-SmaI.

Figure 27. The fiber-deleted adenovirus vector Ad5.bgal.DF was grown in cells expressing either no fiber (293; 'Ad5.bgal.DF/0'), the Ad5 fiber (633; 'Ad5.bgal.DF/5F'), or the Ad37 fiber with modifications as described in the text (705; 'Ad5.bgal.DF/37F') and CsCl-purified. 10 μ g of the purified particles were electrophoresed and transferred to a nylon membrane. As controls, 10 μ g of wild-type Ad37 or the fiber gene-containing vector Ad5.bgal.wt or a sample of purified recombinant Ad37 fiber knob were also run. The blot was probed with polyclonal

- 12 -

antisera against recombinant Ad37 fiber or Ad2 fiber proteins. As a loading control, the same filter was reprobed with an antibody against the Ad2 penton base (the anti-Ad2 sera cross-recognized the very similar Ad5 fiber and Ad5 penton base proteins).

Figure 28 shows PCR analysis for fiber presence.

Figure 29 shows the transduction efficiency for fiberless virus with and without soluble fiber.

Figure 30 shows the transduction efficiency of AD5BgF⁻ on HDF cell line with the presence of different amounts of 633 conditioned media.

To reduce the frequency of contamination with wild-type adenovirus, it is considered desirable to improve either the viral vector or the cell line to reduce the probability of recombination. For example, an adenovirus from a group with less homology to the group C viruses may be used to engineer recombinant viruses with little propensity for recombination with the Ad5 sequence in 293 cells. Similarly, an epithelial cell line -- e.g. the cell line known as 293 -- may be used or further modified according to within-disclosed methods which stably expresses adenovirus proteins or polypeptides from Ad3 and/or proteins or polypeptides from another non-group-C or group C serotype; such a cell line would be useful to support adenovirus-derived viral vectors bearing deletions of regulatory and/or structural genes, irrespective of the serotype from which such a vector was derived.

It is also contemplated that the constructs and methods of the present invention will support the design and engineering of chimeric viral vectors which express amino acid residue sequences derived from two or more Ad serotypes. Thus, unlike methods and constructs available prior to the advent of the present disclosure, this invention allows the greatest possible flexibility in the design and preparation of useful viral vectors and cell lines which support their construction and propagation -- all with a decreased risk of recombining with wild-type Ad to produce potentially-harmful recombinants.

In part, the present invention discloses a simpler, alternative means of reducing the recombination between viral and cellular sequences than those discussed in the art. One such means is to increase the size of the deletion in the recombinant virus and thereby reduce the extent of shared sequences between that

virus and any Ad genes present in a packaging cell line -- e.g., the Ad5 genes in 293 cells, or the various Ad genes in the novel cell lines of the present invention.

- 13 -

Therefore, the present invention makes it feasible to engineer and produce novel viral vectors that are able to package and deliver significantly larger foreign nucleic acid sequences for efficacious use in a variety of therapeutic applications, without endangering the subject to whom they are administered, due to their impaired ability to self-replicate in non-complementing cell lines. Due to the fact that "helper" viruses or plasmids need not be used in conjunction with many of the viral vectors of the present invention, those vectors of the present invention are also simpler to use than those previously described in the art.

In order to provide a clearer understanding of the specification and claims, the following definitions are provided.

Adenoviral Vector or Ad-Derived Vector. Any adenovirus-derived plasmid, genome or virus into which a foreign DNA may be inserted or expressed. This term may also be used interchangeably with "viral vector." This "type" of vector may be utilized to carry nucleotide sequences encoding therapeutic proteins or polypeptides to specific cells or cell types in a subject in need of treatment, as described further herein below.

Amino Acid Residue. An amino acid formed upon chemical digestion (hydrolysis) of a polypeptide at its peptide linkages. The amino acid residues described herein are preferably in the "L" isomeric form. However, residues in the "D" isomeric form can be substituted for any L-amino acid residue, as long as the desired functional property is retained by the polypeptide. NH_2 refers to the free amino group present at the amino terminus of a polypeptide. COOH refers to the free carboxy group present at the carboxyl terminus of a polypeptide. Standard polypeptide nomenclature described in *J. Biol. Chem.*, 243:3552-59 (1969) and adopted at 37 C.F.R. § § 1.821 - 1.822 is used.

It should be noted that all amino acid residue sequences represented herein by formulae have a left to right orientation in the conventional direction of amino-terminus to carboxyl-terminus. In addition, the phrase "amino acid residue" is broadly defined to include the amino acids listed in the Table of Correspondence and modified and unusual amino acids, such as those referred to in 37 C.F.R. § § 1.821-1.822, and incorporated herein by reference. Furthermore, it should be noted that a dash at the beginning or end of an amino acid residue sequence indicates a peptide bond to a further sequence of one or more amino acid residues or to an amino-terminal group such as NH_2 or to a carboxyl-terminal group such as COOH .

- 14 -

Complementing Plasmid: This term is generally used herein to describe plasmid vectors used to deliver particular nucleotide sequences into a packaging cell line, with the intent of having said sequences stably integrate into the cellular genome.

Delivery Plasmid: This term is generally used herein to describe a plasmid vector that carries or delivers nucleotide sequences in or into a cell line (e.g., a packaging cell line) for the purpose of propagating therapeutic viral vectors of the present invention.

DNA Homolog: A nucleic acid having a preselected conserved nucleotide sequence and a sequence encoding a preferred polypeptide according to the present invention, where the nucleic acid is substantially homologous to a named preferred embodiment. By the term "substantially homologous" is meant having at least 80%, preferably at least 90%, most preferably at least 95% homology therewith.

The terms "homology" and "identity" are often used interchangeably. In this regard, percent homology or identity may be determined, for example, by comparing sequence information using a GAP computer program. The GAP program utilizes the alignment method of Needleman and Wunsch (*J. Mol. Biol.* 48:443 (1970), as revised by Smith and Waterman (*Adv. Appl. Math.* 2:482 (1981)). Briefly, the GAP program defines similarity as the number of aligned symbols (i.e., nucleotides or amino acids) which are similar, divided by the total number of symbols in the shorter of the two sequences. The preferred default parameters for the GAP program may include: (1) a unary comparison matrix (containing a value of 1 for identities and 0 for non-identities) and the weighted comparison matrix of Gribskov and Burgess, *Nucl. Acids Res.* 14:6745 (1986), as described by Schwartz and Dayhoff, eds., *ATLAS OF PROTEIN SEQUENCE AND STRUCTURE*, National Biomedical Research Foundation, pp. 353-358 (1979); (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap; and (3) no penalty for end gaps.

Whether any two nucleic acid molecules have nucleotide sequences that are at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% "identical" can be determined using known computer algorithms such as the "FAST A" program, using for example, the default parameters as in Pearson and Lipman, *Proc. Natl. Acad. Sci. USA* 85:2444 (1988). Alternatively the BLAST function of the National Center for Biotechnology Information database may be used to determine identity.

In general, sequences are aligned so that the highest order match is obtained. "Identity" *per se* has an art-recognized meaning and can be calculated

- 15 -

using published techniques. (See, e.g.: *Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data, Part I*, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). While there exist a number of methods to measure identity between two polynucleotide or polypeptide sequences, the term "identity" is well known to skilled artisans (Carillo, H. & Lipton, D., *SIAM J Applied Math* 48:1073 (1988)). Methods commonly employed to determine identity or similarity between two sequences include, but are not limited to, those disclosed in Guide to Huge Computers, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and Carillo, H. & Lipton, D., *SIAM J Applied Math* 48:1073 (1988). Methods to determine identity and similarity are codified in computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, GCG program package (Devereux, J., et al., *Nucleic Acids Research* 12(1):387 (1984)), BLASTP, BLASTN, FASTA (Atschul, S.F., et al., *J Molec Biol* 215:403 (1990)).

Therefore, as used herein, the term "identity" represents a comparison between a test and a reference polypeptide or polynucleotide. For example, a test polypeptide may be defined as any polypeptide that is 90% or more identical to a reference polypeptide. As used herein, the term at least "90% identical to" refers to percent identities from 90 to 99.99 relative to the reference polypeptides. Identity at a level of 90% or more is indicative of the fact that, assuming for exemplification purposes a test and reference polynucleotide length of 100 amino acids are compared. No more than 10% (i.e., 10 out of 100) amino acids in the test polypeptide differs from that of the reference polypeptides. Similar comparisons may be made between a test and reference polynucleotides. Such differences may be represented as point mutations randomly distributed over the entire length of an amino acid sequence or they may be clustered in one or more locations of varying length up to the maximum allowable, e.g. 10/100 amino acid difference (approximately 90% identity). Differences are defined as nucleic acid or amino acid substitutions, or deletions.

An embodiment of the invention may use polynucleotides at least 90% or 95% identical to those encoding the TPL nucleic acid sequences. A further embodiment of the invention may include those polynucleotides that encode a

- 16 -

polypeptide of interest that are at least 95% identical when the variation in such a polynucleotide is due to more than merely degenerate changes.

Expression or Delivery Vector: Any plasmid or virus into which a foreign DNA may be inserted for expression in a suitable host cell -- *i.e.*, the protein or polypeptide encoded by the DNA is synthesized in the host cell's system. Vectors capable of directing the expression of DNA segments (genes) encoding one or more proteins are referred to herein as "expression vectors." Also included are vectors which allow cloning of cDNA (complementary DNA) from mRNAs produced using reverse transcriptase.

Foreign Gene: This term is used to identify a DNA molecule not present in the exact orientation and position as the counterpart DNA molecule found in wild-type adenovirus. It may also refer to a DNA molecule from another organism or species (*i.e.*, exogenous) or from another Ad serotype.

Gene: A nucleic acid whose nucleotide sequence encodes an RNA or polypeptide. A gene can be either RNA or DNA. Genes may include regions preceding and following the coding region (leader and trailer) as well as intervening sequences (introns) between individual coding segments (exons).

Isolated: This term is used to indicate a nucleic acid or polypeptide sequence separated from the genetic environment from which the sequences were obtained. It may also mean altered from the natural state. For example, a polynucleotide or a polypeptide naturally present in a living animal is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein. Thus, a polypeptide or polynucleotide produced and/or contained within a recombinant host cell is considered isolated for purposes of the present invention. Also intended as an "isolated polypeptide" or an "isolated polynucleotide" are polypeptides or polynucleotides that have been purified, partially or substantially, from a recombinant host cell or from a native source. For example, a recombinantly produced version of a compound can be substantially purified by the one-step method described in Smith and Johnson, *Gene* 67:31-40 (1988). The terms isolated and purified are sometimes used interchangeably.

By "isolated" is meant that the DNA is free of the coding sequences of those genes that, in the naturally-occurring genome of the organism (if any) from which the DNA of the invention is derived, immediately flank the gene encoding the DNA of the invention. The isolated DNA may be single-stranded or double-stranded, and may be genomic DNA, cDNA, recombinant hybrid DNA, or synthetic DNA. It

may be identical to a native DNA sequence, or may differ from such sequence by the deletion, addition, or substitution of one or more nucleotides.

Isolated or purified as it refers to preparations made from biological cells or hosts should be understood to mean any cell extract containing the indicated DNA or protein including a crude extract of the DNA or protein of interest. For example, in the case of a protein, a purified preparation can be obtained following an individual technique or a series of preparative or biochemical techniques and the DNA or protein of interest can be present at various degrees of purity in these preparations. The procedures may include for example, but are not limited to, ammonium sulfate fractionation, gel filtration, ion exchange chromatography, affinity chromatography, density gradient centrifugation and electrophoresis.

A preparation of DNA or protein that is "pure" or "isolated" should be understood to mean a preparation free from naturally occurring materials with which such DNA or protein is normally associated in nature. "Essentially pure" should be understood to mean a "highly" purified preparation that contains at least 95% of the DNA or protein of interest.

A cell extract that contains the DNA or protein of interest should be understood to mean a homogenate preparation or cell-free preparation obtained from cells that express the protein or contain the DNA of interest. The term "cell extract" is intended to include culture media, especially spent culture media from which the cells have been removed.

Packaging Cell line: A packaging cell line is a cell line that provides a missing gene product or its equivalent.

Particle: The adenovirus (Ad) particle is relatively complex and may be resolved into various substructures. The particle is the minimal structural or functional unit of a virus. A virus can refer to a single particle, a stock of particles or a viral genome.

Penton: The terms "penton" or "penton complex" are preferentially used herein to designate a complex of penton base and fiber. The term "penton" may also be used to indicate penton base, as well as penton complex. The meaning of the term "penton" alone should be clear from the context within which it is used.

Plasmid: An autonomous self-replicating extrachromosomal circular DNA

Post-transcriptional Regulatory Element (PRE) is a regulatory element found in viral or cellular messenger RNA that is not spliced, i.e. intronless messages. Examples include, but are not limited to, human hepatitis virus, woodchuck

hepatitis virus, the TK gene and mouse histone gene. The PRE may be placed before a polyA sequence and after a heterologous DNA sequence.

Pseudotyping: This term as generally used herein describes the production of adenoviral vectors having modified capsid protein or capsid proteins from a different serotype than the serotype of the vector itself. One example, is the production of an adenovirus 5 vector particle containing a chimeric Ad3/Ad5 fiber protein. This may be accomplished by producing the adenoviral vector in packaging cell lines expressing different fiber proteins.

Promoter: Useful promoters according to the present invention may be inducible or constitutive. Inducible promoters will initiate transcription only in the presence of an additional molecule; constitutive promoters, on the other hand, do not require the presence of any additional molecule to regulate gene expression. A regulatable or inducible promoter may also be described as a promoter wherein the rate of RNA polymerase binding and initiation is modulated by external stimuli. Such stimuli include various compounds or compositions, light, heat, stress, chemical energy sources, and the like. Inducible, suppressible and repressible promoters are considered regulatable promoters.

Receptor: Receptor is a term used herein to indicate a biologically active molecule that specifically binds to (or with) other molecules. The term "receptor protein" may be used to more specifically indicate the proteinaceous nature of a specific receptor.

Recombinant: As used herein, the term is intended to refer to any progeny formed as the result of genetic engineering. This may also be used to describe a virus formed by recombination of plasmids in a packaging cell.

Transgene or Therapeutic Nucleotide Sequence: As described and claimed herein, such a sequence includes DNA and RNA sequences encoding an RNA or polypeptide. Such sequences may be "native" or naturally-derived sequences; they may also be "non-native" or "foreign" sequences which are naturally- or recombinantly-derived. The term "transgene," which may be used interchangeably herein with the term "therapeutic nucleotide sequence," is often used to describe a heterologous or foreign (exogenous) gene that is carried by a viral vector and transduced into a host cell.

Therefore, therapeutic nucleotide sequences may also include antisense sequences or nucleotide sequences which may be transcribed into antisense sequences. Therapeutic nucleotide sequences (or transgenes) further comprise sequences which function to produce a desired effect in the cell or cell nucleus into which said therapeutic sequences are delivered. For example, a therapeutic

- 19 -

nucleotide sequence may encode a functional protein intended for delivery into a cell which is unable to produce that functional protein.

Adenovirus

Fiber plays a crucial role in adenovirus infection by attaching the virus to a specific receptor on the cell surface. The fiber is an elongated protein which exists as a trimer of three identical polypeptides (polypeptide IV) of 582 amino acids in length. An adenovirus fiber consists of three domains: an N-terminal tail domain that interacts with penton base; a shaft composed of variable numbers of repeats of a 15-amino-acid segment that forms beta-sheet and beta-bends; and a knob at the C-terminus ("head domain") that contains the type-specific antigen and is responsible for binding to the cell surface receptor. The gene encoding the fiber protein from Ad2 has been expressed in human cells and has been shown to be correctly assembled into trimers, glycosylated and transported to the nucleus. (See, *e.g.*, Hong and Engler, *Virology* 185: 758-761, 1991). Thus, alteration of the fiber in recombinant Ad vectors can lead to alteration in gene delivery. This has great utility for a variety of gene therapy applications and is one of the objects of the present invention.

Hexon, penton and fiber capsomeres are the major components on the surface of the virion. Their constituent polypeptides, nos. II, III and IV, contain tyrosine residues that are exposed on the surface of the virion and can be labeled -- *e.g.*, by iodination of intact particles.

The 35,000+ base pair (bp) genome of adenovirus type 2 has been sequenced and the predicted amino acid sequences of the major coat proteins (hexon, fiber and penton base) have been described. (See, *e.g.*, Neumann *et al.*, *Gene* 69: 153-157 (1988); Herisse *et al.*, *Nuc. Acids Res.* 9: 4023-4041 (1981); Roberts *et al.*, *J. Biol. Chem.* 259: 13968-13975 (1984); Kinloch *et al.*, *J. Biol. Chem.* 259: 6431-6436 (1984); and Chroboczek *et al.*, *Virol.* 161: 549-554, 1987).

The sequence of Ad5 DNA was completed more recently; its sequence includes a total of 35,935 bp. Portions of many other adenovirus genomes have also been sequenced. It is presently understood that the upper packaging limit for adenovirus virions is about 105% of the wild-type genome length. (See, *e.g.*, Bett, *et al.*, *J. Virol.* 67(10): 5911-21, 1993). Thus, for Ad2 and Ad5, this would be an upper packaging limit of about 38kb of DNA.

Adenovirus DNA also includes inverted terminal repeat sequences (ITRs) ranging in size from about 100 to 150 bp, depending on the serotype. The inverted repeats enable single strands of viral DNA to circularize by base-pairing

- 20 -

of their terminal sequences, and the resulting base-paired "panhandle" structures required for replication of the viral DNA.

For efficient packaging, the ITRs and the packaging signal (a few hundred bp in length) comprise the "minimum requirement" for replication and packaging of a genomic nucleic acid into an adenovirus particle. Helper-dependent vectors lacking all viral ORFs but including these essential *cis* elements (the ITRs and contiguous packaging sequence) have been constructed, but the virions package less efficiently than the helper and package as multimers part of the time, which suggests that the virus may "want" to package a fuller DNA complement (see, *e.g.*, Fisher, *et al.*, *Virology* 217: 11-22, 1996).

The viral vectors of the present invention may retain their ability to express the genome packaged within -- *i.e.*, they may retain their "infectivity" -- they do not act as infectious agents, however, to the extent that they cause disease in the subjects to whom they are administered for therapeutic purposes.

It is to be appreciated that Ad vectors have several distinct advantages over other viral vectors in the art. For example, recombination of such vectors is rare; there are no known associations of human malignancies with adenoviral infections despite common human infection with adenoviruses; the genome may be manipulated to accommodate foreign genes of a fairly substantial size; and host proliferation is not required for expression of adenoviral proteins.

An extension of this invention is that the Ad-derived viral vectors disclosed herein may be used to target and deliver genes into specific cells by incorporating the attachment sequence for other receptors (such as CD4) onto the fiber protein by recombinant DNA techniques, thus producing a chimeric molecule. This should result in the ability to target and deliver genes into a wide range of cell types with the advantage of evading recognition by the host's immune system. The within-disclosed delivery systems thus provide for increased flexibility in gene design to enable gene delivery into proliferating and nonproliferating cell types.

For example, U.S. Patent Nos. 5,756,086 and 5,543,328 as well as, WO95/26412 and WO 98/44121 and Krasnykh, *et al.* (*J. Virol.* 70: 6839-46, 1996) describe modifications that may be made to the adenovirus fiber protein. Such modifications are useful in altering the targeting mechanism and specificity of adenovirus and could readily be utilized in conjunction with the constructs of the present invention to target the novel viral vectors disclosed herein to different receptors and different cells. Moreover, modifications to fiber protein which alter its tropism may permit greater control over the localization of viral vectors in therapeutic applications.

- 21 -

Similarly, incorporation of various structural proteins into cell lines of the present invention, whether or not those proteins are modified, is also contemplated by the present invention. Thus, for example, modified penton base polypeptides such as those described in Wickham, *et al.* (*J. Virol.* 70: 6831-8, 1996) may have therapeutic utility when used according to the within-disclosed methods.

While some of the Examples appearing below specifically recite fiber proteins, polypeptides, and fragments thereof, it is expressly provided herein that other structural and non-structural Ad proteins and polypeptides (*e.g.*, regulatory proteins and polypeptides) may be used as components of the various disclosed vectors and cell lines. Moreover, chimeric molecules comprised of proteins, polypeptides, and/or fragments thereof which are derived from different Ad serotypes may be used in any of the within-disclosed methods, constructs and compositions. Similarly, recombinant DNA sequences of the present invention may be prepared using nucleic acid sequences derived from different Ad serotypes, in order to design useful constructs with broad applicability, as disclosed and claimed herein.

It should also be appreciated that, while the members of Group C or Group D adenovirus -- *i.e.*, Ad serotypes 1, 2, 5, 6 or 37 -- are specifically recited in various examples herein, the present invention is in no way limited to those serotypes alone. In view of the fact that the adenovirus serotypes are all closely-related in structure and functionality, therapeutic viral vectors, packaging cell lines, and plasmids of the present invention may be constructed from components of any and all Ad serotypes -- and the within-disclosed methods of making and using the various constructs and cell lines of the present invention apply to all of said serotypes.

The family of Adenoviridae includes many members with at least 47 known serotypes of human adenovirus (Ad1-Ad47) (Shenk, *Virology*, Chapter 67, in Fields *et al.*, eds. Lippincott-Raven, Philadelphia, 1996,) as well as members of the genus Mastadenovirus including human, simian, bovine, equine, porcine, ovine, canine and opossum viruses, and members of the Aviadenovirus genus, including bird viruses, *e.g.* CELO. Thus it is contemplated that the disclosed inventions can be applied to any adenovirus species, and the invention need not be so limited. One of skill in the art would have knowledge of the different adenoviruses as evidenced by (Shenk, *Virology*, Chapter 67, in Fields *et al.*, eds. Lippincott-Raven, Philadelphia, 1996,) which is herein incorporated by reference.

Packaging Cell Lines A. Adenovirus Complementation Genetics

The first generation of recombinant adenoviral vectors currently available typically have a deletion in the first viral early gene region which is generally referred to as E1, which comprises the E1a and E1b regions. (These regions span genetic map units 1.30 to 9.24.) Figure 3 in chapter 67 of *Fields Virology*, 3d Ed. (Fields *et al.* eds, Lippincott-Raven Publ., Philadelphia, 1996, p. 2116) illustrates a transcription and translation map of adenovirus type 2 (Ad2).

Deletion of the viral E1 region renders the recombinant adenovirus defective for replication and incapable of producing infectious viral particles in subsequently-infected target cells. Thus, to generate E1-deleted adenovirus genome replication and to produce virus particles requires a system of complementation which provides the missing E1 gene product. E1 complementation is typically provided by a cell line expressing E1, such as the human embryonic kidney packaging cell line, i.e. an epithelial cell line, called 293. Cell line 293 contains the E1 region of adenovirus, which provides E1 gene region products to "support" the growth of E1-deleted virus in the cell line (see, *e.g.*, Graham *et al.*, *J. Gen. Virol.* 36: 59-71, 1977). Additionally, cell lines that may be usable for production of defective adenovirus having a portion of the adenovirus E4 region have been reported (WO 96/22378). Multiply deficient adenoviral vectors and complementing cell lines have also been described (WO 95/34671, U.S. Patent No. 5,994,106). Nevertheless, inherent problems exist concerning first-generation recombinant adenoviruses.

B. Adenovirus Particle Packaging Cell Lines

Packaging cell lines disclosed herein support viral vectors with deletions of major portions of the viral genome, without the need for helper viruses. Additionally, the invention provides novel cell lines and helper viruses for use with helper-dependent vectors.

Thus, in one embodiment of the present invention, a packaging cell line is disclosed having DNA sequences stably integrated into the cellular genome wherein the DNA sequences encode one or more adenovirus regulatory and/or structural polypeptides which complement the genes deleted or mutated in the adenovirus vector genome to be replicated and packaged.

In another embodiment, the packaging cell line expresses one or more adenovirus structural proteins, polypeptides, or fragments thereof, wherein said

- 23 -

structural protein is selected from the group consisting of penton base, hexon, fiber, polypeptide IIIa, polypeptide V, polypeptide VI, polypeptide VII, polypeptide VIII, and biologically active fragments thereof.

In one variation, the sequences are constitutively expressed; in another, one or more sequences is under the control of a regulatable promoter. In a preferred embodiment expression is constitutive. In various preferred embodiments, the polypeptides expressed by the DNA sequences are biologically active.

In a further and preferred embodiment the packaging cell line of the present invention supports the production of a viral vector. In a preferred embodiment the viral vector is a therapeutic vector.

The present invention also discloses a packaging cell line which complements a viral vector having a deletion or mutation of a DNA sequence encoding an adenovirus structural protein, regulatory polypeptides E1A and E1B, and/or one or more of the following regulatory proteins or polypeptides: E2A, E2B, E3, E4, L4, or fragments thereof.

Various useful packaging cells are contemplated which complement adenovirus. In one aspect of the present invention, each DNA sequence is introduced into the genome of the within-disclosed cell lines via a separate complementing plasmid. In other embodiments, two or more DNA sequences were introduced into the genome via a single complementing plasmid. In one variation, the complementing plasmid comprises a DNA sequence encoding adenovirus fiber protein, polypeptide or fragment thereof. An example of a useful complementing plasmid according to the present invention is a plasmid having the characteristics of pCLF (for deposit details, see Example 3)

One embodiment discloses a packaging cell useful in the preparation of recombinant adenovirus viral vectors comprising a delivery plasmid comprising an adenovirus genome lacking a nucleotide sequence encoding fiber. In one variation, the delivery plasmid further comprises a nucleotide sequence encoding a foreign polypeptide. A preferred delivery plasmid is pDV44, pE1B gal, or pE1sp1B. In another variation, the cell further comprises a complementing plasmid containing a nucleotide sequence encoding fiber, the plasmid being stably integrated into the cellular genome of the cell.

In one embodiment, a composition comprises a cell containing first and second delivery plasmids wherein a first delivery plasmid comprises an adenovirus genome lacking a nucleotide sequence encoding fiber and incapable of directing the packaging of new viral particles in the absence of a second

- 24 -

delivery plasmid, and a second delivery plasmid comprises an adenoviral genome capable of directing the packaging of new viral particles in the presence of the first delivery plasmid.

In another variation, the first and second delivery plasmids interact within the cell to produce a therapeutic viral vector. In yet another variation, the cell further comprises a complementing plasmid containing a nucleotide sequence encoding fiber, the plasmid being stably integrated into the cellular genome of the cell. In still another, the first or second delivery plasmid further comprises a nucleotide sequence encoding a foreign polypeptide. In various embodiments, the polypeptide is a therapeutic molecule.

Another embodiment discloses a composition as before, wherein the first delivery plasmid lacks adenovirus packaging signal sequences. In another aspect, the second delivery plasmid contains a LacZ reporter construct. In another variation, the second delivery plasmid further lacks a nucleotide sequence encoding an adenovirus regulatory protein. In one variation, the regulatory protein is E1. In one embodiment of the above-noted compositions, the complementing plasmid has the characteristics of pCLF.

In another embodiment, a composition is disclosed wherein the first delivery plasmid lacks a nucleotide sequence encoding an adenovirus structural protein and the second delivery plasmid lacks a nucleotide sequence encoding adenovirus E1 protein. In another, the first delivery plasmid lacks a nucleotide sequence encoding adenovirus E4 protein and the second delivery plasmid lacks a nucleotide sequence encoding adenovirus E1 protein. In still another, the cell contains at least one complementing plasmid encoding an adenoviral regulatory protein and a structural protein.

In one preferred variation of the present invention, a packaging cell line expresses fiber protein. In one embodiment, the fiber protein has been modified to include a non-native amino acid residue sequence which targets a specific receptor, but which does not disrupt trimer formation or transport of fiber into the nucleus. In another variation, the non-native amino acid residue sequence alters the binding specificity of the fiber for a targeted cell type. In still another embodiment, the structural protein is fiber comprising amino acid residue sequences from more than one adenovirus serotype. As disclosed herein, the nucleotide sequences encoding fiber protein or polypeptide need not be modified solely at one or both termini; fiber protein -- and indeed, any of the adenovirus structural proteins, as taught herein -- may be modified "internally" as well as at the termini.

- 25 -

In one variation, the non-native amino acid residue sequence is coupled to the carboxyl terminus of the fiber. In yet another, the non-native amino acid residue sequence further includes a linker sequence. Alternatively, the fiber protein further comprises a ligand coupled to the linker. A suitable ligand may be selected from the group consisting of ligands that specifically bind to a cell surface receptor and ligands that can be used to couple other proteins or nucleic acid molecules. Typically, any of the packaging cell lines of this invention may have a DNA sequence encoding all or part of a fiber protein -- including modified or chimeric proteins -- stably integrated into the genome.

In various aspects of the present invention, a packaging cell line of the present invention is derived from a procaryotic cell line; in another, it is derived from a eucaryotic cell line. While various embodiments suggest the use of mammalian cells, and more particularly, epithelial cell lines, a variety of other, non-epithelial cell lines are used in various embodiments. Thus, while various embodiments disclose the use of a cell line selected from the group consisting of 293, A549, W162, HeLa, Vero, 211, and 211A cell lines, it is understood that various other cell lines are likewise contemplated for use as disclosed herein.

Therapeutic Viral Vectors and Related Systems

A. Nucleic Acid Segments

A therapeutic viral vector or composition of the present invention comprises a nucleotide sequence, nucleic acid molecule or segment as described herein. Typically, the nucleic acid molecule or molecule encodes a protein or polypeptide molecule -- or a biologically active fragment thereof -- which may be used for therapeutic applications. A nucleotide sequence may further comprise an enhancer element or a promoter located 3' or 5' to and controlling the expression of such a therapeutic nucleotide sequence or gene.

A subject nucleotide sequence consists of a nucleic acid molecule that comprises at least 2 different operatively linked DNA segments. The DNA can be manipulated and amplified by PCR as described herein and by using standard techniques, such as those described in *Molecular Cloning: A Laboratory Manual, 2nd Ed.*, Sambrook *et al.*, eds., Cold Spring Harbor, New York (1989). Typically, to produce a nucleotide sequence of the present invention, the sequence encoding the selected polypeptide and the promoter or enhancer are operatively linked to a DNA molecule capable of autonomous replication in a cell either *in vivo* or *in vitro*.

- 26 -

By operatively linking the enhancer element or promoter and the nucleotide sequence to the vector, the attached segments are replicated along with the vector sequences.

Thus, a recombinant DNA molecule (rDNA) of the present invention is a hybrid DNA molecule comprising at least 2 nucleotide sequences not normally found together in nature. In various preferred embodiments, one of the sequences is a sequence encoding an Ad-derived polypeptide, protein, or fragment thereof. Stated another way, a nucleotide sequence of the present invention is one that encodes an expressible protein, polypeptide or fragment thereof, and it may further include an active constitutive or regulatable (*e.g.* inducible) promoter sequence.

A nucleotide sequence of the present invention is optimally from about 20 base pairs to about 40,000 base pairs in length. Preferably the nucleotide sequence is from about 50 bp to about 38,000 bp in length. In various embodiments, the nucleotide sequence is of sufficient length to encode one or more adenovirus proteins or functional polypeptide portions thereof. Since individual Ad polypeptides vary in length from about 19 amino acid residues to about 967 amino acid residues, corresponding nucleotide sequences will range from about 50 bp up to about 3000 bp, depending on the number and size of individual polypeptide-encoding sequences that are "replaced" in the viral vectors by therapeutic nucleotide sequences of the present invention.

1. Tripartite Leader (TPL) Nucleic Acid Sequences

In one aspect of the invention, it has been discovered that expression of adenovirus late proteins such as the structural proteins in a packaging cell line according to the present invention is substantially improved when the expression cassette present on the complementing plasmid or in the packaging cell line's genome contains an adenovirus tripartite leader (TPL) nucleic acid sequence.

Thus, the invention contemplates a nucleic acid molecule comprising a TPL nucleotide sequence. Preferably, the TPL nucleotide sequence may be operatively linked to an intron containing RNA processing signals (such as for example, splice donor or splice acceptor sites) suitable for expression in the packaging cell line. Most preferably, the intron contains a splice donor site and a splice acceptor site. Alternatively, the TPL nucleotide sequence may not comprise an intron.

In one embodiment, a subject nucleic acid molecule of this invention is isolated, *i.e.*, separated from the genetic environment from which the component sequences were obtained. Thus, molecular cloning of fragments of a gene will

- 27 -

produce an isolated nucleic acid, as will the chemical synthesis of an oligonucleotide to build a nucleic acid molecule.

The intron useful in the present invention is any nucleotide sequence which functions in the packaging cell line to provide RNA processing signals, as are well known in the art, including splicing signals. Introns have been well characterized from a large number of structural genes, and therefore the invention should not be considered as limited. Well characterized and preferred introns include a native intron 1 from adenovirus, such as Ad5's TPL intron 1; others include the SV40 VP intron; the rabbit beta-globin intron, and synthetic intron constructs. See, for example, Petitclerc *et al.*, *J. Biothechnol.*, 40:169, 1995, and Choi *et al.*, *Mol. Cell. Biol.*, 11:3070, 1991.

The TPL nucleotide sequence comprises either (a) first and second TPL exons or (b) first, second and third TPL exons, where each TPL exon in the sequence is selected from the group consisting of complete TPL exon 1, partial TPL exon 1, complete TPL exon 2 and complete TPL exon 3. A complete exon is one which contains the complete nucleic acid sequence based on the sequence found in the wild type viral genome. Preferably the TPL exons are from Ad2, Ad3, Ad5, Ad7 and the like, however, they may come from any Ad serotype, as described herein. A preferred partial TPL exon 1 is described in the Examples. The use of a TPL with a partial exon 1 has been reported (WO98/13499).

The intron and the TPL exons can be operatively linked in a variety of configurations to provide a functional TPL nucleotide sequence, although in some embodiments of the invention, an intron may not be a part of the construct. For example, the intron can be positioned between any of TPL exons 1, 2 or 3, and the exons can be in any order of first and second, or first/second/third. The intron can also be placed preceding the first TPL exon or following the last TPL exon. In a preferred embodiment, complete TPL exon 1 is operatively linked to complete TPL exon 2 operatively linked to complete TPL exon 3. In a preferred variation, adenovirus TPL intron 1 is positioned between complete TPL exon 1 and complete TPL exon 2. It may also be possible to use analogous translational regulators from other viral systems such as rabiesvirus.

A preferred "complete" TPL nucleic acid molecule containing complete TPL exons 1, 2 and 3 with adenovirus intron 1 inserted between exons 1 and 2 has a nucleotide sequence shown in SEQ ID NO: 32. A preferred "partial" TPL nucleic acid molecule containing partial TPL exon 1 and complete TPL exons 2 and 3 in that order has a nucleotide sequence shown in SEQ ID NO: 26. The construction of these preferred TPL nucleotide sequences is described in the Examples.

- 28 -

Thus, preferred expression cassettes and complementing plasmids for expressing adenovirus structural genes, particularly fiber protein, contain an adenovirus TPL nucleotide sequence as described herein. Preferred packaging cell lines containing the subject nucleic acid molecules also contain a TPL nucleotide sequence of the invention.

2. Complementing Plasmids

The invention describes in a related embodiment nucleic acid molecules and nucleotide sequences, typically in the form of DNA plasmid vectors, which are capable of expression of an adenovirus structural protein or regulatory protein. Because these expression plasmids are used to complement the defective genes of a recombinant adenovirus vector genome of this invention, the plasmids are referred to as complementing or complementation plasmids.

The complementing plasmid contains an expression cassette, a nucleotide sequence capable of expressing a protein product off the gene encoded by the nucleotide sequence. Expression cassettes are described in more detail herein, but typically contain a promoter and a structural gene operatively linked to the promoter and whose expression is controlled by the promoter. A preferred complementing plasmid further includes a TPL nucleotide sequence described herein to enhance expression of the structural gene product when used in the context of adenovirus genome replication and packaging.

In one embodiment, a complementing plasmid comprises a promoter nucleotide sequence operatively linked to a nucleotide sequence encoding an adenovirus structural polypeptide. The adenovirus structural polypeptide is selected from the group consisting of penton base; hexon; fiber; polypeptide IIIa; polypeptide V; polypeptide VI; polypeptide VII; polypeptide VIII; and biologically active fragments thereof. In another variation, a complementing plasmid further comprises a nucleotide sequence encoding a first adenovirus regulatory polypeptide, a nucleotide sequence encoding a second regulatory polypeptide, a nucleotide sequence encoding a third regulatory polypeptide; or any combination of the foregoing.

The present invention also discloses a complementing plasmid comprising a promoter nucleotide sequence operatively linked to a nucleotide sequence encoding an adenovirus structural protein, polypeptide or fragment thereof and a nucleotide sequence encoding an adenovirus regulatory protein, polypeptide or fragment thereof. In one variation, the early region polypeptide is E4; in another,

- 29 -

the plasmid comprises pE4/Hygro. In still another variation, the early region polypeptides are E1 and E4.

In another aspect of the present invention, the complementing plasmid used to transform a cell line of the present invention further comprises a DNA sequence encoding an adenovirus regulatory protein, polypeptide or fragment thereof. In one variation, the regulatory protein is selected from the group consisting of E1A, E1B, E2A, E2B, E3, E4 and L4 (also referred to as "the 100K protein"); an exemplary complementing plasmid has the characteristics of is pE4/Hygro (for deposit details, see the Examples). In another aspect, the complementing plasmid used to transform a cell line of the present invention further comprises a DNA sequence encoding two or more of the above mentioned adenovirus regulatory proteins, polypeptides or fragments thereof.

Preferred complementing plasmids include pCLF, pDV60, pDV61, pDV67, pDV69, pDV80, pDV90 and the like plasmids described in the Examples. The nucleic acid sequence of particularly preferred complementing plasmids are shown in SEQ ID NO: 43 for pDV60, SEQ ID NO: 44 for pDV67, SEQ ID NO: 47 for pDV69, SEQ ID NO: 64 for pDV80 and SEQ ID NO: 65 for pDV90.

3. Nucleic Acid Molecule Synthesis

A nucleic acid molecule comprising synthetic oligonucleotide sequences of the present invention can be prepared using any suitable method, such as, the phosphotriester or phosphodiester methods. See Narang *et al.*, *Meth. Enzymol.*, 68:90, (1979); U.S. Patent No. 4,356,270; and Brown *et al.*, *Meth. Enzymol.*, 68:109, (1979).

For oligonucleotide sequences in which a family of variants is preferred, the synthesis of the family members can be conducted simultaneously in a single reaction vessel, or can be synthesized independently and later admixed in preselected molar ratios. For simultaneous synthesis, the nucleotide residues that are conserved at preselected positions of the sequence of the family member can be introduced in a chemical synthesis protocol simultaneously to the variants by the addition of a single preselected nucleotide precursor to the solid phase oligonucleotide reaction admixture when that position number of the oligonucleotide is being chemically added to the growing oligonucleotide polymer. The addition of nucleotide residues to those positions in the sequence that vary can be introduced simultaneously by the addition of amounts, preferably equimolar amounts, of multiple preselected nucleotide precursors to the solid phase

- 30 -

oligonucleotide reaction admixture during chemical synthesis. For example, where all four possible natural nucleotides (A,T,G and C) are to be added at a preselected position, their precursors are added to the oligonucleotide synthesis reaction at that step to simultaneously form four variants.

This manner of simultaneous synthesis of a family of related oligonucleotides has been previously described for the preparation of "Degenerate Oligonucleotides" by Ausubel *et al.* (*Current Protocols in Molecular Biology*, Suppl. 8, p.2.11.7, John Wiley & Sons, Inc., New York, 1991), and can readily be applied to the preparation of the therapeutic oligonucleotide compositions described herein.

Nucleotide bases other than the common four nucleotides (A,T,G or C), or the RNA equivalent nucleotide uracil (U), can also be used in the present invention. For example, it is well known that inosine (I) is capable of hybridizing with A, T and G, but not C. Examples of other useful nucleotide analogs are known in the art and may be found referred to in 37 C.F.R. §1.822.

Thus, where all four common nucleotides are to occupy a single position of a family of oligonucleotides, that is, where the preselected nucleotide sequence is designed to contain oligonucleotides that can hybridize to four sequences that vary at one position, several different oligonucleotide structures are contemplated. The composition can contain four members, where a preselected position contains A,T,G or C. Alternatively, a composition can contain two nucleotide sequence members, where a preselected position contains I or C, and has the capacity to hybridize at that position to all four possible common nucleotides. Finally, other nucleotides may be included at the preselected position that have the capacity to hybridize in a non-destabilizing manner with more than one of the common nucleotides in a manner similar to inosine.

Similarly, larger nucleic acid molecules can be constructed in synthetic oligonucleotide pieces, and assembled by complementary hybridization and ligation, as is well known.

B. Adenovirus Expression Vector Systems

One key component of the present invention for producing gene therapy reagents comprised of recombinant adenovirus particles is the recombinant adenovirus vector genome which is encapsulated in the virus particle and which expresses exogenous genes in a gene therapy setting. Thus, the components of an recombinant adenovirus vector genome include the ability to express selected

- 31 -

adenovirus structural genes, to express a desired exogenous protein, and to contain sufficient replication and packaging signals that the genome is packaged into a gene delivery vector particle. The preferred replication signal is an adenovirus inverted terminal repeat containing an adenovirus origin of replication, as is well known and described herein.

According to the present invention, a preferred recombinant adenovirus vector genome is "helper independent" which means the genome can replicate and be packaged without the help of a second, complementing helper virus. Instead, the complementation is provided by a packaging cell line of the present invention. Additional embodiments of the invention, however, are drawn to a vector genome referred to as "gutless" which is "helper dependent."

In a preferred embodiment, the adenovirus vector genome does not encode a functional adenovirus fiber protein. A non-functional fiber gene refers to a deletion, mutation or other modification to the adenovirus fiber gene such that the gene does not express any or insufficient adenovirus fiber protein to package a fiber-containing adenovirus particle without complementation of the fiber gene by a complementing plasmid or packaging cell line. Such a genome is referred to as a "fiberless" genome, not to be confused with a fiberless particle. Alternatively, a fiber protein may be encoded but is insufficiently expressed to result in a fiber containing particle.

Thus, the invention describes a helper-independent fiberless recombinant adenovirus vector genome comprising genes which (a) express all adenovirus structural gene products but express insufficient adenovirus fiber protein to package a fiber-containing adenovirus particle without complementation of said fiber gene, (b) express an exogenous protein, and (c) contains an adenovirus packaging signal and inverted terminal repeats containing adenovirus origin of replication.

The introduction of exogenous DNA into eucaryotic cells has become one of the most powerful tools of the molecular biologist. The term "exogenous" encompasses any therapeutic composition of this invention which is administered by the therapeutic methods of this invention. Thus, "exogenous" may also be referred to herein as "foreign," "non-native," and the like. The methods of this invention preferably require efficient delivery of the DNA into the nucleus of the recipient cell and subsequent identification of cells that are expressing the foreign DNA.

The adenovirus vector genome is propagated in the laboratory in the form of rDNA plasmids containing the genome, and upon introduction into an appropriate

- 32 -

host, the viral genetic elements provide for viral genome replication and packaging rather than plasmid-based propagation. Exemplary methods for preparing an Ad-vector genome are described in the Examples.

A widely-used plasmid is pBR322, a vector whose nucleotide sequence and endonuclease cleavage sites are well known. Various other useful plasmid vectors are described in the Examples that follow.

A nucleic acid vector of the present invention comprises a nucleic acid (preferably DNA) molecule capable of autonomous replication in a cell and to which a DNA segment, *e.g.*, a gene or polynucleotide, can be operatively linked so as to bring about replication of the attached segment. In the present invention, one of the nucleotide segments to be operatively linked to vector sequences encodes at least a portion of a therapeutic nucleic acid molecule -- in effect, a nucleic acid sequence that encodes one or more therapeutic proteins or polypeptides, or fragments thereof.

As one of skill in the art will note, in various embodiments of the present invention, different "types" of vectors are disclosed. For example, one "type" of vector is used to deliver particular nucleotide sequences into a packaging cell line, with the intent of having said sequences stably integrate into the cellular genome; these "types" of vectors are generally identified herein as complementing plasmids. A further "type" of vector described herein carries or delivers nucleotide sequences in or into a cell line (*e.g.*, a packaging cell line) for the purpose of propagating therapeutic viral vectors of the present invention; hence, these vectors are generally referred to herein as delivery plasmids. A third "type" of vector described herein is utilized to carry nucleotide sequences encoding therapeutic proteins or polypeptides to specific cells or cell types in a subject in need of treatment; these vectors are generally identified herein as therapeutic viral vectors or Ad-derived vectors and are in the form of a virus particle encapsulating a viral nucleic acid containing an expression cassette nucleic acid sequence for expressing the therapeutic gene.

1. Nucleic Acid Gene Expression Cassettes

In various embodiments, a peptide-coding sequence of the therapeutic gene is inserted into an expression vector and expressed; however, it is also feasible to construct an expression vector which also includes some non-coding sequences as well. Preferably, however, non-coding sequences are excluded. Alternatively, a nucleotide sequence for a soluble form of a polypeptide may be utilized. Another preferred therapeutic viral vector includes a nucleotide sequence encoding at least

- 33 -

a portion of a therapeutic nucleotide sequence operatively linked to the expression vector for expression of the coding sequence in the therapeutic nucleotide sequence.

As used herein with regard to DNA sequences or segments, the phrase "operatively linked" generally means the sequences or segments have been covalently joined into one piece of DNA, whether in single or double stranded form.

The choice of viral vector into which a therapeutic nucleotide sequence of this invention is operatively linked depends directly, as is well known in the art, on the functional properties desired, *e.g.*, vector replication and protein expression, and the host cell to be transformed -- these being limitations inherent in the art of constructing recombinant DNA molecules. Although certain adenovirus serotypes are recited herein in the form of specific examples, it should be understood that the present invention contemplates the use of *any* adenovirus serotype, including hybrids and derivatives thereof. As one will observe, it is not unusual or outside the scope of the present invention to utilize nucleotide and/or amino acid residue sequences of two or more serotypes in constructs, compositions and methods of the invention.

A translatable nucleotide sequence is a linear series of nucleotides that provide an uninterrupted series of at least 8 codons that encode a polypeptide in one reading frame. Preferably, the nucleotide sequence is a DNA sequence. The vector itself may be of any suitable type, such as a viral vector (RNA or DNA), naked straight-chain or circular DNA, or a vesicle or envelope containing the nucleic acid material and any polypeptides that are to be inserted into the cell.

2. Promoters

As noted elsewhere herein, an expression nucleic acid in an Ad-derived vector of the present invention may also include a promoter sequence.

In general, promoters are DNA segments that contain a DNA sequence that controls the expression of a gene located 3' or downstream of the promoter. The promoter is the DNA sequence to which RNA polymerase specifically binds and initiates RNA synthesis (transcription) of that gene, typically located 3' of the promoter. A promoter also includes DNA sequences which direct the initiation of transcription, including those to which RNA polymerase specifically binds. If more than one nucleic acid sequence encoding a particular polypeptide or protein is included in a therapeutic viral vector or nucleotide sequence, more than one promoter or enhancer element may be included, particularly if that would enhance

- 34 -

efficiency of expression. For purposes of the present invention, regulatable (inducible) as well as constitutive promoters may be used, either on separate vectors or on the same vector.

Both constitutive and regulatable (often called "inducible") promoters are useful in constructs and methods of the present invention. For example, some useful regulatable promoters are those of the CREB-regulated gene family and include inhibin, gonadotropin, cytochrome c, glucagon, and the like. (See, *e.g.*, published International App. No. WO96/14061.

A regulatable or inducible promoter may be described as a promoter wherein the rate of RNA polymerase binding and initiation is modulated by external stimuli. (See U.S. Patent Nos. 5,750,396 and 5,998,205). Such stimuli include various compounds or compositions, light, heat, stress, chemical energy sources, and the like. Inducible, suppressible and repressible promoters are considered regulatable promoters.

Regulatable promoters may also include tissue-specific promoters. Tissue-specific promoters direct the expression of the gene to which they are operably linked to a specific cell type. Tissue-specific promoters cause the gene located 3' of it to be expressed predominantly, if not exclusively, in the specific cells where the promoter expressed its endogenous gene. Typically, it appears that if a tissue-specific promoter expresses the gene located 3' of it at all, then it is expressed appropriately in the correct cell types (see, *e.g.*, Palmiter *et al.*, *Ann. Rev. Genet.* 20: 465-499, 1986).

When a tissue-specific promoter controls the expression of a gene, that gene will be expressed in a small number of tissues or cell types rather than in substantially all tissues and cell types. Examples of tissue-specific promoters include the immunoglobulin promoter described by Brinster *et al.*, *Nature* 306: 332-336 (1983) and Storb *et al.*, *Nature* 310: 238-231 (1984); the elastase-I promoter described by Swift *et al.*, *Cell* 38: 639-646 (1984); the globin promoter described by Townes *et al.*, *Mol. Cell. Biol.* 5: 1977-1983 (1985), and Magram *et al.*, *Mol. Cell. Biol.* 9: 4581-4584 (1989), the insulin promoter described by Bucchini *et al.*, *PNAS USA*, 83: 2511-2515 (1986) and Edwards *et al.*, *Cell* 58: 161 (1989); the immunoglobulin promoter described by Ruscon *et al.*, *Nature* 314: 330-334 (1985) and Grosscheld *et al.*, *Cell* 38: 647-658 (1984); the alpha actin promoter described by Shani, *Mol. Cell. Biol.* 6: 2624-2631 (1986); the alpha crystalline promoter described by Overbeek *et al.*, *PNAS USA* 82: 7815-7819 (1985); the prolactin promoter described by Crenshaw *et al.*, *Genes and Development* 3: 959-972 (1989); the propiomelanocortin promoter described by Tremblay *et al.*,

- 35 -

PNAS USA 85: 8890-8894 (1988); the beta-thyroid stimulating hormone (BTSH) promoter described by Tatsumi *et al.*, *Nippon Rinsho* 47: 2213-2220 (1989); the mouse mammary tumor virus (MMTV) promoter described by Muller *et al.*, *Cell* 54: 105 (1988); the albumin promoter described by Palmiter *et al.*, *Ann. Rev. Genet.* 20: 465-499 (1986); the keratin promoter described by Vassar *et al.*, *PNAS USA* 86: 8565-8569 (1989); the osteonectin promoter described by McVey *et al.*, *J. Biol. Chem.* 263: 11,111-11,116 (1988); the prostate-specific promoter described by Allison *et al.*, *Mol. Cell. Biol.* 9: 2254-2257 (1989); the opsin promoter described by Nathans *et al.*, *PNAS USA* 81: 4851-4855 (1984); the olfactory marker protein promoter described by Danciger *et al.*, *PNAS USA* 86: 8565-8569 (1989); the neuron-specific enolase (NSE) promoter described by Forss-Pelter *et al.*, *J. Neurosci. Res.* 16: 141-151 (1986); the L-7 promoter described by Sutcliffe, *Trends in Genetics* 3: 73-76 (1987) and the protamine 1 promoter described Peschon *et al.*, *Ann. New York Acad. Sci.* 564: 186-197 (1989) and Braun *et al.*, *Genes and Development* 3: 793-802 (1989).

3. Adenovirus Vectors

Although adenovirus consists of many proteins, not all adenovirus proteins are required for assembly of a recombinant adenovirus particle (vector) of this invention. Thus, deletion of the appropriate genes from a recombinant Ad vector as taught herein will thus allow the vector to accommodate even larger "foreign" DNA segments. Thus, if the sequences encoding one or more adenovirus polypeptides or proteins are supplanted by a recombinant nucleotide sequence of the present invention, the length of the recombinant sequence can conceivably extend nearly to the packaging limit of the relevant adenovirus-derived vector.

In view of the fact that preferred embodiments disclosed herein are helper-independent Ad-derived vectors, the entire wild-type Ad genome cannot be completely supplanted by recombinant nucleic acid molecules without transforming such a vector into a vector requiring "help" of some kind. However, most of the Ad-derived vectors of the present invention do not depend on a helper virus; instead, the vectors of the present invention are propagated in cell lines stably expressing proteins or polypeptides that have been removed from said vectors to allow the addition of "foreign" DNA into the vectors. In various disclosed embodiments, specific early region and structural polypeptides are deleted from the vectors of the present invention, thereby enabling the vectors to accommodate recombinant nucleic acid sequences (or cassettes) of various lengths. For example, Ad-derived

- 36 -

vectors of the present invention may easily include 12 kb or more of foreign (or "therapeutic") DNA sequences.

Thus, adenovirus viral vectors are also disclosed which comprise nucleotide sequences encoding a packaging signal and a foreign protein or polypeptide, wherein the nucleotide sequence encoding an adenovirus structural protein has been deleted.

In one variation, the nucleotide sequence encoding the foreign protein or polypeptide is a DNA molecule up to about 3 kb in length; in another, the nucleotide sequence encoding the foreign protein or polypeptide is a DNA molecule up to about 9.5 kb in length; in still another, the nucleotide sequence encoding the foreign protein or polypeptide is a DNA molecule up to about 12.5 kb in length. Nucleotide sequences of intermediate lengths are also contemplated by the present invention, as are sequences in excess of 12.5 kb.

The invention also discloses viral vectors wherein the sequence encoding a foreign protein or polypeptide is a sequence encoding an anti-tumor agent, a tumor suppressor protein, a suicide protein, or a fragment or functional equivalent thereof. In one variation, nucleotide sequences encoding one or more regulatory proteins have also been deleted from the vector. In another, the regulatory proteins are selected from the group consisting of E1A, E1B, E2A, E2B, E3, E4, and L4 (100K protein).

A wide variety of therapeutic viral vectors are also embodiments of the present invention. In one embodiment, a therapeutic viral vector is disclosed which lacks a DNA sequence encoding fiber protein, or a portion thereof. In another variation, a therapeutic viral vector may further or alternatively comprise deletion of a DNA sequence encoding one or more regulatory proteins, polypeptides, or fragments thereof. In various embodiments, foreign DNA sequences are inserted in place of the DNA sequence encoding fiber protein in the viral vectors of the present invention. In other embodiments, the therapeutic viral vectors further comprise foreign DNA sequences inserted in place of the DNA sequences encoding one or more regulatory proteins, polypeptides, or fragments thereof, and/or one or more structural proteins, polypeptides, or fragments thereof.

The present invention further discloses a number of viral vectors. In one variation, a viral vector comprises a deletion or mutation of a DNA sequence encoding an adenovirus structural protein, polypeptide, or fragment thereof. A vector may further comprise deletion or mutation of the DNA sequences encoding regulatory polypeptides E1A and E1B; and it may still further comprise deletion or mutation of the DNA sequence encoding one or more of the following regulatory

- 37 -

proteins or polypeptides: E2A, E2B, E3, E4, L4, or fragments thereof. In another variation, in a viral vector of the present invention, the structural protein comprises fiber. Any combination of the foregoing is also contemplated by the present invention. The viral vectors of the present invention are suitable for the preparation of pharmaceutical compositions comprising any of the therapeutic viral vectors disclosed herein -- including combinations thereof -- are also disclosed herein. A further use of the viral vectors of the present invention is for targeting specific cells in a cell population comprising different cell types.

Yet another variation discloses that a foreign DNA sequence encoding one or more foreign proteins, polypeptides or fragments thereof has been inserted in place of any of the deletions in the therapeutic viral vector. In one embodiment, the foreign DNA encodes a tumor-suppressor protein or a biologically active fragment thereof. In another embodiment, the foreign DNA encodes a suicide protein or a biologically active fragment thereof.

The invention further contemplates that a viral vector comprises a foreign DNA sequence encoding one or more foreign proteins, polypeptides or fragments thereof wherein said DNA sequence has been inserted in place of any structural and/or regulatory proteins (or portions thereof) that have been deleted. Thus, in one embodiment, the foreign DNA encodes a therapeutic molecule such as a tumor-suppressor protein; a suicide protein; a cystic fibrosis transmembrane conductance regulator (CFTR) protein; or a biologically active fragment of any of them.

The therapeutic (or foreign) nucleotide sequence can be a gene or gene fragment that encodes a protein or polypeptide -- or a biologically active fragment thereof. (See, *e.g.*, Crystal, *et al.*, *Nature Genetics* 8: 42-51 (1994); Zabner, *et al.*, *Cell* 75: 207-216 (1993); Knowles, *et al.*, *NEJM* 333(13): 823-831 (1995); and Rosenfeld, *et al.*, *Cell* 68: 143-155 (1992).

It is further contemplated that a therapeutic protein or polypeptide expressed by a therapeutic viral vector of the present invention may be used in conjunction with another therapeutic agent when appropriate -- *e.g.*, a thymidine kinase metabolite may be used in conjunction with the gene encoding thymidine kinase and its gene product -- in order to be even more effective.

Alternatively, a therapeutic viral vector can include a DNA or RNA oligonucleotide sequence that exhibits therapeutic activity without needing to be translated into a polypeptide product before exerting a therapeutic effect. Examples of the latter include antisense oligonucleotides that will inhibit the transcription of deleterious genes or ribozymes that act as site-specific

- 38 -

ribonucleases for cleaving selected mutated gene sequences. In another variation, a therapeutic nucleotide sequence of the present invention may comprise a DNA construct capable of generating therapeutic nucleotide molecules, including ribozymes and antisense DNA, in high copy numbers in target cells, as described in published PCT application No. WO 92/06693 (the disclosure of which is incorporated herein by reference). Other preferred therapeutic nucleotide sequences according to the present invention are capable of delivering HIV antisense oligonucleotides to latently-infected T cells via CD4. Similarly, delivery of Epstein-Barr Virus (EBV) EBNA-1 antisense oligonucleotides to B cells via CR2 is capable of effecting therapeutic results.

A preferred recombinant adenovirus vector genome is based on the vector described in the Examples and designated Ad5. β gal. Δ F. This vector is a helper independent, fiberless vector genome which can host, upon insertion, an exogenous gene for expression of an exogenous or therapeutic protein. The genome of Ad5. β gal. Δ F has a nucleotide sequence shown in SEQ ID NO: 27. A virus particle containing Ad5. β gal. Δ F vector genome has been prepared as described in the Examples and is deposited with the ATCC as Accession No. VR-2636

The Ad5. β gal. Δ F genome nucleic acid can be manipulated to contain any exogenous gene in place of the beta-galactosidase gene present in the construct, as described herein.

Construction of Therapeutic Viral Vectors for Gene Delivery

A. Adenovirus Particles

Various methods of making and using the vectors, plasmids, cell lines and other compositions and constructs of the present invention are also disclosed herein. The following methods are considered exemplary and not limiting.

Thus, in one variation, the invention discloses a method of constructing therapeutic viral vectors, comprising introducing a delivery plasmid into an Ad fiber-expressing complementing cell line, wherein the DNA sequence encoding Ad fiber protein has been deleted from the delivery plasmid. In one variation, the delivery plasmid further includes a DNA sequence encoding a foreign protein, polypeptide, or fragment thereof. In other embodiments, a combination of pDV44 and p Δ E1B β gal or a similar construct such as, for example, that found in pDV44, p Δ E1B β gal or the equivalent.

- 39 -

A recombinant adenovirus particle may be produced with a fiber protein, or it may be produced without a fiber protein ("fiberless particle") according to the present invention. Where the particle is made without fiber, such as by passaging the fiberless viral vector genome, e.g., Ad5. β gal. Δ F in the 293 cells, a fiberless genome is replicated and packaged in a fiberless particle. In contrast, where the fiberless genome Ad5. β gal. Δ F is passaged in the 211B or other fiber expressing cells, a fiberless genome is replicated and packaged into a fiber-containing particle.

Recombinant adenovirus particles may be made such that they include no fiber proteins, modified fiber proteins or other exogenous proteins. They may also be produced in systems using either helper-independent or helper-dependent adenovirus recombinant genomes, i.e. with or without helper viruses.

B. Targeting of Particles to Tissues - Virus Tropism

A preferred viral vector particle in which therapeutic nucleotide compositions of this invention are present is derived from adenovirus (Ad). As taught herein, viral vector particles of this invention may be designed and constructed in such a way that they specifically target a preselected recipient cell type, depending on the nature of therapy one seeks to administer. Methods of making and using therapeutic viral vectors that target specific cells are further described in the Examples that follow.

Novel vectors, viral particles or compositions may also be designed and prepared to preferentially target cells that might not otherwise be targeted by wild-type adenovirus virions. For example, in order to target non-epithelial cells, one following the teachings of the present specification may be able to prepare a therapeutic vector particle including a nucleotide sequence encoding a foreign protein, polypeptide or other ligand directed to a non-epithelial cell or to a different receptor than that generally targeted by a particular adenovirus. Examples of useful ligands directed to specific receptors (identified in parentheses) include the V3 loop of HIV gp120 (CD4); transferrin (transferrin receptor); LDL, apolipoprotein B100, apolipoprotein E (LDL receptors); and deglycosylated proteins (asialoglycoprotein receptor). Various useful ligands which may be added to adenovirus fiber -- and methods for preparing and attaching same -- are set forth in U.S. Patent Nos. 5,756,086 and 5,543,328.

In yet another embodiment, the non-native amino acid residue sequence is incorporated into the fiber amino acid residue sequence at a location other than

- 40 -

one of the fiber termini. Alternatively, the non-native amino acid residue sequence alters the binding specificity of the fiber for a targeted cell type. In other embodiments, the linker sequence alters the binding specificity of the fiber for a targeted cell type. The expressed fiber may, in various embodiments, bind to a specific targeted cell type not usually targeted by adenovirus and/or may comprise amino acid residue sequences from more than one adenovirus serotype.

Useful ligands may be encoded by a foreign nucleotide sequence contained within a viral vector of the present invention, or may be linked to proteins or polypeptides, include antibodies and attachment sequences, as well as receptors themselves. For example, antibodies to cell receptor molecules such as integrins and the like, MHC Class I and Class II, asialoglycoprotein receptor, transferrin receptors, LDL receptors, CD4, and CR2 are but a few which are useful according to the present invention. It is also understood that the ligands typically bound by receptors, as well as analogs to those ligands, may be used as cellular targeting agents, as disclosed herein.

Therapeutic Methods

The recombinant adenovirus vectors of the present invention, typically in the form of an adenovirus particle encapsulating a recombinant adenovirus vector genome containing an expression cassette for expressing a therapeutic gene, are particularly suited for gene therapy. Thus, various therapeutic methods are contemplated by the present invention.

For example, it has now been discovered that Ad-derived viral vectors are capable of delivering a therapeutic nucleotide sequence to a specific cell or tissue, based on the tissue tropism of the particle, thereby expanding and enhancing treatment options available in numerous conditions in which more conventional therapies are of limited efficacy. Accordingly, methods of gene therapy utilizing a recombinant adenovirus particle containing a modified fiber or chimeric fiber which targets a preselected tissue, as described herein, is within the scope of the invention. Vector particles are typically purified and then an effective amount is administered *in vivo* or *ex vivo* (*in vitro*) into the subject.

For *in vitro* or *ex vivo* gene transfer, administration is often accomplished by first isolating a selected cell population from a patient such as lung epithelial cells, lymphocytes and the like followed by *in vitro* or *ex vivo* gene transfer of the therapeutic compositions of this invention and the replacement of the cells into the patient. *In vivo* therapy is also contemplated, *e.g.*, via the administration of

therapeutic compositions of this invention by various delivery means. For example, aerosol administration and administration via subcutaneous, intravenous, intraperitoneal, intramuscular, ocular means and the like are also within the scope of the present invention.

Other gene-delivery methods are also useful in conjunction with the methods, compositions and constructs of the present invention; see, *e.g.*, published International Application No. WO 95/11984.

The present invention also contemplates various methods of targeting specific cells -- *e.g.*, cells in a subject in need of diagnosis and/or treatment. As discussed herein, the present invention contemplates that the viral vectors and compositions of the present invention may be directed to specific receptors or cells, for the ultimate purpose of delivering those vectors and compositions to specific cells or cell types. The viral vectors and constructs of the present invention are particularly useful in this regard.

In general, adenovirus attachment and uptake into cells are separate but cooperative events that result from the interaction of distinct viral coat proteins with a receptor for attachment and α_v integrin receptors for internalization. Adenovirus attachment to the cell surface via the fiber coat proteins has been discovered to be dissociable and distinct from the subsequent step of internalization, and the present invention is able to take advantage of and function in conjunction with these differing receptors.

The invention also discloses methods of transforming a pathologic hyperproliferative mammalian cell comprising contacting the cell with any of the vectors described herein. In another embodiment, methods of infecting a mammalian target cell with a viral vector containing a preselected foreign nucleotide sequence are disclosed. One such variation comprises the following steps: (a) infecting the target cell with a viral vector of the present invention, the viral vector carrying a preselected foreign nucleotide sequence; and (b) expressing the foreign nucleotide sequence in the targeted cell.

The invention also encompasses mammalian target cells infected with a preselected foreign nucleotide sequence produced by the methods disclosed herein. In one variation, the target cells are selected from the group consisting of replicating, slow-replicating and non-replicating human cells.

Methods of treating an acquired or hereditary disease are also disclosed. One method comprises (a) administering a pharmaceutically acceptable dose of a viral vector to a target cell, wherein the vector comprises a preselected therapeutic nucleotide sequence; and (b) expressing the therapeutic sequence in the target

- 42 -

cell for a time period sufficient to ameliorate the acquired or hereditary disease in the cell. Method of gene therapy comprising administering to a subject an effective amount of a therapeutic viral vector produced by a packaging cell line of the present invention are also disclosed.

Also contemplated by the present invention are various methods of inhibiting the proliferation of a tumor in a subject comprising administering an effective amount of a therapeutic viral vector of the present invention under suitable conditions to the subject. In one variation, the gene encodes an anti-tumor agent. In another variation, the agent is a tumor-suppressor gene. In still another embodiment, the agent is a suicide gene or a functional equivalent thereof. In another variation, the vector is administered via intra-tumoral injection.

A composition of this invention may be used prophylactically or therapeutically *in vivo* to disrupt HIV infection and mechanisms of action by inhibiting gene expression or activation, via delivery of antisense HIV sequences or ribozymes to T cells or monocytes. Using methods of the present invention, one may target therapeutic viral vectors as disclosed herein to specific cells and tissues, including hematopoietic cells, as infection of such cells appears to be mediated by distinct integrins to which viral vectors of the present invention may readily be targeted. (See, *e.g.*, Huang, *et al.*, *J. Virol.* 70: 4502-8, 1996).

Other useful therapeutic nucleotide sequences include antisense nucleotide sequences complementary to EBV EBNA-1 gene. Use of such therapeutic sequences may remediate or prevent latent infection of B cells with EBV. As discussed herein and in the Examples below, targeting and delivery may be accomplished via the use of various ligands, receptors, and other appropriate targeting agents.

Thus, in one embodiment, a therapeutic method of the present invention comprises contacting the cells of a subject infected with EBV or HIV with a therapeutically effective amount of a pharmaceutically acceptable composition comprising a therapeutic nucleotide sequence of this invention. In a related embodiment, the contacting involves introducing the therapeutic nucleotide sequence composition into cells having an EBV or HIV-mediated infection.

Methods of gene therapy are well known in the art (see, *e.g.*, Larrick and Burck, *Gene Therapy: Application of Molecular Biology*, Elsevier Science Publ. Co., Inc., New York, NY (1991); Kriegler, *Gene Transfer and Expression: A Laboratory Manual*, W. H. Freeman and Company, New York, 1990). The term "subject" should be understood to include any animal -- particularly mammalian --

- 43 -

patient, such as any murine, rat, bovine, porcine, canine, feline, equine, ursine, or human patient.

When the foreign gene carried in the vector encodes a tumor suppressor gene or another anti-tumor protein, the vector is useful to treat or reduce hyperproliferative cells in a subject, to inhibit tumor proliferation in a subject or to ameliorate a particular, related pathology.

The present invention also contemplates methods of depleting suitable samples of pathologic mammalian hyperproliferative cells contaminating hematopoietic precursors during bone marrow reconstitution via the introduction of a wild-type tumor suppressor gene into the cell preparation using a vector of this invention. As used herein, a suitable sample is defined as a heterogeneous cell preparation obtained from a patient, *e.g.*, a mixed population of cells containing both phenotypically normal and pathogenic cells.

Administration includes -- but is not limited to -- the introduction of therapeutic agents of the present invention into a cell or subject via various means, including direct injection, intravenously, intraperitoneally, via intra-tumor injection, via aerosols, or topically. Therapeutic agents as disclosed herein may also be combined for administration of an effective amount of the agents with a pharmaceutically-acceptable carrier, as described herein.

As used herein, "effective amount" generally means the amount of vector particle (or proteins produced/released thereby) which achieves a positive outcome in the subject to whom the vector is administered. The total volume administered will necessarily vary depending on the mode of administration, as those of skill in the relevant art will appreciate, and dosages may vary as well.

The dose of a biologic vector (particle) is somewhat complex and may be described in terms of the concentration (in plaque-forming units per milliliter (pfu/ml)), the total dose (in pfus), or the estimated number of particles administered per cell (the estimated multiplicity of infection or MOI). Thus, if a vector is administered via infusion -- say, across nasal epithelium -- at a constant total volume, the respective concentration, etc. may be described as follows:

- 44 -

In general, when recombinant adenoviral vector particles are administered via infusion across the nasal epithelium (e.g. an area of nasal epithelium containing 2×10^7 cells,) administered amounts producing an estimated MOI (multiplicity of infection) of about 10 or greater are much more effective than lower

Concentration <u>(pfu/ml)</u>	Volume <u>(ml)</u>	Dose <u>(pfu)</u>	Estimated <u>MOI</u>
10 ⁷	2	2×10^7	1
10 ⁸	2	2×10^8	10
10 ⁹	2	2×10^9	100
10 ¹⁰	2	2×10^{10}	1000

Table 2

dosages. (See, e.g., Knowles, *et al.*, *New Eng. J. Med.* 333: 823-831, 1995). Similarly, when direct injection is the preferred treatment modality -- e.g., direct injection of a viral vector into a tumor -- doses of 1×10^9 pfu or greater are generally preferred. (See, e.g., published International App. No. WO95/11984.)

Thus, depending on the mode of administration, an effective amount administered in a single dose preferably contains from about 10^6 to about 10^{15} infectious units. A typical course of treatment would be one such dose per day over a period of five days. As those of skill in the art will appreciate, an effective amount may vary depending on (1) the pathology or other condition to be treated, (2) the status and sensitivity of the patient, and (3) various other factors well known to those of skill in the art, such as the patient's tolerance to other courses of treatment that may have been applied previously. Thus, those of skill in the art may easily and precisely determine effective amounts of the agents/vectors of the present invention which may be administered to a particular patient, based on their understanding of and evaluation of such factors.

The present invention also contemplates methods of ameliorating pathologies characterized by hyperproliferative cells or genetic defects in a subject, by administering to the subject an effective amount of a vector as described herein. Such vectors preferably contain a foreign gene encoding a gene product (e.g. polypeptide or protein) having the ability to ameliorate the pathology, under suitable conditions. As used herein, the term "genetic defect" means any disease,

- 45 -

condition or abnormality which results from inherited factors, e.g. Huntington's Disease, Tay-Sachs Disease, or Sickle Cell Disease.

The present invention further provides methods for reducing the proliferation of tumor cells in a subject by introducing into the tumor mass an effective amount of an adenoviral expression vector containing an anti-tumor gene other than a tumor suppressor gene. The anti-tumor gene can encode, for example, thymidine kinase (TK). An effective amount of a therapeutic agent is then administered to the subject; the therapeutic agent, in the presence of the anti-tumor gene, is toxic to the cell.

Using thymidine kinase as exemplary, the therapeutic agent is a thymidine kinase metabolite such as ganciclovir (GCV), 6-methoxypurine arabinonucleoside (araM), or a functional equivalent thereof. Both the thymidine kinase gene and the thymidine kinase substrate must be used concurrently in order to exert a toxic effect on the host cell. In the presence of the TK gene, GCV is phosphorylated and becomes a potent inhibitor of DNA synthesis, whereas araM is converted to the cytotoxic anabolite araATP. Thus, the precise method of action or synergism is not relevant to therapeutic efficacy; what is relevant is the fact that the concurrent use of appropriate genes and therapeutic agents may effectively ameliorate a specific disease condition.

Another useful example contemplates use of a vector of the present invention which expresses the enzyme cytosine deaminase. Such a vector could be used in conjunction with administration of the drug 5-fluorouracil (Austin and Huber, *Mol. Pharm.* 43: 380-387, 1993) or the recently-described *E. coli* Deo gene in combination with 6-methyl-purine-2'-deoxyribonucleoside (Sorscher *et al.*, *Gene Therapy* 1: 233-238, 1994).

As with the use of the tumor suppressor genes described previously, the use of other anti-tumor genes, either alone or in combination with the appropriate therapeutic agent, provides a treatment for the uncontrolled cell growth or proliferation characteristic of tumors and malignancies. Thus, the present invention provides therapies to halt the uncontrolled cellular growth in a patient, thereby alleviating the symptoms or the disease or cachexia present in the patient. The effect of this treatment includes, but is not limited to, prolonged survival time of the patient, reduction in tumor mass or burden, apoptosis of tumor cells, or the reduction in the number of circulating tumor cells. Means of quantifying the beneficial effects of this therapy are well known to those of skill in the art.

The present invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of one or more adenoviral structural

- 46 -

protein genes, such as the gene encoding fiber, which allows the vector to accommodate a therapeutic, foreign nucleic acid sequence encoding a functional foreign polypeptide, protein, or biologically active fragment thereof. A therapeutic gene sequence may be introduced into a tumor mass by combining the adenoviral expression vector with a suitable pharmaceutically acceptable carrier. Introduction can be accomplished, for example, via direct injection of the recombinant Ad vector into the tumor mass.

A method of tumor-specific delivery of a tumor-suppressor gene is accomplished by contacting target tissue in a subject with an effective amount of a recombinant Ad-derived vector of this invention. In the case of anti-tumor therapy, the gene is intended to encode an anti-tumor agent, such as a functional tumor suppressor gene product or suicide gene product. The term "contacting" is intended to encompass any delivery method for the efficient transfer of the vector, such as via intra-tumoral injection.

In another example, adenovirus vectors of the present invention can be used to transfer genes to central nervous system (CNS) tumors *in vivo*.

The present invention also contemplates methods for determining the efficacy of the within-disclosed therapeutic compositions and methods. One such method for confirming efficacy utilizes the human/SCID (severe combined immunodeficient) mouse model of EBV-induced LPD (lymphoproliferative disease) to ascertain whether EBV-antisense therapeutic nucleotide sequences block tumor formation. (See, *e.g.*, Pisa, *et al.*, *Blood* 79: 173-179 (1992); Rowe, *et al.*, *Curr. Top. Microbiol. Immunol.* 166: 325 (1990); and Cannon, *et al.*, *J. Clin. Invest.* 85: 1333-1337 (1990).

Finally, the use of Ad vectors of the present invention to prepare medicaments for the treatment, therapy and/or diagnosis of various diseases is also contemplated by this invention. Moreover, other anti-tumor genes may be used in combination with the corresponding therapeutic agent to reduce the proliferation of tumor cells. Such other gene-and-therapeutic-agent combinations are known to those of skill in the art and may be applied as taught herein.

A. Therapeutic Compositions

In various alternative embodiments of the present invention, therapeutic sequences and compositions useful for practicing the therapeutic methods described herein are contemplated. Therapeutic compositions of the present invention may contain a physiologically tolerable carrier together with one or more

- 47 -

therapeutic nucleotide sequences of this invention, dissolved or dispersed therein as an active ingredient. In a preferred embodiment, the composition is not immunogenic or otherwise able to cause undesirable side effects when administered to a subject for therapeutic purposes.

As used herein, the terms "pharmaceutically acceptable," "physiologically tolerable" and grammatical variations thereof, as they refer to compositions, carriers, diluents and reagents, are used interchangeably and represent that the materials are capable of administration to or upon a subject -- *e.g.*, a mammal -- without the production of undesirable physiological effects such as nausea, dizziness, gastric upset and the like.

For example, the present invention comprises therapeutic compositions useful in the specific targeting of epithelial or non-epithelial cells as well as in delivering a therapeutic nucleotide sequence to those cells. Therapeutic compositions designed to preferentially target to epithelial cells may comprise a recombinant adenovirus-derived vector particle including a therapeutic nucleotide sequence. As described herein, a number of adenovirus-derived moieties are described, including particles lacking fiber, particles that contain wild type adenovirus fiber, and particles that contain modified or chimeric fiber, each type providing a different tissue tropism to the particle.

The preparation of a pharmacological composition that contains active ingredients dissolved or dispersed therein is well understood in the art. Typically such compositions are prepared as injectables -- either as liquid solutions or suspensions -- however, solid forms suitable for solution or suspension in liquid prior to use can also be prepared. A preparation can also be emulsified, or formulated into suppositories, ointments, creams, dermal patches, or the like, depending on the desired route of administration.

Physiologically tolerable carriers are well known in the art. Exemplary of liquid carriers are sterile aqueous solutions that contain no materials in addition to the active ingredients and water, or contain a buffer such as sodium phosphate at physiological pH value, physiological saline or both, such as phosphate-buffered saline. Still further, aqueous carriers can contain more than one buffer salt, as well as salts such as sodium and potassium chlorides, dextrose, polyethylene glycol and other solutes.

Liquid compositions can also contain liquid phases in addition to and to the exclusion of water. Exemplary of such additional liquid phases are glycerin, vegetable oils such as cottonseed oil, and water-oil emulsions.

- 48 -

A therapeutic composition typically contains an amount of a therapeutic material, *i.e.*, a nucleotide sequence or adenovirus vector particle of the present invention, sufficient to deliver a therapeutically effective amount to the target tissue, typically an amount of at least 0.1 weight percent to about 90 weight percent of therapeutic material per weight of total therapeutic composition. A weight percent is a ratio by weight of therapeutic material, *e.g.*, a nucleotide sequence, to total composition. Thus, for example, 0.1 weight percent is 0.1 grams of DNA segment per 100 grams of total composition.

Other Applications

The cell lines, viral vectors and methods of the present invention may also be used for purposes other than the direct administration of therapeutic nucleotide sequences. In one such application, the production of large quantities of biologically active proteins or polypeptides in cells transfected with the within-disclosed viral vectors is contemplated herein. For example, human lymphoblastoid cells may be transfected with a viral vector of the present invention carrying a human hematopoietic growth factor such as the gene for erythropoietin (EPO); cells so transfected are thus able to produce biologically active EPO. (See, *e.g.*, Lopez *et al.*, *Gene* 148: 285-91, 1994).

Various other applications and uses of the within-described methods, cell lines, plasmids, vectors, and compositions of the present invention shall become apparent upon closer examination of the Examples that follow.

The following examples are intended to illustrate, but not limit, the present invention. As such, the following description provides details of the manner in which particular embodiments of the present invention may be made and used. This description, while exemplary of the present invention, is not to be construed as specifically limiting the invention. Variations and equivalents, now known or later developed, which would be within the understanding and technical competence of one skilled in this art are to be considered as falling within the scope of this invention.

Example 1

Preparation of Adenovirus Packaging Cell Lines

- 49 -

Cell lines that are commonly used for growing adenovirus are useful as host cells for the preparation of adenovirus packaging cell lines. Preferred cells include 293 cells, an adenovirus-transformed human embryonic kidney cell line obtained from the ATCC, having Accession Number CRL 1573; HeLa, a human epithelial carcinoma cell line (ATCC Accession Number CCL-2); A549, a human lung carcinoma cell line (ATCC Accession Number CCL 1889); and the like epithelial-derived cell lines. As a result of the adenovirus transformation, the 293 cells contain the E1 early region regulatory gene. All cells were maintained in complete DMEM + 10% fetal calf serum unless otherwise noted.

The cell lines of this invention allow for the production and propagation of novel adenovirus-based gene delivery vectors having deletions in preselected gene regions, that are obtained by cellular complementation of adenoviral genes. To provide the desired complementation of such deleted adenoviral genomes in order to generate a novel viral vector of the present invention, plasmid vectors that contain preselected functional units were designed as described herein. Such units include but are not limited to E1 early region, E4 and the viral fiber gene. The preparation of plasmids providing such complementation, thereby being "complementary plasmids or constructs," that are stably inserted into host cell chromosomes are described below.

A. Preparation of an E4-Expressing Plasmid for Complementation of E4-Gene-Deleted Adenoviruses

The viral E4 regulatory region contains a single transcription unit which is alternately spliced to produce several different mRNAs. The E4-expressing plasmid prepared as described herein and used to transfect the 293 cell line contains the entire E4 transcriptional unit as shown in Figure 1. A DNA fragment extending from 175 nucleotides upstream of the E4 transcriptional start site including the natural E4 promoter to 153 nucleotides downstream of the E4 polyadenylation signal including the natural E4 terminator signal, corresponding to nucleotides 32667-35780 of the adenovirus type 5 (hereinafter referred to as Ad5) genome as described in Chroboczek *et al.* (*Virology*, 186:280-285 (1992), GenBank Accession Number M73260), was amplified from Ad5 genomic DNA, obtained from the ATCC, via the polymerase chain reaction (PCR). Sequences of the primers used were 5'CGGTACACAGAATTCAGGAGACACAACTCC3' (forward or 5' primer referred to as E4L) (SEQ ID NO: 1) and 5'GCCTGGATCCGGGAAGTTACGTAACGTGGGAAAAC3' (SEQ ID NO: 2)

- 50 -

(backward or 3' primer referred to as E4R). To facilitate cloning of the PCR fragment, these oligonucleotides were designed to create novel sites for the restriction enzymes EcoRI and BamHI, respectively, as indicated with underlined nucleotides. DNA was amplified via PCR using 30 cycles of 92 C for 1 minute, 50 C for 1 minute, and 72 C for 3 minutes resulting in amplified full-length E4 gene products.

The amplified DNA E4 products were then digested with EcoRI and BamHI for cloning into the compatible sites of pBluescript/SK+ by standard techniques to create the plasmid pBS/E4. A 2603 base pair (bp) cassette including the herpes simplex virus thymidine kinase promoter, the hygromycin resistance gene, and the thymidine kinase polyadenylation signal was excised from the plasmid pMEP4 (Invitrogen, San Diego, CA) by digestion with FspI followed by addition of BamHI linkers (5'CGCGGATCCGCG3') (SEQ ID NO: 3) for subsequent digestion with BamHI to isolate the hygromycin-containing fragment. The isolated BamHI-modified fragment was then cloned into the BamHI site of pBS/E4 containing the E4 region to create the plasmid pE4/Hygro containing 8710 bp (Figure 2). The pE4/Hygro plasmid has been deposited with the ATCC as described in Example 3. The complete nucleotide sequence of pE4/Hygro is listed in SEQ ID NO: 4. Position number 1 of the linearized vector corresponds to approximately the middle portion of the pBS/SK+ backbone as shown in Figure 2 as a thin line between the 3' BamHI site in the hygromycin insert and the 3' EcoRI site in the E4 insert. The 5' and 3' ends of the E4 gene are located at respective nucleotide positions 3820 and 707 of SEQ ID NO: 4 while the 5' and 3' ends of the hygromycin insert are located at respective nucleotide positions 3830 and 6470. In the clone that was selected for use, the E4 and hygromycin resistance genes were divergently transcribed.

B. Preparation of a Fiber-Expressing Plasmid for Complementation of Fiber-Gene-Deleted Adenoviruses

To prepare a fiber-encoding construct, primers were designed to amplify the fiber coding region from Ad5 genomic DNA with the addition of unique BamHI and NotI sites at the 5' and 3' ends of the fragment, respectively. The Ad5 nucleotide sequence is available with the GenBank Accession Number M18369. The 5' and 3' primers had the respective nucleotide sequences of 5'ATGGGATCCAAGATGAAGCGCGCAAGACCG3' (SEQ ID NO: 5) and 5'CATAACGCGGCCGCTTCTTTATTCTTGGGC3' (SEQ ID NO: 6), where the inserted BamHI and NotI sites are indicated by underlining. The 5' primer also contained a nucleotide substitution 3 nucleotides 5' of the second ATG codon (C to A) that is the initiation site. The nucleotide substitution was included so as to improve the consensus for initiation of fiber protein translation.

The amplified DNA fragment was inserted into the BamHI and NotI sites of pCDNA3 (Invitrogen) to create the plasmid designated pCDNA3/Fiber having 7148 bp, the plasmid map of which is shown in Figure 3. The parent plasmid contained the CMV promoter, the bovine growth hormone (BHG) terminator and the gene for conferring neomycin resistance. The viral sequence included in this construct corresponds to nucleotides 31040-32791 of the Ad5 genome.

The complete nucleotide sequence of pCDNA3/Fiber is listed in SEQ ID NO: 7 where the nucleotide position 1 corresponds to approximately the middle of the pCDNA3 vector sequence. The 5' and 3' ends of the fiber gene are located at respective nucleotide positions 916 with ATG and 2661 with TAA.

To enhance expression of fiber protein by the constitutive CMV promoter provided by the pcDNA vector, a BglII fragment containing the tripartite leader (TPL) of adenovirus type 5 was excised from pRD112a (Sheay *et al.*, *BioTechniques*, 15:856-862 (1993) and inserted into the BamHI site of pCDNA3/Fiber to create the plasmid pCLF having 7469 bp, the plasmid map of which is shown in Figure 4. The adenovirus tripartite leader sequence, present at the 5' end of all major late adenoviral mRNAs as described by Logan *et al.*, *Proc. Natl. Acad. Sci., USA*, 81:3655-3659 (1984) and Berkner, *BioTechniques*, 6:616-629 (1988), also referred to as a "partial TPL" since it contains a partial exon 1, shows correspondence with the Ad5 leader sequence having three spatially separated exons corresponding to nucleotide positions 6081-6089 (the 3' end of the first leader segment), 7111-7182 (the entire second leader segment), and

- 52 -

9644-9845 (the third leader segment and sequence downstream of that segment). The corresponding cDNA sequence of the partial tripartite leader sequence present in pCLF is listed in SEQ ID NO: 8 bordered by BamHI/BglII 5' and 3' sites at respective nucleotide positions 907-912 to 1228-1233. The nucleotide sequence of an isolated partial TPL of the present invention is also listed separately as SEQ ID NO: 26 with the noted 5' and 3' restriction sites and with the following nucleotide regions identified: 1-6 nt BglII site; 1-18 nt polylinker; 19-27 nt last 9 nt of the first leader segment (exon 1); 28-99 nt second leader segment (exon 2); 100-187 nt third leader segment (exon 3); 188-301 nt contains the nt sequence immediately following the third leader in the genome with an unknown function; and 322-327 nt BglII site.

The pCLF plasmid has been deposited with the ATCC as described in Example 3. The complete nucleotide sequence of pCLF is listed in SEQ ID NO: 8 where the nucleotide position 1 corresponds to approximately the middle of the pcDNA3 parent vector sequence. The 5' and 3' ends of the Ad5 fiber gene are located at respective nucleotide positions 1237-1239 with ATG and 2980-2982 with TAA. The rest of the vector construct has been previously described above.

C. Generation of an Adenovirus Packaging Cell Line Carrying Plasmids Encoding Functional E4 and Fiber Proteins

The 293 cell line was selected for preparing the first adenovirus packaging line as it already contains the E1 gene as prepared by Graham *et al.*, *J. Gen. Virol.*, 36:59-74 (1977) and as further characterized by Spector, *Virol.*, 130:533-538 (1983). Before electroporation, 293 cells were grown in RPMI medium + 10% fetal calf serum. Four x 10⁶ cells were electroporated with 20 µg each of pE4/Hygro DNA and pCLF DNA using a BioRad GenePulser and settings of 300 V, 25 µF. DNA for electroporation was prepared using the Qiagen system according to the manufacturer's instructions (Bio-Rad, Richmond, CA).

Following electroporation, cells were split into fresh complete DMEM + 10% fetal calf serum containing 200 µg/ml Hygromycin B (Sigma, St. Louis, MO).

From expanded colonies, genomic DNA was isolated using the "MICROTURBOGEN" system (Invitrogen) according to manufacturer's instructions. The presence of integrated E4 DNA was assessed by PCR using the primer pair E4R and ORF6L (5'TGCTTAAGCGGCCGCGAAGGAGA AGTCC3') (SEQ ID NO: 9), the latter of which is a 5' forward primer near adenovirus 5 open reading frame 6. Refer to Figure 1 for position of the primers relative to the E4 genes.

- 53 -

One clone, designated 211, was selected exhibiting altered growth properties relative to that seen in parent cell line 293. The 211 clone contained the expected product, indicating the presence of inserted DNA corresponding to most, if not all, of the E4 fragment contained in the pE4/Hygro plasmid. The 211 cell line has been deposited with the ATCC as described in Example 3. This line was further evaluated by amplification using the primer pair E4L/E4R described above, and a product corresponding to the full-length E4 insert was detected. Genomic Southern blotting was performed on DNA restricted with EcoRI and BamHI. The E4 fragment was then detected at approximately one copy/genome compared to standards with the EcoRI/BamHI E4 fragment as cloned into pBS/E4 for use as a labeled probe with the Genius system according to manufacturer's instructions (Boehringer Mannheim, Indianapolis, IN). In DNA from the 211 cell line, the expected labeled internal fragment pE4/Hygro hybridized with the isolated E4 sequences. In addition, the probe hybridized to a larger fragment which may be the result of a second insertion event (Figure 5).

Although the 211 cell line was not selected by neomycin resistance, thus indicating the absence of fiber gene, to confirm the lack of fiber gene, the 211 cell line was analyzed for expression of fiber protein by indirect immunofluorescence with an anti-fiber polyclonal antibody and a FITC-labeled anti-rabbit IgG (KPL) as secondary. No immunoreactivity was detected. Therefore, to generate 211 clones containing recombinant fiber genes, the 211 clone was expanded by growing in RPMI medium and subjected to additional electroporation with the fiber-encoding pCLF plasmid as described above.

Following electroporation, cells were plated in DMEM + 10% fetal calf serum and colonies were selected with 200 µg/ml G418 (Gibco, Gaithersburg, MD). Positive cell lines remained hygromycin resistant. These candidate sublines of 211 were then screened for fiber protein expression by indirect immunofluorescence as described above. The three sublines screened, 211A, 211B and 211R, along with a number of other sublines, all exhibited nuclear staining qualitatively comparable to the positive control of 293 cells infected with AdRSVβgal (1 pfu/cell) and stained 24 hours post-infection.

Lines positive for nuclear staining in this assay were then subjected to Western blot analysis under denaturing conditions using the same antibody. Several lines in which the antibody detected a protein of the expected molecular weight (62 kd for the Ad5 fiber protein) were selected for further study including 211A, 211B and 211R. The 211A cell line has been deposited with ATCC as described in Example 3.

- 54 -

Immunoprecipitation analysis using soluble nuclear extracts from these three cell lines and a semipreparative electrophoresis system demonstrated that the fiber protein expressed is in the functional trimeric form characteristic of the native fiber protein as shown in Figure 6. The predicted molecular weight of a trimerized fiber is 186 kd. The lane marked 293 lacks fiber while the sublines contain detectable fiber. Under denaturing conditions, the trimeric form was destroyed resulting in detectable fiber monomers as shown in Figure 6. Those clones containing endogenous E1, newly expressed recombinant E4 and fiber proteins were selected for use in complementing adenovirus gene delivery vectors having the corresponding adenoviral genes deleted as described in Example 2.

D. Preparation of an E1-Expressing Plasmid for Complementation of E1-Gene-Deleted Adenoviruses

In order to prepare adenoviral packaging cell lines other than those based on the E1-gene containing 293 cell line as described in Example 1C above, plasmid vectors containing E1 alone or in various combinations with E4 and fiber genes are constructed as described below.

The region of the adenovirus genome containing the E1a and E1b gene is amplified from viral genomic DNA by PCR as previously described. The primers used are E1L, the 5' or forward primer, and E1R, the 3' or backward primer, having the respective nucleotide sequences 5'CCG AGCTAGC GACTGAAAATGAG3' (SEQ ID NO: 10) and 5'CCTCTCGAG AGACAGC AAGACAC3' (SEQ ID NO: 11). The E1L and E1R primers include the respective restriction sites NheI and XhoI as indicated by the underlines. The sites are used to clone the amplified E1 gene fragment into the NheI/XhoI sites in pMAM commercially available from Clontech (Palo Alto, CA) to form the plasmid pDEX/E1 having 11152 bp, the plasmid map of which is shown in Figure 7.

The complete nucleotide sequence of pDEX/E1 is listed in SEQ ID NO: 12 where the nucleotide position 1 corresponds to approximately 1454 nucleotides from the 3' end of the pMAM backbone vector sequence. The pDEX/E1 plasmid includes nucleotides 552 to 4090 of the adenovirus genome positioned downstream (beginning at nucleotide position 1460 and ending at 4998 in the pDEX/E1 plasmid) of the glucocorticoid-inducible mouse mammary tumor virus (MMTV) promoter of pMAM. The pMAM vector contains the E. coli *gpt* gene that allows stable transfectants to be isolated using

- 55 -

hypoxanthine/aminopterin/thymidine (HAT) selection. The pMAM backbone occupies nucleotide positions 1-1454 and 5005-11152 of SEQ ID NO: 12.

E. Generation of an Adenovirus Packaging Cell Line Carrying Plasmids Encoding Functional E1, and Fiber Proteins

To create separate adenovirus packaging cell lines equivalent to that of the 211 sublines, 211A, 211B and 211R, as described in Example 1C, alternative cell lines lacking adenoviral genomes are selected for transfection with the plasmid constructs as described below. Acceptable host cells include A549, Hela, Vero and the like cell lines as described in Example 1. The selected cell line is transfected with the separate plasmids, pDEX/E1 and pCLF, respectively for expressing E1, and fiber complementary proteins. Following transfection procedures as previously described, clones containing stable insertions of the two plasmids are isolated by selection with neomycin and HAT. Integration of full-length copy of the E1 gene is assessed by PCR amplification from genomic DNA using the primer set E1L/E1R, as described above. Functional insertion of the fiber gene is assayed by staining with the anti-fiber antibody as previously described.

The resultant stably integrated cell line is then used as a packaging cell system to complement adenoviral gene delivery vectors having the corresponding adenoviral gene deletions as described in Example 2.

F. Preparation of a Plasmid Containing Two or More Adenoviral Genes for Complementing Gene-Deleted Adenoviruses

The methods described in the preceding Examples rely on the use of two plasmids, pE4/Hygro and pCLF, or, pCLF and pDEX/E1 for generating adenoviral cell packaging systems. In alternative embodiments contemplated for use with the methods of this invention, complementing plasmids containing two or more adenoviral genes for expressing of encoded proteins in various combinations are also prepared as described below. The resultant plasmids are then used in various cell systems with delivery plasmids having the corresponding adenoviral gene deletions. The selection of packaging cell, content of the delivery plasmids and

- 56 -

content of the complementing plasmids for use in generating recombinant adenovirus viral vectors of this invention thus depends on whether other adenoviral genes are deleted along with the adenoviral fiber gene, and, if so, which ones.

1. Preparation of a Complementing Plasmid Containing Fiber and E1 Adenoviral Genes

A DNA fragment containing sequences for the CMV promoter, adenovirus tripartite leader, fiber gene and bovine growth hormone terminator is amplified from pCLF prepared in Example 1B using the forward primer 5'GACGGATCGGGAGATCTCC3' (SEQ ID NO: 13), that anneals to the nucleotides 1-19 of the pCDNA3 vector backbone in pCLF, and the backward primer 5'CCGCCTCAGAAGCCATAGAGCC3' (SEQ ID NO: 14) that anneals to nucleotides 1278-1257 of the pCDNA3 vector backbone. The fragment is amplified as previously described and then cloned into the pDEX/E1 plasmid, prepared in Example 1D. For cloning in the DNA fragment, the pDEX/E1 vector is first digested with NdeI, that cuts at a unique site in the pMAM vector backbone in pDEX/E1, then the ends are repaired by treatment with bacteriophage T4 polymerase and dNTPs.

The resulting plasmid containing E1 and fiber genes, designated pE1/Fiber, provides both dexamethasone-inducible E1 function as described for DEX/E1 and expression of Ad5 fiber protein as described above. A schematic plasmid map of pE1/Fiber, having 14455 bp, is shown in Figure 8.

The complete nucleotide sequence of pE1/Fiber is listed in SEQ ID NO: 15 where the nucleotide position 1 corresponds to approximately to 1459 nucleotides from the 3' end of the parent vector pMAM sequence. The 5' and 3' ends of the Ad5 E1 gene are located at respective nucleotide positions 1460 and 4998 followed by pMAM backbone and then separated from the Ad5 fiber from pCLF by the filled-in blunt ended NdeI site. The 5' and 3' ends of the pCLF fiber gene fragment are located at respective nucleotide positions 10922-14223 containing elements as previously described for pCLF.

The resultant pE1/Fiber plasmid is then used to complement one or more delivery plasmids expressing E1 and fiber.

The pE1/Fiber construct is then used to transfect a selected host cell as described in Example 1E to generate stable chromosomal insertions performed as previously described followed by selection on HAT medium. The stable cells are then used as packaging cells as described in Example 2.

- 57 -

2. Preparation of a Complementing Plasmid Containing E4 and Fiber Adenoviral Genes

pCLF prepared as described in Example 1B is partially digested with BglII to cut only at the site in the pCDNA3 backbone. The pE4/Hygro plasmid prepared in Example 1A is digested with BamHI to produce a fragment containing E4. The E4 fragment is then inserted into the BamHI site of pCLF to form plasmid pE4/Fiber. The resultant plasmid provides expression of the fiber gene as described for pCLF and E4 function as described for pE4/Hygro.

A schematic plasmid map of pE4/Fiber, having 10610 bp, is shown in Figure 9. The complete nucleotide sequence of pE4/Fiber is listed in SEQ ID NO: 16 where the nucleotide position 1 corresponds to approximately 14 bp from the 3' end of the parent vector pCDNA3 backbone sequence. The 5' and 3' ends of the Ad5 E4 gene are located at respective nucleotide positions 21 and 3149 followed by fused BglII/BamHI sites and pCDNA3 backbone including the CMV promoter again followed by BglII/BamHI sites. The adenovirus leader sequence begins at nucleotide position 4051 and extends to 4366 followed by fused BamHI/BglII sites and the 5' and 3' ends of the fiber gene located at respective nucleotide positions 4372 and 6124.

Stable chromosomal insertions of pE4/Fiber in host cells are obtained as described above.

Example 2

Preparation of Adenoviral Gene Delivery Vectors Using Adenoviral Packaging Cell Lines

Adenoviral delivery vectors of this invention are prepared to separately lack the combinations of E1/fiber and E4/fiber. Such vectors are more replication-defective than those previously in use due to the absence of multiple viral genes. A preferred adenoviral delivery vector of this invention that is replication competent but only via a non-fiber means is one that only lacks the fiber gene but contains the remaining functional adenoviral regulatory and structural genes. Furthermore, the adenovirus delivery vectors of this invention have a higher capacity for insertion of foreign DNA.

A. Preparation of Adenoviral Gene Delivery Vectors Having Specific Gene Deletions and Methods of Use

To construct the E1/ fiber deleted viral vector containing the LacZ reporter gene construct, two new plasmids were constructed. The plasmid p Δ E1B β gal was constructed as follows. A DNA fragment containing the SV40 regulatory sequences and *E. coli* β -galactosidase gene was isolated from pSV β gal (Promega) by digesting with *VspI*, filling the overhanging ends by treatment with Klenow fragment of DNA polymerase I in the presence of dNTP's and digesting with *Bam* HI. The resulting fragment was cloned into the *Eco*RV and *Bam*HI sites in the polylinker of p Δ E1sp1B (Microbix Biosystems, Hamilton, Ontario) to form p Δ E1B β gal that therefore contained the left end of the adenovirus genome with the *Ela* region replaced by the LacZ cassette (nucleotides 6690 to 4151) of pSV β gal. Plasmid DNA may be prepared by the alkaline lysis method as described by Birnboim and Doly, *Nuc. Acids Res.*, 7:1513-1523 (1978) or by the Quiagen method according to the manufacturer's instruction, from transformed cells used to expand the plasmid. DNA was then purified by CsCl-ethidium bromide density gradient centrifugation. Alternatively, plasmid DNAs may be purified from *E. coli* by standard methods known in the art (e.g. see Sambrook *et al.*)

The second plasmid (pDV44), prepared as described herein, is derived from pBHG10, a vector prepared as described by Bett *et al.*, *Proc. Natl. Acad. Sci., USA*, 91:8802-8806 (1994), now described in International Application Publication Number WO 9500655, with methodology well known to one of ordinary skill in the art and also is commercially available from Microbix, which contains an Ad5 genome with the packaging signals at the left end deleted and the E3 region (nucleotides 28133:30818) replaced by a linker with a unique site for the restriction enzyme *PacI*. An 11.9 kb *Bam*HI fragment, which contains the right end of the adenovirus genome, is isolated from pBHG10 and cloned into the *Bam*HI site of pBS/SK(+) to create plasmid p11.3 having approximately 14,658 bp. A schematic of the plasmid map is shown in Figure 13. The p11.3 plasmid was then digested with *PacI* and *Sall* to remove the fiber, E4, and inverted terminal repeat (ITR) sequences.

This fragment was replaced with a 3.4 kb fragment containing the ITR segments and the E4 gene which was generated by PCR amplification from pBHG10 using the following oligonucleotide sequences (5' TGTACACCG GATCCGGCGCACACC3' SEQ ID NO: 17) and (5'CACAACGAGCTC

- 59 -

AATTAATTAATTGCCACATCCTC3' SEQ ID NO: 18). These primers incorporated sites for *PacI* and *BamHI*. Cloning this fragment into the *PacI* and blunt ended *Sall* sites of the p11.3 backbone resulted in a substitution of the fused ITRs, E4 region and fiber gene present in pBHG10, by the ITRs and E4 region alone. The resultant p11.3 plasmid containing the ITR and E4 regions, now called plasmid pDV43a, was then digested with *BamHI*. This *BamHI* fragment was then used to replace a *BamHI* fragment in pBHG10 thereby creating pDV44 in a pBHG10 backbone.

In an alternative approach to preparing pDV44 with an additional subcloning step to facilitate the incorporation of restriction cloning sites, the following cloning procedure was performed. pDV44 as above was constructed by removing the fiber gene and some of the residual E3 sequences from pBHG10 (Microbix Biosystems). As above, to simplify manipulations, the 11.9 kb *BamHI* fragment including the rightmost part of the Ad5 genome was removed from pBHG10 and inserted into pBS/SK. The resulting plasmid was termed p11.3. The 3.4 kb DNA fragment corresponding to the E4 region and both ITRs of adenovirus type 5 was amplified as described above from pBHG10 using the oligonucleotides listed above and subcloned into the vector pCR2.1 (Invitrogen) to create pDV42. This step is the additional cloning step to facilitate the incorporation of a *Sall* restriction site. pDV42 was then digested with *PacI*, which cuts at a unique site (bold type) in one of the PCR primers, and with *Sall*, which cuts at a unique site in the pCR2.1 polylinker. This fragment was used to replace the corresponding *PacI/XhoI* fragment of p11.3 (the pBS polylinker adjacent to the Ad DNA fragment contains a unique *XhoI* site), creating pDV43. Finally, pDV44 was constructed by replacing the 11.9 kb *BamHI* fragment of pBHG10 by the analogous *BamHI* fragment of pDV43. As generated in the first procedure, pDV44 therefore differs from pBHG10 by the deletion of Ad5 nucleotides 30819:32743 (residual E3 sequences and all but the 3'-most 41 nucleotides of the fiber open reading frame).

Thus, to summarize, the cloning procedures described above result in the production of a fiber-deleted Ad5 genomic plasmid (pDV44) that was constructed by removing the fiber gene and some of the residual E3 sequences from pBHG10 (Figure 16A). pDV44 contains a wild-type E4 region, but only the last 41 nucleotides of the fiber ORF (this sequence was retained to avoid affecting expression of the adjacent E4 transcription unit). Both pBHG10 and pDV44 contain unpackageable Ad5 genomes, and must be rescued by cotransfection and subsequent homologous recombination with DNA carrying functional packaging signals. In order to generate vectors marked with a reporter gene, either pDV44 or pBHG10 was cotransfected with pΔE1Bβgal, which contains the left end of the Ad5

- 60 -

genome with an SV40-driven β -galactosidase reporter gene inserted in place of the E1 region.

In general, and as described below, the method for virus production by recombination of plasmids followed by complementation in cell culture involves the isolation of recombinant viruses by cotransfection of any one of the adenovirus packaging cell systems prepared in Example 1, namely 211A, 211B, 211R, A549, Vero cells, and the like, with plasmids carrying sequences corresponding to viral gene delivery vectors.

A selected cell line is plated in dishes and cotransfected with pDV44 and p Δ E1B β gal using the calcium phosphate method as described by Bett *et al.*, *Proc. Natl. Acad. Sci., USA*, 91:8802-8806 (1994). Recombination between the overlapping adenovirus sequences in the two plasmids leads to the creation of a full-length viral chromosome where pDV44 and p Δ E1B β gal recombine to form a recombinant adenovirus vector having multiple deletions. The deletion of E1 and of the fiber gene from the viral chromosome is compensated for by the sequences integrated into the packaging cell genome, and infectious virus particles are produced. The plaques thus generated are isolated and stocks of the recombinant virus are produced by standard methods.

A pDV44-derived virus is expected to be replication-defective due to the fiber deletion, so that the cells in which it is grown must complement this defect. The 211B cell line (a derivative of 293 cells which expresses the wild-type (wt) AD5 fiber and is equivalent to 211A on deposit with ATCC as described in Example 3) was used for rescue and propagation of the virus described here. pDV44 and p Δ E1B β gal were cotransfected into 211B cells, and the monolayers were observed for evidence of cytopathic effect (CPE). Briefly, for virus construction, cells were transfected with the indicated plasmids using the Gibco Calcium Phosphate Transfection system according to the manufacturer's instructions and observed daily for evidence of CPE.

One of a total of 58 transfected dishes showed evidence of spreading cell death at day 15. A crude freeze-thaw lysate was prepared from these cells and the resulting virus (termed Ad5. β gal. Δ F) was plaque purified twice and then expanded. To prepare purified viral preparations, cells were infected with the indicated Ad and observed for completion of CPE. Briefly, at day zero, 211B cells were plated in DMEM plus 10% fetal calf serum at approximately 1×10^7 cells/150 cm² flask or equivalent density. At day one, the medium was replaced with one half the original volume of fresh DMEM containing the indicated Ad, in this case Ad5. β gal. Δ F, at approximately 100 particles/cell. At day two, an equal volume of medium was

- 61 -

added to each flask and the cells were observed for CPE. Two to five days after infection, cells were collected and virus isolated by lysis via four rapid freeze-thaw cycles. Virus was then purified by centrifugation on preformed 15-40% CsCl gradients ($111,000 \times g$ for three hours at 4°C). The bands were harvested, dialyzed into storage buffer (10 mM Tris-pH 8.1, 0.9% NaCl, and 10% glycerol), aliquoted and stored at -70°C . Purified Ad5. β gal. Δ F virus particles containing human adenovirus Ad5. β gal. Δ F genome (described further below) have been deposited with the ATCC on January 15, 1999 as further described in Example 3.

For viral titering, as necessary in the below Examples, Ad preparations were titered by plaque assay on 211B cells. Cells were plated on polylysine-coated 6 well plates at 1.5×10^6 cells/well. Duplicate dilutions of virus stock were added to the plates in 1 ml/well of complete DMEM. After a five hour incubation at 37°C , virus was removed and the wells overlaid with 2 ml of 0.6% low-melting agarose in Medium 199 (Gibco). An additional 1 ml of overlay was added at five day intervals.

As a control, the first-generation virus Ad5. β gal.wt, which is identical to Ad5. β gal. Δ F except for the fiber deletion, was constructed by cotransfection of pBHG10 and p Δ E1 β gal (Figure 16B). In contrast to the low efficiency of recovery of the fiberless genome (1/58 dishes), all of 9 dishes cotransfected with p Δ E1 β gal and pBHG10 produced virus.

In a preferred embodiment of this invention as more fully described herein and below, a delivery plasmid is prepared that does not require the above-described recombination events to prepare a viral vector having a fiber gene deletion. In one embodiment, a single delivery plasmid containing all the adenoviral genome necessary for packaging but lacking the fiber gene is prepared from plasmid pFG140 containing full-length Ad5 that is commercially available from Microbix. The resultant delivery plasmid referred to as pFG140-f is then used with pCLF stably integrated cells as described above to prepare a viral vector lacking fiber. In a preferred aspect of this invention, the fiber gene is replaced with a therapeutic gene of interest for preparing a therapeutic delivery adenoviral vector. Other embodiments including production of fiberless vector with a complete TPL are described in Example 5.

Vectors for the delivery of any desired gene and preferably a therapeutic gene are prepared by cloning the gene of interest into the multiple cloning sites in the polylinker of commercially available p Δ E1sp1B (Microbix Biosystems), in an analogous manner as performed for preparing pE1 β gal as described above. The same cotransfection and recombination procedure is then followed as described herein to obtain viral gene delivery vectors as further discussed in later Examples.

1. Characterization of the Ad5. β gal. Δ F Genome

To confirm that the vector genomes had the expected structures and that the fiber gene was absent from the Ad5. β gal. Δ F chromosome, the DNA isolated from viral particles was analyzed. Briefly, purified viral DNA was obtained by adding 10 μ l of 10 mg/ml proteinase K, 40 μ l of 0.5 M EDTA and 50 μ l of 10% SDS to 800 μ l of adenovirus-containing culture supernatant. The suspension was then incubated at 55°C for 60 minutes. The solution was then extracted once with 400 μ l of a 24:1 mixture of chloroform:isoamyl alcohol. The aqueous phase was then removed and precipitated with sodium acetate/ethanol. The pellet was washed once with 70% ethanol and lightly dried. The pellet was then suspended in 40 μ l of 10 mM Tris-HCl, pH 8.0, 1 mM EDTA. Genomic DNA from both Ad5. β gal.wt and Ad5. β gal. Δ F produced the expected restriction patterns (Figure 17A) following digestion with either EcoRI (Figure 17B) or with NdeI (data not shown). Southern blotting, performed with standard methods, with labeled fiber DNA as a probe demonstrated the presence of fiber sequence in Ad5. β gal.wt but not in Ad5. β gal. Δ F DNA (Figure 17C). As a positive control, the blot was stripped and reprobed with labeled E4 sequence. Fiber and E4 sequences were detected by using labeled inserts from pCLF and pE4/Hygro, respectively. As expected, E4 signal was readily detectable in both genomes at equal intensities (Figure 17C).

The complete nucleotide sequence of Ad5. β gal. Δ F is presented in SEQ ID NO: 27 and is contained in the virus particle on deposit with ATCC.

2. Characterization of the Fiberless Adenovirus Ad5. β gal. Δ F

To verify that Ad5. β gal. Δ F was fiber-defective, 293 cells (which are permissive for growth of E1-deleted Ad vectors but do not express fiber) were infected with Ad5. β gal. Δ F or with Ad5. β gal.wt. Twenty-four hours post infection, the cells were stained with polyclonal antibodies directed either against fiber or against the penton base protein. Cells infected with either virus were stained by the anti-penton base antibody, while only cells infected with the Ad5. β gal.wt control virus reacted with the anti-fiber antibody. This confirms that the fiber-deleted Ad mutant does not direct the synthesis of fiber protein.

3. Growth of the Fiber-Deleted Ad5. β gal. Δ F Vector in Complementing Cells

- 63 -

Ad5. β gal. Δ F was found to readily be propagated in 211B cells. As assayed by protein concentration, CsCl-purified stocks of either Ad5. β gal. Δ F or Ad5. β gal.wt contained similar numbers of viral particles (Table 1), and the particles appeared to band normally on CsCl gradients. However, infectivity of the Ad5. β gal. Δ F particles was lower than the Ad5. β gal.wt control, as indicated by an increased particle/PFU ratio (Table 1). This is likely due to a reduced amount of fiber protein incorporated into mutant particles during growth in the

Virus	CsCl-purified prepn	Cell line	Particles/ml ^a	PFU/ml ^b	Particle /PFU ratio	Fiber source
Ad5.βgal.wt	1	211 B	7.4×10^{11}	7.5×10^{10}	10	Ad chromosome
	2	211 B	3.0×10^{11}	5.0×10^9	60	Ad chromosome
Ad5.βgal.ΔF	3	211 B	7.7×10^{11}	3.5×10^8	2200	Packaging cells
	4	211 B	1.9×10^{12}	2.3×10^9	808	Packaging cells
	5	293	4.5×10^{11}	9.5×10^6	47400	None
	6	293	3.4×10^{11}	3.5×10^7	9700	None

^aCalculated from viral protein concentration (1ug of protein = 4×10^9 particles).

^bAssayed by plaquing on 211B cells.

Table 3

*Particle numbers and infectious titers of representative adenovirus preps. Each line represents a single CsCl-purified preparation of the indicated virus. Particle numbers were calculated from viral protein concentration (1 μg protein = 4×10^9 particles). Pfu was assayed by plaquing on 211B cells (see above). 211B cells (see below). Ad5.βgal.ΔF was also found to plaque more slowly than the control virus. When plated on 211B cells, Ad5.βgal.wt plaques appeared within 5-7 days, while plaques of Ad5.βgal.ΔF continued to appear until as much as 15-18 days post infection. Despite their slower formation, the morphology of Ad5.βgal.ΔF plaques was essentially normal.

4. Production of Fiberless Ad5. β gal. Δ F Particles

As Ad5. β gal. Δ F represents a true fiber null mutation and its stocks are free of helper virus, the fiber mutant phenotype was readily investigated. A single round of growth in cells (such as 293) which do not produce fiber generating a homogeneous preparation of fiberless Ad allowed for the determination of whether such particles would be stable and/or infectious. Either Ad5. β gal.wt or Ad5. β gal. Δ F was grown in 293 or 211B cells, and the resulting particles purified on CsCl gradients as previously described. Ad5. β gal. Δ F particles were readily produced in 293 cells at approximately the same level as the control virus and behaved similarly on the gradients, indicating that there was not a gross defect in morphogenesis of fiberless capsids (Table 1).

As shown in Figure 18, particles of either virus contained similar amounts of penton base regardless of the cell type in which they were grown. This demonstrated that fiber is not required for assembly of the penton base complex into virions. However, as predicted, the Ad5. β gal. Δ F particles produced in 293 cells did not contain fiber protein. 211B-grown Ad5. β gal. Δ F also contained less fiber than the Ad5. β gal.wt control virus (Figure 18). Importantly, the infectivities of the different viral preparations on epithelial cells (Table 1) correlated with the amount of fiber protein present. The fiberless Ad particles were several thousand-fold less infectious than the first-generation vector control on a per-particle basis, while infectivity of 211B-grown Ad5. β gal. Δ F was only 50-100 fold less than that of Ad5. β gal.wt. These studies confirmed fiber's crucial role in infection of epithelial cells via CAR binding.

5. Composition and Structure of the Fiberless Ad5. β gal. Δ F Particles

The proteins contained in particles of 293-grown Ad5. β gal. Δ F were compared to those in Ad5. β gal.wt, to determine whether proteolysis or particle assembly was defective in this fiber null mutant (data not shown). The overall pattern of proteins in the fiberless particles was observed to be quite similar to that of a first-generation vector, with the exception of reduced intensity of the composite band resulting from both proteins IIIa and IV (fiber) (data not shown). The fiberless particles also had a reduced level of protein VII. Although substantial amounts of uncleaved precursors

to proteins VI, VII, and VIII were not seen, it is possible that the low-molecular weight bands migrating ahead of protein VII represent either aberrantly cleaved viral proteins or their breakdown products.

Cryo-electron microscopy was used to more closely examine the structure of the 293 grown Ad5.βgal.ΔF and of Ad5βgal.wt. The fiber, which consists of an extended stalk with a knob at the end, was faintly visible in favorable orientations of wild-type Ad5 particles, but not in images of the fiberless particles (data not shown). Filamentous material likely corresponding to free viral DNA was seen in micrographs of fiberless particles. This material was also present in micrographs of the first-generation control virus, albeit at much lower levels.

Three-dimensional image reconstructions of fiberless and wild-type particles at ~20 Å resolution showed similar sizes and overall features, with the exception that fiberless particles lacked density corresponding to the fiber protein. The densities corresponding to other capsid proteins, including penton base and proteins IIIa, VI, and IX, were comparable in the two structures. This confirms that absence of fiber does not prevent assembly of these components into virions. The fiber was truncated in the wild-type structure as only the lower portion of its flexible shaft follows icosahedral symmetry. The RGD protrusions on the fiberless penton base were angled slightly inward relative to those of the wild-type structure. Another difference between the two penton base proteins was that there is a ~30 Å diameter depression in the fiberless penton base around the five-fold axis where the fiber would normally sit. The Ad5 reconstructions confirm that capsid assembly, including addition of penton base to the vertices, is able to proceed in the complete absence of fiber.

6. Integrin-Dependent Infectivity of Fiberless Ad5.βgal. ΔF Particles

While attachment via the viral fiber protein is a critical step in the infection of epithelial cells, an alternative pathway for infection of certain hematopoietic cells has been described. In this case, penton base mediates both binding to the cells (via β2 integrins) and internalization (through interaction with αv integrins). Particles lacking fiber might therefore be expected to be competent for infection of these cells, even though on a per-particle basis they are several thousand-fold less infectious than normal Ad vectors on epithelial cells.

To investigate this, THP-1 monocytic cells were infected with Ad5. β gal.wt or with Ad5. β gal. Δ F grown in the absence of fiber. Infection of THP-1 cells was assayed by infecting 2×10^5 cells at the indicated m.o.i. in 0.5 ml of complete RPMI. Forty-eight hours post-infection, the cells were fixed with glutaraldehyde and stained with X-gal, and the percentage of stained cells was determined by light microscopy.

The results of the infection assay showed that the fiberless particles were only a few-fold less infectious than first-generation Ad on THP-1 cells (Figure 19A). In contrast to this, very large differences were seen in plaquing efficiency on epithelial (211B) cells (Table 1). Infection of THP-1 cells by either Ad5. β gal. Δ F or Ad5. β gal.wt was not blocked by an excess of soluble recombinant fiber protein, but could be inhibited by the addition of recombinant penton base (Figure 19B). These results indicate that the fiberless Ad particles use a fiber-independent pathway to infect these cells. Furthermore, the lack of fiber protein did not prevent Ad5. β gal. Δ F from internalizing into the cells and delivering its genome to the nucleus, demonstrating that fiberless particles are properly assembled and are capable of uncoating.

The foregoing results with the recombinant viruses thus produced indicates that they can be used as gene delivery tools both in cultured cells and *in vivo* as described more fully in the Examples. For example, for studies of the effectiveness and relative immunogenicity of multiply-deleted vectors, virus particles are produced by growth in the packaging lines described in Example 1 and are purified by CsCl gradient centrifugation. Following titering, virus particles are administered to mice via systemic or local injection or by aerosol delivery to lung. The LacZ reporter gene allows the number and type of cells which are successfully transduced to be evaluated. The duration of transgene expression is evaluated in order to determine the long-term effectiveness of treatment with multiply-deleted recombinant adenoviruses relative to the standard technologies which have been used in clinical trials to date. The immune response to the improved vectors described here is determined by assessing parameters such as inflammation, production of cytotoxic T lymphocytes directed against the vector, and the nature and magnitude of the antibody response directed against viral proteins.

Versions of the vectors which contain therapeutic genes such as CFTR for treatment of cystic fibrosis or tumor suppressor genes for cancer treatment are evaluated in the animal system for safety and efficiency of gene transfer and expression. Following this evaluation, they are used as experimental therapeutic agents in human clinical trials.

B. Retargeting of Adenoviral Gene Delivery Vectors by Producing Viral Particles Containing Different or Altered Fiber Proteins

As the specificity of adenovirus binding to target cells is largely determined by the fiber protein, viral particles that incorporate modified fiber proteins or fiber proteins from different adenoviral serotypes (pseudotyped vectors) have different specificities. Thus, the methods of expression of the native Ad5 fiber protein in adenovirus packaging cells as described above is also applicable to production of different fiber proteins.

In one aspect of invention, chimeric fiber proteins are produced according to the methods of Stevenson *et al.*, *J. Virol.*, 69:2850-2857 (1995). The authors showed that the determinants for fiber receptor binding activity are located in the head domain of the fiber and that isolated head domain is capable of trimerization and binding to cellular receptors. The head domains of adenovirus type 3 (Ad3) and Ad5 were exchanged in order to produce chimeric fiber proteins. Similar constructs for encoding chimeric fiber proteins for use in the methods of this invention are contemplated. Thus, instead of the using the intact Ad5 fiber-encoding construct prepared in Example 1 as a complementing viral vector in adenoviral packaging cells, the constructs described herein are used to transfect cells along with E4 and/or E1-encoding constructs.

Briefly, full-length Ad5 and Ad3 fiber genes were amplified from purified adenovirus genomic DNA as a template. The Ad5 and Ad3 nucleotide sequences are available with the respective GenBank Accession Numbers M18369 and M12411. Oligonucleotide primers are designed to amplify the entire coding sequence of the full-length fiber genes, starting from the start codon, ATG, and ending with the termination codon TAA. For cloning purposes, the 5' and 3' primers contain the respective restriction sites BamHI and NotI for cloning into pcDNA plasmid as described in Example 1A. PCR is performed as described above.

The resultant products are then used to construct chimeric fiber constructs by PCR gene overlap extension, as described by Horton *et al.*, *BioTechniques*, 8:525-535 (1990). The Ad5 fiber tail and shaft regions (5TS; the nucleotide region encoding amino acid residue positions 1 to 403) are connected to the Ad3 fiber head region (3H; the nucleotide region encoding amino acid residue positions 136 to 319) to form the 5TS3H fiber chimera. Conversely, the Ad3 fiber tail and shaft regions (3TS; the nucleotide region encoding amino acid residues positions 1 to 135) are

connected to the Ad5 fiber head region (5H; the nucleotide region encoding the amino acid residue positions 404 to 581) to form the 3TS5H fiber chimera. The fusions are made at the conserved TLWT (SEQ ID NO: 19) sequence at the fiber shaft-head junction.

The resultant chimeric fiber PCR products are then digested with BamHI and NotI for separate directional ligation into a similarly digested pcDNA 3.1. The TPL sequence is then subcloned into the BamHI as described in Example 1A for preparing an expression vector for subsequent transfection into 211 cells as described above or into the alternative packaging cell systems as previously described. The resultant chimeric fiber construct-containing adenoviral packaging cell lines are then used to complement adenoviral delivery vectors as previously described. Other fiber chimeric constructs are obtained using a similar approach with the various adenovirus serotypes known.

In an alternative embodiment, the methods of this invention contemplate the use of the modified proteins including novel epitopes as described by Michael *et al.*, *Gene Therapy*, 2:660-668 (1995) and in International Publication WO 95/26412. Both publications describe the construction of a cell-type specific therapeutic viral vector having a new binding specificity incorporated into the virus concurrent with the destruction of the endogenous viral binding specificity. In particular, the authors described the production of an adenoviral vector encoding a gastrin releasing peptide (GRP) at the 3' end of the coding sequence of the Ad5 fiber gene. The resulting fiber-GRP fusion protein was expressed and shown to assemble functional fiber trimers that were correctly transported to the nucleus of HeLa cells following synthesis.

Based on the teachings in the paper and International Publication, similar constructs are contemplated for use in the complementing adenoviral packaging cell systems of this invention for generating new adenoviral gene delivery vectors that are targetable, replication-deficient and less immunogenic. Heterologous ligands contemplated for use herein to redirect fiber specificity range from as few as 10 amino acids in size to large globular structures, some of which necessitate the addition of a spacer region so as to reduce or preclude steric hindrance of the heterologous ligand with the fiber or prevent trimerization of the fiber protein. The ligands are inserted at the end or within the linker region. Preferred ligands include those that target specific cell receptors or those that are used for coupling to other moieties such as biotin and avidin.

A preferred spacer includes a short 12 amino acid peptide linker composed of a series of serines and alanine flanked by a proline residue at each end. One of ordinary skill in the art is familiar with the preparation of linkers to accomplish sufficient protein presentation and for altering the binding specificity of the fiber protein without compromising the cellular events that follow viral internalization. Moreover, within the context of this invention, preparation of modified fibers having ligands positioned internally within the fiber protein and at the carboxy terminus as described below are contemplated for use with the methods described herein.

The preparation of a fiber having a heterologous binding ligand is prepared essentially as described in the above-cited paper. Briefly, for the ligand of choice, site-directed mutagenesis is used to insert the coding sequence for a linker into the 3' end of the Ad5 fiber construct in pCLF as prepared in Example 1.

The 3' or antisense or mutagenic oligonucleotide encodes a preferred linker sequence of ProSerAlaSerAlaSerAlaSerAlaProGlySer (SEQ ID NO: 20) followed by a unique restriction site and two stop codons, respectively, to allow the insertion of a coding sequence for a selected heterologous ligand and to ensure proper translation termination. Flanking this linker sequence, the mutagenic oligonucleotide contains sequences that overlap with the vector sequence and allow its incorporation into the construct. Following mutagenesis of the pCLF sequence adding the linker and stop codon sequences, a nucleotide sequence encoding a preselected ligand is obtained, linkers corresponding to the unique restriction site in the modified construct are attached and then the sequence is cloned into linearized corresponding restriction site. The resultant fiber-ligand construct is then used to transfect 211 or the alternative cell packaging systems previously described to produce complementing viral vector packaging systems for use with the methods of this invention.

In a further embodiment, intact fiber genes from different Ad serotypes are expressed by 211 cells or an alternative packaging system as previously described. A gene encoding the fiber protein of interest is first cloned to create a plasmid analogous to pCLF, and stable cell lines producing the fiber protein are generated as described above for Ad5 fiber. The adenovirus vector described which lacks the fiber gene is then propagated in the cell line producing the fiber protein relevant for the purpose at hand. As the only fiber gene present is the one in the packaging cells, the adenoviruses produced contain only the fiber protein of interest and therefore have the binding specificity conferred by the complementing protein. Such viral particles are used in studies such as those described above to determine their properties in experimental animal systems.

Example 3

Deposit of Materials

The following cell lines and plasmids have been deposited on September 25, 1996, with the American Type Culture Collection, 10801 University Blvd, Manassas, Virginia, USA (ATCC) under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty): Plasmid pE4/Hygro (accession number 97739), Plasmid pCLF (accession number 97737), 211 Cell Line (accession number CRL-12193) and 211A Cell Line (accession number CRL-12194)

The following virus, Ad5. β gal. Δ F, deposit was deposited on January 15, 1999, with the ATCC as listed above and provided with accession number VR2636.

Additionally, plasmids pDV60, pDV67, pDV69, pDV80 and pDV90 were also deposited at the ATCC on 5 January, 2000 and provided with accession numbers PTA-1144, PTA-1145, PTA-1146, PTA-1147 and PTA-1148 respectively.

Example 4

Complementation of Fiber-Defective and Fiber-Modified Virus

The native fiber protein is a homotrimer (Henry L.J. *et al.*, *J. Virol.* 68:5239-5246 (1994)), and trimerization is essential for assembly of the penton/fiber complex (Novelli A *et al.*, *J. Biol. Chem.* 266:9299-9303 (1991)). To assess the multimeric structure of the recombinant fiber protein produced by the cell lines, cells were labeled with 50 μ Ci/ml [35 S] Translabel (ICN) for two hours at 37°C, lysed in RIPA buffer, and fiber protein was immunoprecipitated as described (Harlow E *et al.*, *Antibodies*. Cold Spring Harbour Laboratory, Cold Spring Harbor (1988). Immune complexes were collected on Protein A-Sepharose beads (Pierce), extensively washed with RIPA buffer, and incubated at room temperature in 0.1 M triethylamine, pH 11.5 to release bound fiber protein. A portion of the precipitated fiber was electrophoresed on a 8% SDS-PAGE gel under denaturing (1% SDS in loading buffer, samples boiled for 5 minutes) or semi-native (0.1% SDS in loading buffer, samples not heated) conditions.

As seen in Fig. 13, lines 211A, 211B, and 211R, but not the control 293 cells, expressed an immunologically reactive protein which migrated at the predicted molecular weight for trimer (186 kD) under seminaive conditions and for monomer

(62 kD) under denaturing conditions. The behavior of the precipitated fiber was indistinguishable from that of purified baculovirus-produced recombinant Ad2 fiber (Wickham T *et al.*, *Cell* 73:309-319 (1993)) (the 58 kD Ad2 and 62 kD Ad5 fibers have very similar mobilities under these conditions).

To determine whether the fiber-expressing lines could support the growth of a fiber-defective adenovirus, we performed one-step growth experiments using the temperature-sensitive fiber mutant Ad H5ts142 (the gift of Harold Ginsberg). At the restrictive temperature (39.5°C), this mutant produces an underglycosylated fiber protein which is not incorporated into mature virions (Chee-Sheung C. C *et al.*, *J. Virol* 42: 932-950 (1982)). This results in the accumulation of non-infectious viral particles. We asked whether the recombinant fiber protein expressed by our cell lines could complement the H5ts142 defect and rescue viral growth.

Cell lines 293, 211A, 211B and 211R (2×10^6 cells/sample) were infected with H5ts142 at 10 pfu/cell. 48 hours later, cells were detached with 25 mM EDTA and virus was harvested by four rapid freeze-thaw cycles. Debris was removed by a 10 minute spin at 1500 x g, and viral titers determined by fluorescent focus assay (Thiel J.F *et al.*, *Proc. Soc. Exp. Biol. Med.* 125:892-895 (1967)) on SW480 cells with a polyclonal anti-penton base Ab (Wickham T *et al.*, *Cell* 73:309-319 (1993)). As shown in Fig. 14, the fiber mutant virus replicated to high titers in 293 cells at 32.5°C (the permissive temperature), but to a much lower extent at the restrictive temperature of 39.5°C. The fiber-producing packaging lines 211A, 211B, or 211R supported virus production at 39°C to levels within two- to three-fold of those seen at the permissive temperature in 293 cells, indicating that these cells provided partial complementation of the fiber defect.

Interestingly, virus yields from the fiber-producing cell lines were also somewhat higher than those from 293 cells at 32.5°C (the 'permissive' temperature). This suggests that fiber produced by the ts142 virus may be partially defective even at the permissive temperature. Alternatively, a non-specific increase in adenoviral titer could result when viruses are grown in the packaging cells, by a mechanism not involving fiber complementation. However, it was found that viruses with wild type fiber genes (such as Ad.RSVβgal) replicate to identical levels either in our packaging lines or in 293 cells (data not shown). Taken together, these results demonstrate that the observed increase in H5ts142 growth is due to specific complementation of the fiber mutation.

Even in the fiber-expressing cell lines, the fiber mutant grows to higher titers at 32°C than at 39.5°C. This incomplete complementation may be due to the

packaging lines' expression of fiber at a level somewhat below that seen in a wild-type infection (data not shown). A recent study reported an E4-deleted vector which coincidentally reduced fiber protein expression, resulting in a large reduction in the titer of virus produced (Brough *et al.*, *J. Virol.* 70:6497-6501 (1996)). Another possibility is that the defective ts142 fiber protein produced at the restrictive temperature might form complexes with some of the wild type protein produced by the cells and prevent its assembly into particles.

Although the fiber proteins of different Ad serotypes differ in the length of their shaft domains and in their receptor-binding knob domains, the N-terminal regions responsible for interaction with the viral penton base are highly conserved (Arnberg *et al.*, *Virology* 227:239-244 (1997)) (Figure 15A). This suggests that fibers from many viral serotypes, with their different cell-binding specificities, may be amenable for use in producing gene delivery vectors.

In order to determine whether the recombinant Ad5 fiber produced by the packaging cells could be incorporated into particles of another adenovirus serotype, adenovirus type 3 was grown either in fiber-producing cell lines or in 293 cells. Viral particles were purified by two sequential centrifugations (3 h at 111,000 x g) on preformed 15-40% CsCl gradients to remove soluble cellular proteins and then dialyzed extensively against 10 mM Tris-HCl, pH 8.1, 150 mM NaCl, 10% glycerol. Ad5 fiber protein was detected by immunoblotting using the polyclonal anti-fiber serum, followed by detection with a horseradish peroxidase-conjugated goat anti-rabbit antibody (Kirkegaard and Perry Laboratories) and the ECL chemiluminescence substrate (Amersham). The purified Ad3 particles contained Ad5 fiber protein after a single passage through a fiber-expressing cell line but not after passage through 293 cells (Figure 15B). Previous work has demonstrated that Ad2 fiber is capable of interacting *in vitro* with Ad3 penton base (Fender *et al.*, *Nature Biotech.* 15:52-56 (1997)), and our result demonstrates that the type 5 fiber protein produced by the cells is capable of assembling into complete Ad3 particles.

A vector based on Ad5 but containing the gene for the Ad7 fiber protein has been described (Gall J. *et al.*, *J. Virol.* 70:2116-2123 (1996)), as well as Ads containing chimeric fiber genes (Krasnykh *et al.*, *J. Virol.* 70:6839-6846 (1996) and Stevenson *et al.*, *J. Virol.* 69:2850-2857 (1995)). Chimeric Ad5/Ad3 vectors have also been reported (Stevenson, S. *et al.*, *J. Virol.* 71:4782-4790, (1997)). Addition of a short peptide linker to the fiber in order to confer binding to a different cellular protein has also been reported (Michael *et al.*, *Gene Therapy* 2:660-668 (1995)). By

using packaging technology such as that presented here, Ad vectors equipped with different fiber proteins may be produced simply by growth in cells expressing the fiber of interest, without the time-consuming step of generating a new vector genome for each application.

Replacing or modifying the fiber gene in the vector chromosome would also require that the new fiber protein bind a receptor on the surface of the cells in which it is to be grown. The packaging cell approach will allow the generation of Ad particles containing a fiber which can no longer bind to its host cells, by a single round of growth in cells expressing the desired fiber gene. This will greatly expand the repertoire of fiber proteins which can be incorporated into particles, as well as simplifying the process of retargeting gene delivery vectors.

Finally, a novel fiber-independent pathway of infection has recently been described in hematopoietic cells, in which penton base provides the initial virus-cell interaction by binding to integrin $\alpha_5\beta_1$ (Huang S. *et al.*, *J. Virol* 70: 4502-4508 (1996)). This suggests that viral particles lacking fiber protein may be useful in targeting gene delivery to specific cell types via this pathway.

Example 5

Preparation of Alternative TPLs

The present invention contemplates the use of tripartite leader sequences (TPLs) that are useful in enhancing the expression of complementing adenoviral proteins, particularly fiber protein, for use in preparing an adenoviral gene delivery vector. One preferred TPL is the complete Ad5 tripartite leader contained in complementing vectors such as pDV67 and pDV69, both of which are prepared as described below. The complete Ad5 TPL was constructed by assembling PCR fragments. First, the third TPL exon (exon 3) (nt 9644-9731 of the Ad5 genome) was amplified from Ad5 genomic DNA using the synthetic oligonucleotide primers 5'CTCAACAATTGTGGATCCGTACTCC3' (SEQ ID NO: 28) and 5'GTGCTCAGCAGATCTTGCGACTGTG3' (SEQ ID NO: 29). The resulting product was cloned to the BamHI and BglII sites of pΔE1Sp1a (Microbix Biosystems) using novel sites in the primers (shown in bold) to create plasmid pDV52. A fragment corresponding to the first TPL exon (exon 1), the natural first intron (intron 1), and the second TPL exon (exon 2) (Ad5 nt 6049-7182) was then amplified using primers 5'GGCGCGTTCCGGATCCACTCTCTTCC3' (SEQ ID NO:30) and 5'CTA CATGCTAGGCAGATCTCGTTCGGAG3' (SEQ ID NO: 31), and cloned into the

BamHI site of pDV52 (again using novel sites in the primers) to create pDV55. This plasmid contains a 1.2 kb BamHI/BglII fragment consisting of the first TPL exon, the natural first intron, and the fused second and third TPL exons. The nucleotide sequence of the complete TPL containing the noted 5' and 3' restriction sites is shown in SEQ ID NO: 32 with the following nucleotide regions identified: 1-6 nt BamHI site; 7-47 nt first leader segment (exon 1); 48-1068 nt natural first intron (intron 1); 1069-1140 nt second leader segment (exon 2); 1141-1146 nt fused BamHI and BglII sites; 1147-1234 nt third leader segment (exon 3); and 1235-1240 nt BglII site.

TPLs fragments containing two of the three exons, exons in non-native order, or containing either the first or second TPL intron are also constructed for use in preparing complementing plasmids for use in the methods of the present invention. Briefly, DNA fragments containing any combination of 2 TPL exons can be constructed as follows: Exon 1 is amplified from genomic DNA as prepared above by using the oligonucleotides 5'GGCGCGTTCGGATCCACTCTCTTCC3' (SEQ ID NO: 33) and 5'GGGAGTAGATCTCCCAACAG3' (SEQ ID NO: 34). Exon 2 is similarly amplified from the same genomic DNA using oligonucleotides 5'CCCTTTTTTTTGGATCCCTCGCGG3' (SEQ ID NO: 35) and 5'CTACATGCTAGGCAGATCTCGTTCGGAG3' (SEQ ID NO: 36). Exon 3 is amplified using the oligonucleotides 5'CTCAACAATTGTTGGATCCGTA CTCC3' (SEQ ID NO: 37) and 5'GTGCTCAGCAGATCTTGCGACTGTG3' (SEQ ID NO: 38).

The amplified exons are ligated together in any desired number and/or order by virtue of the unique BamHI and BglII restriction sites (bold) in the primers for subsequent ligation into a construct analogous to pDV67, prepared as described below, for expression of viral structural genes.

Similarly, a fragment consisting of the first TPL exon (exon 1), the native first intron (intron 1), and the second TPL exon (exon 2) is produced by amplification from Ad5 genomic DNA with the oligonucleotide pair 5'GGCGCGTTCGGATCC ACTCTCTTCC3' (SEQ ID NO: 39) and 5'CTACATGCTAGGCAGATCT CGTTCGGAG3' (SEQ ID NO: 40). Finally, a fragment consisting of the second TPL exon (exon 2), the native second intron (intron 2), and the third TPL exon (exon 3) is produced by amplification using the oligonucleotides 5'CCCTTTTTTTTGGATCC CTCGCGG3' (SEQ ID NO: 41) and 5'GTGCTCAGCAGATCTTGCGACTGTG3' (SEQ ID NO: 42). Either of the intron-containing fragments are used either alone or in combination with another TPL fragment(s) in constructs analogous to pDV67. Introns in addition to adenoviral intron 1 used herein that have been shown to

increase the expression of recombinant proteins when included in expression constructs include SV40 VP1 intron, rabbit β -globin intron among others. The use of these alternative intron sequences are contemplated for use in preparing a TPL in the present invention.

Example 6
Preparation and Use of Adenoviral Packaging Cell Lines
Containing Plasmids Containing Alternative TPLs

Plasmids were first constructed as described below that contained TPLs are described above. The resultant plasmids containing different selectable markers such as neomycin or zeocin were then used to prepare stable cell lines for use as complementing vectors for preparing adenoviral vectors for use in the present invention. In a preferred embodiment, the resulting cell lines represent improvements over preexisting fiber-complementing cell lines in that fiber expression is enhanced with the use of alternative TPLs.

A. pDV60

pDV60 was constructed by inserting this TPL cassette of SEQ ID NO: 32 into the BamHI site upstream of the Ad5 fiber gene in pcDNA3/Fiber, a neomycin selectable plasmid, prepared as described in Example 1 and also as described by Von Seggern *et al.*, *J. Gen Virol.*, 79: 1461 (1998). The nucleotide sequence of pDV60 is listed in SEQ ID NO: 43.

B. pDV61

To construct pDV61, an Asp718/NotI fragment containing the CMV promoter, partial Ad5 TPL, wildtype Ad5 fiber gene, and bovine growth hormone terminator was transferred from pCLF, prepared as described in Example 1 and also as described by Von Seggern *et al.*, *J. Gen Virol.*, 79: 1461 (1998), to a zeocin selectable cloning vector referred to as pCDNA3.1/Zeo (+) (commercially available from Invitrogen and the sequence is also available).

C. pDV67

In an analogous process, pDV67 containing complete TPL was constructed by transferring an Asp 718/XbaI fragment from pDV60 to the pcDNA3.1/Zeo(+) backbone. The nucleotide sequence of pDV67 is listed in SEQ ID NO: 44.

D. pDV69

To prepare pDV69 containing a modified fiber protein, the chimeric Ad3/Ad5 fiber gene was amplified from pGEM5TS3H (Stevenson *et al.*, *J. Virol.*, 69: 2850-2857, 1995)) using the primers 5'ATGGGATCAAGATGAAGCGCGCAAGACCG3' (SEQ ID NO: 45) and 5'CACTATAGCGGCCGCGCATTCTCAGTCATCTT3' (SEQ ID NO: 46), and cloned to the BamHI and NotI sites of pcDNA3.1/Zeo(+) via novel BamHI and NotI sites engineered into the primers to create pDV68. Finally, the complete TPL fragment described above was then added to the unique BamHI site of pDV68 to create pDV69. The nucleotide sequence of pDV69 is listed in SEQ ID NO: 47.

E. Preparation of Stable Adenovirus Packaging Cell Lines

E1-2a S8 cells are derivatives of the A549 lung carcinoma line (ATCC # CCL 185) with chromosomal insertions of the plasmids pGRE5-2.E1 (also referred to as GRE5-E1-SV40-Hygro construct and listed in SEQ ID NO: 48) and pMNeoE2a-3.1 (also referred to as MMTV-E2a-SV40-Neo construct and listed in SEQ ID NO: 49), which provide complementation of the adenoviral E1 and E2a functions, respectively. This line and its derivatives were grown in Richter's modified medium (BioWhittaker) + 10% FCS. E1-2a S8 cells were electroporated as previously described (Von Seggern *et al.*, *J. Gen Virol.*, 79: 1461 (1998)) with pDV61, pDV67, or with pDV69, and stable lines were selected with zeocin (600 µg/ml). The cell line generated with pDV61 is designated 601. The cell line generated with pDV67 is designated 633 while that generated with pDV69 is designated 644. Candidate clones were evaluated by immunofluorescent staining with a polyclonal antibody raised against the Ad2 fiber. Lines expressing the highest level of fiber protein were further characterized.

For the S8 cell complementing cell lines, to induce E1 expression, 0.3 µM of dexamethasone was added to cell cultures 16-24 hours prior to challenge with virus for optimal growth kinetics. For preparing viral plaques, 5 X 10⁵ cells/well in 6 well plates are prepared and pre-induced with the same concentration of dexamethasone

the day prior to infection with 0.5 μ M included at a final concentration in the agar overlay after infection.

F. Development of Cell Lines for Complementation of E1⁻/E2a⁻ Vectors

This example shows the construction of S.8 cells

The Adenovirus 5 genome was digested with *ScaI* enzyme, separated on an agarose gel, and the 6,095 bp fragment comprising the left end of the virus genome was isolated. The complete Adenovirus 5 genome is registered as Genbank accession #M73260, incorporated herein by reference, and the virus is available from the American Type Culture Collection, Manassas, Virginia, U.S.A., under accession number VR-5. The *ScaI* 6,095 bp fragment was digested further with *Clal* at bp 917 and *BglII* at bp 3,328. The resulting 2,411 bp *Clal* to *BglII* fragment was purified from an agarose gel and ligated into the superlinker shuttle plasmid pSE280 (Invitrogen, San Diego, CA), which was digested with *Clal* and *BglII*, to form pSE280-E. (Figure 23).

Polymerase chain reaction (PCR) was performed to synthesize DNA encoding an *XhoI* and *Sall* restriction site contiguous with Adenovirus 5 DNA bp 552 through 924. The primers which were employed were as follows:

5' end, Ad5 bp 552-585:

5'-GTCACTCGAGGACTCGGTC-GACTGAAAATGAGACATATTATCTGCCACGGAC
C-3' (SEQ ID NO: 66)

3' end, Ad5 bp 922-891:

5'-CGAGATCGATCACCTCCGGTACAAGGTTTGGCATAG-3' (SEQ ID NO: 67)

This amplified DNA fragment (sometimes hereinafter referred to as Fragment A) then was digested with *XhoI* and *Clal*, which cleaves at the native *Clal* site (bp 917), and ligated to the *XhoI* and *Clal* sites of pSE280-E, thus reconstituting the 5' end of the E1 region beginning 8 bp upstream of the ATG codon.

PCR then was performed to amplify Adenovirus 5 DNA from bp 3,323 through 4,090 contiguous with an *EcoRI* restriction site. The primers which were employed were as follows:

5' end, Ad5 bp 3323-3360:

5'-CATGAAGATCTGGAAGGTGCTGAGGTACGATGAGACC-3' (SEQ ID NO: 68)

3' end, Ad5 bp 4090-4060:

5'-GCGACTTAAGCAGTCAGCTG-AGACAGCAAGACACTTGCTTGATCCAAATCC-3'
' (SEQ ID NO: 69)

This amplified DNA fragment (sometimes hereinafter referred to as Fragment B) was digested with BglII, thereby cutting at the Adenovirus 5 BglII site (bp 3,382) and EcoRI, and ligated to the BglII and EcoRI sites of pSE280-AE to reconstruct the complete E1a and E1b region from Adenovirus 5 bp 552 through 4,090. The resulting plasmid is referred to as pSE280-E1 (Figure 23).

A construct containing the intact E1a/b region under the control of the synthetic promoter GRE5 was prepared as follows. The intact E1a/b region was excised from pSE280-E1, which was modified previously to contain a BamHI site 3' to the E1 gene, by digesting with XhoI and BamHI. The XhoI to BamHI fragment containing the E1a/b fragment was cloned into the unique XhoI and BamHI sites of pGRE5-2/EBV (Figure 4, U.S. Biochemicals, Cleveland, Ohio) to form pGRE5-E1 (Figure 24).

Bacterial transformants containing the final construct were identified. Plasmid DNA was prepared and purified by banding in CsTFA prior to use for transfection of cells.

Construction of plasmid including Adenovirus 5 E2A sequence.

The Adenovirus 5 genome was digested with BamHI and SpeI, which cut at bp 21,562 and 27,080, respectively. Fragments were separated on an agarose gel and the 5,518 bp BamHI to SpeI fragment was isolated. The 5,518 bp BamHI to SpeI fragment was digested further with SmaI, which cuts at bp 23,912. The resulting 2,350 bp BamHI to SmaI fragment was purified from an agarose gel, and ligated into the superlinker shuttle plasmid pSE280, and digested with BamHI and SmaI to form pSE280-E2 BamHI-SmaI (Figure 26).

PCR then was performed to amplify Adenovirus 5 DNA from the SmaI site at bp 23,912 through 24,730 contiguous with NheI and EcoRI restriction sites. The primers which were employed were as follows:

5' end, Ad5 bp 24,732-24,708:

5'-CACGAATTCGTCAGCGCTTCTCGTCGCGTCCAAGACCC-3' (SEQ ID NO: 70)

3' end, Ad5 bp 23,912-23,934:

5'-CACCCCGGGGAGGCGGCGGCGACGGGGACGGG-3' (SEQ ID NO: 71)

This amplified DNA fragment was digested with SmaI and EcoRI, and ligated to the SmaI and EcoRI sites of pSE280-E2 Bam-Sma to reconstruct the complete E2a region from Ad5 bp 24,730 through 21,562. The resulting construct is pSE280-E2a. (Figure 27.)

In order to convert the BamHI site at the 3' end of E2a to a Sall site, the E2a region was excised from pSE280-E2a by cutting with BamHI and NheI, and recloned into the unique BamHI and NheI sites of pSE280. (Figure 6.) Subsequently, the E2a region was excised from this construction with NheI and Sall in order to clone into the NheI and Sall sites of the pMAMneo (Clonetech, Palo Alto, CA) multiple cloning site in a 5' to 3' orientation, respectively. The resulting construct is pMAMneo E2a. (Figure 27).

Bacterial transformants containing the final pMAMneo-E2a were identified. Plasmid DNA was prepared and purified by banding in CsTFA. Circular plasmid DNA was linearized at the XmnI site within the ampicillin resistance gene of pMAMneo-E2a, and further purified by the phenol/chloroform extraction and ethanol precipitation prior to use for transfection of cells.

Transfection and selection of cells.

In general, this process involved the sequential introduction, by calcium phosphate precipitation, or other means of DNA delivery, of two plasmid constructions each with a different viral gene, into a single tissue culture cell. The cells were transfected with a first construct and selected for expression of the associated drug resistance gene to establish stable integrants. Individual cell clones were established and assayed for function of the introduced viral gene. Appropriate candidate clones then were transfected with a second construct including a second viral gene and a second selectable marker. Transfected cells then were selected to establish stable integrants of the second construct, and cell clones were established. Cell clones were assayed for functional expression of both viral genes.

In order to determine the most suitable cell lines for the above-mentioned transfections, sequential transfections and selections were carried out with the following parental cell types:

A549 (ATCC Accession No. CCL-185);
Hep-2 (ATCC Accession No. CCL-23); or
KB (ATCC Accession No. CCL-17).

Appropriate selection conditions were established for both G418 and hygromycin B for all three cell lines by standard kill curve determination. Transfection of cell lines with plasmids including E1 and E2a regions.

pMAMNeo-E2a was linearized with XmnI with the Amp^R gene, introduced into cells by transfection, and cells were selected for stable integration of this plasmid by G418 selection until drug resistant colonies arose. The clones were isolated and screened for E2a expression by staining for E2a protein with a polyclonal antiserum,

and visualizing by immunofluorescence. E2a function was screened by complementation of the temperature-sensitive mutant Ad5ts125 virus which contains a temperature-sensitive mutation in the E2a gene. (Van Der Vliet, et al., J. Virology, Vol. 15, pgs. 348-354 (1975)). Positive clones expressing the E2a gene were identified and used for transfection with the 7 kb EcoRV to XmnI fragment from pGRE5-E1 (Figure 5), which contains the GRE5 promoted E1a/b region plus the hygromycin^R gene. Cells were selected for hygromycin resistance and assayed for E1a/b expression by staining with a monoclonal antibody for the E1 protein (Oncogene Sciences, Uniondale, N.Y.). E1 function was assayed by ability to complement an E1-deleted vector. At this point, expression and function of E2a was verified as described above, thus establishing the expression of both E1a/b and E2a in the positive cell clones.

One of the transfected A549 cell lines showed good E1a/b and E2a expression and was selected for further characterization. It was designated the S8 cell line.

G. Preparation of Adenoviral Vectors Containing Ad5.βgal.ΔF Genome in S8 Improved Fiber-Complementing Cell Lines

To prepare adenoviral vectors containing Ad5.βgal.ΔF in S8 cells containing alternative forms of TPL for enhancing the expression of fiber proteins, the protocol as described in Example 2 for preparing Ad5.βgal.ΔF in 211B cells was followed with the exception of pretreatment with 0.3 μM dexamethasone for 24 hours as described above. Thus, viral particles with the wildtype Ad5 fiber protein on their surface and containing the fiberless Ad5.βgal.ΔF genome were produced in 633 cells. Particles produced in 644 cells also contained the fiberless Ad5.βgal.ΔF genome, but had the chimeric 5T3H fiber protein, with the Ad3 fiber knob, on their surface.

The preparation of the cell lines and demonstration of stable nuclear expression of either wild-type Ad5 fiber protein or chimeric Ad5/Ad3 protein is shown in Figure 20. In the figure, schematic diagrams are presented of the constructs used to generate the cell lines as well as immunofluorescence results indicating the presence of expressed fiber protein in the nucleus of the cells. An indirect immunofluorescence assay of A549 based cell lines which stably express the different Ad fibers is shown. Line 633 expresses the native Ad5 fiber protein and line 644 expresses a chimeric fiber protein with the tail and shaft domains of the Ad5

protein and the knob domain of the Ad3 fiber. Previous work (Stevenson et al., 1996) showed that a virus containing this protein had the tropism expected for Ad3.

Thus, these viral preparations, prepared as described herein and in Example 2, are useful for targeting delivery of Ad5. β gal. Δ F fiberless genome with either wild-type or modified fibers, embodiments of which uses have been previously discussed and as further exemplified with the pseudotyping and infectivity results described in Example 7.

Example 7

Pseudotyping and Infectivity of Recombinant Adenoviral Vectors Produced with Improved Fiber-Complementing Cell Lines

A. Pseudotyping of Ad5. β gal. Δ F

To verify that adenoviral vectors were produced had altered tropisms, viral particles were purified from either 633 (expressing wild type Ad5 fiber) or 644 cells (expressing the chimeric Ad5/Ad3 fiber) 10 μ g of the purified particles were Western blotted and probed with a polyclonal rabbit antibody against the Ad2 fiber (which detects both the Ad5 and chimeric 5T3H fiber proteins.). Equal amounts of purified Ad. β gal.wt or Av9LacZ (which has the chimeric fiber gene in the viral chromosome) were run as controls. The results are shown in Figure 21 where both fiber proteins were detectable confirming pseudotyping.

B. Infectivity of Cells with 633 or 644 Generated Virus Particles

The cell lines, 633 or 644, prepared as described above, were infected with the indicated number of particles/cell of Ad5. β gal. Δ F and virus particles produced. Virus was then used to infect, as previously described, selected cell lines as shown in Figure 22, including 211B, MRC-5 human fibroblasts, A-10 rat aortic endothelial cells, and THP-1 human monocytic cells. Unbound virus was removed by washing the cells and the cells were further incubated at 37°C for 48 hours. Cells were then fixed with glutaraldehyde and stained with X-gal. The percentage of stained cells was then determined by light microscopy where all experiments were done in triplicate.

The results shown in Figure 22 indicate that adenoviral vectors could be retargeted by pseudotyping using packaging cell lines expressing different fiber

proteins. The data marked with "none" indicates virus grown in 293 cells and lacking fiber, while "Ad5" indicates virus prepared in 633 cells (containing the wild type fiber) and Ad3 indicates virus prepared in 644 cells (containing the chimeric 5T3H fiber.) Particles containing either fiber were equally infectious on 211B cells, while MRC-5 fibroblasts and THP-1 cells were more readily infected by virus containing the chimeric fiber. The A-10 rat endothelial cells were more readily infected by particles containing the wildtype Ad5 fiber protein.

Example 8

Targeted Gene Delivery Using Viral Vector Particles Lacking Fiber Protein

An alternative mode of entry for adenoviral infection of hematopoietic cells has been described by Huang, *et al.*, *J. Virol.*, 69:2257-2263 (1995) which does not involve the fiber protein-host cell receptor interaction. As infection of most other cell types does require the presence of fiber protein, vector particles which lack fiber may preferentially infect hematopoietic cells, such as monocytes or macrophages.

To produce a fiber-free adenovirus vector particle, a vector lacking the fiber gene as described above in Example 2A but containing a gene of interest for delivery is amplified by growth in cells which do not produce a fiber protein, such as the 211 cells prepared in Example 1 or 293 or S8 cells as described herein, thereby producing large numbers of particles lacking fiber protein. The recovered fiber-free viral particles are then used to deliver the inserted gene of interest following the methods of this invention via targeting mechanisms provided by other regions of the adenoviral vector, *i.e.*, via the native penton base.

A. Construction of an Adenovirus Vector Deleted for E1, E3, and Fiber, and Carrying a Therapeutic Gene of Interest

A general method of constructing a fiber-deleted Ad vector containing a therapeutic gene of interest (in this example, the Herpes Simplex Virus Thymidine Kinase (TK) gene) is described here. Linear viral DNA is isolated from a preparation of Ad5.βgal.ΔF particles. This DNA is digested with the restriction enzyme ClaI, which removes the leftmost viral sequences including the left ITR, the

packaging signals, and part of the SV40-driven β -galactosidase gene. The large *Clal* fragment with the remainder of the fiber-deleted viral genome is then isolated by centrifugation on a sodium chloride or sucrose gradient. The plasmid pAdShuttleTK, which contains the left part of the Ad chromosome with an RSV-driven TK gene inserted in place of the E1 region, is linearized by digestion with *NotI*. The nucleotide sequence of the pAdShuttleTK is shown in SEQ ID NO: 50. The large *Clal* fragment of Ad5. β gal. Δ F and the linearized pAdShuttleTK are cotransfected into 211B cells, and an infectious adenovirus genome is generated by homologous recombination. A virus deleted for E1, E3, and fiber that contains the TK cassette in the place of the E1 deletion is thus recovered. A virus containing any desired therapeutic gene of interest can be created in this manner by replacing the TK gene of the example with the gene of interest.

An alternative method of constructing a fiber-deleted genome containing a therapeutic gene (in this example the *retinal degeneration-slow (RDS)* gene driven by the CMV immediate early promoter) is described here. RDS is a protein expressed in photoreceptors, and essential for their proper development and functioning. RDS mutations have been implicated in retinal degenerative disorders, and transfer of the wildtype RDS gene by means of an Ad vector provides an avenue towards treating such disorders.

A plasmid (pDV50) analogous to p Δ E1B β gal but containing a CMV-driven RDS gene was constructed as follows. First, a fragment containing the CMV promoter and enhancer was excised from pCHaMIEP by digestion with *HindIII*, filling the overhanging ends with the large fragment of *E. coli* DNA polymerase 1, ligation of *Bam*HI linkers (5'CGCGGATCCCG3' SEQ ID NO: 51) to the blunt ends, and digesting with *Bam*HI. The resulting fragment was then ligated into the *Bam*HI site of p Δ E1sp1a (Mikrobix) to create pDV45. A fragment containing the SV40 polyadenylation signal was amplified from pSV β gal (Promega) using the oligonucleotides 5'CTGACAAACTCAGATCTTGTATTG3' (SEQ ID NO: 51) and 5'GTCGACTCTAGAGGATCCAGA3' (SEQ ID NO: 52). This fragment was ligated into the *Bgl*II site of pDV45 to create pDV46, using the unique *Bam*HI and *Bgl*II sites (bold type) in the primers. Finally, the human RDS open reading frame was amplified from the plasmid pRDS-T7 using the oligonucleotides 5'CCGGACTCTAGATGGCAACCATGGCGCTAC3' (SEQ ID NO: 53) and 5'GGA GGGGAAGCTTGGCCCTCAGCCAGCCTCT3' (SEQ ID NO: 54). This fragment was inserted into the *Hind*III and *Xba*I sites of pDV46, again using unique restriction sites in the primers, to create pDV50. pDV50 therefore contains a cassette

consisting of the CMV promoter, the *RDS* open reading frame, and the SV40 terminator sequences inserted in place of the Ad5 E1 region.

In a manner analogous to the construction of Ad5. β gal. Δ F , pDV50 and pDV44 are then co-transfected into 211B cells, and an infectious Ad genome (Ad5.*RDS*. Δ F) is recovered. A fiber-deleted Ad vector containing any desired gene to be expressed can be constructed by replacing the *RDS* gene of this example with the gene of interest.

Example 9

Transient Transcomplementation

Human adenovirus type 5 (Ad5) is being developed as a vector for gene therapy. Its ability to deliver therapeutic genes to cells is mediated by the interaction of the adenoviral fiber protein with the coxsackievirus-adenoviral receptor (CAR). Because a wide-range of cells express CAR, it can be difficult to use adenoviruses to deliver genes to specific cell types. One way to address this is to target the virus to a particular cell type by genetically altering the fiber. However, the genetic manipulations involved in cloning and production of the viruses with altered fibers can be time-consuming. Thus it would be a significant advancement in the field of adenoviral gene therapy to have a more streamlined system for testing modified fiber genes. An *in vitro* system has thus been developed that involves infection of tissue culture cells with a fiber-deleted Ad and transient co-transfection with a plasmid directing fiber expression. This system allows one to produce and evaluate such modified fibers in the context of a viral particle easily and quickly. In addition this system can be envisioned to actually produce therapeutic quantities of adenoviral vectors with modified fiber proteins, with such fibers having a new tropism added by insertion of a desired ligand into the fiber gene. These fibers may also have the natural tropism (*i.e.* binding to CAR) ablated.

Plasmids used were pDV60 and pDV55, prepared as described herein. pDV60 is an pcDNA3.1-based expression plasmid that contains the CMV promoter, Ad5 tripartite leader, an intron, and the Ad5 fiber gene sequence. pDV55 contains no fiber gene and serves as the negative control. Ad5. β gal. Δ F and 211B are described above. 293T cells are identical to 293 cells except they express an integrated SV40 large T antigen gene. HDF cells are human diploid fibroblasts. 293T cells express CAR and α_v integrins; HDF cells express α_v integrins but no CAR. Transfections with fiber expression plasmids were performed with

Lipofectamine (GIBCO-BRL) using 20mg DNA and 50ml Lipofectamine per 15cm dish. Cells were maintained in DMEM supplemented with 10% fetal bovine serum.

The fiber deletion mutation of Ad5. β gal. Δ F is complemented in *trans* by passing virions through 211B, a cell line that stably expresses functional Ad5 fiber. The present system was designed to complement Ad5. β gal. Δ F by modified fibers expressed from transfected episomal plasmids in 293T cells. The result is a simplified and rapid method to incorporate modified fibers on a viral particle containing the Ad5. β gal. Δ F genome that does not require propagation of the virus.

The feasibility of transcomplementation of Ad5. β gal. Δ F with episomal fiber-expressing plasmids was demonstrated in the following experiment. 293T cells were transfected with one of two plasmids: pDV55, which expresses no fiber or pDV60, which expresses wildtype Ad5 fiber. Fiber expression persists for at least six days, suggesting that the plasmid is stable as an episome for this amount of time. Twenty-four hours after transfection, these cells were infected at 2000 particles/cell with Ad5. β gal. Δ F passaged through 211B cells. Seventy-two hours later, a crude viral lysate (CVL) was generated by exposing the cells to five freeze-thaw cycles. Viral particles were purified by cesium chloride gradient centrifugation. The resulting virions incorporated the fiber expressed from the episomal plasmid, as confirmed by Western blots performed with an antibody specific to the Ad5 fiber.

To demonstrate the functionality of these virions, the transduction efficiency was tested. The virions containing no fiber (pDV55) or wildtype fiber (pDV60) were applied to monolayers of 293T and HDF cells at different multiplicity of infection (MOI's). 293T cells express CAR and α_v integrins; HDF cells express α_v integrins but no CAR. After 2 days, the cells were fixed and stained with X-gal to detect the β galactosidase reporter gene activity. The results showed low transduction efficiency for the pDV55-complemented virions in both cell lines. As expected, the pDV60-complemented virions transduced 293T cells to a high degree but did not transduce HDF cells, indicating that functional fiber proteins had been expressed from the episomal plasmids and incorporated into the virions. This transduction efficiency was comparable to or better than that of Ad5. β gal. Δ F virions passaged through the 211B cells.

Episomal plasmid transcomplementation system is suitable for quickly expressing and evaluating the properties of modified fibers in the context of a viral particle. Episomal plasmid transcomplementation will also be of great utility for quickly evaluating a bank of modified fibers for other binding properties, including novel tropism and the ablation of the native tropism. In addition to the rapid

generation and testing of large numbers of modified fibers, there are other advantages to the Ad5. β gal. Δ F transcomplementation system in terms of production and safety. Episomal plasmid transcomplementation has the inherent advantage over transcomplementation in that it is not necessary to make a stable cell line for every modified fiber with which you want to complement Ad5. β gal. Δ F. Because the Ad5. β gal. Δ F is deleted in E1, E3 and fiber, there is an additional gene deletion compared to other first generation vectors. This makes Ad5. β gal. Δ F more replication defective and presumably safer. In addition, the presence of the fiber gene deletion decreases the opportunity to generate replication-competent virus via recombination in the packaging cells. In terms of production a single Ad vector prep could be retargeted to any number of different cell types simply by transfecting the cells with the appropriate fiber-expression construct.

Example 10

Adenoviral Gene Delivery Vectors Containing the Ad37 Fiber Protein

Adenovirus type 37 (subgroup D) has been associated with infections of the eye and genital tract, and may be useful for targeting these tissues or other mucous membranes, as well as other cell types. The tropism of Ad37 is due to the binding preference of its fiber protein, which binds to an as yet-unidentified receptor located on the surface of cells including Chang C, conjunctival epithelial cell line (Huang *et al.*, *J. Virology* 73(4):2798-2802 (1999)). As this fiber directs viral infection to cell types different than those infected by Ad5, it is likely to provide a method for targeting gene delivery. This example describes construction of packaging cell lines expressing the Ad37 fiber protein, and their use in generating particles of a fiber-deleted Ad vector (such as Ad5. β gal. Δ F) containing this fiber protein. The fiber protein is attached to the viral capsid by binding to the penton base protein through its N-terminus, and the Ad37 fiber was modified in order to make its N-terminal sequence more closely match that of the Ad5 protein to ensure that it would efficiently bind the Ad5 penton base in these vectors.

- 1. Construction of an Expression Plasmid for the Ad37 Fiber Protein (pDV80)**

This plasmid uses the same regulatory elements as contained in pDV60, pDV67, and pDV69 to express the Ad37 fiber in packaging lines, and was constructed in two steps. First, the Ad37 fiber open reading frame was amplified from Ad37 genomic DNA (obtained from the ATCC - accession number VR-929) using the synthetic oligonucleotides primers L37 (5' TGT CTT **GGA TCC AAG ATG AAG CGC GCC CGC CCC AGC** GAA GAT GAC TTC 3') (SEQ ID NO: 56) and 37FR (5' AAA CAC **GGC GGC CGC** TCT TTC ATT CTT G 3') (SEQ ID NO: 57). L37 contains nucleotides that differ from the Ad37 genomic sequence in order to add an unique *Bam* H1 site (bold in the above sequence) and create point mutations to make the N-terminal sequence of the fiber more closely match that of the Ad6 protein (underlined in the above sequence; the start codon is italicized). 37FR incorporates changes to create a unique *Not* 1 site (bold). The PCR product was inserted into the *Bam* H1 and *Not* 1 sites of pCDNA3.1zeo(+) (Invitrogen) to create pDV78. The correct sequence of the Ad37 fiber gene, including the predicted changes, was confirmed by sequencing.

Second, a 1.2 kb *Bam* H1/*Bgl* II fragment containing an adenovirus type 5 tripartite leader was excised from pDV55 (DVS 1999) and inserted into the *Bam* H1 site of pDV78 to create pDV80 (SEQ ID NO:64)

2. Isolation of Cell Lines Expressing the Ad37 Fiber Protein

pDV80 DNA was purified using the Qiagen method and electroporated into the adenovirus-complementing cell line E1-2a S8 (Gorziglia *et al.*, *J. Virology* 70(5):4173-4178 (1996)) as previously described (Von Seggern, *et al.*, *J. Gen. Virol.* 79:1461-1418), and stable clones were selected with 600 µg/ml zeocin (Invitrogen). Clones were expanded and screened for fiber expression by indirect immunofluorescence using a rabbit polyclonal antibody directed against the Ad37 fiber. Two clones (lines 705 and 731) that expressed the protein at a uniformly high level were selected for further study.

3. Production of Pseudotyped Ad Vector Particles

To generate vector particles equipped ('pseudotyped') with the Ad37 fiber protein, the Ad37 fiber-expressing 705 cells were infected (approximately 1000 particles/cell) with Ad5.βgal.ΔF or with Ad5.GFP.ΔF.

Ad5. β gal. Δ F is prepared as previously described. Ad5.GFP. Δ F was constructed by recombination in bacteria using a modification of the method of (He, *et al.*, *PNAS* 95:2509-2514 (1998)). First, a fiber-deleted genomic plasmid was constructed by removing the fiber gene from pAdEasy1 (He, *et al.*, *PNAS* 95:2509-2514 (1998)). pDV43 (Von Seggern, *et al.*, *J. Virol.* 73:1601-1608 (1999)) was digested with *Pac* 1, the ends blunted by treatment with the large fragment of *E. coli* DNA polymerase and dNTPs, and the product re-ligated. The resulting plasmid, pDV76, is identical to pDV43 except for loss of the *Pac* 1 site and contains the right end of the Ad5 genome with E3 and fiber deletions. A 4.2 kb fragment was amplified from pDV76 using the oligonucleotides primers 5' CGC GCT GAC TCT TA GGA CTA GTT TC 3' (SEQ ID NO: 58) (including the unique *Spe* 1 site in the Ad5 genome, bold) and 5' GCG CTT AAT TAA CAT CAT CAA TAA TAT ACC TTA TTT T 3' (SEQ ID NO: 59) (including a novel *Pac* 1 site (bold) adjacent to the right Ad5 ITR). This PCR fragment therefore contains nucleotides 27,082 to 35,935 of the Ad5 genome with a deletion of nucleotides 28133 to 32743 (the E3 and fiber genes), and was used to replace the corresponding *Spe* 1/*Pac* 1 fragment of PAdEasy1 to create pDV77.

E. coli strain BJ5183 was electroporated with a mixture of pDV77 and *Pme* 1-linearized pAdTrack as described (He *et al.*, 1998), and DNA was isolated from kanamycin-resistant colonies. The resulting plasmid, pDV83, contains a complete E1-, E3-, and fiber-deleted Ad5 genome with a CMV-driven GFP reporter gene inserted at the site of the E1 deletion. The full-length Ad chromosome was isolated by *Pac* 1 digestion, and transfected to the E1- and fiber-complementing 633 cells (Von Seggern *et al.*, *J. Virol* January 2000). The recovered virus was then plaque purified by plating on 633 cells and stocks were prepared.

Ad5-pseudotyped particles were generated by virus growth in 633 cells, which express the wild type Ad5 fiber protein. Viral particles were isolated and purified over CsCl gradients as previously described (Von Seggern *et al.*, *J. Virol.* 73:1601-1608, 1999). For analysis of viral proteins, ten μ g of the purified particles were electrophoresed on 8-16% gradient gels and the protein transferred to nylon membranes. The blot was then probed with rabbit polyclonal antibodies raised against recombinant Ad37 fiber or Ad5 fiber or penton base proteins expressed in baculovirus-infected cells (Figure 27).

Example 11

Construction of a Fiber Expression Construct Containing a Post-Transcriptional Regulatory Element

Previous studies have shown that mRNA transcribed from the woodchuck hepatitis virus (WHV) genome contains an element (the WHV post-transcriptional regulatory element, or WPRE) which can increase expression of a protein encoded by the mRNA via a post-transcriptional mechanism (Loeb *et al.*, *Human Gene Therapy* 10:2295-2305 (1999)). The WPRE has also been shown to enhance expression of transgenes delivered by retroviral vectors. (Zufferey, R. *et al.*, *J. Virol.* 73:2886-2892 (1999)). This example describes the construction of a fiber expression construct (pDV90) containing a WPRE as well as the promoter and TPL sequences as contained in pDV67.

A plasmid (pBS/WPRE) which contains the WPRE was obtained from Dr. Thomas Hope, Salk Institute. Digestion of pBS/WPRE with *Cla*I releases a 600 bp fragment containing the WPRE (nt 193-1684 of the WHV genome.) Following *Cla*I digestion, the ends of this fragment were filled by treatment with the large fragment of *E. coli* DNA polymerase 1 in the presence of dNTPs to render them blunt. pDV67 DNA was digested with *Xba*I (which cuts at a unique site in the transcribed region downstream of the Ad5 fiber open reading frame) and the ends filled by the same treatment. The filled WPRE fragment was then ligated into the filled *Xba*I site of pDV67 to create pDV90 (SEQ ID NO: 65). The sequence is found at GenBank accession no. J04514 (entire genome) in Zufferey, R. *et al.*, *J. Virol.* 73:2886-2892 (1999).

pDV90 was electroporated into E1-2a S8 cells and stable clones expressing fiber isolated as described previously for pDV80.

Example 12

Construction of an Ad5 Fiber Protein with Heterologous Peptide Sequences Inserted in the HI Loop

The receptor-binding knob domain of the Ad5 fiber protein contains several surface loops which are attractive candidates for the insertion of heterologous peptide sequence, as an additional ligand for vector targeting. This example describes the construction of a fiber gene which encodes a fiber protein containing a 6 amino acid peptide linker in the HI loop, and retains the ability to trimerize. The

modified gene also contains a unique novel restriction site at the position of the linker insertion to facilitate addition of the targeting ligand into the HI loop.

The Ad5 fiber gene was amplified from Ad5 genomic DNA (ATCC accession number VR-5) using the primers Fiber ATG (5' TGA AGC GCG CAA GAC CGT CTG AAG 3') (SEQ ID NO: 60) and Fiber TAA (5' CAT AAC ACT **GCA** GAT TCT TTA TTC TTG G 3') (SEQ ID NO: 61), and cloned to the *Nde*1 (filled with the large fragment of *E. coli* DNA polymerase 1 in the presence of dNTPs) and *Pst* 1 sites of pT7-7 using a unique *Pst* 1 site (bold) in the 'Fiber TAA' oligo. The resulting plasmid, pT7/fiber, was digested with *Xba* 1 and *Pst* 1 to excise the fiber gene, which was then cloned into the *Pst* 1 and *Xba* 1 sites of pUC119 to create pUC/fiber. This pUC-derived plasmid contains an origin for single-stranded DNA replication and can therefore be used to create template DNA for site-directed mutagenesis.

Site-directed mutagenesis was carried out according to the method of Kunkel (T.A. Kunkel, *PNAS* 82:488-492 (1985)) using the oligonucleotide primer T542 (5' GGT ACA CAG GAA ACA GGA GGT TCC GGA GGT GGA GGA GAC ACA ACT CC 3') (SEQ ID NO: 62). This results in the addition of 18 new bases (underlined) encoding the sequence Gly Gly Ser Gly Gly Gly (SEQ ID NO: 63), with a novel *Bsp*E1 site (bold) for the addition of further sequences. The inserted sequence is between Thr542 and Gly543 of the Ad5 fiber protein, in the HI loop. The modified plasmid is termed pDV14.

Finally, the modified fiber gene was excised from pDV14 by digestion with *Pst* 1 and *Xba* 1 and cloned into the *Pst* 1 and *Xba* 1 sites of pGEM3Z (Promega) to create pDV18. *In vitro* transcription/translation experiments with pDV18 (using the TNT™ kit, Promega) demonstrated that the modified fiber gene encoded a protein which was capable of trimerizing.

Alternatively an Ad5 fiber open reading frame (ORF) is amplified from Ad5 genomic DNA (wildtype Ad5 was purchased from the ATCC) using the oligonucleotides 5' ATG GGA TCC AAG ATG AAG CGC GCA AGA CCG 3' (SEQ ID NO: 72) and 5' CAT AAC CTG CAG GAT TCT TTA TTC TTG GGC 3' (SEQ ID NO: 73) and inserted into the *Bam*HI and *Pst* 1 sites of pGEM-3Zf(+) (Promega Inc., Madison, WI) via novel restriction sites (bold type) designed into the primers. The 5' oligonucleotide also contains a G to A change 3 nucleotides 5' of the initial ATG codon (underlined), designed to improve the consensus for translation initiation.

Site-directed mutagenesis is performed by the method of Kunkel (Proc. Nat. Acad. Sci. 82:488-492 (1985)), using the synthetic oligonucleotide 5' GGT ACA CAG GAA ACA GGA GGT TCC GGA GGT GGA GGA GAC ACA ACT CC 3' ((SEQ ID

NO: 74). This operation introduced sequence (bold type) encoding 6 novel amino acids (Gly Gly Ser Gly Gly Gly) immediately following Threonine 542 of the Ad5 fiber, and including a unique restriction site for the insertion of further heterologous sequences (underlined). The resulting plasmid (pDV18A) contains the modified fiber gene under the control of the T7 promoter in the parental pGEM-3Zf(+) and can be used for *in vitro* transcription/translation reactions to produce labeled fiber protein.

Example 13

Use of the Fiber Expression System to Retarget (‘Pseudotype’) Hybrid Ad/AAV Vectors

Adenoviral vectors which lack essentially all Ad genes (‘helper-dependent’ or ‘gutless’ vectors) have recently been developed. In a modification of this idea, vectors (‘hybrid’ vectors) which contain an adeno-associated virus (AAV) or retroviral genome have been generated. As AAV and retroviral genomes integrate into the chromosome of the target cells, the hybrid Ad/AAV or Ad/retroviral vectors have the potential to provide very long-term gene expression.

Lieber *et al.*, (*J. Virol.* 73(11):9314-9324) describe an Ad vector (Ad.AAV1) which contains an AAV vector genome (a transgene insert flanked by the AAV inverted terminal repeats) inserted into the E1 region. When 293 cells are infected by Ad.AAV1, recombination between the AAV sequences generates a minimal Ad chromosome which carries the Ad inverted terminal repeats and packaging signal flanking the AAV vector genome. This chromosome cannot direct the synthesis of Ad proteins, but can be packaged into Ad vector particles. The remaining unrecombined Ad chromosomes provide the Ad structural proteins in trans, and both the full-length and minimal genomes are packaged into particles. The particles carrying the minimal Ad/AAV hybrid vector are then isolated by CsCl centrifugation.

These particles have the capsid structure of adenovirus, and infect cells using the efficient fiber- and penton base-mediated pathway used by Ad. Following infection, the hybrid genome is able to integrate into the cell’s chromosomes by virtue of its AAV sequences. In this example, the AAV vector genome is inserted into the E1 region of a fiber-deleted vector, and the resulting vector is grown in packaging lines expressing either the Ad5 or Ad37 fiber proteins. The particles recovered therefore have the tropisms expected from the respective fiber proteins combined with the ability to integrate their AAV genome into target cells. Such

pseudotyping should be possible with any of a number of modified fiber proteins, as for the fiber-deleted vectors already described by us.

The Ad vector is constructed in a manner analogous to that described for Ad5. β gal. Δ F, by recombination between pAd.AAV1 (Lieber *et al.* *J. Virol.* 73:9314-9324, 1999) and pDV44 (as described earlier in the specification.) pAd.AAV1 carries an MLV promoter-driven secreted alkaline phosphatase gene (SEAP) as a reporter, and an SV40-driven neomycin phosphotransferase (neo) gene to allow the selection of cells stable transduced by the AAV cassette. The resulting vector (Ad.AAV1. Δ F) has the AAV vector cassette of Ad.AAV1 inserted into the E1 region of a genome with the fiber deletion of Ad5. β gal. Δ F. Growth of Ad.AAV1. Δ F in 633 cells results in particles carrying the AAV genome and the Ad5 fiber, and which have the tropism associated with Ad5. Growth of Ad.AAV1. Δ F in 705 cells produces particles bearing the Ad37 fiber and therefore having its associated different tropism.

Tropism is evaluated by infecting Chang C cells (which express the Ad37 receptor) and A549 cells which do not express this protein but do express the Ad5 receptor (CAR). The extent of infection is monitored by assaying alkaline phosphatase expression, and the fraction of cells stable transduced is assayed by selection with neomycin. By using purified recombinant Ad5 or Ad37 fiber proteins as competitors during infection, the usage of the expected receptors by the pseudotyped particles is evaluated.

Example 14

Use of the Fiber Expression System to Retarget (‘Pseudotype’) Helper-dependent Ad Vectors

Gutted Ad vectors are those from which most or all viral genes have been deleted. They are grown by co-infection of the producing cells with a "helper" virus (such as using an E1-deleted Ad vector). The helper virus *trans*-complements the missing Ad functions, including production of the viral structural proteins needed for particle assembly. In one embodiment of this invention, the helper virus is a fiber-deleted Ad (such as that described in Von Seggern *et al.*, *J. Virol.* 73:1601-1608 (1999)). The vector is prepared in a fiber expressing cell line such as has been previously described by Von Seggern *et al.*, *J. Gen. Virol.* 79:1461-1468 (1998), Von Seggern *et al.*, *J. Virol.* 74:354-362 (2000). All the necessary Ad proteins except fiber are provided by the fiber-deleted helper virus, and the particles are equipped with the particular fiber expressed by the host cells. A concern with gutted vectors



One way to do this is to mutate the packaging sequence by deleting one or more of the nucleotides comprising the sequence or otherwise mutating the sequence to inactivate or hamper the packaging function. An alternative approach is to engineer the helper genome so that recombinase target sites flank the packaging sequence and to provide a recombinase in the packaging cell. The action of recombinase on such sites results in the removal of the packaging sequence from the helper virus genome. Preferably, the recombinase is provided by a nucleotide sequence in the packaging cell that encodes the recombinase. Most preferably, such sequence is stably integrated into the genome of the packaging cell. Various kinds of recombinase are known by those skilled in the art. The preferred recombinase is Cre recombinase, which operates on so-called lox sites, which are engineered on either side of the packaging sequence as discussed above. Further information about the use of Cre-loxP recombination is found in U.S. Pat. No. 5,919,676 and Morsy and Caskey, *Molecular Medicine Today*, Jan. 1999, pgs. 18-24, both incorporated herein by reference.

This example demonstrates how the fiber-expressing packaging lines can be used to generate pseudotyped particles of helper-dependent or 'gutless' vectors with altered tropisms. As the gutless vectors lack many or all Ad genes, they must be grown as mixed cultures in the presence of a helper virus which can provide the missing functions. To date, such helper viruses have provided all Ad functions except E1, and E1 is complemented by growth in 293 cells or the equivalent. The resulting virus particles are harvested, and the helper virus is typically removed by CsCl gradient centrifugation (the vector chromosome is generally shorter than the helper chromosome, resulting in a difference in buoyant density between the two particles).

An example of a gutless vector is pAd Δ RSVDys (Haecker *et al.*, *Human Gene Therapy* 7:1907-1914 (1996)). This plasmid contains a full-length human dystrophin cDNA driven by the RSV promoter and flanked by Ad inverted terminal repeats and packaging signals. 293 cells are infected with a first-generation Ad which serves as a helper virus, and then transfected with purified pAd Δ RSVDys DNA. Both the helper Ad genome and the pAd Δ RSVDys DNA are replicated as Ad chromosomes, and packaged into particles using the viral proteins produced by the helper virus. Particles are isolated and the pAd Δ RSVDys-containing particles separated from the helper by virtue of their smaller genome size and therefore different density on CsCl gradients.

To generate pseudotyped particles containing the pAd Δ RSVDys genome, the vector is grown in either 633 or 705 cells and Ad5. β gal. Δ F is used as a helper virus. As in the published method, both the Ad5. β gal. Δ F and Ad Δ RSVDys genomes replicate and are packaged into particles. The Ad5. β gal. Δ F helper provides all the essential Ad proteins except fiber, and the fiber protein is that produced by the cells (Ad5 fiber in 633 cells and Ad37 fiber in the case of 705 cells). The particles containing Ad Δ RSVDys genomes are then isolated by centrifugation.

Tropism is evaluated by infecting Chang C cells (which express the Ad37 receptor) and A549 cells which do not express this protein but do express the natural Ad5 receptor (CAR). The extent of infection is assessed by immunofluorescence staining of the infected cells with an anti-dystrophin antibody. By using purified recombinant Ad5 and Ad37 fiber proteins as competitors during infection, the usage of the expected receptors by the pseudotyped particles is evaluated.

Example 15

Targeting EBV-Infected B Cells

There are a number of cell types, such as EBV-transformed B-lymphocytes, that are involved in human disease which are not transducible using standard Ad vectors. To address this problem 'pseudotyped' Ad5. β gal. Δ F particles containing either the wildtype Ad5 fiber protein or a chimeric fiber with the receptor-binding knob domain of the adenovirus type 3 (Ad3) fiber were generated. (Von Seggern *et al.*, *J. Virol.* January, 2000). The strategy used for targeting the B-cells should be broadly applicable for targeting gene delivery to other specific cell types.

Cells and Viruses. THP-1, MRC-5, FaDu, and A-10 cells were purchased from the ATCC. 211B is a 293-derived cell line that expresses the wild-type Ad5 fiber protein (Von Seggern *et al.*, *J. Gen. Virol.* 79:1461-1468 (1998)). E1- 2a (Gorziglia *et al.*, *J. Virol.* 70:4173-4178 (1996)) is an A549-derived cell line which complements adenoviral E1 and E2a functions. The JR, TO, and TL LCL lines were established as described (Huang *et al.*, *Proc. Natl. Acad. Sci.* 94:8156-8161 (1997))

by EBV infection of lymphocytes from three normal donors. THP-1 and all LCL lines were maintained in RPMI 1640 medium (Gibco) + 10% fetal calf serum (FCS) (Hyclone). 211B, MRC-5, and A-10 cells were grown in DMEM + 10% FCS. E1-2a and its derivatives were grown in Richter's modified medium (BioWhitaker) + 10% FCS. Peripheral blood mononuclear cells were isolated from normal human blood (General Clinical Research Center, Scripps Clinic) by sedimentation on Ficoll-Paque (Pharmacia) per the manufacturer's instructions. Wild type Ad2 and Ad3 were purchased from the ATCC. Construction of Ad5. β gal.wt and Ad5. β gal. Δ F (Von Seggern *et al.*, *J. Virol.* 73:1601-1608 (1999)) has been previously described. Av1LacZ4 (Mittereder *et al.*, *J. Virol.* 70:7498-7509 (1996)) is a first-generation Ad5 vector containing an RSV-driven β -galactosidase reporter gene. Av9LacZ4 (Stevenson *et al.*, *J. Virol.* 71:4782-4790 (1997)) is identical to Av1LacZ4 except that the fiber gene in the vector chromosome was replaced by a recombinant gene encoding a chimeric fiber protein with the receptor-binding domain of the Ad3 fiber (Stevenson *et al.*, *J. virol.* 69:2850-2857 (1995)). Accession numbers for the above are as follows. THP-1: TIB-202, MRC-5: CCL-171, FaDu: HTB-43, A-10: CRL-1476, Ad2: VR-846, Ad3: VR-3.

DNA constructs. The complete Ad5 tripartite leader contained in pDV67 and pDV69 was constructed by assembly of PCR fragments. pDV55 was constructed similar to Example 5. This plasmid contains a 1.2 kb *Bam* HI/*Bgl* II fragment consisting of the first TPL exon, the natural first intron, and the fused second and third TPL exons. Finally, pDV60 was constructed by inserting this TPL cassette into the *Bam* HI site upstream of the Ad5 fiber gene in pcDNA3/Fiber (Von Seggern *et al.*, *J. Gen. Virol.* 79:1461-1468 (1998)). pDV61 and pDV67 were then constructed similar to example 6.

The chimeric Ad3/Ad5 fiber gene was amplified from pGEM5T3H (Stevenson *et al.*, *J. Virol.* 69:2850-2857 (1995) using the primers 5' ATG **GGA TCC** AAG ATG AAG CGC GCA AGA CCG 3' (SEQ ID NO: 75) and 5' CAC TAT **AGC GGC CGC** ATT CTC AGT CAT CTT 3' (SEQ ID NO:76) , and cloned to the *Bam* HI and *Not* I sites of pcDNA3.1/Zeo(+) via novel *Bam* HI and *Not* I sites (bold) engineered into the primers to create pDV68. Finally, the complete TPL fragment described above was then added to the unique *Bam* HI site of this plasmid to create pDV69.

Construction of Stable Cell Lines. E1-2a cells were electroporated as previously described (Von Seggern *et al.*, *J. Gen. Virol.* 79:1461-1468 (1998)) with pDV61, pDV67, or pDV69, and stable lines were selected with 600 μ g/ml Zeocin (Invitrogen). Candidate clones were evaluated by immunofluorescence (Von

Seggern *et al.*, *J. Gen. Virol.* 79:1461-1468 (1998)) using a polyclonal antibody generated against the Ad2 fiber (Wickham *et al.*, *Cell* 73:309-319 (1993). Those lines expressing the highest level of nuclear fiber expression were further characterized. Line 601 and 633 were produced by transfection of pDV61 and pDV67, respectively, and therefore express the wildtype Ad5 fiber. Line 644 contains pDV69 and expresses the chimeric 5T3H fiber.

Virus Growth and Analysis. Adenovirus stocks were prepared in the indicated cell lines, and plaque-titered on 633 cells essentially as described (Von Seggern *et al.*, *J. Virol.* 73:1601-1608 (1999)). E1-2a cells (Gorziglia *et al.*, *J. Virol.* 70:4173-4178 (1996). and their derivatives contain a dexamethasone-inducible construct for complementation of E1a. 601, 633, or 644 cells were therefore treated with 0.3 μ M dexamethasone for 24 hours prior to infection, and 0.5 μ M dexamethasone was included in the overlay for plaque assays. Protein concentration of viral preparations was determined using the BioRad Protein Assay (BioRad) with purified bovine serum albumin as a standard. Particle number was calculated using the formula 1 μ g protein = 4×10^9 viral particles. Western blotting was performed as described (Von Seggern *et al.*, *J. Gen. Virol.* 79:1461-1468 (1998)) using polyclonal rabbit antibodies raised against either the Ad2 (Wickham *et al.*, *Cell* 73:309-319 (1993) or Ad3 fibers (Stevenson *et al.*, *J. Virol.* 71:4782-4790 (1997).

Determination of infection and binding to receptor was performed using methods known to those of skill in the art. 2×10^5 cells in a total volume of 200 μ l were incubated with the indicated Ad preparation for three hours at 37 °C. Cells were then washed twice with fresh medium, and returned to 37 °C. Two days later, cells were fixed and stained with X-gal and counted by light microscopy as described (Von Seggern *et al.*, *J. Virol.* 73:1601-1608 (1999)). For competition assays, cells were pre-incubated on ice for one hour with either recombinant Ad3 fiber (10 μ g/ml) purified from baculovirus or with a crude baculovirus lysate (100 μ g/ml) containing the recombinant Ad2 fiber protein (Wickham *et al.*, *Cell* 73:309-319 (1997)). Expression of α_v integrins on cell surfaces was assayed by FACS assay using monoclonal antibodies (the gift of David Cheresh, TSRI) against either $\alpha_v\beta_3$ (LM609) or $\alpha_v\beta_5$ (P1F6) as previously described (Huang *et al.*, *Proc. Natl. Acad. Sci. USA* 94:8156-8161 (1997)). For virus binding assays, CsCl-purified Ad2 or Ad3 was labeled with 125 I using Iodogen tubes (Pierce). Free iodine was removed by filtration with a PD-10 Sephadex column (Pharmacia). Cells (1×10^6 cells in a volume of 200 μ l either with or without a 100-fold excess of unlabeled virus) were rocked at 4 °C for

two hours with 1×10^6 cpm of the labeled virus, washed three times with PBS and counted.

Altered in vitro tropism and infection of B lymphoid cell lines.

Experiments with genetically modified viruses showed that a number of different cell types are more readily infected through interaction with the Ad3 receptor than by the CAR-dependent pathway used by Ad5 (Stevenson *et al.*, *J. Virol.* 71:4782-4790 (1997)). In order to further evaluate the pseudotyping system, the ability of Ad5. β gal. Δ F carrying either the Ad5 or chimeric 5T3H fibers to infect several cell lines was assayed: FaDu (a head and neck tumor line), THP-1 monocytic cells, and MRC-5 fibroblasts were assayed. Consistent with the previous studies (Stevenson *et al.*, *J. Virol.* 71:4782-4790 (1997)), use of the chimeric Ad5/Ad3 fiber protein increased infection of all of these lines at equal particle/cell ratios. In contrast, the rat smooth muscle cell line A-10 was infected somewhat more readily by Ad5- than by Ad3-pseudotyped particles.

Gene delivery to EBV-infected B cells could allow the development of therapies for a variety of lymphoproliferative disorders. For example, *ex vivo* purging of donor marrow to eliminate infected cells could reduce the risk of EBV-associated lymphoproliferative disease, and EBV-induced malignancies such as AIDS-associated lymphoma are also potential targets. However, neither B cells nor EBV-transformed lymphoblastoid cell lines (LCLs) are efficiently infected by Ad5-based vectors. As the tropism of Ad3-pseudotyped particles appeared to be somewhat broader, it was asked whether EBV-infected LCLs could be infected using this system. The ability of Ad3-pseudotyped particles to infect LCLs generated by EBV infection of lymphocytes from three different normal human donors was tested. In agreement with previous reports, there was little or no infection of these by particles carrying the Ad5 fiber. In contrast, virus particles equipped with the chimeric fiber protein were able to efficiently infect all of these lines. At equal particle/cell ratios, all LCLs examined were at least 10-fold more infectible using the Ad3 receptor.

Further studies were performed to correlate the efficiency of infection with the level of attachment and internalization receptors expressed by the cells. The three LCL lines tested all bound very low levels of radiolabeled Ad2 particles, indicating that they expressed little or no CAR. In contrast, all three were able to specifically bind labeled Ad3 particles. This result suggested that fiber receptor distribution was largely responsible for the increased infection of these cells by Ad3-pseudotyped particles. *Selective gene delivery to EBV-infected cells.* The results above

suggested that the minority of EBV-infected B cells present in donor marrow or peripheral blood would be preferentially infected by vectors using the Ad3 receptor. To test this hypothesis, a mixing experiment with normal uninfected peripheral blood mononuclear cells (PBMCs) and EBV-infected cells was performed. JR-LCL cells were mixed at varying ratios with PBMCs isolated from a normal human donor, and the mixture was then infected with Ad5. β gal. Δ F particles containing the 5T3H fiber protein. No infection of normal PBMCs alone was detected. Moreover, the percent of total cells infected increased with the fraction of JR cells added. These experiments indicate that EBV-infected cells can be selectively infected *in vitro* by relatively short (3 hours) exposure to a retargeted Ad vector.

Example 16

Production of Adenovirus Vectors by Addition of Exogenous Fiber

The production of fiberless viruses by growth in a complementing cell line may result in a preparation that also contains contaminating fiber genome resulting from recombination in the complementing cell lines. This disadvantage is eliminated by addition of exogenous fiber to a fiberless adenovirus vector.

Production of fiberless virus by standard methods may include a two-step preparation protocol. This has been described in the earlier examples and is briefly described here again as follows:

Step I - amplification of fiber containing fiberless virus (Ad5/F⁻/F⁺ or Ad5. β gal. Δ F - fiberless, but there is fiber on the surface, not encoded in genome) on 211B cell line (which stably expresses fiber), followed by CsCl-purification and characterization.

Step II - preparation of virus particles lacking fiber (Ad5F⁻) by infection of S.8 cell line with Ad5/F⁻/F⁺, followed by CsCl purification and characterization. This produces a large stock of particles which do not contain fiber.

Step 1 is necessary because the infection efficiency of fiberless virus is extremely low, e.g. the dose of 20,000 particles/cell of Ad5/ β g F⁻ gives only 10% infected cells.

Contrary to the above, the production of fiberless virus by addition of exogenous fiber involves only a one-step protocol. The fiberless virus is amplified using the S.8 cell line with addition of exogenous fiber into infection media. The

amount of exogenous fiber necessary for production is very low, no more than 75ng of purified fiber required per roller bottle. If desired the process may be followed by CsCl purification. As mentioned above, one advantage to this protocol is that it should provide no chance for recombination of adenovector during preparation.

A 10 roller bottle (RB) preparation of fiberless virus was made using the above two-step procedure. The yield of adenovector was 6.6×10^{12} particles - total Ad/ β galF. A 1 RB preparation of fiberless adenovector was also made from the same initial material using a one-step procedure with exogenous fiber. The total yield was 2.5×10^{11} particles - Ad5 β galF (one step procedure).

DNA was isolated from both preparations and a PCR assay for fiber contamination was performed. (Figure 28). The PCR assay was developed for detection of very low amounts of fiber contamination, as low as 10^{-18} g. PCR assay showed much lower contamination for the preparation which was done by adding exogenous fiber (10^{-15} g one-step procedure) vs. 10^{-8} two-step procedure). Therefore, less contamination was obtained by simpler one-step approach.

Experiments were done using soluble purified fiber which does not have His-taq on the end (Ad5Fiber = 5F) and with His-taq on the end (Ad5Fiber His = 5FHis). These experiments showed that addition of Ad5Fiber can dramatically increase transduction efficiency of fiberless adenovector by simply adding it exogenously to a fiberless vector. The presence of the His tag on the Ad5FiberHis doesn't have any effect.

The results of these experiments suggest that the fiber is self-assembling with the fiberless vector. This self-assembled virus can then infect cell through the normal entry pathway. (Figure 29) Also, an experiment was done using conditioned media from 633 cell line, which can stably express fiber. A Western blot analysis for 633 condition media, showed that soluble fiber was present in the media during the period of cultivation of this cell line. Presence of soluble fiber in the media gives the possibility to increase transduction efficiency of fiberless adenovector on the HDF cell line. (Figure 30) Because the HDF cell line doesn't have a CAR-receptor, it is especially difficult to transduce this particular cell line, not only with fiberless vector, but also with regular fiber containing adenovector. Different amounts of 633 conditioned media (250 μ l, 500 μ l or 1000 μ l) were added to infectious media during the incubation period with fiberless adenovector.

This experiment also showed a role of soluble fiber in the process of cell entry. The conclusion is that by adding any fiber (wild-type, mutated, with ligand fusions) as long as one has the wild-type shaft (or region necessary to bind penton) one can retarget fiberless vector with any genome inside (gutless, oncolytic, expressing any transgene, etc.) to any cell type that your fiber is specific to. The advantage of this approach is that one does not have to make vectors with each new ligand. Just one fiberless vector need be made that can then be used to make different backbones by adding an exogenous "targetable" fiber off the shelf.

The foregoing specification, including the specific embodiments and examples, is intended to be illustrative of the present invention and is not to be taken as limiting. Numerous other variations and modifications can be effected without departing from the true spirit and scope of the present invention. All publications, patents and patent applications cited herein are incorporated by reference in their entirety into the present disclosure.

What is claimed is:

1. An isolated nucleic acid molecule comprising an adenovirus tripartite leader (TPL) nucleotide, said TPL nucleotide sequence comprising (a) first and second different TPL exons or (b) first, second and third same or different TPL exons, said TPL exons selected from the group consisting of complete TPL exon 1, partial TPL exon 1, complete TPL exon 2 and complete TPL exon 3, wherein said isolated nucleic acid molecule may not comprise the nucleic acid sequence consisting of partial TPL exon 1, complete TPL exon 2 and complete TPL exon 3.
2. The isolated nucleic acid molecule of claim 1, wherein said sequence is operatively linked to an intron containing an RNA processing signal.
3. The isolated nucleic acid molecule of claim 1 or 2 wherein said TPL nucleotide sequence consists essentially of complete TPL exon 1 operatively linked to complete TPL exon 2 operatively linked to complete TPL exon 3.
4. The isolated nucleic acid molecule of claim 2 wherein said intron is native adenovirus intron 1.
5. The isolated nucleic acid molecule of any one of claims 1 to 4 wherein said TPL nucleotide sequence is shown in SEQ ID NO: 32.
6. The isolated nucleic acid molecule of claim 5 further comprising a promoter and a nucleic acid sequence which encodes an adenoviral structural protein, operatively linked to said promoter and said TPL sequence.
7. The isolated nucleic acid molecule of claim 6 wherein said adenoviral structural protein is a fiber protein or a chimeric protein which includes an adenovirus fiber protein tail domain.
8. The isolated nucleic acid molecule of claim 7 wherein said chimeric protein comprises an Ad3 head domain and an Ad5 tail domain or an Ad5 head domain and an Ad3 tail domain.

9. The isolated nucleic acid molecule of claim 7 wherein said molecule is contained in a plasmid selected from the group consisting of plasmids pCLF, pDV60, pDV67, pDV69, pDV80 and pDV90.
10. The isolated nucleic acid molecule of claim 9 wherein said molecule has a nucleotide sequence selected from the group consisting of sequences shown in SEQ ID NO: 8, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 64 and SEQ ID NO: 65.
11. An adenovirus vector complementing plasmid comprising an isolated nucleic acid molecule according to any one of claims 1 to 10.
12. An adenovirus vector packaging cell line comprising a stably integrated nucleic acid molecule as claimed in any one of claims 1 to 11, an operatively-linked promoter and a nucleic acid sequence which encodes an adenovirus structural protein, wherein said TPL sequence consists essentially of a first complete TPL exon operatively linked to a complete second TPL exon operatively linked to a complete third TPL exon.
13. The cell line of claim 12 wherein said first TPL exon is a complete or partial first TPL exon.
14. The cell line of claim 13 wherein said TPL molecule comprises complete TPL exon 1 having the nucleotide sequence of SEQ ID NO: 32 or partial TPL exon 1 having the nucleotide of SEQ ID NO: 26.
15. The cell line of claim 12 wherein said promoter is an inducible promoter.
16. The cell line of claim 12 wherein said adenovirus structural protein is adenovirus fiber protein or a chimeric protein which includes an adenovirus fiber protein tail domain.
17. The cell line of claim 12 wherein said chimeric protein comprises an Ad3 head domain and an Ad5 tail domain or an Ad5 head domain and an Ad3 tail domain.

18. The cell line of claim 12 wherein said nucleic acid molecule is selected from the group consisting of plasmids pDV60, pDV67, pDV69, pDV80 and pDV90.

19. The cell line of claim 18 wherein said nucleic acid molecule has a nucleotide sequence from the group consisting of sequences shown in SEQ ID NO: 43, SEQ ID NO: 44 and SEQ ID NO: 47.

20. The cell line of claim 12 wherein said cell line is an epithelial cell line.

21. The cell line of claim 20 wherein said cell line supports the production of a recombinant adenovirus vector genome by complementation of a deficient viral gene in said vector genome.

22. The cell line of claim 21 wherein said cell line further produces an adenovirus protein and thereby complements a deficient adenovirus gene in said vector genome, and wherein said cell line complements an adenovirus early protein gene and a fiber gene.

23. The cell line of claim 22 wherein the deletion of said deficient adenovirus gene is complemented by the expression of said gene under the control of an inducible promoter.

24. A recombinant adenovirus particle comprising a recombinant adenovirus vector genome wherein said genome does not encode or does not express sufficient adenovirus fiber protein to support packaging of a fiber-containing adenovirus particle without complementation of said fiber gene in a packaging cell, wherein said packaging cell comprises an isolated nucleic acid molecule comprising an adenovirus tripartite leader (TPL) nucleotide sequence, and optionally an exogenous protein, said TPL nucleotide sequence comprising (a) first and second different TPL exons or (b) first, second and third same or different TPL exons, said TPL exons selected from the group consisting of complete TPL exon 1, partial TPL exon 1, complete TPL exon 2 and complete TPL exon 3 and, wherein said isolated nucleic acid molecule may not comprise the nucleic acid sequence consisting of partial TPL exon 1, complete TPL exon 2 and complete TPL exon 3.

25. The recombinant adenovirus particle of claim 24 wherein said adenovirus vector genome does not encode one or more functional proteins selected from the group consisting of E1A, E1B, E2A, E2B, E3 and E4 protein.
26. The particle of claim 24 wherein said adenovirus vector genome is Ad5.Bgal. Δ F.
27. The particle of claim 24 wherein said adenovirus vector genome is contained in the adenovirus particle deposited under ATCC accession # VR2636 and corresponding to Ad5.Bgal. Δ F.
28. The particle of claim 24 wherein said particle lacks fiber protein or contains a modified fiber protein.
29. The particle of claim 24 wherein said particle comprises an adenovirus fiber protein or a chimeric protein having an adenovirus fiber protein tail domain, said chimeric protein comprising an Ad3 head domain and an Ad5 tail domain or an Ad5 head domain and an Ad3 tail domain.
30. The particle of claim 24 wherein said exogenous protein is a therapeutic gene product.
31. A helper-independent fiberless recombinant adenovirus vector genome comprising genes which:
- (a) encode all adenovirus structural gene products but do not express sufficient adenovirus fiber protein to package a fiber-containing adenovirus particle in a packaging cell without complementation of said fiber gene or said genome lacks at least the fibre gene, wherein said packaging cell comprises an isolated nucleic acid molecule comprising an adenovirus tripartite leader (TPL) nucleotide sequence, said TPL nucleotide sequence comprising (a) first and second different TPL exons or (b) first, second and third same or different TPL exons, said TPL exons selected from the group consisting of complete TPL exon 1, partial TPL exon 1, complete TPL exon 2 and complete TPL exon 3 and, wherein said isolated nucleic acid molecule may not comprise the nucleic acid sequence consisting of partial TPL exon 1, complete TPL exon 2 and complete TPL exon 3. and
 - (b) encode an exogenous protein.

32. The adenovirus vector genome of claim 31 wherein said adenovirus vector genome does not encode one or more functional proteins selected from the group consisting of E1A, E1B, E2A, E2B, E3 and E4 protein.

33. The adenovirus vector genome of claim 31 wherein said adenovirus vector genome is Ad5.Bgal. Δ F.

34. The adenovirus vector genome of claim 33 wherein said adenovirus vector genome has a nucleotide sequence shown in SEQ ID NO:27 and corresponds to Ad5.Bgal. Δ F.

35. The adenovirus vector genome of claim 31 wherein said adenovirus vector genome is contained in the adenovirus particle deposited under ATCC accession VR-2636 corresponding to Ad5.Bgal. Δ F.

36. The adenovirus vector genome of claim 31 wherein said exogenous protein is a therapeutic gene product.

37. An isolated nucleic acid that comprises the adenovirus vector genome of claim 31.

38. A method for producing an adenovirus vector particle containing a helper-independent fiberless recombinant adenovirus vector genome, said method comprising providing a packaging cell line which complements replication and packaging of said genome and a helper-independent fiberless recombinant adenovirus vector genome which is deficient in expressing sufficient functional fiber protein to support assembly of fiber-containing particles, wherein said packaging cell comprises an isolated nucleic acid molecule comprising an adenovirus tripartite leader (TPL) nucleotide, said TPL nucleotide sequence comprising (a) first and second different TPL exons or (b) first, second and third different TPL exons, said TPL exons selected from the group consisting of complete TPL exon 1, partial TPL exon 1, complete TPL exon 2 and complete TPL exon 3 and, wherein said isolated nucleic acid molecule may not comprise the nucleic acid sequence consisting of partial TPL exon 1, complete TPL exon 2 and complete TPL exon 3, and harvesting said particles produced by said cell line.

39. The method of claim 38 wherein said packaging cell line complements adenovirus fiber protein.

40. The method of claim 38 wherein said adenovirus vector genome comprises genes that:

(a) express all adenovirus structural gene products but do not express sufficient adenovirus fiber protein to package a fiber-containing adenovirus particle without complementation of said fiber gene or said genome lacks at least the fibre gene, and

(b) express an exogenous protein.

41. The method of claim 38 wherein said packaging cell line comprises a stably integrated first nucleic acid molecule alternatively operatively linked to a promoter, and said first nucleic acid is operatively linked to a second nucleic acid molecule encoding an adenovirus structural protein, wherein said first nucleic acid molecule comprises an adenovirus tripartite leader (TPL) nucleotide sequence operatively linked to an intron containing an RNA processing signal, said TPL nucleotide sequence comprising (a) first and second different TPL exons or (b) first, second and third different TPL exons, said TPL exons selected from the group consisting of complete TPL exon 1, partial TPL exon 1, complete TPL exon 2 and complete TPL exon 3 and wherein said isolated nucleic acid molecule may not comprise the nucleic acid sequence consisting of partial TPL exon 1, complete TPL exon 2 and complete TPL exon 3..

42. The method of claim 38 wherein said helper-independent fiberless recombinant adenovirus vector genome is introduced by infecting said cell line with a virus particle containing said genome.

43. The method of claim 42 wherein said particle is a particle comprising a helper-independent recombinant adenovirus vector genome comprising genes that:

(a) encode all adenovirus structural gene products but do not express sufficient adenovirus fiber protein to support packaging of a fiber-containing adenovirus particle without complementation of said fiber gene or said genome lacks at least the fibre gene, and

(b) encode an exogenous protein,

wherein said particle comprises an adenovirus fiber protein or a chimeric protein that includes an adenovirus fiber protein tail domain.

44. The method of claim 38 wherein said helper-independent fiberless recombinant adenovirus vector genome is introduced into said cell line by transfecting said cell line with said helper-independent fiberless recombinant adenovirus vector genome

45. The method of claim 44 wherein said adenovirus vector genome comprises genes which:

(a) encode all adenovirus structural gene products but do not express sufficient adenovirus fiber protein to package a fiber-containing adenovirus particle without complementation of said fiber gene or said genome lacks at least the fibre gene, and

(b) encode an exogenous protein.

46. The method of claim 38 wherein said packaging cell line is transfected with a nucleic acid molecule encoding adenovirus fiber protein.

47. The method of claim 46 wherein said nucleic acid molecule is a nucleic acid molecule comprising an adenovirus tripartite leader (TPL) nucleotide sequence, said TPL nucleotide sequence comprising (a) first and second different TPL exons or (b) first, second and third different TPL exons, said TPL exons selected from the group consisting of complete TPL exon 1, partial TPL exon 1, complete TPL exon 2 and complete TPL exon 3 and said molecule further comprises a sequence encoding adenovirus fiber protein.

48. The method of claim 39 wherein said adenovirus fiber protein is a modified fiber protein.

49. The method of claim 38 further comprising the step of coating said particle with adenovirus fiber protein.

50. A method for delivery of an exogenous gene to a target cell comprising contacting said cell with an amount of a recombinant adenovirus particle of claim 24 sufficient to infect said cell.

51. The method of claim 50 wherein said exogenous gene encodes a therapeutic gene product.
52. The method of claim 51 wherein said recombinant adenovirus particle contains a modified fiber protein which binds a preselected target cell and directs delivery of the particle to said target cell.
53. The method of claim 50 wherein said recombinant adenovirus particle comprises a helper-independent fiberless recombinant adenovirus vector genome comprising genes that:
- (a) encode all adenovirus structural gene products but do not express sufficient adenovirus fiber protein to package a fiber-containing adenovirus particle without complementation of said fiber gene or said genome lacks at least the fibre gene, and
 - (b) encode an exogenous protein.
54. The method of claim 50 wherein said modified fiber protein has an amino terminal head domain which binds to α_v integrins and thereby targets cells with α_v integrin receptors.
55. The method of claim 50 wherein said contacting is conducted *in vitro*.
56. The method of claim 55 wherein said contacting is conducted on cells of a tissue which are first removed from the body of a patient, and the cells are subsequently returned to said patient.
57. The method of claim 50 wherein said contacting is conducted *in vivo* by administering said recombinant adenovirus particle to a tissue of said patient.
58. The method of claim 57 wherein said administering is intravenously, intraperitoneally, by aerosol, topically or by injection.
59. A method for pseudotyping recombinant viral vectors comprising complementing a missing fiber gene of a helper-independent or helper dependent fiberless recombinant adenovirus vector genome by expressing in packaging cells a

fiber gene from a different adenoviral serotype than said recombinant adenovirus vector, thereby pseudotyping said vector.

60. A method for specifically targeting an adenovirus vector to a cell of choice comprising introducing a helper-independent or helper-dependent fiberless recombinant adenovirus vector genome into a packaging cell line for producing a fiber gene-deleted adenovirus vector, wherein said gene for a missing fiber protein is complemented with a gene for a desired modification for targeting the vector to a cell of choice.

61. A method for producing a modified adenovirus comprising providing *in vitro* an exogenous fiber protein to a fiberless adenovirus.

62. The method of claim 61, wherein said fiber is provided by adding fiber protein in a suitable buffer to a fiberless virus preparation, thereby producing a modified adenovirus.

63. The method of claim 61, wherein a helper-independent or helper-dependent fiberless recombinant adenovirus vector genome is introduced into a packaging cell line to produce a fiberless adenovirus to which exogenous fiber protein will be provided.

64. A method for delivering a heterologous gene to EBV-infected B cells comprising infecting said B cells with a pseudotyped Ad5 β gal. Δ F particle or other fiber-deleted adenovirus particle, said particle having a chimeric fiber including the receptor-binding knob domain of the adenovirus type 3 fiber.

65. The adenovirus particle of claim 24 wherein said adenovirus vector genome lacks a fibre gene or lacks a portion of the fibre gene sequence such that fibre protein is not expressed in sufficient quantities to support packaging.

66. The recombinant adenovirus particle of claim 24 comprising a helper-independent recombinant adenovirus vector genome comprising genes that:

(a) encode all adenovirus structural gene products but do not express sufficient adenovirus fiber protein to support packaging of a fiber-containing adenovirus particle without complementation of said fiber gene or said genome lacks at least the gene encoding fibre, and

(b) optionally encodes an exogenous protein.

67. The recombinant adenovirus particle of claim 24 wherein said particle further comprises a nucleic acid encoding an exogenous protein.

68. A method for producing a modified adenovirus comprising providing a packaging cell line for producing a fiberless adenovirus helper-dependent fiberless recombinant adenovirus vector genome and a helper virus vector, wherein said cell line complements at least a deficient fiber protein gene, thereby producing the modified adenovirus.

69. The packaging cell line of claim 9 wherein said cell line is selected from the group consisting of 293, A549, W163, HeLa, Vero, 211, 211A and an epithelial cell line comprising the stably integrated nucleic acid molecule.

70. The recombinant adenovirus particle of claim 21 wherein said exogenous protein is selected from a group consisting of a tumor-suppressor protein, a biologically active fragment thereof, a suicide protein and a biologically active fragment thereof.

71. A composition for preparing a therapeutic vector, said composition comprising a plasmid comprising an adenovirus genome lacking a nucleotide sequence encoding a fiber protein or a genome that is incapable of expressing sufficient fiber to result in packaging.

72. A method of delivering a heterologous gene to a human or any animal comprising providing said heterologous gene to a target cell wherein said target cell is contacted *in vivo* or *ex vivo* with an amount of a recombinant adenovirus particle of claim 24 sufficient to infect said cell and thereby deliver the heterologous gene.

73. The recombinant adenovirus vector particle of either claim 24 or 31, wherein no fiber protein is expressed.

74. The recombinant adenovirus vector particle of claim 24, wherein said genome expresses insufficient fiber to allow incorporation of said protein into the particle such that the particle cannot use the fiber pathway for infection.

75. The recombinant adenovirus genome of claim 31, wherein said genome expresses insufficient fiber to allow incorporation of said protein into a particle such that the particle cannot use the fiber pathway for infection.

76. A method for producing a gutless adenoviral vector particle comprising:

a) delivering a helper adenovirus vector genome to an adenovirus vector packaging cell, wherein said helper adenovirus vector genome lacks any gene encoding adenovirus fiber protein or lacks the ability to encode sufficient adenovirus fiber protein to produce an adenoviral vector comprising fiber protein in the absence of complementation by said packaging cell and wherein said packaging cell comprises the nucleic acid molecule of claim 2 operably linked to a promoter and to an adenoviral fiber protein or to a chimeric protein that includes an adenovirus fiber protein tail domain;

(b) delivering a gutless adenovirus vector genome to said packaging cell; and

(c) recovering the gutless adenoviral vector particle produced by said cell.

77. The method of claim 76, wherein said helper adenovirus vector genome is delivered by viral infection.

78. The method of claim 77, wherein said gutless adenovirus vector genome is delivered by transfection.

79. The method of claim 76, wherein said gutless adenovirus vector genome comprises an operable packaging sequence.

80. The method of claim 79, wherein said helper adenovirus vector genome has a mutation in its packaging sequence that renders said genome substantially incapable of being packaged as an adenoviral vector particle by said packaging cell.

81. The method of claim 79, wherein said helper adenovirus vector genome comprises recombinase sites flanking its packaging sequence and said packaging cell further comprises a nucleotide sequence encoding a recombinase.

82. The method of claim 81, wherein said recombinase site is a lox site and said recombinase is Cre.
83. A helper adenovirus particle comprising an adenovirus vector genome that does not encode or does not express sufficient adenovirus fiber protein to support packaging of a fiber-containing adenovirus particle without complementation of said fiber gene, wherein said genome has a mutation in its packaging sequence that renders said genome substantially incapable of being packaged.
84. The helper adenovirus particle of claim 83, wherein said mutation comprises a deletion of at least one nucleotide in said packaging sequence.
85. The helper adenovirus particle of claim 84, wherein said adenovirus vector genome does not encode functional proteins selected from the group consisting of E1A, E1B, E2A, E2B, E3, and E4 proteins.
86. A helper adenovirus particle comprising an adenovirus vector genome with recombinase sites flanking its packaging sequence, wherein said vector genome does not encode or does not express sufficient adenovirus fiber protein to support packaging of a fiber-containing adenovirus particle without complementation of said fiber gene.
87. The helper adenovirus particle of claim 86, wherein said adenovirus vector genome does not encode functional proteins selected from the group consisting of E1A, E1B, E2A, E2B, E3, and E4 proteins.
88. An adenovirus particle comprising a gutless adenoviral vector genome and a fiberless capsid.
89. An adenovirus particle comprising a gutless adenoviral vector genome and a capsid comprising a modified fiber protein.
90. A packaging cell for the production of a fiberless or fiber-modified gutless adenovirus particle comprising an adenovirus vector complementing plasmid and a nucleotide sequence encoding a recombinase, wherein said complementing plasmid

comprises the nucleic acid molecule of claim 2 operably linked to a promoter and to a nucleotide sequence encoding an adenoviral fiber protein or a chimeric adenoviral fiber protein.

91. The packaging cell of claim 90, wherein said complementing plasmid and said nucleotide sequence encoding a recombinase are stably integrated into the genome of said cell.

92. The packaging cell of claim 90, further comprising a helper adenovirus vector genome.

93. The packaging cell of claim 90, wherein said recombinase is Cre..




FIG. 1

- 2/30 -




FIG. 2

- 3/30 -




FIG. 3

- 4/30 -




FIG. 4

- 5/30 -




FIG. 5

B




FIG. 6

- 7/30 -




FIG. 7

- 8/30 -




FIG. 8

- 9/30 -




FIG. 9

pΔE1Bβgal




FIG. 10




FIG. 11

- 12/30 -




FIG. 12

- 13/30 -




FIG. 13

- 14/30 -




FIG. 14

- 15/30 -

A

Ad2/5	M	K	R	A	P	S	E	D	T	F	N	P	V	P	V	D	T	E	T	G	P	P	T	V	P	F	L	T	P	P	F	V	S	P	N	G	F	O	E	S	P		
Ad3	M	A	K	R	A	R	L	S	-	T	S	F	N	P	V	P	Y	E	D	E	S	S	-	Q	H	P	F	I	N	P	G	F	I	S	P	D	G	F	T	Q	S	P	
Ad19/37	M	S	K	R	A	R	V	E	D	-	F	N	P	V	P	Y	Q	A	R	N	Q	-	N	I	P	F	L	T	P	P	F	V	S	S	D	G	F	K	N	F	P		
Ad40 (1)	M	-	K	R	A	R	F	-	E	D	-	F	N	P	V	P	Y	E	H	Y	N	-	P	L	D	I	P	F	L	T	P	P	F	A	S	S	N	G	L	O	E	K	P
Ad40 (2)	M	-	K	R	T	R	-	I	E	D	-	F	N	P	V	P	Y	D	T	S	S	T	P	S	-	I	P	Y	V	A	P	P	F	V	S	S	D	G	L	O	E	N	P

B




FIG. 15

- 16/30 -




FIG. 16

- 17/30 -




FIG. 17

- 18/30 -





FIG. 18

- 19/30 -

A



B




FIG. 19

Improved Fiber-complementing Cell Lines




FIG. 20

- 21/30 -






FIG. 21

- 22/30 -


211B Cells (Human Embryonic Kidney)



MRC-5 Human Fibroblasts



A-10 Rat Aortic Endothelial Cells



THP-1 Human Monocytic Cells




FIG. 22

- 23/30 -




FIG. 23




FIG. 24

- 25/30 -




FIG. 25

- 26/30 -




FIG. 26




FIG. 27

PCR analysis for fiber presence contamination of fiberless adenonovectors.




FIG. 28

- 29/30 -




FIG. 29

- 30/30 -




FIG. 30

-1-

SEQUENCE LISTING

<110> Novartis Ag
The SCRIPPS RESEARCH INSTITUTE

<120> ADENOVIRUS VECTORS, PACKAGING CELL LINES, COMPOSITIONS,
AND METHODS FOR PREPARATION AND USE

<130> 1294.0010001

<140>

<141>

<160> 76

<170> PatentIn Ver. 2.1

<210> 1

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 1

cggtacacag aattcaggag acacaactcc

30

<210> 2

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 2

gcctggatcc gggaggttac gtaacgtggg aaac

35

<210> 3

<211> 12

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: linker

<400> 3

cgcggatccg cg

12

<210> 4

<211> 8710

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 4

cacctaaatt	gtaagcggtta	atattttgtt	aaaatttcg	ttaaattttt	gttaaatcag	60
ctcatttttt	aaccaatagg	ccgaaatcgg	caaaatccct	tataaatcaa	aagaatagac	120
cgagataggg	ttgagtgttg	ttccagtttg	gaacaagagt	ccactattaa	agaacgtgga	180
ctccaacgct	aaagggcgaa	aaaccgtcta	tcagggcgat	ggcccactac	gtgaaccatc	240
accctaatac	agtttttttg	ggtcgaggtg	ccgtaaagca	ctaaatcggg	accctaaggg	300
gagcccccga	tttagagctt	gacggggaaa	gccggcgaa	gtggcgagaa	aggaagggaa	360
gaaagcgaaa	ggagcggg	ctagggcgct	ggcaagtgt	gcggtcacgc	tgccgctaac	420
caccacaccc	gccgcgctta	atgcgcgcgt	acagggcgcg	tccatttcgc	cattcaggct	480
gcgcaactgt	tggaaggggc	gatcgggtgc	ggcctcttcg	ctattacgcc	agctggcgaa	540
agggggatgt	gctgcaaggc	gattaagttg	ggtaacgcca	gggttttccc	agtcacgacg	600
ttgtaaaacg	acggccagtg	aattgtaata	cgactcacta	tagggcgaa	tggttaccgg	660
gccccccctc	gaggtcgacg	gtatcgataa	gcttgataac	gaattcagga	gacacaactc	720
caagtgcata	ctctatgtca	ttttcatggg	actggtctgg	ccacaactac	attaatgaaa	780
tatttggcac	atcctcttac	actttttcat	acattgccca	agaataaaga	atcggttgtg	840
ttatgtttca	acgtgtttat	ttttcaattg	cagaaaattt	caagtcattt	ttcattcagt	900
agtatagccc	caccaccaca	tagcttatac	agatcacccg	accttaatca	aactcacaga	960
accctagtat	tcaacctgcc	acctccctcc	caacacacag	agtacacagt	cctttctccc	1020
cggctggcct	taaaaagcat	catatcatgg	gtaacagaca	tattcttagg	tggttatattc	1080
cacacggttt	octgtcgagc	caaacgctca	tcagtgatat	taataaactc	cccgggcagc	1140
tcacttaagt	tcattgtcgt	gtccagctgc	tgagccacag	gctgctgtcc	aacttgccgt	1200
tgcttaacgg	ggcggaagg	agaagtccac	gcctacatgg	gggtagagtc	ataatcgctc	1260
atcaggatag	ggcgggtggtg	ctgcagcagc	gcgcgaataa	actgctgccg	ccgcgcgtcc	1320
gtcctgcagg	aatacaacat	ggcagtggtc	tcctcagcga	tgattcgcac	cgcccgacgc	1380
ataaggcgcc	ttgtctctcg	ggcacagcag	cgcaccctga	tctcacttaa	atcagcacag	1440
taactgcagc	acagcaccac	aattattgtt	aaaatcccac	agtgaaggc	gctgtatcca	1500
aagctcatgg	cggggaccac	agaaccacgc	tgcccatcat	accacaagcg	caggtagatt	1560
aagtggcgac	ccctcataaa	cacgctggac	tggaaacatta	cctcttttgg	catgttgtaa	1620
ttcaccacct	cccggtacca	tataaacctc	tgattaaaca	tgccgccatc	caccaccatc	1680
ctaaaccagc	tgcccaaaac	ctgcccgcgg	gctatacact	gcagggaacc	gggactggaa	1740
caatgacagt	ggagagccca	ggactcgtaa	ccatggatca	tcattgctcg	catgatatac	1800
atgttggcac	aacacaggca	cacgtgcata	cacttcctca	ggattacaag	ctcctccgcg	1860
gtagaaccac	tatcccagg	aacaacccat	tcctgaatca	gcgtaaatcc	cacactgcag	1920
ggaagacctc	gcacgtaact	cacgttgtgc	attgtcaaag	tggtacattc	gggcagcagc	1980
ggatgatcct	ccagtatggt	agcgcgggtt	tctgtctcaa	aaggaggtag	acgatcccta	2040
ctgtacggag	tgccgcgaga	caaccgagat	cgtgttggtc	gtagtgtcat	gccaaatgga	2100
acgcgcgacg	tagtcatatt	tcctgaagca	aaaccagggt	cgggcggtgac	aaacagatct	2160
gcgtctccgg	tctgcgcgct	tagatcgctc	tgtgtagtag	ttgtagtata	tccactctct	2220
caaagcatcc	aggcgccccc	tggtctcggt	ttctatgtaa	actccttcat	gcgcgcgtgc	2280
cctgataaca	tccaccaccg	cagaataagc	cacaccacgc	caacctacac	attcgttctg	2340
cgagtccac	acgggaggag	cgggaagagc	atgttttttt	ttttattcca	ttttattcca	2400
aaagattatc	caaaacctca	aaatgaagat	ctattaagtg	aacgcgctcc	cctccggtgg	2460
cgtggtcaaa	ctctacagcc	aaagaacaga	taatggcatt	tgtaagatgt	tgcaaatggg	2520
cttccaaaag	gcaaacggcc	ctcacgtcca	agtgagcgta	aaggctaaac	ccttcagggtg	2580
gaatctctct	tataaacatt	ccagcacctt	caacctatgc	caaataattc	tcattctcgcc	2640
accttctcaa	tatatctcta	agcaaatccc	gaatattaag	tccggccatt	gtaaaaatct	2700
gctccagagc	gccctccacc	ttcagcctca	agcagcgaat	catgattgca	aaaattcagg	2760
ttctctcacg	acctgtataa	gattcaaaag	cggaacatta	acaaaaatac	cgcgatcccg	2820
taggtccctt	cgcagggcca	gctgaacata	atcgtgcagg	tctgcacgga	ccagcgcgcc	2880
cacttccccg	ccaggaaacct	tgacaaaaga	accacactg	attatgacac	gcatactcgg	2940
agctatgtct	accagcgtag	ccccgatgta	agctttgttg	catgggcggc	gatataaaat	3000
gcaaggtgct	gctcaaaaaa	tcaggcaaa	cctcgcgcaa	aaaagaaagc	acatcgtagt	3060
catgctcatg	cagataaagg	caggtaagct	ccggaaccac	cacagaaaaa	gacaccattt	3120
ttctctcaaa	catgtctgcg	ggtttctgca	taaacacaaa	ataaaaatac	aaaaaacat	3180
ttaaacatta	gaagcctgtc	ttacaacagg	aaaacaacc	cttataagca	taagacggac	3240
tacggccatg	ccggcgtagc	cgtaaaaaaa	ctggtaaccg	tgattaaaaa	gcaccaccga	3300
cagctcctcg	gtcatgtccg	gagtcataat	gtaagactcg	gtaaacacat	caggttgatt	3360
catcggtcag	tgctaaaaag	cgaccgaaat	agccccgggg	aatacatacc	cgcaggcgta	3420
gagacaacat	tacagcccc	ataggaggta	taacaaaatt	aataggagag	aaaaaacat	3480

aaacacctga	aaaaccctcc	tgcctaggca	aaatagcacc	ctcccgtccc	agaacaacat	3540
acagcgcttc	acagcggcag	cctaaccagtc	agccttacca	gtaaaaaaga	aaacctatta	3600
aaaaaacacc	actcgacacg	gcaccagctc	aatcagtcac	agtgtaaaaa	agggccaaagt	3660
gcagagcgag	tatatatagg	actaaaaaat	gacgtaacgg	ttaaagtcca	caaaaaacac	3720
ccagaaaaacc	gcacgcgaac	ctacgcccag	aaacgaaagc	caaaaaaccc	acaacttcoct	3780
caaatcgctca	cttcggtttt	cccacgtttac	gtaacttccc	ggatccgcgg	cattcacagt	3840
tctccgcaag	aattgattgg	ctccaattct	tggagtgggt	aatccggttag	cgagggtgccg	3900
ccggcttcca	ttcaggtcga	ggtggcccgg	ctccatgcac	cgcgacgcaa	cgcggggagg	3960
cagacaagggt	atagggcggc	gcctacaatc	catgccaaacc	cggttccatgt	gctcgccgag	4020
gcggcataaaa	tgcgcgtgac	gatcagcggt	ccagtgatcg	aagttaggct	ggttaagagcc	4080
gcgagcgatc	cttgaagctg	tccctgatgg	tcgtcatcta	cctgcctgga	cagcatggcc	4140
tgcaacgcgg	gcattccgat	gccgccggaa	gcgagaagaa	tcataatggg	gaaggccatc	4200
cagcctcgcg	tgcggaacgc	cagcaagacg	tagcccagcg	cgctcgccgc	catgccctgc	4260
ttcatccccg	tggcccgttg	ctcgcgtttg	ctggcggtgt	ccccggaaga	aatatatttg	4320
tatgtcttta	gttctatgat	gacacaaacc	ccgcccagcg	tcttgtcatt	ggcgaattcg	4380
aacacgcaga	gtcagtcggg	gcggcgcggt	cccaggtcca	cttcgcatat	taaggtgacg	4440
cgtgtggcct	cgaacaccga	gcgaccctgc	agcgaccgcg	ttaacagcgt	caacagcgtg	4500
ccgcagatcc	cgggcaatga	gatatgaaaa	agcctgaact	caccgcgacg	tctgtcgaga	4560
agtttctgat	cgaaaagtgc	gacagcgtct	ccgacctgat	gcagctctcg	gagggcgaag	4620
aatctcgtgc	tttcagcttc	gatgtagtag	ggcgtggata	tgtcctgcgg	gtaaatagct	4680
gcgcccgatgg	tttctacaaa	gatcgttatg	tttatcggca	ctttgcatcg	gccgcgctcc	4740
cgattccgga	agtgcctgac	attggggaaat	tcagcgagag	cctgacctat	tgcattctcc	4800
gccgtgcaca	gggtgtcacg	ttgcaagacc	tgctgaaac	cgaaactgcc	gctgtctctgc	4860
agccggtcgc	ggaggccatg	gatgcgatcg	ctgcggccga	tcttagccag	acgagcgggt	4920
tcggcccat	gggaccgcaa	ggaatcggtc	aatacactac	atggcggtgat	ttcatatgcg	4980
cgattgctga	tccccatgtg	tatcactggc	aaactgtgat	ggacgacacc	gtcagtgctg	5040
ccgtcgcgca	ggctctcgat	gagctgatgc	tttgggcccga	ggactgcccc	gaagtccggc	5100
acctcgtgca	cgcggatttc	ggctccaaca	atgtcctgac	ggacaatggc	cgcataacag	5160
cggtcattga	ctggagcgag	gcgatgttcg	gggattccca	atacgagggtc	gccaacatct	5220
tcttctggag	gcogtggttg	gcttgtatgg	agcagcagac	gcgctacttc	gagcggaggc	5280
atccggagct	tgcaggatcg	ccgcggctcc	gggcgtatat	gctccgcatt	ggtcttgacc	5340
aactctatca	gagcttggtt	gacggcaatt	ctgatgatgc	agcttgggcg	cagggtcgat	5400
gcgacgcaat	cgctccgatcc	ggagccggga	ctgtcgggcg	tacacaaatc	gcccgcagaa	5460
gcgcggccgt	ctggaccgat	ggctgtgtag	aagtactcgc	cgatagtggg	aaccgacgcc	5520
ccagcactcg	tccgagggca	aaggaaatagg	ggagatgggg	gaggctaact	gaaacacgga	5580
aggagacaat	accggaagga	acccgcgcta	tgacggcaat	aaaaagacag	aataaaacgc	5640
acgggtgttg	ggtcgtttgt	tcataaacgc	ggggttcggt	cccagggtcg	gcactctgtc	5700
gataccccac	cgagacccca	ttggggccaa	tacgcccgcg	tttcttcctt	ttccccacc	5760
caccccccaa	gttcgggtga	aggcccaggg	ctcgacgcca	acgtcggggc	ggcaggccct	5820
gccatagcca	ctggcccggt	gggttaggga	cgggggtccc	catggggaat	ggtttatggt	5880
tcgtgggggt	tattattttg	ggcgttgctg	ggggtctggt	ccacgactgg	actgacgaga	5940
cagaccatg	gtttttggat	ggcctgggca	tggaccgcat	gtactggcgc	gacacgaaca	6000
ccgggctct	gtggctgcca	aacacccccg	acccccaaaa	accacgcgcg	ggatttctgg	6060
cgcccagtg	cgtcgaccgg	tcatggctgc	gccccgacac	ccgccaaacac	ccgctgacgc	6120
gccctgacgg	gcttgtctgc	tcccggcatc	cgcttacaga	caagctgtga	ccgtctccgg	6180
gagctgcatg	tgtcagaggt	tttcaccgtc	atcacccgaa	cgcgcgaggc	agccggatca	6240
taatcagcca	taccacattt	gtagaggttt	tacttgcttt	aaaaaacctc	cccacctccc	6300
cctgaacctg	aaacataaaa	tgaatgcaat	tgttgttgtt	aacttgttta	ttcgagctta	6360
taatggttac	aaataaagca	atagcatcac	aaatttcaca	aataaagcat	ttttttcact	6420
gcattctagt	tgtggtttgt	ccaaactcat	caatgtatct	tatcatgtct	ggatccacta	6480
gttctagagc	ggcgcgccacc	gcggtggagc	tccagctttt	gttcccttta	gtgagggtta	6540
atttcgagct	tggcgtaatc	atggctcatag	ctgttttctg	tgtgaaattg	ttatccgctc	6600
acaattccac	acaacatacg	agccgggaagc	ataaagtgtg	aagcctgggg	tgccataatga	6660
gtgagctaac	tcacattaat	tgcggtgcgc	tcactgcccg	ctttccagtc	gggaaacctg	6720
tcgtgccagc	tgcattaatg	aatcggccaa	cgcgcgggga	gaggcggttt	gcgtattggg	6780
cgtcttccg	cttctcgtct	cactgactcg	ctgcgctcgg	tcgttcggct	gcggcgagcg	6840
gtatcagctc	actcaaaggc	ggtaatacgg	ttatccacag	aatcagggga	taacgcagga	6900
aagaacatgt	gagcaaaagg	ccagcaaaag	gccaggaacc	gtaaaaaggc	cgcggttgctg	6960
gcgtttttcc	ataggtccg	ccccctgac	gagcatcaca	aaaatcgacg	ctcaagtcag	7020
aggtggcgaa	acccgacagg	actataaaga	taccaggcgt	ttccccctgg	aagctccctc	7080
gtgcgctctc	ctgttccgac	cctgcccgtt	accggatacc	tgtccgcctt	tctcccttcg	7140
ggaagcgtgg	cgctttctca	tagctcacgc	tgtaggtatc	tcagttcggt	gtaggtcggt	7200

-4-

```

cgctccaagc tgggctgtgt gcacgaaccc cccggtcage ccgaccgctg cgccttatcc 7260
ggtaactatc gtcttgagtc caaccggtg agacacgact tatcgccact ggcagcagcc 7320
actggtaaca ggattagcag agcgagggtat gtaggcggtg ctacagagtt cttgaagtgg 7380
tggcctaact acggctacac tagaaggaca gtatttggta tctgcgctct gctgaagcca 7440
gttaccttcg gaaaaagagt tggtagctct tgatccggca aacaaaccac cgctggtagc 7500
ggtgggtttt ttgtttgcaa gcagcagatt acgcgcagaa aaaaaggatc tcaagaagat 7560
cctttgatct tttctacggg gtctgacgct cagtggaaacg aaaactcacg ttaagggtatt 7620
ttggtcatga gattatcaaa aaggatcttc acctagatcc ttttaaatta aaaatgaagt 7680
tttaaatcaa tctaaagtat atatgagtaa acttgggtctg acagttacca atgcttaatc 7740
agtgaaggcac ctatctcagc gatctgtcta tttcgttcat ccatagttgc ctgactcccc 7800
gtcgtgtaga taactacgat acgggagggc ttaccatctg gccccagtgc tgcaatgata 7860
ccgcgagacc cacgctcacc ggctccagat ttatcagcaa taaaccagcc agccggaagg 7920
gccgagcgca gaagtgggcc tgcaacttta tccgcctcca tccagtctat taattgttgc 7980
cgggaagcta gagtaagtag ttccgaggtt aatagtttgc gcaacgttgt tgccattgct 8040
acaggcatcg tgggtgcacg ctctgctgtt ggtatggctt cattcagctc cgggtcccaa 8100
cgatcaaggc gagttacatg atcccccatg ttgtgcaaaa aagcggttag ctccctcggt 8160
cctccgatcg ttgtcagaag taagttggcc gcagtgttat cactcatggt tatggcagca 8220
ctgcataatt ctcttactgt catgccatcc gtaagatgct tttctgtgac tgggtgagtac 8280
tcaaccaagt cattctgaga atagtgtatg cggcgaccga gttgtctctg cccggcgctca 8340
atacgggata ataccgcgcc acatagcaga actttaaaag tgctcatcat tggaaaacgt 8400
tcttcggggc gaaaactctc aaggatctta ccgctgttga gatccagttc gatgtaaccc 8460
actcgtgcac ccaactgata ttcagcatct tttactttca ccagcgtttc tgggtgagca 8520
aaaaacaggaa ggcaaaaatgc cgcaaaaaag ggaataaggg cgacacggaa atggtgaata 8580
ctcatactct tcctttttca atattattga agcatttatc aggggtattg tctcatgagc 8640
ggatacatat ttgaatgtat ttagaaaaat aaacaaatag gggttccgcg cacatttccc 8700
cgaaaaagtc

```

<210> 5
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 5
 atgggatcca agatgaagcg cgcaagaccg

30

<210> 6
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 6
 cataacgcgg ccgcttcttt attcttgggc

30

<210> 7
 <211> 7148
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: plasmid

<400> 7
 gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg 60

ccgcatagtt	aagccagtat	ctgctccctg	cttgtgtgtt	ggagggtcgt	gagtagtgcg	120
cgagcaaaat	taaagctaca	acaaggcaag	gcttgaccga	caattgcatg	aagaatctgc	180
ttagggttag	gcgtttttgcg	ctgcttcgcg	atgtacgggc	cagatatacg	cgttgacatt	240
gattattgac	tagttattaa	tagtaatcaa	ttacggggtc	attagttcat	agccccatata	300
tggagttccg	cgttacataa	cttacggtaa	atggccccgc	tggctgaccg	cccaacgacc	360
cccgccatt	gacgtcaata	atgacgtatg	ttcccatagt	aacgcccaata	gggactttcc	420
attgacgtca	atgggtggac	tatttaacgg	aaactgcccc	cttggcagta	catcaagtgt	480
atcatatgcc	aagtacgccc	cctattgacg	tcaatgacgg	taaatggccc	gcctggcatt	540
atgcccagta	catgacctta	tgggactttc	ctacttgcca	gtacatctac	gtattagtca	600
tcgctattac	catggtgatg	cggttttggc	agtacatcaa	tgggcgtgga	tagcggtttg	660
actcacgggg	atttccaaagt	ctccacccca	ttgacgtcaa	tgggagtttg	ttttggcacc	720
aaaatcaacg	ggactttcca	aaatgtcgta	acaactccgc	cccattgacg	caaatgggcg	780
gtaggcgtgt	acggtgggag	gtctatataa	gcagagctct	ctggctaact	agagaaccca	840
ctgcttactg	gcttatcgaa	attaatacga	ctcactatag	ggagacccaa	gcttggtacc	900
gagctcggat	ccaagatgaa	gcgcgcaaga	ccgtctgaag	ataccttcaa	ccccgtgtat	960
ccatatgaca	cggaacccgg	tcctccaact	gtgccttttc	ttactcctcc	ctttgtatcc	1020
cccaatgggt	ttcaagagag	tccccctggg	gtactctctt	tgcgcctatc	cgaacctcta	1080
gttacctcca	atggcatgct	tgcgctcaaa	atgggcaacg	gcctctctct	ggacgaggcc	1140
ggcaacctta	cctcccaaaa	tgtaaccaat	gtgagccac	ctctcaaaaa	aaccaagtca	1200
aacataaacc	tggaaatatac	tgcacccctc	acagttacct	cagaagccct	aactgtggct	1260
gccgcgcgac	ctctaattggt	cgcgggcaac	acactcacca	tgcaatcaca	ggccccgcta	1320
accgtgcacg	actccaaact	tagcattgcc	acccaaggac	ccctcacagt	gtcagaagga	1380
aagctagccc	tgcaaacatc	aggccccctc	accaccaccg	atagcagta	cttactatc	1440
actgcctcac	ccccctctaac	tactgccact	ggtagcttgg	gcattgactt	gaaagagccc	1500
atttatacac	aaaatggaaa	actaggacta	aagtacgggg	ctcctttgca	tgtaacagac	1560
gacctaaaca	ctttgaccgt	agcaactgg	ccaggtgtga	ctattaataa	tacttccctg	1620
caaaactaaag	ttactggagc	cttgggtttt	gattcacaa	gcaatatgca	acttaagtga	1680
gcaggaggac	taaggattga	ttctcaaaac	agacgcctta	tacttgatgt	tagttatccg	1740
tttgatgctc	aaaaccaact	aaatctaaga	ctaggacagg	gccctctttt	tataaaactca	1800
gcccacaact	tggatattaa	ctacaacaaa	ggcctttact	tgtttacagc	ttcaaaacaat	1860
tccaaaaagc	ttgagggttaa	cctaagcaact	gccaaggggt	tgatgtttga	cgctacagcc	1920
atagccatta	atgcaggaga	tgggccttga	tttgggtcac	ctaattgcacc	aaacacaaat	1980
cccctcaaaa	caaaaattgg	ccatggccta	gaatttgatt	caaacaaggc	tatggttcc	2040
aaactaggaa	ctggccttag	ttttgacagc	acaggtgcc	ttacagtagg	aaacaaaaat	2100
aatgataagc	taactttgtg	gaccacacca	gtcccatctc	ctaactgtag	actaaatgca	2160
gagaaagatg	ctaaactcac	tttggcttta	acaaaatgtg	gcagtcaa	acttgctaca	2220
gtttcagttt	tggctgttaa	aggcagtttg	gtcccaatat	ctggaacagt	tcaaagtgt	2280
catcttatta	taagatttga	cgaaaatgga	gtgctactaa	acaattcctt	cctggaccca	2340
gaatattgga	actttagaaa	tggagatctt	actgaaggca	cagcctatac	aaacgctgtt	2400
ggatttatgc	ctaacctatc	agcttatcca	aaatctcacg	gtaaaactgc	caaaagtaac	2460
attgtcagtc	aagtttactt	aaacggagac	aaaactaaac	ctgtaacact	aaccattaca	2520
ctaaacggta	cacaggaaac	aggagacaca	actccaagt	catactctat	gtcattttca	2580
tgggactgg	ctggccacaa	ctacattaat	gaaatatttg	ccacatcctc	ttacactttt	2640
tcatacattg	cccaagaata	aagaagcggc	cgctcgagca	tgcactctaga	gggccctatt	2700
ctatagtgtc	acctaaatgc	tagagctcgc	tgateagcct	cgactgtgcc	ttctagtgtc	2760
cagccatctg	ttgtttgccc	ctccccctg	ccttccctga	ccctggaagg	tgccactccc	2820
actgtccttt	cctaataaaa	tgaggaaatt	gcategcatt	gtctgagtag	gtgtcattct	2880
attctggggg	gtgggggtgg	gcaggacagc	aagggggagg	attgggaaga	caatagcagg	2940
catgctgggg	atgcgggtgg	ctctatggct	tctgaggcgg	aaagaaccag	ctggggctct	3000
agggggtatc	cccacgcgcc	ctgtagcggc	gcattaaagc	cggcggtgt	ggtggttacg	3060
cgcagcgtga	ccgctacact	tgccagcgcc	ctagcgcccg	ctcctttcgc	tttcttccct	3120
tcctttctcg	ccacgttcgc	cggctttccc	cgtaagctc	taaatcgggg	catcccttta	3180
gggttccgat	ttagtgtctt	acggcacctc	gaccccaaaa	aacttgatta	gggtgatgg	3240
tcacgtagt	ggccatcgcc	ctgatagacg	gtttttcgcc	ctttgacgtt	ggagtccacg	3300
ttctttaata	gtggactctt	gttccaaact	ggaacaacac	tcaacctat	ctcggctctat	3360
tcttttgatt	tataagggat	tttggggatt	tcggcctatt	ggttaaaaaa	tgagctgatt	3420
taacaaaaat	ttaacgcgaa	ttaattctgt	ggaatgtgtg	tcagttagg	tgtggaaagt	3480
ccccaggctc	cccaggcagg	cagaagtatg	caaagcatgc	atctcaatta	gtcagcaacc	3540
aggtgtggaa	agtccccagg	ctccccagca	ggcagaagta	tgcaaagcat	gcactcctca	3600
tagtcagcaa	ccatagtccc	gcccctaact	cgccccaatc	cgccccaatc	tcggccagct	3660
tccgccatt	ctccgccca	tggctgacta	atttttttta	tttatgcaga	ggccgaggcc	3720
gcctctgcct	ctgagctatt	ccagaagtag	tgaggaggct	tttttgagg	cctaggcttt	3780

tgcaaaaagc	tcccgggagc	ttgtatatcc	attttcggat	ctgatcaaga	gacaggatga	3840
ggatcgtttc	gcatgattga	acaagatgga	ttgcacgcag	gttctccggc	cgcttgggtg	3900
gagaggctat	tccggctatga	ctgggcacaa	cagacaatcg	gctgctctga	tgccgccgtg	3960
ttccggctgt	cagcgcaggg	ggcccccgtt	ctttttgtca	agaccgacct	gtccggtgcc	4020
ctgaatgaac	tgcaggacga	ggcagcgcgg	ctatcgtggc	tggccacgac	gggcgttcc	4080
tgcgcagctg	tgtctgcagc	tgtcactgaa	gcgggaaggg	actggctgct	attgggcgaa	4140
gtgccggggc	aggatctcct	gtcatctcac	cttgctcctg	ccgagaaagt	atccatcatg	4200
gctgatgcaa	tgcggcggct	gcatacgcct	gatccggcta	cctgccatt	cgaccaccaa	4260
gcgaacatc	gcatcgagcg	agcacgtact	cggatggaag	ccggtcttgt	cgatcaggat	4320
gatctggacg	aagagcatca	ggggctcgcg	ccagccgaac	tggtcgccag	gctcaaggcg	4380
cgcatgcccc	acggcgagga	tctcgtcgtg	acccatggcg	atgcctgctt	gccgaatata	4440
atggtggaaa	atggccgctt	ttctggattc	atcgactgtg	gccggctggg	tgtggcgga	4500
cgctatcagg	acatagcgtt	ggctaccctg	gatattgctg	aagagcttgg	cggcgaatgg	4560
gctgaccgct	tcctcgtgct	ttacggtatc	gccgctcccc	attcgcagcg	catcgcttc	4620
tatcgcttct	ttgacgagtt	cttctgagcg	ggactctggg	gttcgaaatg	accgaccaag	4680
cgacgcccac	cctgccatca	cgagatttct	attccaccgc	cgcttcttat	gaaaggttgg	4740
gcttcggaat	cgttttccgg	gacgcgggct	ggatgatcct	ccagcgcggg	gatctcatgc	4800
tggagttctt	cgcccccccc	aacttggtta	ttgcagctta	taatggttac	aaataaagca	4860
atagcatcac	aaatttcaca	aataaagcat	ttttttcact	gcattctagt	tgtggtttgt	4920
ccaaactcat	caatgtatct	tatcatgtct	gtataccgtc	gacctctagc	tagagcttgg	4980
cgtaatcatg	gtcatagctg	tttctgtgtg	gaaattgtta	tccgctcaca	attccacaca	5040
acatacagag	cggaagcata	aagtgtaaag	cctgggggtg	ctaattgagt	agctaactca	5100
cattaattgc	gttgcgctca	ctgcccgcct	tccagtcggg	aaacctgtcg	tgccagctgc	5160
attaatgaat	cggccaaacgc	gcggggagag	gcggtttgcg	tattgggcgc	tcttccgctt	5220
cctcgctcac	tgactcgctg	cgctcggtcg	ttcggctgcg	gcgagcggta	tcagctcact	5280
caaaagcggt	aatacgggta	tccacagaat	caggggataa	cgcaggaaag	aacatgtgag	5340
gaaagggcca	gcaaaaggcc	aggaaccgta	aaaaggccgc	gttgctggcg	tttttccata	5400
ggctccgccc	ccctgacgag	catcacaaaa	atcgacgctc	aagtcagagg	tggcgaaacc	5460
cgacaggact	ataaagatac	caggcgcttc	cccctgggag	ctccctcgtg	cgctctcctg	5520
ttccgaccct	gccgcttacc	ggatacctgt	ccgcctttct	cccttcggga	agcgtggcgc	5580
tttctcaatg	ctcacgctgt	aggtatctca	gttcgggtgta	ggtegttcgc	tccaagctgg	5640
gctgtgtgca	cgaaccccc	gttcagcccg	accgctgcgc	cttatccggt	aactatcgte	5700
ttgagtccaa	cccggtaaga	cacgacttat	cgccactggc	agcagccact	ggtaacagga	5760
ttagcagagc	gagggtatgta	ggcgggtgta	cagagttctt	gaagtgttgg	cctaactacg	5820
gctacactag	aaggacagta	tttggtatct	gcgctctgct	gaagccagtt	accttcggaa	5880
aaagagttgg	tagctcttga	tccggcaaac	aaaccaccgc	tggtagcggt	ggtttttttg	5940
tttgcaagca	gcagattacg	cgcagaaaaa	aaggatctca	agaagatcct	ttgatctttt	6000
ctacggggtc	tgacgctcag	tggaaacgaaa	actcacgtta	agggattttg	gtcatgagat	6060
tatcaaaaag	gatcttccac	tagatccttt	taaattaaaa	atgaagtttt	aaatcaatct	6120
aaagtataata	tgagtaaaact	tggctcgaca	gttaccatg	cttaatcagt	gaggcaccta	6180
tctcagcgat	ctgtctatct	cgttcatcca	tagttgcctg	actccccgtc	gtgtagataa	6240
ctacgatacg	ggagggctta	ccatctggcc	ccagtgcgtc	aatgataccg	cgagaccac	6300
gctcaccggc	tccagattta	tcagcaataa	accagccagc	cggaagggcc	gagcgcagaa	6360
gtggtcctgc	aacttttatcc	gcctccatcc	agtctattaa	ttgttgccgg	gaagctagag	6420
taagtagttc	gccagttaat	agtttgcgca	acgttggtgc	cattgctaca	ggcatcggtg	6480
tgtcacgctc	gtcgtttggg	atggcttcat	tcagctccgg	ttcccaacga	tcaaggcgag	6540
ttacatgatc	ccccatggtg	tgcaaaaaag	cggttagctc	cttcggctcct	ccgatcgttg	6600
tcagaagtaa	gttgccgcga	gtgttatcac	tcattggtat	ggcagcactg	cataattctc	6660
ttactgtcat	gccatccgta	agatgctttt	ctgtgactgg	tgagtactca	accaagtcat	6720
tctgagaata	gtgtatgcgg	cgaccgagtt	gctcttgccc	ggcgtaata	cggtataata	6780
ccgcgccaca	tagcagaact	ttaaaagtgc	tcacattggg	aaaacgttct	tccgggcgaa	6840
aactctcaag	gatcttaccg	ctgttgagat	ccagttcgat	gtaaccact	cgtgcaccca	6900
actgatcttc	agcatctttt	actttcacca	gcgtttctgg	gtgagcaaaa	acaggaaggc	6960
aaaaatgcgc	aaaaaaggga	ataaggcgga	cacggaaatg	ttgaatactc	atactcttc	7020
tttttcaata	ttattgaagc	atttatcagg	gttattgtct	catgagcgga	tacatatttg	7080
aatgtattta	gaaaaataaa	caaatagggg	ttccgcgcac	atttccccga	aaagtgccac	7140
ctgacgctc						7148

<210> 8
 <211> 7469
 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 8

```
gacggatcgg gagatctccc gatcccttat ggtcgactct cagtacaatc tgctctgatg 60
ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180
ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt 240
gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata 300
tggagttccg cgttacataa cttacggtaa atggcccgc tggtgaccg cccaacgacc 360
ccgcccatt cagctcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420
attgacgtca atgggtggac tatttacggt aaactgccc cttggcagta catcaagtgt 480
atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540
atgcccagta catgacctta tgggactttc ctacttgga gtacatctac gtattagtca 600
tcgctattac catgggtgat cgggttttggc agtacatcaa tgggcgtgga tagcggtttg 660
actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc 720
aaaatcaacg ggactttcca aaatgtcgta gacagctct ctggctaact caaatgggcg 780
gtaggcgtgt acggtgggag gtctatataa ctcactatag ggagaccгаа gcttggtaac 840
gagctcggt ctgaattcga gctcgctgtt gggctcgcg ttgaggacaa actcttcgcg 960
gtctttccag tactcttgga tcggaaaccc cggaaaacct ctcgagaaag gcgtctaacc 1020
gggacctgag cgagtcgcga tcgaccggat ctgagcaccg tggcggggcg cagcgggtgg cggtcggggg 1080
agtcacagtc gcaaggtagg ctgagcaccg tggcggggcg ggcggtcttg agacggcgga 1140
tggtttctggc ggaggtgctg ctgatgatgt aattaaagta agcgcgcaag accgtctgaa 1200
tggtcgaggt gaggtgtggc aggccttga tccaagatga accgaaaccg gtctccaac tgtgcctttt 1320
gataccttca acccgtgta tccatatgac cccaatggg tttcaagaga gtcccccctg ggtactctct 1380
cttactctc cctttgtate agttacctcc aatggcatgc ttgcgctcaa aatgggcaac 1440
ttgcgcctat ccgaacctct cggcaacctt acctcccaaa atgtaaccac tgtgagccca 1500
ggcctctctc tggacgaggg aaacataaac cctctaattg tcgcgggcaa cacagttaac 1560
cctctcaaaa taactgtggc tgccgcccga cctctaattg ttgacattgc caccaccacc 1620
tcagaagccc agggcccgt aaccgtgcac gactccaaac ttagcattgc caccaccacc 1680
atgcaatcac agggcccgt aaagctagcc ctgcaaacat caggcccctt caggcccctt 1740
cccctcacag tgtcagaagg cactgcctca cccctctaaa ctactgccac tggtagcttg 1800
gatagcagta cccttactat cactgcctca ccaaatggaa aactaggact aaagtacggg 1860
ggcattgact tgaagagacc catttataca caaaatggaa aactaggact tccaggtgtg 1920
gtcctcttgc atgtaacaga cgacctaaac actttgaccg tagcaactgg tgcattcaca 1980
actattaata atactcctt gcaaactaaa gttactggag ccttgggttt cagacgcctt 2040
ggcaatatgc aacttaattg agcaggagga ctaaggattg attctcaaaa actaggacag 2100
atacttgatg ttagttatcc gtttgatgct gttgataatg taaatctaag aggcctttac 2160
ggccctcttt ttataaaact agcccacaac ttggatatta actacaacaa aggcctttac 2220
ttgtttacag cttcaaaaca ttccaaaag cttgaggtta acctagcagc tgccaagggg 2280
ttgatgttg acgctacagc catagccatt aatgcaggag atgggcttga atttggttca 2340
cctaattgcac caaacacaaa tcccctcaaa acaaaaattg gccatggcct agaatttgat 2400
tcaaaacaagg ctatggttcc taaactagga actggcctta gttttgacag cacaggtgcc 2460
attacagtag gaaacaaaaa taatgataag ctaactttgt ggaccacacc agctccatct 2520
cctaactgta gactaaatgc agagaaagat gctaaactca ctttggctct aacaaaatgt 2580
ggcagtcaaa tacttgctac agtttcagtt ttggtgttta aaggcagttt ggctccaata 2640
tctggaacag ttcaaaagtgc tcatcttatt ataagatttg acgaaaatgg agtgctacta 2700
aacaattcct tcctggaccc agaatttttg aacttttaga atggagatct tactgaaggc 2760
acagcctata caaacgctgt tggatttatg cctaacctat cagcttatcc aaaaactcac 2820
ggtaaaactg ccaaaagtaa cattgtcagt caagtttact taaacggaga aactccaagt 2880
cctgtaacac taaccattac actaaacggt acacaggaaa caggagacac aactccaagt 2940
gcatactcta tgtcattttc atgggactgg tctggccaca actacattaa tgaaatattt 3000
gccacatcct cttacacttt tcatcacatt gcccagaat aaagaagcgg ccgctcgagc 3060
atgcatctag agggccctat tctatagtgt cacctaaatg cttagagctg ctgacagcc 3120
tcgactgtgc cttctagtgt ccagccatct gttgtttgcc cctccccgtg gccttccttg 3180
accctggaag gtgccactcc cactgtcctt tcttaataaa atgaggaaat tgcacgcat 3240
tgtctgagta ggtgtcattc tattctgggg gctgaggtgg ggcaggacag caagggggag 3300
gattgggaag acaatagcag gcatgctggg gatgcggtgg gctctatggc ttctgaggcg 3360
gaaagaacca gctggggctc taggggggtat ccccaacgcg cctgtagcgg cgcattaaag
```

gcgccgggtg	tgggtggttac	gcgcagcgtg	accgctacac	ttgccagcgc	cctagcgcgc	3420
gctccttttcg	ctttcttccc	ttcctttctc	gccacgttcg	ccggctttcc	ccgtcaagct	3480
ctaaatcggg	gcaccccttt	aggggtccga	tttagtgctt	tacggcacct	cgaccccaaa	3540
aaacttgatt	aggtgatgg	ttcacgtagt	gggccatcgc	cctgatagac	ggtttttcgc	3600
cctttgacgt	tggagtccac	gttctttaat	agtggactct	tggtccaaac	tggacaaca	3660
ctcaacccta	tctcggctta	ttcttttgat	ttataaggga	ttttggggat	ttcggcctat	3720
tggttaaaaa	atgagctgat	ttaacaaaaa	tttaacgcga	attaattctg	tggaaatgtg	3780
gtcagttagg	gtgtggaaag	tccccaggct	ccccaggcag	gcagaagtat	gcaaagcatg	3840
catctcaatt	agtcagcaac	cagggtgtgga	aagtccccag	gctccccagc	aggcagaagt	3900
atgcaaagca	tgcattctca	ttagtacgca	accatagtc	cgccccctaac	tccgccccatc	3960
ccgccccctaa	ctccgcccag	ttccgccccat	tctccgcccc	atggctgact	aatttttttt	4020
atztatgcag	aggccgaggc	cgcctctgccc	cttgagctat	tccagaagta	gtgaggaggc	4080
ttttttggag	gcctaggctt	ttgcaaaaag	ctccggggag	cttgatatatc	catttttcgga	4140
tctgatcaag	agacaggatg	aggatcggtt	cgcatgattg	aacaagatgg	attgcacgca	4200
ggttctccgg	ccgcttgggt	ggagaggcta	ttcggctatg	actgggcaca	acagacaatc	4260
ggctgctctg	atgccgccgt	gttccggctg	tcagcgcagg	ggcgcccggt	tctttttgtc	4320
aagaccgacg	tgtccgggtg	cctgaatgaa	ctgcaggacg	aggcagcgcg	gctatcggtg	4380
ctggccacga	cggtcggtcc	ttgcgcagct	gtgctcgacg	ttgtcactga	agcgggaagg	4440
gactggctgc	tattgggcga	agtgcggggg	caggatctcc	tgctatctca	ccttgctcct	4500
gccgagaaaag	tatccatcat	ggctgatgca	atgcggcggc	tgcatacgct	tgatccggct	4560
acctgcccat	tgcaccacca	agcgaaacat	cgcactcgagc	gagcacgtac	tccgattgga	4620
cccggtcttg	tcgatcagga	tgatctggac	gaagagcatc	aggggctcgc	gccagccgaa	4680
ctgttcgccca	ggctcaaggc	gcgcattgcc	gacggcgagg	atctcgtcgt	gacccatggc	4740
gatgcctgct	tgccgaatat	catggtggaa	aatggccgct	tttctggatt	catcgactgt	4800
ggccggctgg	gtgtggcgga	ccgctatcag	gacatagcgt	tggctaccgg	tgatattgct	4860
gaagagcttg	gcggcgaaatg	ggctgaccgc	ttcctcgtgc	tttacggtat	cgccgctccc	4920
gattcgacgc	gcattgcctt	ctatgcctt	cttgacgagt	tcttctgagc	gggactctgg	4980
ggttcgaaat	gaccgaccaa	gcgacgccc	acctgccatc	acgagatttc	gattccaccg	5040
ccgcctttcta	tgaagggttg	ggcttcggaa	tcgttttccg	ggacgccggc	tggatgatcc	5100
tccagcgcgg	ggatctcatg	ctggagttct	tcgcccaccc	caacttgttt	attgcagctt	5160
ataatggtta	caaataaagc	aatagcatca	caaatttcac	aaataaagca	tttttttcac	5220
tgcattctag	ttgtggtttg	tccaaactca	tcaatgtatc	ttatcatgtc	tgtataccgt	5280
cgacctctag	ctagagcttg	gcgtaatcat	ggcatagct	gtttctctgtg	tgaattgtt	5340
atccgctcac	aattccacac	aacatacag	ccggaagcat	aaagtgtaaa	gcctggggtg	5400
cctaattgagt	gagctaactc	acattaaattg	cgttgcgctc	actgcccgct	ttccagtcgg	5460
gaaacctgtc	gtgccagctg	cattaatgaa	tcggccaacg	cgcggggaga	ggcggtttgc	5520
gtattgggag	ctcttccgct	tectcgctca	ctgactcgct	gcgctcggtc	gttcggctgc	5580
ggcgagcggt	atcagctcac	tcaaaggcgg	taatacgggt	atccacagaa	tcaggggata	5640
acgcaggaaa	gaacatgtga	gcaaaaaggc	agcaaaaaggc	caggaaaccgt	aaaaaggccg	5700
cgttgctgg	gtttttccat	aggctccgcc	cccctgacga	gcatacacia	aatcgacgct	5760
caagtcaag	gtggcgaaac	ccgacaggac	tataaagata	ccaggcggtt	ccccctggaa	5820
gtccctcgt	gcgctctcct	gttccgaccc	tgccgcttac	cggataacctg	tccgcctttc	5880
tcccttcggg	aagcgtggcg	ctttctcaat	gctcacgctg	taggtatctc	agttcggtgt	5940
aggctggttcg	ctccaagctg	ggctgtgtgc	acgaaccccc	cgttcagccc	gaccgctgcg	6000
ccttatccgg	taactatcgt	cttgagtcca	acccggtaag	acacgactta	tcgccactgg	6060
cagcagccac	tggtaacagg	attagcagag	cgaggatgt	aggcggtgct	acagagttct	6120
tgaagtgggt	gcctaactac	ggctacacta	gaaggacagt	atthggtatc	tgcgctctgc	6180
ctgaagccagt	taccttcgga	aaaagagttg	gtagctcttg	atccggcaaa	caaaccaccg	6240
ctggtagcgg	tggttttttt	gtttgcaagc	agcagattac	gcgcagaaaa	aaaggatctc	6300
aagaagatcc	tttgatcttt	tctacggggg	ctgacgctca	gtggaacgaa	aactcacgtt	6360
aagggatttt	ggtcatgaga	ttatcaaaaa	ggatottcac	ctagatcctt	ttaaattaaa	6420
aatgaagttt	taaatcaatc	taaagtatat	atgagtaaac	ttggtctgac	agttaccaat	6480
gcttaatcag	tgaggcacct	atctcagcga	tctgtctatt	tcgttcaccc	atagttgcct	6540
gactccccgt	cgtgtagata	actacgatac	gggagggctt	accatctggc	ccagtgctg	6600
caatgatacc	gcgagaccca	cgctcaccgg	ctccagattt	atcagcaata	aaccagccag	6660
ccggaagggc	cgagcgcaga	agtggctcctg	caactttatc	cgctccatc	cagttctatta	6720
attggtgccg	ggaagctaga	gtaagtgtt	cgccagttta	tagtttgccg	aacgttggtg	6780
ccattgctac	aggcatcgctg	gtgtcacgct	cgctggttgg	tatggcttca	ttcagctccg	6840
gttcccaacg	atcaaggcga	gttacatgat	cccccatgtt	gtgcaaaaaa	gcggttagct	6900
ccttcgggtc	tccgatcggt	gtcagaagta	agttggccgc	agtggtatca	ctcatggtta	6960
tggcagcact	gcataattct	cttactgtca	tgccatccgt	aagatgcttt	tctgtgactg	7020
gtgagtactc	aaccaagtca	ttctgagaat	agtgtatgcg	gcgaccgagt	tgctcttgcc	7080

-9-

```

cggcgtcaat acgggataat accgcgccac atagcagaac tttaaaagtg ctcattcattg 7140
gaaaacgttc ttcggggcga aaactctcaa ggatcttacc gctgttgaga tccagttcga 7200
tgtaacccac tcgtgcaccc aactgatctt cagcatcttt tactttcacc agcgtttctg 7260
ggtgagcaaa aacaggaagg caaaatgccg caaaaaaggg aataaggcg acacggaaat 7320
gttgaatact catactcttc ctttttcaat attattgaag catttatcag ggttattgtc 7380
tcatgagcgg atacatattt gaatgtattt agaaaaataa acaaataagg gttccgcgca 7440
catttccccg aaaagtgcc cctgacgtc 7469

```

<210> 9
 <211> 28
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 9
 tgcttaagcg gccgcgaagg agaagtcc 28

<210> 10
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 10
 ccgagctagc gactgaaaat gag 23

<210> 11
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 11
 cctctcgaga gacagcaaga cac 23

<210> 12
 <211> 11152
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: plasmid

<400> 12
 aagcttgggc agaaatggtt gaactcccga gagtgtccta cacctagggg agaagcagcc 60
 aaggggttgt tccccaccaa ggacgaccg tctgcgcaca aacggatgag cccatcagac 120
 aaagacatat tcattctctg ctgcaaaactt ggcatagctc tgctttgcct ggggctattg 180
 ggggaagttg cgttcgtgc tcgcagggt ctcacccttg actcttttaa tagctcttct 240
 gtgcaagatt acaatctaaa caattcggag aactcgacct tcctcctgag gcaaggacca 300
 cagccaactt cctcttacia gccgcacgca tttgtcctt cagaaataga aataagaatg 360
 cttgctaaaa attatatatt taccaataag accaatccaa taggtagatt attagtact 420
 atgttaagaa atgaatcatt atcttttagt actattttta ctcaaattca gaagttagaa 480

atgggaatag	aaaatagaaa	gagacgctca	acctcaattg	aagaacaggt	gcaaggacta	540
ttgaccacag	gcctagaagt	aaaaaaggga	aaaaagagtg	tttttgtcaa	aataggagac	600
aggtggtggc	aaccaggggac	ttatagggga	ccttacatct	acagaccaac	agatgcccc	660
ttaccatata	caggaagata	tgacttaaat	tgggataggt	gggttacagt	caatggctat	720
aaagtgttat	atagatccct	cccttttctg	gaaagactcg	ccagagctag	acctccttgg	780
tgtatgttgt	ctcaagaaga	aaaagacgac	atgaaacaac	aggtagatga	ttatatattat	840
ctaggaacag	gaatgcactt	ttggggaaaag	attttccata	ccaaggaggg	gacagtggct	900
ggactaatag	aacattattc	tgcaaaaact	catggcatga	gttattatga	atagccttta	960
ttggcccaac	cctgcggttc	ccagggctta	agtaagtttt	tgggttcaaaa	ctgttcttaa	1020
aacgaggatg	tgagacaagt	ggtttccctga	cttgggttgg	tatcaaaggt	tctgatctga	1080
gctctgagtg	ttctattttc	ctatgttctt	ttggaattta	tccaaatctt	atgtaaatgc	1140
ttatgtaaac	caagatataa	aagagtgtcg	attttttgag	taaacttgca	acagtcctaa	1200
cattcacctc	ttgtgtgttt	gtgtctgttc	gccatcccg	ctccgctcgt	cacttatcct	1260
tcactttcca	gaggttcccc	ccgcagaccc	cggcgaccct	caggtcggcc	gactgcggca	1320
gctggcgccc	gaacaggggac	cctcggataa	gtgacccttg	tctctatttc	tactatttgg	1380
tgtttgtctt	gtattgtctc	tttcttgtct	ggctatcatc	acaagagcgg	aacggactca	1440
ccatagggac	caagctagcg	actgaaaatg	agacatatta	tctgccacgg	agggtgtatt	1500
accgaagaaa	tggccgcccag	tcttttggac	cagctgatcg	aagaggtact	ggctgataat	1560
cttccacctc	ctagccattt	tgaaccacct	acccttcacg	aactgtatga	tttagacgtg	1620
acggcccccg	aagatcccaa	cgaggaggcg	gtttcgcaga	tttttcccga	ctctgtaatg	1680
ttggcggtgc	aggaagggat	tgacttactc	acttttccgc	cggcgcccgg	ttctccggag	1740
ccgcctcacc	tttcccggca	gcccagcag	ccggagcaga	gagccttggg	tccggtttct	1800
atgccaaacc	ttgtaccgga	ggtgatcgat	cttacctgcc	acgaggctgg	ctttccaccc	1860
agtgcagacg	aggatgaaga	gggtgaggag	tttgtgttag	attatgtgga	gcaccccggg	1920
cacgggttgca	ggtcttgtca	ttatcaccgg	aggaatacgg	gggaccaga	tattatgtgt	1980
tcgctttgct	atatgaggac	ctgtggcatg	tttgtctaca	gtaagtga	attatgggca	2040
gtgggtgata	gagtgggtgg	tttgggtgtg	taattttttt	tttaattttt	acagttttgt	2100
ggttttaaga	attttgtatt	gtgatttttt	taaaagggtc	tgtgtctgaa	cctgagcctg	2160
agcccagagc	agaaccggag	cctgcaagac	ctacccgcgg	tcctaaaatg	gcgcctgtga	2220
tcttgagacg	cccagacatca	cctgtgtcta	gagaatgcaa	tagtagtacg	gatagctgtg	2280
atcccggtcc	ttctaacaca	cctcctgaga	tacacccgg	ggtcccgcgt	tgccccatta	2340
aaccagttgc	cgtgagagtt	ggtgggcgtc	gccaggctgt	ggaatgtatc	gaggacttgc	2400
ttaacgagcc	tgggcaacct	ttggacttga	gctgtaaacg	ccccaggcca	taaggtgtaa	2460
acctgtgatt	gcgtgtgtgg	ttaacgcctt	tgtttgcctg	atgagttgat	gtaagtttaa	2520
taaaggggtga	gataatgttt	aacttgcattg	gcgtgttaaa	tggggcgggg	cttaaagggt	2580
atataatgcg	ccgtgggcta	atccttggtta	catctgacct	catggaggct	tgggagtgtt	2640
tggaaagattt	ttctgtctgtg	cgtaacttgc	tggaaacagag	ctctaacagt	acctccttgg	2700
tttgagggtt	tctgtggggc	tcaccccagg	caaagttagt	ctgcagaatt	aaggaggatt	2760
acaagtggga	atttgaagag	cttttgaat	cctgtggtga	gctgtttgat	tctttgaatc	2820
tgggtcacca	ggcgcttttc	caagagaagg	tcattcaagac	tttggatttt	tccacaccgg	2880
ggcgcgctgc	ggctgtctgtt	gcttttttga	gttttataaa	ggataaatgg	agcgaagaaa	2940
cccactctgag	cgggggggtac	ctgctggatt	ttctggccat	gcactctgtg	agagcgggtg	3000
tgagacacaa	gaatcgccctg	ctactgttgt	cttccgtccg	cccggcgata	ataccgacg	3060
aggagcagca	gcagcagcag	gaggaagcca	ggcgggcgcg	gcaggagcag	agccccatgga	3120
acccgagagc	cggcctggac	cctcgggaat	gaatgttgta	cagggtggctg	aactgtatcc	3180
agaactgaga	cgcattttga	caattacaga	ggatgggcag	gggctaaagg	gggtaaagag	3240
ggagcggggg	gcttgtgagg	ctacagagga	ggctaggaat	ctagctttta	gcttaatgac	3300
cagacaccgt	cctgagtgtg	ttacttttca	acagatcaag	gataattgcg	ctaagtgcct	3360
tgatctgctg	gcgcagaagt	attccataga	gcagctgacc	acttactggc	tgacgccagg	3420
ggtgattttt	gaggaggcta	ttagggtata	tgcaaaagg	gcacttaggc	cagattgcaa	3480
gtacaagatc	agcaaaacttg	taaatatcag	gaattgttgc	tacatttctg	ggaacggggc	3540
cgagggtggag	atagatacgg	aggatagggt	ggcctttaga	tgtagcatga	taaatatgtg	3600
gccgggggtg	cttggcatgg	acgggggtgt	tattatgaat	gtaaggttta	ctggcccaaa	3660
ttttagcggg	acggttttcc	tggccaatac	caaccttacc	ctacacgggtg	taagcttcta	3720
tgggtttaac	aatacctgtg	tggaaagcctg	gaccgatgta	agggttcggg	gctgtgcctt	3780
ttactgtctg	tggaaagggg	tggtgtgtcg	ccccaaaagc	agggttcaa	ttaagaaatg	3840
cctctttgaa	agggtgtacct	tgggtatcct	gtctgagggt	aactccaggg	tgccgccaaa	3900
tgtggcctcc	gactgtggtt	gcttcatgct	agtgaaaaagc	gtggctgtga	ttaagcataa	3960
catggtatgt	ggcaactcgc	aggacagggc	ctctcagatg	ctgacctgct	cggacggcaa	4020
ctgtcacctg	ctgaagacca	ttcacgtagc	cagccactct	cgcaaggcct	ggccagtggt	4080
tgagcataac	atactgaccc	gctgttcctt	gcatttgggt	aacaggaggg	gggtgttcc	4140
accttacc	tgcaatttga	gtcacactaa	gatattgctt	gagcccagga	gcatgtccaa	4200

ggtgaacctg	aacgggggtg	ttgacatgac	catgaagatc	tggaagggtg	tgagggtacga	4260
tgagaccgcg	accaggtgca	gacctgcgca	gtgtggcggt	aaacatatta	ggaaccagcc	4320
tgtgatgctg	gatgtgaccg	aggagctgag	gcccgatcac	ttggtgctgg	cctgcacccg	4380
cgctgagttt	ggctctagcg	atgaagatac	agattgaggt	actgaaatgt	gtgggctggg	4440
cttaaggggtg	ggaaagaata	tataaggtgg	gggtcttatg	tagttttgta	tctgttttgc	4500
agcagccgcc	gccgccatga	gcaccaactc	gtttgatgga	agcattgtga	gctcatattt	4560
gacaacgcgc	atgcccccat	gggcccgggt	gcgtcagaat	gtgatgggct	ccagcattga	4620
tggtcgcccc	gtcctgcccc	caaactctac	taccttgacc	tacgagaccg	tgtctggaac	4680
gccgttggag	actgcagcct	ccgcccgcgc	ttcagccgct	gcagccaccg	cccgcgggat	4740
tgtgactgac	tttgctttcc	tgagcccgtc	tgaagcagt	gcagcttccc	gttcatccgc	4800
ccgcgatgac	aagttgacgg	ctcttttggc	acaattggat	tctttgacct	gggaacctaa	4860
tgtcgtttct	cagcagctgt	tggtctcgcg	ccagcaggtt	tctgccctga	aggcttctct	4920
ccctcccaat	gcggtttaaa	acataaataa	aaaaccagac	tctgtttgga	tttggatcaa	4980
gcaagtgtct	tgtgtctctc	cgagggatct	ttgtgaagga	accttacttc	tgtgggtgtga	5040
cataattgga	caaactacct	acagagattt	aaagctctaa	ggtaaatata	aaatttttaa	5100
gtgtataatg	tggttaaacta	ctgattctaa	ttgtttgtgt	atttttagatt	ccaacctatg	5160
gaactgatga	atgggagcag	tggtggaatg	cctttaatga	ggaaaacctg	ttttgctcag	5220
aagaaatgcc	atctagtgat	gatgaggcta	ctgctgactc	tcaacattct	actcctccaa	5280
aaaagaagag	aaaggtagaa	gaccccaagg	actttccttc	agaattgcta	agttttttga	5340
gtcatgctgt	gttttagtaat	agaactcttg	cttgccttgc	tattttacacc	acaaaggaaa	5400
aagctgcact	gctatacaag	aaaattatgg	aaaaatattc	tgtaaccttt	ataagtaggc	5460
ataacagtta	taatcataac	atactgtttt	ttcttactcc	acacaggcat	agagtgtctg	5520
ctattaataa	ctatgctcaa	aaattgtgta	ccttttagctt	tttaatttgt	aaaggggtta	5580
ataaggaata	tttgatgtat	agtgccttga	ctagagatca	taatcagcca	taccacattt	5640
gtagagggtt	tacttgcttt	aaaaaacctc	ccacacctcc	ccctgaacct	gaaacataaa	5700
atgaatgcaa	ttgttggtgt	taacttggtt	attgcagctt	ataatgggtta	caataaagc	5760
aatagcatca	caaatttcac	aaataaagca	tttttttcac	tgcatctctag	ttgtggtttg	5820
tccaaactca	tcaatgtatc	ttatcatgtc	tggtaccggc	tggtggaatgt	gtgtcagtta	5880
gggtgtggaa	agtccccagg	ctccccagca	ggcagaagta	tgcaaagcat	gcatctcaat	5940
tagtcagcaa	ccagggtgtg	aaagtcccca	ggctccccag	caggcagaag	tatgcaaagc	6000
atgcatctca	attagtcagc	aacctatagc	ccgcccctaa	ctcgcgccat	cccgccccta	6060
actccgcccc	gttcgcgcca	ttctccgccc	catggctgac	taattttttt	tatttatgca	6120
gaggecgagg	ccgcctcggc	ctctgagcta	ttccagaagt	agtgaggagg	cttttttggg	6180
ggcctaggct	tttgcaaaaa	gcttgacac	aagacaggct	tgcgagatat	gtttgagaat	6240
accactttat	cccgcgctcag	ggagaggcag	tgcgtaaaaa	gacgcggact	catgtgaaat	6300
actgggtttt	agtgcgccag	atctctataa	tctcgcgcaa	cctattttcc	cctcgaaacac	6360
tttttaagcc	gtagataaac	aggctgggac	acttcacatg	agcgaaaaat	acatcgtoac	6420
ctgggacatg	ttgcagatcc	atgcacgtaa	actcgcaagc	cgactgatgc	cttctgaaca	6480
atggaaaaggc	attattgccg	taagccgtgg	cggctctggt	ccgggtgcgt	tactggcgcg	6540
tgaactgggt	attcgatcat	tcgataccgt	ttgtatttcc	agctacgatc	acgacaacca	6600
gcgcgagctt	aaagtgtctga	aacgcgcaga	aggcgatggc	gaaggcttca	tcgttattga	6660
tgacctgggtg	gataccgggtg	gtactgcggt	tgcgattcgt	gaaatgtatc	caaaagcgca	6720
ctttgtcacc	atcttcgcaa	aaccggctgg	tcgtccgctg	gttgatgact	atgttgttga	6780
tatcccgcaa	gatacctgga	ttgaacagcc	gtgggatatg	ggcgtcgat	tcgtcccgcc	6840
aatctccggt	cgctaattctt	ttcaacgcct	ggcactgccg	ggcgttggtc	tttttaacct	6900
caggcggggt	acaatagttt	ccagtaagta	ttctggaggc	tgcatccatg	acacaggcaa	6960
acctgagcga	aacctgttc	aaaccccgct	tgcaagtcgg	tgaacctcgc	acgctagtcc	7020
gccgctttaa	tcacggcgca	caaccgcctg	tgtagtgcgc	ccttgatggg	aaaaccatcc	7080
ctcactggta	tcgcatgatt	aaccgtctga	tgtggatctg	gcgcggcatt	gacccacgcg	7140
aaatcctcga	cgtccaggca	cgtattgtga	tgagcgatgc	cgaacgtacc	gacgatgatt	7200
tatacgatac	ggtgattggc	taccgtggcg	gcaactggat	ttatgagtgg	gccccggatc	7260
tttgtgaagg	aaccttactt	ctgtggtgtg	acataattgg	acaaactacc	tacagagatt	7320
taaagctcta	aggtaaataat	aaaattttta	agtgtataat	gtgttaaact	actgattcta	7380
attgtttgtg	tatttttagat	tccaacctat	ggaactgatg	aatgggagca	gtggtggaat	7440
gcctttaatg	aggaaaacct	gttttgctca	gaagaaatgc	catctagtga	tgatgaggct	7500
actgctgact	ctcaacattc	tactcctcca	aaaaagaaga	gaaaaggtaga	agaccccaag	7560
gactttcctt	cagaattgct	aagttttttg	agtcagtctg	tgtttagtaa	tagaactctt	7620
gcttgctttg	ctattttacac	cacaaaggaa	aaagctgcac	tgctatacaa	gaaaattatg	7680
gaaaaatatt	ctgtaacctt	tataagtagg	cataacagtt	ataatcataa	catactgttt	7740
tttcttactc	cacacaggca	tagagtgtct	gctattaata	actatgctca	aaaattgtgt	7800
accttttagct	ttttaatttg	taaaggggtt	aataagggaat	atttgatgta	tagtgccctg	7860
actagagatc	ataatcagcc	ataccacatt	tgtagaggtt	ttacttgctt	taaaaaacct	7920

cccacacctc cccctgaacc tgaacataaa aatgaatgca attgtgtgtg ttaacttgtt 7980
tattgcagct tataatgggt acaataaaag caatagcatc acaaatttca caaataaagc 8040
atTTTTTTca ctgcattcta gtgtgtgttt gtccaaactc atcaatgtat cttatcatgt 8100
ctggatcccc aggaagctcc tctgtgtcct cataaacctt aacctcctct acttgagagg 8160
acattccaat cataggtgc ccattccacc tctgtgtcct cctgttaatt aggtcactta 8220
acaaaaagga aattgggtag gggTTTTTca cagaccgtt tctaagggtg attttaaaat 8280
atctgggaag tccctccac tgctgtgttc cagaagtgtt ggtaaacagc ccacaaatgt 8340
caacagcaga aacatacaag ctgtcagctt tgcacaaggg cccaacaccc tgctcatcaa 8400
gaagcactgt ggttgcgtgt ttagtaatgt gcaaaacagg aggcacattt tccccacctg 8460
tgtaggttcc aaaatatcta gtgttttcat ttttacttgg atcaggaacc cagcactcca 8520
ctggataagc attatcctta tccaaaacag ccttgtgttc agtggtcatc tgctgactgt 8580
caactgtagc attttttggg gttacagttt gagcaggata tttggtcctg tagtttgcta 8640
acacaccctg cagctccaaa ggttccccac caacagcaaa aaaatgaaa tttgaccctt 8700
gaatgggttt tccagcacca ttttcatgag ttttttgtgt cctgaatgc aagtttaaca 8760
tagcagttac cccaataacc tcagttttaa cagtaaacagc tccccacatc aaaatatttc 8820
cacaggttaa gtcctcattt aaattaggca aaggaattct tgaagacgaa agggcctcgt 8880
gatacgccca tttttatagg ttaatgtcat gataataatg gtttcttaga cgtcaggttg 8940
cacttttccg ggaatgtgc gcggaacccc tatTTTgtta ttttctaaa tacattcaaa 9000
tatgtatccg ctcatgagac aataaccctt ataaatgctt caataatatt gaaaaaggaa 9060
gagtatgagt attcaacatt tccgtgtcgc ccttattccc ttttttgcgg cattttgcct 9120
tctgtttttt gctcaccag aaacgctggt gaaagtaaaa gatgctgaag atcagttggg 9180
tgcacgagtg gtttacatcg aactggatct caacagcggg aagatccttg agagttttcg 9240
ccccgaagaa cgttttccaa tgatgagcac ttttaaagtt ctgctatgtg gcgcggtatt 9300
atcccgtgtt gacgccgggc aagagcaact cgggtgcgcg atacactatt ctcaaatga 9360
cttgggttag tactaccag tcacagaaaa gcatcttacg gatggcatga cagtaagaga 9420
attatgcagt gctgccataa ccatgagtga taacactgcg gccaaactac ttctgacaac 9480
gatcggagga ccgaaggagc taaccgctt tttgcacaac atgggggatc atgtaactcg 9540
ccttgatgtt tgggaaccgg agctgaatga aacgacgagc gtgacaccac 9600
gatgccctga gcaatggcaa caacgttgcg caaactatta actggcgaac tacttactct 9660
agcttccccg caacaattaa tagactggat ggaggcggat aaagtgcag gaccacttct 9720
gcgctcggcc cttccggctg gctggtttat tgctgataaa tctggagccg gtgagcgttg 9780
gtctcgggtt atcattgcag cactggggcc agatggtaag ccctcccgtg tcgtagttat 9840
ctacacgacg gggagtcagg caactatgga tgaacgaaat agacagatcg ctgagatagg 9900
tgctcactg attaaacatt ggtaactgtc agaccaagtt tactcatata tacttttagat 9960
tgattttaaaa cttcattttt aattttaaaag gatctagggt aagatccttt ttgataatct 10020
catgacccaa atcccttaac gtgagttttc gttccactga gcgtcagacc cgtagaaaa 10080
gatcaaaagg tcttcttgag atcctttttt tctgcgcgta atctgctgct tgcaaacaaa 10140
aaaaccaccg ctaccagcgg tggtttgttt gccggatcaa gagctaccaa ctctttttcc 10200
gaaggtaact ggcttcagca gagcgcagat accaaatact gtccttctag ttagccgta 10260
gttaggccac cacttcaaga actctgtagc accgcctaca tacctcgctc tgctaactct 10320
gttaccagtg gctgctgcca gtggcgataa ctcgtgtctt ctgaacgggg ggttcgtgca cacagcccag 10440
atagttaccg gataaggcgc agcggtcggg atacctacag cgtgagctat gagaaagcgc 10500
cttggagcga acgacctaca ccgaactgag gtatccggta agcggcaggg tcggaacagg 10560
cacgcttccc gaagggagaa aggggggaaa cgcctggtat ctttatagtc ctgtcgggtt 10620
agagcgcacg agggagcttc caggggggaa gtgatgctcg tcaggggggc ggagcctatg 10680
tcgccacctc tgacttgagc gtcgattttt gttcctggcc ttttgcggc cttttgctca 10740
gaaaaacgcc agcaacgcgg cctttttacg tgtggataac cgtattaccg cttttgagtg 10800
catgttcttt cctgcgttat cccctgattc tgtggataac cgtattaccg cttttgagtg 10800
agctgatacc gctcgcgcga gccgaacgac cgagcgcagc gagtcaagtga gcgaggaagc 10860
ggaagagcgc ctgatgggtt attttctcct tacgcactctg tgcggtattt cacaccgcat 10920
atggtgcaat ctcagtacaa tctgctctga tgcgcgatag ttaagccagt atacactccg 10980
ctatcgctac gtgactgggt catggctgcg ccccgacacc cgccaacacc cgctgacgcg 11040
ccctgacggg cttgtctgct cccggcatcc gcttacagac aagctgtgac cgtctccggg 11100
agctgcatgt gtcagaggtt ttcaccgtca tcaccgaaac gcgcgaggca gc 11152

<210> 13

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

-13-

<223> Description of Artificial Sequence: primer

<400> 13
gacggatcgg gagatctcc

19

<210> 14
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 14
ccgcctcaga agccatagag cc

22

<210> 15
<211> 14455
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: plasmid

<400> 15
aagcttgggc agaaatggtt gaactccga gagtgccta cacctagggg agaagcagcc 60
aaggggttgt ttcccaccaa ggacgaccg tctgcgcaca aacggatgag cccatcagac 120
aaagacatat tcattctctg ctgcaaaactt ggcatagctc tgctttgcct ggggctattg 180
ggggaagtgt cggttcgtgc tcgcagggtct ctcacccttg actcttttaa tagctcttct 240
gtgcaagatt acaatctaaa caattcggag aactcgacct tcctcctgag gcaaggacca 300
cagccaactt cctcttacia gccgcacga ttttgcctt cagaaataga aataagaatg 360
cttgctaaaa attatatttt taccaataag accaatccaa taggtagatt attagttact 420
atgttaagaa atgaatcatt atcttttagt actattttta ctcaaattca gaagttagaa 480
atgggaatag aaaatagaaa gagacgctca acctcaattg aagaacaggt gcaaggacta 540
ttgaccacag gcctagaagt aaaaaaggga aaaaagagtg tttttgtcaa aataggagac 600
agggtggtggc aaccagggac ttatagggga ccttacatct acagaccaac agatgcccc 660
ttaccatata caggaagata tgacttaaat tgggtaggtt gggttacagt caatggctat 720
aaagtgttat atagatccct cccttttcgt gaaagactcg ccagagctag acctccttgg 780
tgtatgttgt ctcaagaaga aaaagacgac atgaaacaac aggtacatga ttatatttat 840
ctaggaacag gaatgcactt ttggggaaag attttccata ccaaggaggg gacagtggct 900
ggactaatag aacattattc tgcaaaaact catggcatga gttattatga atagccttta 960
ttggcccaac cttgcggttc ccagggtcta agtaagtttt tggttacaaa ctgttcttaa 1020
aacgaggatg tgagacaagt ggtttcctga cttggtttgg tatcaaagg tctgatctga 1080
gctctgagtg ttctattttc ctatgttctt ttggaattta tccaaatctt atgtaaatgc 1140
ttatgtaaac caagatataa aagagtgtctg attttttgag taaacttgca acagtcttaa 1200
cattcacctc ttgtgtgttt gtgtctgttc gccatcccg tcccgctcgt cacttatcct 1260
tcactttcca gaggttcccc ccgcagaccc cggcgaccct caggtcggcc gactcggcca 1320
gctggcgccc gaacagggac cctcggataa gtgacccttg tctctatttc tactatttgg 1380
tgtttgtctt gtattgtctc tttcttgtct ggctatcatc acaagagcgg aacggactca 1440
ccatagggac caagctagcg actgaaaatg agacatatta tctgccacgg aggtgttatt 1500
accgaagaaa tggccgcccag tcttttggac cagctgatcg aagaggtact ggctgataat 1560
cttcacctc ctagccattt tgaaccacct acccttcacg aactgtatga tttagacgtg 1620
acggcccccg aagatcccaa cgaggaggcg gtttcgcaga tttttcccg ctctgtaatg 1680
ttggcggtgc aggaagggat tgacttactc acttttccgc cggcgcccgg ttctccggag 1740
ccgcctcacc tttcccgcca gcccgagcag ccggagcaga gagccttggg tccggtttct 1800
atgccaaacc ttgtaccgga ggtgatcgat cttacctgcc acgaggctgg ctttccaccc 1860
agtgcagcag aggatgaaga gggtagggag tttgtgttag attatgtgga gcaccccggg 1920
cacggttgca ggtcttgtca ttatcaccgg aggaatacgg gggaccaga tattatgtgt 1980
tcgctttgct atatgaggac ctgtggcatg tttgtctaca gtaagtgaat attatgggca 2040
tggggtgata gagtgggtggg tttgggtgtg taattttttt ttttaattttt acagttttgt 2100

ggtttaaaga	atattgtatt	gtgatttttt	taaaagggtcc	tgtgtotgaa	cctgagcctg	2160
agccccgagcc	agaaccggag	cctgcaagac	ctaccgcgcg	tcctaaaatg	gcgcctgcta	2220
tcctgagacg	cccgacatca	ctgtgtgtcta	gagaatgcaa	tagtagtacg	gatagctgtg	2280
actccgggtcc	ttctaacaca	cctcctgaga	tacaccgggt	ggccccgctg	tgccccatta	2340
aaccagttgc	cgtgagagtt	gggtggcgctc	gccaggcgtg	ggaatgtatc	gaggacttgc	2400
ttaacgagcc	tgggcaaccc	ttggacttga	gctgtaaacg	ccccaggcca	taaggtgtaa	2460
acctgtgatt	gcgtgtgtgg	ttaacgcctt	tgtttgctga	atgagttgat	gtaagtttaa	2520
taaaagggtga	gataatgttt	aacttgcatg	gcgtgttaaa	tggggcgggg	cttaaagggt	2580
atataatgcg	ccgtgggcta	atcttgggta	catctgacct	catggaggct	tgggagtggt	2640
tggagatttt	ttctgctgtg	cgtaacttgc	tggacagag	ctctaacagt	acctcttggt	2700
tttgagggtt	tctgtggggc	tcaccccagg	caaagttagt	ctgcagaatt	aaggaggatt	2760
acaagtggga	atltgaagag	cttttgaaat	cctgtgggtga	gctgtttgat	tctttgaatc	2820
tgggtcacca	ggcgcttttc	caagagaagg	tcacaaagac	tttggttttt	tccacaccgg	2880
ggcgcgctgc	ggctgctgtt	gcttttttga	gttttataaa	ggataaatgg	agcgaagaaa	2940
cccatctgag	cggggggtac	ctgctggatt	ttctggccat	gcactctgtg	agagcggttg	3000
tgagacacaa	gaatcgccctg	ctactgttgt	cctcggtccg	ccccggcgata	ataccgacgg	3060
aggagcagca	gcagcagcag	gaggaaagcca	ggcgggcgcg	gcaggagcag	agcccatgga	3120
acccgagagc	cggcctggac	cctcggaat	gaatgttgta	cagggtggctg	aactgtatcc	3180
agaactgaga	cgcatttttga	caattacaga	ggatgggcag	gggctaaagg	gggtaaagag	3240
ggagcggggg	gcttgtgagg	ctacagagga	ggctaggaat	ctagctttta	gcttaatgac	3300
cagacaccgt	cctgagtgtg	ttacttttca	acagatcaag	gataattgag	ctaattgagct	3360
tgatctgctg	gcgcagaagt	attccataga	gcagctgacc	acttactggc	tgcagccagg	3420
ggatgatttt	gaggaggcta	ttaggggtata	tgcaaagggtg	gcacttaggc	cagattgcaa	3480
gtacaagatc	agcaaacttg	taaatatcag	gaattgttgc	tacatttctg	ggaacggggc	3540
cgagggtggag	atagatacgg	aggatagggt	ggcctttaga	tgtagcatga	tgaatatgtg	3600
gccgggggtg	cttggcatgg	acggggtggt	tattatgaat	gtaagggtta	ctggcccaaa	3660
ttttagcggg	acgggttttcc	tggccaatac	caaccttatt	ctacacgggtg	taagcttcta	3720
tgggtttaac	aatacctgtg	tggaaagcctg	gaccgatgta	aggggttcggg	gctgtgcctt	3780
ttactgctgc	tggaaagggg	tggtgtgtcg	ccccaaaagc	agggcttcaa	ttaagaaatg	3840
cctctttgaa	aggtgtacct	tgggtatcct	gtctgagggt	aactccaggg	tgcgccacaa	3900
tgtggcctcc	gactgtgggt	gcttcatgct	agtgaagagc	gtggctgtga	ttaagcataa	3960
catggtatgt	ggcaactgcg	aggacagggc	ctctcagatg	ctgacctgct	cggacggcaa	4020
ctgtcacctg	ctgaagacca	ttcacgtagc	cagccactct	cgcaaggcct	ggccagtgtt	4080
tgagcataaa	atactgacct	gctgttcctt	ggcctttggg	aacaggaggg	gggtgttcc	4140
accttaccac	tgcaatttga	gtcacactaa	gatattgctt	gagcccgaga	gcattgtccaa	4200
ggtgaacctg	aacgggggtg	ttgacatgac	catgaagatc	tggaaaggtg	tgaggtaacga	4260
tgagaccgcg	accagggtgca	gaccttgca	gtgtggcggt	aaacatatta	ggaaccagcc	4320
tgtgatgctg	gatgtgaccg	aggagctgag	gcccgatcac	ttgggtgctg	cctgcacccg	4380
cgtgagttt	ggctctagcg	atgaagatac	agattgaggt	actgaaatgt	gtggcggtgg	4440
cttaagggtg	ggaaagaata	tataagggtg	gggtcttatg	tagttttgta	tctgttttgc	4500
agcagccgcc	gccgccatga	gcaccaactc	gtttgatgga	agcattgtga	gctcatattt	4560
gacaacgcgc	atgcccccat	gggcccgggt	gcgtcagaat	gtgatgggct	ccagcattga	4620
tggtcgcccc	gtcctgcccc	caaaactctac	taccttgacc	tacgagaccg	tgtctggaac	4680
gccgttggag	actgcagcct	ccgcccgcgc	ttcagccgct	gcagccaccg	cccgcgggat	4740
tgtgactgac	tttgctttcc	tgagcccgct	tgcaagcagt	gcagcttccc	gttcatccgc	4800
ccgcgatgac	aagttgacgg	ctcttttggc	acaattggat	tctttgaccc	gggaacttaa	4860
tgtcgtttct	cagcagctgt	tggatctgcg	ccagcaggtt	tctgcccctga	aggcttccct	4920
ccctcccaat	gcggttttaa	acataaataa	aaaaccagac	tctgttttga	tttgatcaa	4980
gcaagtgtct	tgtgtctctc	cgagggatct	ttgtgaagga	accttacttc	tgtgtgtgta	5040
cataattgga	caaactacct	acagagattt	aaagctctaa	ggtaaatata	aaatttttaa	5100
gtgtataatg	tgttaaaacta	ctgattctaa	ttgtttgtgt	attttagatt	ccaacctatg	5160
gaactgatga	atgggagcag	tggtggaatg	cctttaatga	ggaaaacctg	ttttgctcag	5220
aagaaatgcc	atctagtgat	gatgaggcta	ctgctgactc	tcaacattct	actcctccaa	5280
aaaagaagag	aaaggtagaa	gacccaagg	actttccttc	agaattgcta	agttttttga	5340
gtcatgctgt	gttttagtaat	agaactcttg	cttgctttgc	tatttacacc	acaaaggaaa	5400
aagctgcact	gctatacaag	aaaattatgg	aaaaatattc	tgtaaccttt	ataagtaggc	5460
ataacagtta	taatcataac	atactgtttt	ttcttactcc	acacaggcat	agagtgtctg	5520
ctattataaa	ctatgctcaa	aaattgtgta	ccttttagctt	tttaatttgt	aaaggggtta	5580
ataaggaata	tttgatgtat	agtgccctga	ctagagatca	taatcagcca	taccacattt	5640
gtagagggtt	tacttgcttt	aaaaaacctc	ccacacctcc	ccctgaacct	gaaacataaa	5700
atgaatgcaa	ttgttggttg	taactgtttt	attgcagctt	ataatgggtta	caaataaagc	5760
aatagcatca	caaattttcac	aaataaagca	tttttttcac	tgcattctag	ttgtgggttg	5820

tccaaactca	tcaatgtatc	ttatcatgtc	tggatccggc	tgtggaatgt	gtgtcagtta	5880
gggtgtggaa	agtccccagg	ctccccagca	ggcagaagta	tgcaaagcat	gcatctcaat	5940
tagtcagcaa	ccaggtgtgg	aaagtcacca	ggctccccag	caggcagaag	tatgcaaagc	6000
atgcattctca	attagtcagc	aaccatagtc	ccgcccctaa	ctccgcccct	cccgcctcta	6060
actccgcccc	gttccgcccc	ttctccgccc	catggctgac	taattttttt	tatttatgca	6120
gaggccgagg	ccgcctcggc	ctctgagcta	ttccagaagt	agtgaggagg	cttttttgga	6180
ggcctaggct	tttgcaaaaa	gcttggacac	aagacaggct	tgcgagatat	gtttgagaat	6240
accactttat	cccgcgtcag	ggagaggcag	tgcgtaaaaa	gacgaggact	catgtgaaat	6300
actgggtttt	agtgcgccag	atctctataa	tctcgcgcaa	cctattttcc	cctcgaacac	6360
tttttaagcc	gtagataaac	aggctgggac	acttcacatg	agcgaaaaat	acatcgtcac	6420
ctgggacatg	ttgcagatcc	atgcacgtaa	actcgcaagc	cgactgatgc	cttctgaaca	6480
atggaaaggc	attattgccc	taagccgtgg	cggtctggtg	ccgggtgctg	tactggcgcg	6540
tgaaactggg	attcgtcatg	tcgataccgt	ttgtatttcc	agctacgatc	acgacaacca	6600
gcgcgagctt	aaagtgtctg	aacgcgcaga	aggcgatggc	gaaggcttca	tcgttattga	6660
tgacctgggtg	gataccgggtg	gtactgcggg	tgcgattcgt	gaaatgtatc	caaaagcgca	6720
ctttgtcacc	atcttcgcaa	aaccggctgg	tgctccgctg	gttgatgact	atgttggtga	6780
tatcccgcaa	gataccctgga	ttgaacagcc	gtgggatatg	ggcgctcgat	tcgtcccggc	6840
aatctccggg	cgctaattctt	ttcaacgcct	ggcactgccg	ggcggtgttc	tttttaactt	6900
caggcggggt	acaatagttt	ccagtaagta	ttctggaggc	tgcatccatg	acacaggcaa	6960
acctgagcga	aaccctgttc	aaaccccgct	ttaaacatcc	tgaaacctcg	acgctagtcc	7020
gccgctttta	tcacggcgca	caaccgcctg	tgcatcgccg	ccttgatggg	aaaaccatcc	7080
ctcactgggtg	tcgcatgatt	aaccgtctga	tgtggatctg	gcgcggcatt	gacccacgcg	7140
aaatcctcga	cgtccaggca	cgtattgtga	tgagcgatgc	cgaacgtacc	gacgatgatt	7200
tatacgatac	gggtgattggc	taccgtggcg	gcaactggat	ttatgagtgg	gccccggatc	7260
tttgtaagg	aaccttactt	ctgtgggtgtg	acataattgg	acaaactacc	tacagagatt	7320
taaagctcta	aggtaaatat	aaaattttta	agtgtataat	gtgttaaact	actgattcta	7380
attgtttgtg	tatttttagat	tccaacctat	ggaactgatg	aatgggagca	gtgggtggaat	7440
gcctttaatg	aggaaaacct	gttttgctca	gaagaaatgc	catctagtga	tgatgaggct	7500
actgctgact	ctcaacattc	tactctcca	aaaaagaaga	gaaaggtaga	agaccccaag	7560
gactttcctt	cagaattgct	aagttttttg	agtcattgctg	tgtttagtaa	tagaactcct	7620
gcttgctttg	ctatttacac	cacaaaggaa	aaagctgcac	tgctatacaa	gaaaattatg	7680
gaaaaatatt	ctgtaacctt	tataagtagg	cataacagtt	ataatcataa	catactgttt	7740
tttcttactc	cacacaggca	tagagtgtct	gctattaata	actatgctca	aaaattgtgt	7800
accttttagct	ttttaatttg	taaaggggtt	aataagggaat	atttgatgta	tagtgccctg	7860
actagagatc	ataatcagcc	ataccacatt	tgtagagggt	ttacttgctt	taaaaaacct	7920
cccacacctc	cccctgaacc	tgaaacataa	aatgaatgca	attgttggtg	ttaaactgtt	7980
tattgcagct	tataatgggt	acaaataaag	caatagcatc	acaaatttca	caaataaagc	8040
atttttttca	ctgcattcta	gttggtggtt	gtccaaactc	atcaatgtat	cttatcatgt	8100
ctggatcccc	aggaagctcc	tctgtgtcct	cataaaccct	aacctcctct	acttgagagg	8160
acattccaat	cataggctgc	ccatccaccc	tctgtgtcct	cctgttaatt	aggctcactta	8220
acaaaaagga	aattgggtag	gggtttttca	cagaccgctt	tctaagggtg	atttttaaat	8280
atctgggaag	tcctttccac	tgctgtgttc	cagaagtgtt	ggtaaacagc	ccacaaatgt	8340
caacagcaga	aacatacaag	ctgtcagctt	tgcaacaagg	cccaacacct	tgctcatcaa	8400
gaagcactgt	ggttgctgtg	ttagtaatgt	gcaaaacagg	aggcacattt	tccccacctg	8460
tgtaggttcc	aaaatatcta	gtgttttcat	ttttacttgg	atcaggaacc	cagcactcca	8520
ctggataagc	attatcctta	tccaaaacag	ccttggtgtc	agtgttcac	tgctgactgt	8580
caactgtagc	attttttggg	gttacagttt	gagcaggata	tttggtcctg	tagtttgcta	8640
acacaccctg	cagctccaaa	ggttccccac	caacagcaaa	aaaatgaaaa	tttgaccctt	8700
gaatgggttt	tccagcacca	ttttcatgag	ttttttgtgt	ccctgaatgc	aagtttaaca	8760
tagcagttac	cccaataacc	tcagttttta	cagtaacagc	ttccccatc	aaaatatttc	8820
cacaggttaa	gtcctcattt	aaattaggca	aaggaattct	tgaagacgaa	agggcctcgt	8880
gatacgccca	tttttatagg	ttaatgtcat	gataataatg	gtttcttaga	cgtcaggtgg	8940
cacttttccg	ggaaatgtgc	ggggaacccc	tatttggtta	tttttctaaa	tacattcaaa	9000
tatgtatccg	ctcatgagac	aataaccctg	ataaatgctt	caataatatt	gaaaaaggaa	9060
gagtatgagt	attcaacatt	tccgtgtcgc	ccttattccc	ttttttgcgg	cattttgcct	9120
tcctgttttt	gctcaccacg	aaacgctggt	gaaagtaaaa	gatgctgaag	atcagttggg	9180
tgcacgagtg	ggttacatcg	aactggatct	caacagcggg	aagatccttg	agagttttcg	9240
ccccgaagaa	cgttttccaa	tgatgagcac	tttttaaagt	ctgctatgtg	gcgcggtatt	9300
atcccggttt	gacgccgggc	aagagcaact	cggtcgccgc	atacactatt	ctcagaatga	9360
cttggttgag	tactcaccag	tcacagaaaa	gcattcttacg	gatggcatga	cagtaagaga	9420
attatgcagt	gctgccataa	ccatgagtga	taacactgag	gccaacttac	ttctgacaac	9480
gatcggaggga	ccgaaggagc	taaccgcttt	tttgcacaac	atgggggatc	atgtaactcg	9540

ccttgatcgt	tgggaaccgg	agctgaatga	agccatacca	aacgacgagc	gtgacaccac	9600
gatgcctgca	gcaatggcaa	caacgttgcg	caaactatta	actggcgaaac	tacttactct	9660
agcttcccgg	caacaattaa	tagactggat	ggaggcggat	aaagttgcag	gaccacttct	9720
gcgctcggcc	cttccggctg	gctggtttat	tgctgataaa	tctggagccg	gtgagcgtgg	9780
gtctcgcggg	atcattgcag	caactggggc	agatggtaag	ccctcccgtg	tcgtagtatt	9840
ctacacgacg	gggagtcagg	gtaactgtc	tgaacgaaat	agacagatcg	ctgagatagg	9900
tgccctcaactg	attaagcatt	aattttaaag	gatctaggtg	tactcatata	tacttttagat	9960
tgatttaaaa	cttcattttt	gtgagttttc	gttccactga	aagatccctt	ttgataaatct	10020
catgaccaaaa	atcccttaac	atcctttttt	tctgcgcgta	gcgtcagacc	ccgtagaaaa	10080
gatcaaaagga	tcttcttgag	tggtttgttt	gcccgaatcaa	atctgctgct	tgcaaacaaa	10140
aaaaccaccg	ctaccagcgg	gagcgcagat	accaaatact	gagctaccaa	ctctttttcc	10200
gaagggtaaact	ggcttcagca	actctgtagc	accgcctaca	gtccttctag	tgtagccgta	10260
gttaggccac	cacttcaaga	gtggcgataa	gtcgtgtctt	tacctcgctc	tgctaatect	10320
gttaccagtg	gctgctgcc	agcggtcggg	ggttcgtgca	accgggttgg	actcaagacg	10380
atagttaccg	gataaggcgc	ccgaactgag	gttcctgctg	gggtccgtgca	cacagcccag	10440
cttgagcgcg	acgacctaca	aggcggacag	gtatccggtg	cgtgagctat	gagaaagcgc	10500
cacgcttccc	gaagggagaa	cagggggaaa	cgctggttat	agcggcaggg	tcggaacagg	10560
agagcgcacg	agggagcttc	gtcgattttt	gtgatgctcg	ctttatagtc	ctgtcgggtt	10620
tcgccacctc	tgacttgagc	ccttttttacg	gttccctggc	tcaggggggc	ggagcctatg	10680
gaaaaacgcg	agcaacgcgg	ccctgtattc	tggtggataac	ttttgctggc	cttttgctca	10740
catgttcttt	ctgcggttat	gccgaacgac	cgagcgcagc	cgtattaccg	cctttgagtg	10800
agctgatacc	gctcgcgcga	atcttctcct	tacgcctctg	gagtcagtg	qcgaggaagc	10860
ggaagagcgc	ctgatgcggg	gcccacgcga	gcccagcat	tgccgtattt	cacaccgcat	10920
accgcctcag	aagccataga	ccccacccca	ccccccagaa	gcctgctatt	gtcttcccaa	10980
tcctccccct	tgctgtcctg	atcttattag	gaaaggacag	tagaatgaca	cctactcaga	11040
caatgcgatg	caatttcctc	ggggcaaaaca	acagatggct	tgaggagtgg	accttccagg	11100
gtcaaggaaag	gcacggggga	agcatttagg	tgacactata	gaatagggcc	aggcacagtc	11160
gaggctgatc	agcagagctc	ttattcttgg	gcaatgtatg	aaaaagtgtg	ctctagatgc	11220
atgctcgagc	ggcgcgttct	gttgtggcca	gaccagctcc	atgaaaatga	agaggatgtg	11280
gcaaatattt	cattaatgta	tgtttcctgt	gtaccgttta	gtgtaatggt	catagagtat	11340
gcacttggag	ttgtgtctcc	taagtaaact	tgactgacaa	tggtactttt	tagtggtaca	11400
ggtttagttt	tgtctccggt	tgataggtta	ggcataaatc	tggtactttt	ggcagtttta	11460
ccgtgagatt	ttggataagc	atctctaaag	ttccaatatt	caacagcgtt	tgataggctt	11520
gtgccttcag	taagatctcc	gtcaaatctt	ataataagat	ctgggtccag	gaaggaattg	11580
tttagtagca	ctccattttc	tttaacagcc	aaaactgaaa	gagcactttg	aactgttcca	11640
gatatgtgag	ccaaactgcc	agttagttta	gcactcttct	ctgtagcaag	tatttgactg	11700
ccacattttg	ttaagaccaa	ccacaaagtt	agcttatcat	ctgcatttag	tctacagtta	11760
ggagatggag	ctgggtgggt	actaaggcca	gttcctagtt	tatttttggt	tcctactgta	11820
atggcacctg	tgctgtcaaa	gccaattttt	gttttgaggg	taggaaccat	agccttggtt	11880
gaatcaaatt	ctaggccatg	atctcctgca	ttaatggcta	gatttggtgt	tggtgcatta	11940
ggtgaaccaa	attcaagccc	gttaacctca	agctttttgg	tggtctgtagc	gtcaaacatc	12000
aacccttggg	cagtgtcttag	gttaatatcc	aagtgtggg	aattggttga	agctgtaaac	12060
aagtaaaaggc	ctttgttgta	tagttgggtt	tgagcatcaa	ctgagtttat	aaaaagaggg	12120
ccctgtccta	gtcttagatt	atcaatcctt	agtcctcctg	acggataact	aacatcaagt	12180
ataaggcgtc	tgttttgaga	ggctccagta	actttagttt	ctacattaag	ttgcataattg	12240
ccttgtgaat	caaaaaccaa	gtgttttaggt	cgtctgttac	gcaaggaaagt	attattaata	12300
gtcacacactg	gaccagttgc	ttttccattt	tggtgtataaa	cgtctgttac	atgcaaaagga	12360
gccccgtact	ttagtccctag	agtttagagg	gggtgaggcag	tggtgtcttt	caagtcaatg	12420
cccaagctac	cagtggcagt	tgatgtttgc	agggctagct	tgatagtaag	ggtactgcta	12480
tcgggtgggtg	tgagggggcc	aagtttgag	tcgtgcacgg	ttccttctga	cactgtgagg	12540
ggtccttggg	tggaatgct	gaccattaga	gggtgcggcg	ttagcggggc	ctgtgattgc	12600
atggtgagtg	tggtgcccgc	agatatttcc	aggtttatgt	cagccacagt	tagggcttct	12660
gaggtaaactg	tgaggggtgc	atcttgggag	gttaggttgc	ttgacttggt	ttttttgaga	12720
ggtgggctca	cagtgggttac	aagcatgcc	ttggaggtta	cgccctcgte	cagagagagg	12780
ccgttgccca	ttttgagcgc	actctcttga	aacctattgg	ctagaggttc	ggataggcgc	12840
aaagagagta	ccccaggggg	accggtttcc	gtgtcatatg	gggatacaaa	gggaggagta	12900
agaaaaggca	cagttggagg	cttcatcttg	gatctcaagc	gatacacggg	gttgaaggta	12960
tcttcagacg	gtcttgcgog	cctactttta	ttacatcctc	ctgccacacc	tcacctcgac	13020
catccgcccgt	ctcaagaccg	tgccgccgcg	cacggtgctc	agcctacctt	ccgccagaaa	13080
caaccccgac	cgccacccgc	agaggttttc	cgatccggtc	gatcgggact	gcgactgtga	13140
ctgggttagc	gcctttctcg	tcggaggccg	acgggtttcc	gatccaagag	cgctcaggte	13200
cctcggtggc	ggagtaaccg				tactggaaa	13260

-17-

accgcgaaga	gtttgtcctc	aaccgcgagc	ccaacagcga	gctcgaattc	agatccgagc	13320
tccgtaccaa	gcttgggtct	ccctatagtg	agtcgtatta	atttcgataa	gccagtaagc	13380
agtgggttct	ctagttagcc	agagagctct	gcttatatag	acctcccacc	gtacacgcct	13440
accgcccatt	tgcgtcaatg	ggcgaggatt	gttacgacat	tttggaaggt	cccgttgatt	13500
ttggtgccaa	aacaaactcc	cattgacgtc	aatgggggtg	agacttgga	atccccgtga	13560
gtcaaacgcg	tatccacgcc	cattgatgta	ctgccaaaac	cgcatcacca	tggtaatagc	13620
gatgactaat	acgtagatgt	actgccaaag	aggaaagtcc	cataagggtc	tgtactgggc	13680
ataatgccag	gcggggccatt	taccgtcatt	gacgtcaata	ggggggcgta	ttggcatatg	13740
atacacttga	tgtactgcca	agtgggcagt	ttaccgtaaa	tagtccaccc	attgacgtca	13800
atggaaagtc	cctattggcg	ttactatggg	aacatacgtc	attattgacg	tcaatgggcg	13860
ggggtcggtg	ggcgggtcagc	caggcgggcc	atctaccgta	agttatgtaa	cgcggaactc	13920
catatatggg	ctatgaacta	atgaccccg	aattgattac	tattaataac	tagtcaataa	13980
tcaatgtcaa	cgcgatatatc	tggcccgta	atcgcggaagc	agcgcaaaac	gcctaaccct	14040
aagcagattc	ttcatgcaat	tgtcgtgcaa	gccttgccct	gttgtagctt	aaattttgct	14100
cgcgactac	tcagcgacct	ccaacacaca	agcagggagc	agatactggc	ttaactatgc	14160
ggcatcagtc	cagattgtac	tgagagtcga	ccatagggga	tcgggagatc	tcccgatccg	14220
tctatgggtg	actctcagta	caatctgtct	tgatgccgca	tagttaagcc	agtatacact	14280
ccgctatcgc	tacgtgactg	ggtcatggct	gcgccccgac	accgcgcaac	accgcgtgac	14340
ggcgcctgac	gggcttgtct	gctcccgcca	tccgcttaca	gacaagctgt	gaccgtctcc	14400
gggagctgca	tgtgtcagag	gttttcaccg	tcatacccca	aacgcgcgag	gcagc	14455

<210> 16

<211> 10610

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 16

gacggatcgg	gagatccgcg	cggtacacag	aattcaggag	acacaactcc	aagtgcatac	60
tctatgtcat	tttcatggga	ctgggtctggc	cacaactaca	ttaatgaaat	atttgccaca	120
tccctcttaca	ctttttcata	cattgcccaa	gaataaagaa	tcgtttgtgt	tatgtttcaa	180
cgtgttttatt	tttcaattgc	agaaaatttc	aagtcatttt	tcattcagta	gtatagcccc	240
accaccacat	agcttatata	gatcaccgta	ccttaatcaa	actcacagaa	ccctagtatt	300
caacctgcca	cctccctccc	aacacacaga	gtacacagtc	ctttctcccc	ggctggcctt	360
aaaaagcatc	atatcatggg	taacagacat	attcttaggt	gttatattcc	acacggtttc	420
ctgtcgagcc	aaacgctcat	cagtgtatatt	aataaactcc	ccgggcagct	cacttaagtt	480
catgtcgtcg	tccagctgct	gagccacagc	ctgctgtcca	acttgcggtt	gcttaacggg	540
cgggcgaagga	gaagtccacg	cctacatggg	ggtagagtca	taatcgtgca	tcaggatagg	600
gcgggtgggtg	tgcagcagcg	cgcgaataaa	ctgctgccgc	cgccgctccg	tcctgcagga	660
atacaacatg	gcagtggtct	cctcagcgat	gatctgcacc	gcccgcagca	taaggcgctt	720
tgtcctccgg	gcacagcagc	gcaccctgat	ctcacttaaa	tcagcacagt	aactgcagca	780
cagcaccaca	atattgttca	aaatcccaca	gtgcaaggcg	ctgtatccaa	agctcatggc	840
gggggaccaca	gaacccacgt	ggccatcata	ccacaagcgc	aggtagatta	agtggcgacc	900
cctcataaac	acgctggaca	taaacattac	ctcttttggc	atgttgtaat	tcaccacctc	960
ccggttaccat	ataaacctct	gattaaacat	ggcgccatcc	accaccatcc	taaaccagct	1020
ggccaaaacc	tgcccgccgg	ctatacactg	cagggaaaccg	ggactggaac	aatgacagt	1080
gagagcccag	gactcgtaac	catggatcat	catgctcgtc	atgatatcaa	tgttggcaca	1140
acacaggcac	acgtgcatac	acttccctcag	gattacaagc	tcctcccgcg	ttagaaccat	1200
atcccaggga	acaacccatt	cctgaatcag	cgtaaatccc	acactgcagg	gaagacctcg	1260
cacgtaaactc	acgttgtgca	ttgtcaaagt	gttacattcg	ggcagcagcg	gatgatcctc	1320
cagtatggta	gcgcgggttt	ctgtctcaaa	aggaggtaga	cgatccctac	tgtacggagt	1380
gcgcgcgagac	aaccgagatc	gtgttggtcg	tagtgtcatg	ccaaatggaa	cgccggacgt	1440
agtcataat	cctgaagcaa	aaccaggtgc	ggcggtgaca	aacagatctg	cgtctccggt	1500
ctcgccgctt	agatcgctct	gtgtagtagt	tgtagtatat	ccactctctc	aaagcatcca	1560
ggcgccccct	ggcttcgggt	tctatgtaaa	ctccttcgat	cgccgctgcc	ctgataacat	1620
ccaccaccgc	agaataagcc	acacccagcc	aacctacaca	ttcgttctgc	gagtcacaca	1680
cgggaggagac	gggaagagct	ggaagaacca	tgtttttttt	tttattccaa	aagattatcc	1740
aaaacctcaa	aatgaagatc	tattaagtga	acgcgctccc	ctccggtggc	gtggtcaaac	1800
tctacagcca	aagaacagat	aatggcattt	gtaagatgtt	gcacaatggc	ttccaaaagg	1860

caaacggccc tcacgtccaa gtggacgtaa aggctaaacc cttcaggggtg aatctcctct 1920
ataaacattc cagcaccttc aaccatgccc aaataattct catctcgcca ccttctcaat 1980
atatctctaa gcaaatcccg aatattaagt cgggccattg taaaaatctg ctccagagcg 2040
ccctccacct tcagcctcaa gcagcgaatc atgattgcaa aaattcaggt tcctcacaga 2100
cctgtataag attcaaaagc ggaacattaa caaaaatacc gcgatcccg aggtcccttc 2160
gcaggggccag ctgaacataa tcgtgcaggt ctgcacggac cagcgcgggc acttccccgc 2220
caggaaacctt gacaaaagaa cccacactga ttatgacacg catactcgga gctatgctaa 2280
ccagcgtagc cccgatgtaa gctttgttgc atggggcgcg atataaaatg caaggtgctg 2340
ctcaaaaaat caggcaaagc ctgcgcgcaa aaagaaagca catcgtagtc atgtctatgc 2400
agataaaggc aggtaaagctc cggaaccacc acagaaaaag acaccatttt tctctcaaac 2460
atgtctgcgg gtttctgcat aaacacaaaa ttataagcat aagacggact acggccatgc 2520
aagcctgtct tacaacagga aaaaacaccc gattaaaaag caccaccgac agctcctcgg 2580
cggcgtgacc gtaaaaaaac tggtcaccgt taagactcgg taacacatc aggttgattc atcggtcagt 2640
tcatgtccgg agtcataatg gccgggggga atacataccc gcaggcgtag agacaacatt 2700
gctaaaaagc gaccgaaata gcccggggga ataggagaga aaaacacata aacacctgaa 2760
acagccccc a taggaggtat aacaaaatta tccgcgtcca gaacaacata cagcgcttca 2820
aaacccctct gcctaggcaa aatagcaccg gccttaccag taaaaaagaa aacctattaa cagagcgagt 2880
cagcggcagc caccagctca atcagtcaca gctgaaaaaa gggccaagtg aaaaaacacc cagaaaaacc 2940
ctcgacacgg ctcaaaaaatg acgtaacggg aacgaaagcc gatcctctcc cgaatcccc aatcgtcac 3000
atatatagga ctaaaaaatg aacgaaagcc taacttcccc taagccagta aacaaggcaa ggcttgaccg 3060
cacgcgaacc ccacgttacg taacttcccc gccgcatagt tttaagctac gctgcttcgc gatgtacggg 3120
ttccgttttc ctgctctgat tgagtagtgc cttaggggta ctagttatta acttacgta aatggcccc 3180
tcagtacaat ctgctctgat tgagtagtgc cttaggggta ctagttatta acttacgta aatggcccc 3240
tgaggtgcgc gaagaatctg gctgttgacat atggagttcc tgacgtcaat aatgacgtat gttcccatag 3300
acaattgcat gctgttgacat atggagttcc tgacgtcaat aatgacgtat gttcccatag 3360
ccagatatac tagcccatat ccccaacgac cattgacgtc aatgggtgga ctatttacgg ccctattgac 3420
cattagttca tagcccatat ccccaacgac cattgacgtc aatgggtgga ctatttacgg ccctattgac 3480
ctggctgacc gcccacgac cattgacgtc aatgggtgga ctatttacgg ccctattgac 3540
taacgccaat agggactttc atcatcaagt tatcatatgc caagtacgcc acatgacctt atggggactt 3600
acttggcagt cgctggcat atcgtctatta gactcacggg caaaatcaac gggactttcc aaaatgtcgt aacaactccg 3660
gtaaatggcc cgtattagtc gactcacggg caaaatcaac gggactttcc aaaatgtcgt aacaactccg 3720
agtacatctg ctgattagtc gactcacggg caaaatcaac gggactttcc aaaatgtcgt aacaactccg 3780
atgggcgtgg atagcgggtt gttttggcac gcaaattggg actgcttact tctgaattcg agctcgctgt tgggctcgcg 3840
atgggcgtgg atagcgggtt gttttggcac gcaaattggg actgcttact tctgaattcg agctcgctgt tgggctcgcg 3900
ccccattgac gcaaattggg actgcttact tctgaattcg agctcgctgt tgggctcgcg 4020
tctgggtaac tagagaaccc agcttgggtac ggtccttcca gtactcttg atcgacogga gctgagcacc gtggcgggcg 4080
gggagaccga aactcttcgc tccgccaccg agggacctga cagtcacagt cgcaaggtag gctgatgatg taattaaagt 4140
cgaacggtag ggcgtctaac cagtcacagt cgcaaggtag gctgatgatg taattaaagt 4200
tctcgagaaa ggcgtctaac cagtcacagt cgcaaggtag gctgatgatg taattaaagt 4260
gcagcgggtg ggcgtctaac cagtcacagt cgcaaggtag gctgatgatg taattaaagt 4320
aggcgggtct gacacggcgg gacggctctga agataccttc aaccccggtg ccccttctgt tccgaacctc ctggacgagg 4380
aagcgcgcaa gctgtgcctt tcttactcct tttgccccta cggcctctct acctctcaaa aaaaccaagt ctaactgtgg 4440
ggctctccaa gctgtgcctt tcttactcct tttgccccta cggcctctct acctctcaaa aaaaccaagt ctaactgtgg 4500
agtccccctg ggtactctc aaatgggcaa ctgtgagccc acctctcaaa aaaaccaagt ctaactgtgg 4560
cttgcgctca aaatgggcaa ctgtgagccc acctctcaaa aaaaccaagt ctaactgtgg 4620
aatgtaacca ctgtgagccc acctctcaaa aaaaccaagt ctaactgtgg 4680
tctgcacccc tcacagttac ctgagaagcc catgcaatca caggccccgc taaccgtgca cgaactcaaa 4740
gtcgcgggca acacactcac acacactcac catgcaatca caggccccgc taaccgtgca cgaactcaaa 4800
cttagcattg ccacccaagg acccctcaca cgatagcagt ttgaaaagag ccatttatac acaaaatgga 4860
tcaggccccc ctggtagctt gggcattgac ggctcctttg catgtaacag aacacttcc tgcacactaa cactttgacc 4920
actactgcca taaagtacgg gactattaat aggcaatatg caacttaatg tagcaggagg actaaaggatt 4980
aaactaggac gtagcaactg gccttgggtt ttgattcaca tatacttgat tttataaact gcttcaaaaca attccaaaaa gcttgaggtt 5040
gtagcaactg gtagcaactg gccttgggtt ttgattcaca tatacttgat tttataaact gcttcaaaaca attccaaaaa gcttgaggtt 5100
gtagcaactg gtagcaactg gccttgggtt ttgattcaca tatacttgat tttataaact gcttcaaaaca attccaaaaa gcttgaggtt 5160
gtagcaactg gtagcaactg gccttgggtt ttgattcaca tatacttgat tttataaact gcttcaaaaca attccaaaaa gcttgaggtt 5220
gtagcaactg gtagcaactg gccttgggtt ttgattcaca tatacttgat tttataaact gcttcaaaaca attccaaaaa gcttgaggtt 5280
gtagcaactg gtagcaactg gccttgggtt ttgattcaca tatacttgat tttataaact gcttcaaaaca attccaaaaa gcttgaggtt 5340
gtagcaactg gtagcaactg gccttgggtt ttgattcaca tatacttgat tttataaact gcttcaaaaca attccaaaaa gcttgaggtt 5400
gtagcaactg gtagcaactg gccttgggtt ttgattcaca tatacttgat tttataaact gcttcaaaaca attccaaaaa gcttgaggtt 5460
gtagcaactg gtagcaactg gccttgggtt ttgattcaca tatacttgat tttataaact gcttcaaaaca attccaaaaa gcttgaggtt 5520
gtagcaactg gtagcaactg gccttgggtt ttgattcaca tatacttgat tttataaact gcttcaaaaca attccaaaaa gcttgaggtt 5580

tggaaccacac	cagctccatc	tcctaactgt	agactaaatg	cagagaaaga	tgctaaactc	5640
acttttggtct	taacaaaatg	tggcagtcac	atacttgcta	cagtttcagt	tttggctgtt	5700
aaaggcagtt	tggtcccaat	atctggaaca	gttcaaagt	ctcatcttat	tataagattt	5760
gacgaaaatg	gagtgtact	aaacaattcc	ttcctggacc	cagaatattg	gaactttaga	5820
aatggagatc	ttactgaagg	cacagcctat	acaaacgctg	ttggatttat	gcctaacct	5880
tcagctttatc	caaaatctca	cggtaaaact	gccaaaagta	acattgtcag	tcaagtttac	5940
ttaaacggag	acaaaactaa	acctgtaaca	ctaaccatta	cactaaacgg	tacacaggaa	6000
acaggagaca	caactccaag	tgcatactct	atgtcatctt	catgggactg	gtctggccac	6060
aactacatta	atgaaatatt	tgccacatcc	tcttacactt	tttcatacat	tgcccaagaa	6120
taaaagaagcg	gccgctcgag	catgcatcta	gagggcccta	ttctatagt	tcacctaata	6180
gctagagctc	gctgatcagc	ctcgactgtg	ccttctagt	gccagccatc	tggtgtttgc	6240
ccctcccccg	tgcttccctt	gaccctggaa	gggtgccactc	ccactgtcct	ttcctaataa	6300
aatgagggaaa	ttgcatcgca	ttgtctgagt	aggtgtcatt	ctattctggg	gggtgggggtg	6360
gggcaggaca	gcaaggggga	ggattgggaa	gacaatagca	ggcatgctgg	ggatgcggtg	6420
ggctctatgg	cttctgaggc	ggaaagaacc	agctggggct	ctagggggta	tccccacgcg	6480
ccctgtagcg	gcgcattaa	cgcgccgggt	gtgggtggta	cgcgcagcgt	gaccgctaca	6540
ccttgccagcg	ccctagcgcc	cgctccttcc	gctttcttcc	cttccttctc	cgccacgttc	6600
gccggctttc	cccgctcaagc	tctaaatcgg	ggcatccctt	taggggtccg	atttagtgct	6660
ttacggccacc	tcgaccccaa	aaaacttgat	taggggtgat	gttcacgtag	tgggccatcg	6720
ccctgataga	cggtttttcg	ccctttgacg	ttggagtcca	cgttccttaa	tagtggaactc	6780
ttgttccaaa	ctggaacaac	actcaaccct	atctcggtct	attcttttga	tttataaggg	6840
attttgggga	tttcggccta	ttggttaaaa	aatgagctga	tttaacaaaa	atttaacgcg	6900
aattaattct	gtggaatgtg	tgtagcttag	gggtgtggaaa	gtccccaggc	tccccaggca	6960
ggcagaagta	tgcaaagcat	gcattctcaat	tagtcagcaa	ccagggtgtg	aaagtcccca	7020
ggctccccag	caggcagaag	tatgcaaagc	atgcattcca	attagtcagc	aaccatagtc	7080
ccgcccctaa	ctccgcccct	cccgccccta	actccgcccc	gttccgcccc	ttctccgccc	7140
catggctgac	taattttttt	tatttatgca	gagggccagg	ccgctctctg	ctctgagcta	7200
ttccagaagt	agtgaggagg	cttttttgga	ggcctaggct	tttgcaaaaa	gctcccggga	7260
gcttgtatat	ccattttcgg	atctgatcaa	gagacaggat	gaggatcggt	tcgcatgatt	7320
gaacaagatg	gattgcaagc	agggttctccg	gccgcttggg	tgagagggt	attcggtctat	7380
gactgggcac	aacagacaat	cggtctctct	gatgccgcg	tggtccggt	gtcagcgag	7440
gggcgcccg	ttctttttgt	caagaccgac	ctgtccggtg	ccctgaatga	actgcaggac	7500
gaggcagcgc	ggctatcggt	gctggccaag	acgggcttcc	cttgccgagc	tggtctcgac	7560
gttgctactg	aagcggggaag	ggactggctg	ctattgggag	aagtgcgggg	gcaggatctc	7620
ctgtcatctc	accttgctcc	tgccgagaaa	gtatccatca	tggtgatgc	aatgcggcgg	7680
ctgcatacgc	ttgatccggc	tacctgccca	ttcgaccacc	aagcgaacaa	tcgcatcgag	7740
cgagcacgta	ctcggtatga	agccggtctt	gtcgatcagg	atgatctgga	cgaagagcat	7800
caggggctcg	cgccagccga	actgttccgc	aggctcaagg	cgcgcattgcc	cgacggcgag	7860
gatctcgctg	tgacccatgg	cgatgcctgc	ttgccgaata	tcatggtgga	aaatggccgc	7920
ttttctggat	tcategactg	tgcccggtg	gggtgtggcg	accgctatca	ggacatagcg	7980
tttgctaccc	gtgatattgc	tgaagagctt	ggcgccgaat	gggtgaccg	cttctctgtg	8040
ctttacggta	tcgcccgtcc	cgattccgag	cgcatcgctt	tctatcgctt	ctttgacgag	8100
ttcttctgag	cgggactctg	gggttcgaaa	tgaccgacca	agcgaacgccc	aacctgccat	8160
cacgagattt	cgattccacc	gccgccttct	atgaaagggt	gggcttcgga	atcgttttcc	8220
gggacgccgg	ctggatgac	ctccagcgcg	gggatctcat	gctggagtcc	ttcgcccacc	8280
ccaacttggt	tattgcagct	tataatgggt	acaaataaag	caatagcatc	acaaatttca	8340
caaataaagc	atttttttca	ctgcattcta	gttgtgtgtt	gtccaaactc	atcaatgtat	8400
cttatcatgt	ctgtataaccg	tcgacctcta	gctagagctt	ggcgtaatac	tggtcatagc	8460
tggttctctgt	gtgaaattgt	tatccgctca	caattccaca	caacatacga	gccggaagca	8520
taaaagtgtaa	agcctggggt	gcctaattgag	tgagctaaact	cacattaatt	gcgttgcgct	8580
cactgccgcg	tttccagtcg	ggaaacctgt	cgtgccagct	gcattaatga	atcgcccaac	8640
gcgcggggag	aggcggtttg	cgtattgggc	gctcttcgct	ttcctcgctc	actgactcgc	8700
tgcgctcggt	cggttcggctg	cggcgagcgg	tatcagctca	ctcaaaggcg	gtaatacgg	8760
tatccacaga	atcaggggat	aacgcaggaa	agaacatgtg	agcaaaaggc	cagcaaaagg	8820
ccaggaacgg	taaaaaggcc	gcgttgctgg	cggttttcca	taggctccgc	ccccctgacg	8880
agcatcacaa	aaatcgacgc	tcaagtccga	gggtggcgaaa	cccgaaggga	ctataaagat	8940
accaggcggt	tccccctgga	agctccctcg	tgcgctctcc	tggtccgacc	ctgcccgtta	9000
ccggatacct	gtccgccttt	ctcccttcgg	gaagcggtgg	gctttctcaa	tgctcacgct	9060
gtaggatctc	cagttcggtg	taggtcgctc	gctccaagct	gggctgtgtg	cacgaacccc	9120
ccgttcagcc	cgaccgctgc	gccttatccg	gtaactatcg	tcttgagtcc	aaccgggtaa	9180
gacacgactt	atcgccactg	gcagcagcca	ctggtaacag	gattagcaga	gcgaggtatg	9240
taggcgggtg	tacagagttc	ttgaagtggg	ggcctaacta	cggctacact	agaaggacag	9300

-20-

```

tatttgggtat ctgcgctctg ctgaagccag ttaccttcgg aaaaagagtt ggtagctctt 9360
gatccggcaa acaaaccacc gctggtagcg gtgggttttt tgtttgcaag cagcagatta 9420
cgcgagaaa aaaaggatct caagaagatc ctttgatctt ttctacggg tctgacgctc 9480
agtggaaacga aaactcacgt taagggaatt tggatcatgag attatcaaaa aggatcttca 9540
cctagatcct tttaaattaa aaatgaagtt ttaaataaat ctaaagtata tatgagtaaa 9600
cttgggtctga cagttaccaaa tgcttaataca gtgaggcacc tatctcagcg atctgtctat 9660
ttcgttcacg catagttgcc tgactcccg tcgtgtagat aactacgata cgggaggggt 9720
taccatctgg cccagtgct gcaatgatac cgcgagacc acgctcaccg gctccagatt 9780
tatcagcaat aaaccagcca gccggaagg cggagcgag aagtggteet gcaactttat 9840
ccgcctccat ccagtctatt aattgttgcc gggaagctag agtaagtagt tcgccagtta 9900
atagtttgcg caacgttggt gccattgcta caggcatcgt ggtgtcacgc tcgtcgtttg 9960
gtatggcttc attcagctcc ggttcccaac gatcaaggcg agttacatga tccccatgt 10020
tgtgcaaaaa agcgggttagc tccttcgggc ctccgatcgt tgtcagaagt aagttggccg 10080
cagtgttatc actcatgggt atggcagcac tgcataattc tcttactgtc atgccatccg 10140
taagatgctt ttctgtgact ggtgagtact caaccaagtc attctgagaa tagtgtatgc 10200
ggcgaccgag ttgctcttgc ccggcgtaaa tacgggataa taccgcgcca catagcagaa 10260
ctttaaaagt gctcatcatt ggaaaacgtt cttcggggcg aaaactctca aggatcttac 10320
cgctgttgag atccagttcg atgtaaccca ctctgcacc caactgatct tcagcatctt 10380
ttactttcac cagcgtttct gggtagcaaa aaacaggaag gcaaaatgcc gcaaaaaagg 10440
gaataagggc gacacggaaa tgttgataac tcatactctt cctttttcaa tattattgaa 10500
gcatttatca gggttattgt ctcatgagcg gatacatatt tgaatgtatt tagaaaaata 10560
aacaaatagg ggttcgcgc acatttcccc gaaaagtgcc acctgacgtc ; 10610

```

<210> 17
 <211> 24
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Primer

<400> 17
 tgtacaccgg atccggcgca cacc

24

<210> 18
 <211> 35
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Primer

<400> 18
 cacaacgagc tcaattaatt aattgccaca toctc

35

<210> 19
 <211> 4
 <212> PRT
 <213> adenovirus

<400> 19
 Thr Leu Trp Thr
 1

<210> 20
 <211> 12
 <212> PRT
 <213> adenovirus

-21-

<400> 20

Pro Ser Ala Ser Ala Ser Ala Ser Ala Pro Gly Ser
 1 5 10

<210> 21

<211> 44

<212> PRT

<213> adenovirus

<400> 21

Met Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn Pro Val Tyr Pro
 1 5 10 15

Tyr Asp Thr Glu Thr Gly Pro Pro Thr Val Pro Phe Leu Thr Pro Pro
 20 25 30

Phe Val Ser Pro Asn Gly Phe Gln Glu Ser Pro Pro
 35 40

<210> 22

<211> 43

<212> PRT

<213> adenovirus

<400> 22

Met Ala Lys Arg Ala Arg Leu Ser Thr Ser Phe Asn Pro Val Tyr Pro
 1 5 10 15

Tyr Glu Asp Glu Ser Ser Ser Gln His Pro Phe Ile Asn Pro Gly Phe
 20 25 30

Ile Ser Pro Asp Gly Phe Thr Gln Ser Pro Asn
 35 40

<210> 23

<211> 43

<212> PRT

<213> adenovirus

<400> 23

Met Ser Lys Arg Leu Arg Val Glu Asp Asp Phe Asn Pro Val Tyr Pro
 1 5 10 15

Tyr Gly Tyr Ala Arg Asn Gln Asn Ile Pro Phe Leu Thr Pro Pro Phe
 20 25 30

Val Ser Ser Asp Gly Phe Lys Asn Phe Pro Pro
 35 40

<210> 24

<211> 42

<212> PRT

<213> adenovirus

<400> 24

Met Lys Arg Ala Arg Phe Glu Asp Asp Phe Asn Pro Val Tyr Pro Tyr
 1 5 10 15

-22-

Glu His Tyr Asn Pro Leu Asp Ile Pro Phe Ile Thr Pro Pro Phe Ala
 20 25 30
 Ser Ser Asn Gly Leu Gln Glu Lys Pro Pro
 35 40

<210> 25
 <211> 42
 <212> PRT
 <213> adenovirus

<400> 25
 Met Lys Arg Thr Arg Ile Glu Asp Asp Phe Asn Pro Val Tyr Pro Tyr
 1 5 10 15
 Asp Thr Ser Ser Thr Pro Ser Ile Pro Tyr Val Ala Pro Pro Phe Val
 20 25 30
 Ser Ser Asp Gly Leu Gln Glu Asn Pro Pro
 35 40

<210> 26
 <211> 327
 <212> DNA
 <213> adenovirus

<400> 26
 agatctgaat tcgagctcgc tgttgggctc gcggttgagg acaaactctt cgcggtcttt 60
 ccagtactct tggatcggaa acccgtcggc ctccgaacgg tactccgcca ccgagggacc 120
 tgagcgagtc cgcacgcacc ggatcggaaa acctctcgag aaaggcgctt aaccagtcac 180
 agtcgcaagg taggctgagc accgtggcgg gcggcagcgg gtggcggtcg gggttgtttc 240
 tggcgagggt gctgctgatg atgtaattaa agtaggcggg cttgagacgg cggatggctg 300
 aggtgaggtg tggcaggctt gagatct 327

<210> 27
 <211> 32480
 <212> DNA
 <213> adenovirus

<400> 27
 catcatcaat aatatacctt attttggatt gaagccaata tgataatgag ggggtggagt 60
 ttgtgacgtg gcgcggggcg tgggaacggg gcgggtgacg tagtagtgtg gcggaagtgt 120
 gatgttgcaa gtgtggcgga acacatgtaa gcgacggatg tggcaaaagt gacgtttttg 180
 gtgtgcgccg gtgtacacag gaagtgacaa ttttcgcgcg gttttaggcg gatgtgtgag 240
 taaatttggg cgtaaccgag taagatttgg ccattttcgc gggaaaactg aataagagga 300
 agtgaaatct gaataatttt gtgttactca tagcgcgtaa tctctagcat cgatgtcgac 360
 aagcttgaat tcgattaatg tgagttagct cactcattag gcaccccagg ctttacactt 420
 tatgcttccg gctcgtatgt tgtgtggaat tgtgagcggg taacaatttc acacaggaaa 480
 cagctatgac catgattacg aattcggcgc agcaccatgg cctgaaataa cctctgaaag 540
 aggaacttgg ttaggtacct tctgaggcgg aaagaaccag ctgtggaatg tgtgtcagtt 600
 aggggtgtgga aagtccccag gctccccagc aggcagaagt atgcaaagca tgcattctca 660
 ttagtcagca accaggtgtg gaaagtcccc aggtccccca gcaggcagaa gtatgcaaag 720
 catgcatctc aattagtcag caaccatagt cccgccctta actccgcca tcccgcctct 780
 aactccgccc agttccgccc attctccgcc ccatggctga ctaatttttt ttatttatgc 840
 agaggccgag gccgcctcgg cctctgagct attccagaag tagtgaggag gcttttttgg 900
 aggcctaggg ttttgcaaaa agcttgggat ctctataatc tcgcgcaacc tattttcccc 960
 tcgaacactt tttaagccgt agataaacag gctgggacac ttcacatgag cgaaaaatac 1020
 atcgtcacct gggacatgtt gcagatccat gcacgtaaac tcgcaagccg actgatgcct 1080
 tctgaacaat ggaaaggcat tattgccgta agccgtggcg gtctggtacc ggtgggtgaa 1140

gaccagaaac	agcacctcga	actgagccgc	gatattgccc	agcgtttcaa	cgcgctgtat	1200
ggcgagatcg	atcccgcgtg	tttacaacgt	cgtgactggg	aaaaccctgg	cgttacccaa	1260
cttaatcgcc	ttgcagcaca	tecccccttc	gccagctggc	gtaatagcga	agaggcccg	1320
accgatcgcc	cttcccaaca	gttgccgcagc	ctgaatggcg	aatggcgctt	tgccctgggtt	1380
ccggcaccag	aagcggtgcc	ggaaagctgg	ctggagtgcg	atcttcctga	ggccgatact	1440
gtcgtcgtcc	cctcaaactg	gcagatgcac	ggttacgatg	cgcccatcta	caccaacgta	1500
acctatccca	ttacgggtcaa	tcgcgcgttt	gttcccacgg	agaatccgac	gggttggttac	1560
tcgctcacat	ttaatgttga	tgaaagctgg	ctacaggaa	gccagacgcg	aattattttt	1620
gatggcggtta	actcggcggtt	tcatctgtgg	tgcaacgggc	gctgggtcgg	ttacggccag	1680
gacagtcgtt	tgccgtctga	atltgacctg	agcgcatttt	tacgcgcggg	agaaaaccgc	1740
ctcgcgggtga	tggtgctgcg	ttggagtgcg	ttcggttatc	tggaagatca	ggatatgtgg	1800
cggtatgagcg	gcattttccg	tgacgtctcg	ttgctgcata	aaccgactac	acaaatcagc	1860
gattttccatg	ttgccactcg	ctttaatgat	gatttcagcc	gcgctgtact	ggaggtgaa	1920
gttcagatgt	gcggcgagtt	gcgtgactac	ctacgggtaa	cagtttcttt	atggcagggg	1980
gaaacgcagg	tcgccagcgg	cacccgcgct	ttcggcggtg	aaattatcga	tgagcgtggg	2040
ggttatgccg	atcgcgtcac	actacgtctg	aacgtcgaaa	acccgaaact	gtggagcgcc	2100
gaaatcccgga	atctctatcg	tgccgtgggt	gaactgcaca	ccgcgcagcg	cacgctgatt	2160
gaagcagaag	cctgcgatgt	cggtttccgc	gaggtgcgga	ttgaaaatgg	tctgctgctg	2220
ctgaacggga	agccgttgct	gatttcgaggg	gttaaccgtc	acgagcatca	tcctctgcac	2280
ggtcagggtca	tggtatgagca	gacgatgggtg	caggatatcc	tgctgatgaa	gcagaacaac	2340
tttaacgccg	tgccgtgttc	gcattatccg	aaccatccgc	tgtggtacac	gctgtgcgac	2400
cgctacggcc	tgatgtggtg	ggatgaagcc	aattattgaaa	cccacggcat	ggtgccaatg	2460
aatcgtctga	ccgatgatcc	gcgctggcta	ccggcgatga	gcgaacgcgt	aacgcgaatg	2520
gtgcagcgcg	atcgtaatca	cccagtggtg	atcatctggt	cgctggggaa	tgaatcaggc	2580
cacggcgcta	atcacgacgc	gctgtatcgc	tggtacaaat	ctgtcgatcc	ttcccgcccg	2640
gtgcagtatg	aaggcggcgg	agccgacacc	acggccaccg	atattatttg	cccgatgtac	2700
gcgcgcgtgg	atgaagacca	gcccttcccg	gctgtgccga	aatggtccat	caaaaaatgg	2760
ctttcgctac	ctggagagac	gcgcgcgctg	atcctttgcg	aatacgcaca	cgcgatgggt	2820
aacagtcctg	gcggtttcgc	taaatactgg	caggcgtttc	gtcagtatcc	ccgtttacag	2880
ggcggtctcg	tctgggactg	ggtggatcag	tcgctgatta	aatatgatga	aaacggcaac	2940
ccgtggtcgg	cttacggcgg	tgattttggc	gatacgccga	acgatcgcca	gttctgtatg	3000
aacggtctcg	tctttgccga	ccgcacgcgg	catccagcgc	tgacgggaagc	aaaacaccag	3060
cagcagtttt	tccagttccg	tttatccggg	caaaccatcg	aagtgaaccg	cgaataacctg	3120
ttccgtcata	gcgataacga	gctcctgcac	tggatgggtg	cgctggatgg	taagccgctg	3180
gcaagcggtg	aagtgcctct	ggatgtcgct	ccacaaggta	aacagttgat	tgaactgcct	3240
gaactaccgc	agccggagag	cgccgggcaa	ctctgggtca	cagtacgcgt	agtgcaccg	3300
aacgcgaccg	catggtcaga	agccgggcac	atcagcgctt	ggcagcagtg	gcgtctggcg	3360
gaaaacctca	gtgtgacgct	ccccgcgcg	tcccacgcca	tcccgcatct	gaccaccagc	3420
gaaatggatt	tttgcacgca	gctgggtaat	aagcgttggc	aatttaaccg	ccagtacagg	3480
tttctttcac	agatgtggat	tggcgataaa	aaacaactgc	tgacgcgcgt	gcgcgatcag	3540
ttcaccctg	caccgctgga	taacgacatt	ggcgtaagt	aagcgaccgg	cattgaccct	3600
aacgcctggg	tcgaacgctg	gaaggcggcg	ggccattacc	aggccgaagc	agcgttgttg	3660
cagtgcacgg	cagatacact	tgctgatgcg	gtgctgatta	cgacgcgtca	cgctggcgag	3720
catcagggga	aaaccttatt	tatcagccgg	aaaacctacc	ggattgatgg	tagtggtcaa	3780
atggcgatta	ccgttgatgt	tgaagtggcg	agcgatacac	cgcatccggc	gcggattggc	3840
ctgaactgcc	agctggcgca	ggtagcagag	cgggtaaaact	ggctcggatt	agggccgcaa	3900
gaaaactatc	ccgaccgcct	tactgccggc	tggtttgacc	gctgggatct	gccattgtca	3960
gacatgtata	ccccgtacgt	cttcccagac	gaaaacggtc	tgccgtgcgg	gacgcgcgaa	4020
ttgaattatg	gcccacacca	gtggcgcggc	gacttccagt	tcaacatcag	ccgtcacagt	4080
caacagcaac	tgatggaaac	cagccatcgc	catctgctgc	acgcggaaga	aggcacatgg	4140
ctgaatatcg	acgggtttcca	tatggggatt	gggtggcgacg	actcctggag	cccgctcagta	4200
tcggcggaat	tccagctgag	cgccggtcgc	taaccattacc	agttggtctg	gtgtcaaaaa	4260
taataataac	cgggcaggcc	atgtctgccc	gtatttcgcg	taaggaaatc	cattatgtac	4320
tattttaaaaa	acacaaaactt	ttggatgttc	ggtttattct	ttttctttta	cttttttatc	4380
atgggagcct	acttcccgtt	tttcccgtat	tggctacatg	acatcaacca	tatcagcaaa	4440
agtgtacagg	gtattatttt	tgccgctatt	tctctgttct	cgctattatt	ccaaccgctg	4500
tttggctctgc	tttctgacaa	actcggaact	tggtttattgc	agcttataat	ggttacaaat	4560
aaagcaatag	catcacaaat	ttcacaaata	aagcattttt	ttactgcat	tctagttgtg	4620
gtttgtccaa	actcatcaat	gtatcttatc	ctgtctggat	ccagatctgg	gcgtggccta	4680
aggggtggaa	agaatatata	aggtgggggt	cttatgtagt	tttgtatctg	ttttgcagca	4740
gccgcgcgg	ccatgagcac	caactcgttt	gatggaagca	ttgtgagctc	atatttgaca	4800
acgcgcgatgc	ccccatgggc	cgggggtgcgt	cagaatgtga	tgggctccag	cattgatggt	4860

cgccccgtcc tgccccgcaaa ctctactacc ttgacctagc agaccgtgtc tggaaacgcg 4920
 ttggagactg cagcctccgc cgcgcgttca gccgctgcag ccaccgcccc cgggattgtg 4980
 actgactttg ctttcctgag cccgcttgca agcagtgcag cttcccgttc atccgccccg 5040
 gatgacaagt tgacggctct tttggcacia ttggattctt tgaccgggga acttaaatgtc 5100
 gtttctcagc agctgttgga tctgcgccag caggtttctg ccctgaaggc ttcctccctc 5160
 cccaatgcgg tttaaaacat aaataaaaaa ccagactctg tttggatttg gatcaagcaa 5220
 gtgtcttgct gtctttattt aggggttttg cgcgcgcggt agggccggga ccagcggtct 5280
 cggtcggtga ggtcctgtg tattttttcc aggacgtggt aaagtgact ctggatgttc 5340
 agatacatgg gcataagccc gtctctgggg tggaggtagc accactgcag agcttcatgc 5400
 tgcgggggtg tggttagat gatccagtcg tagcaggagc gctgggcgtg gtgcctaaaa 5460
 atgtctttca gtagcaagct gattgccagg ggaggccct tgggtgaagt gtttaciaaag 5520
 cggttaagct gggatgggtg catacgtggg gatatgagat gcatcttgga ctgtattttt 5580
 aggttggtta tgttcccagc catatccctc cgggatttca tgttggtcag aaccaccagc 5640
 acagtgtatc cgggtgcactt gggaaatttg tcatgtagct tagaaggaaa tgcgtggaag 5700
 aacttgagga cgcccttggt acctccaaga ttttccatgc attcgtccat aatgatggca 5760
 atgggcccac gggcggcggc ctgggccaag atatttcttg gatcactaac gtcatagttg 5820
 tgttccagga tgagatcgtc ataggccatt tttaciaaagc gcgggcgag ggtgccagac 5880
 tgcggtataa tggttccatc cgccccaggg gcgtagtta cctcacagat ttgcatttcc 5940
 cacgctttga gttcagatgg ggggatcatg tctacctgcg gggcgatgaa gaaaacggtt 6000
 tccggggtag gggagatcag ctgggaagaa agcaggttcc tgagcagctg cgacttaccg 6060
 cagccggtgg gcccgtaaat cacacctatt accgggtgca actggttaa gcatgtccct gactcgcatg 6120
 cagctgccgt catccctgag cagggggggc acttcgttaa gcgatagcag ttcttgcaag 6240
 ttttccctga ccaaatccgc cagaaggcgc tccgcgtag gcatgctttt gagcgtttga 6300
 gaagcaaaag ttttcaacgg tttgagaccg ccacagctcg gtcacctgct ctacggcatc 6360
 ccaagcagtt ccaggcggtc ttggggcggc tttcgctgta cggcagtagt cgggtgctcg 6420
 atatctctc caggggtcatg ttttccacg ggcgcagggt cctcgctcagc gtagtctggg 6480
 ccagacgggc ggggtgcgt ccgggtgcg cgctggccag ggtgcgcttg aggtggtcc 6540
 tcacggtgaa ggggtgcgt cggtcttcgc cctgcgcgtc ggccaggtag catttgacca 6600
 tgctggtgct gaagcgtgc cgcgcttgcc ggcagcttg cccttgagg 6660
 tgggtgtcata gtccagcccc tccgcggcgt ggcagcttg gagcttgagg gcgagaaata 6720
 aggcgcgcga cgaggggca gtagacttt tccgcgcgc tcccccaggtt ctttctatgc 6780
 ccgattccgg ggagtaggca tccgcgcgc aaaccagggtt ggtgacgaaa aggtgtccg 6840
 gccaggtgag ctctggccgt tcggggtcaa atagccggt cctcgagcgg tggtccgcgg 6900
 gtttcttacc tctggtttcc tacagacttg gagaccaactc aaggaggcta 7020
 tgtccccgta cagacttg gtagcggtcg ttgtccacta ggggttccac tgcgtccagg gtgtgaagac 7080
 atagaaactc gtagcggtcg ctcttcggca tcaaggaagg tgattggtt gcgttcgtcc 7140
 agtgggaggg gtagcggtcg ctcttcggca tcaaggaagg tgattggtt gcgttcgtcc 7200
 acatgtcgcc cgggtgttcc gtagcggtcg ctcttcggca tcaaggaagg tgattggtt gcgttcgtcc 7260
 cgggtgttcc gtagcggtcg ctcttcggca tcaaggaagg tgattggtt gcgttcgtcc 7320
 tgacttctgc ccgcggtgat ggtggcaaac gaccttgagg gtggccgat ccacttggtc 7380
 ccgcggtgat ggtggcaaac gaccttgagg gtggccgat ccacttggtc 7440
 tgtcaagctt ggtggcaaac gaccttgagg gtggccgat ccacttggtc 7500
 gcagggtttg gttttgtcg gttttgtcg gttttgtcg gttttgtcg 7560
 attcgcggc aacgcaccgc accgcgggtg gttggtccag cgtctcgtec 7620
 gcacgcgcca accgcgggtg gttggtccag cgtctcgtec gtagtctatc 7680
 gtaggcgctc gtagtctatc gtagtctatc gtagtctatc gtagtctatc 7740
 gtaggcgctc gtagtctatc gtagtctatc gtagtctatc gtagtctatc 7800
 gtaggcgctc gtagtctatc gtagtctatc gtagtctatc gtagtctatc 7860
 gtaggcgctc gtagtctatc gtagtctatc gtagtctatc gtagtctatc 7920
 gtaggcgctc gtagtctatc gtagtctatc gtagtctatc gtagtctatc 7980
 gtaggcgctc gtagtctatc gtagtctatc gtagtctatc gtagtctatc 8040
 gtaggcgctc gtagtctatc gtagtctatc gtagtctatc gtagtctatc 8100
 gtaggcgctc gtagtctatc gtagtctatc gtagtctatc gtagtctatc 8160
 gtaggcgctc gtagtctatc gtagtctatc gtagtctatc gtagtctatc 8220
 gtaggcgctc gtagtctatc gtagtctatc gtagtctatc gtagtctatc 8280
 gtaggcgctc gtagtctatc gtagtctatc gtagtctatc gtagtctatc 8340
 gtaggcgctc gtagtctatc gtagtctatc gtagtctatc gtagtctatc 8400
 gtaggcgctc gtagtctatc gtagtctatc gtagtctatc gtagtctatc 8460
 gtaggcgctc gtagtctatc gtagtctatc gtagtctatc gtagtctatc 8520
 gtaggcgctc gtagtctatc gtagtctatc gtagtctatc gtagtctatc 8580

ttcccgcgcg	aggcataaag	ttgctgtgta	tgcggaagg	tcccgccacc	tcggaacggt	8640
tgtaattac	ctgggcgcg	agcacgatct	cgtaaaagcc	gttgatgttg	tgccccacaa	8700
tgtaaggtc	caagaagcgc	gggatgccct	tgatggaagg	caatttttta	agttcctcgt	8760
aggtgagctc	ttcaggggag	ctgagcccgt	gctctgaaag	ggcccagctc	gcaagatgag	8820
ggttggaagc	gacgaatgag	ctccacaggt	cacgggcat	tagcatttgc	aggtggtcgc	8880
gaaaggtcct	aaactggcga	cctatggcca	ttttttctgg	ggtgatgcag	tagaaggtaa	8940
gcggttcttg	ttcccagcgg	tcccatccaa	ggttcgcggc	taggtctcgc	gcggcagtc	9000
ctagaggctc	atctccgcgc	aacttcatga	ccagcatgaa	gggcacgagc	tgcttcccaa	9060
aggcccccat	ccaagtatag	gtctctacat	cgtaggtgac	aaagagacgc	tcggtgcgag	9120
gatgcgagcc	gatcggaag	aactggatct	cccgccacca	attggaggag	tggtatttga	9180
tgtggtgaaa	gtagaagtcc	ctgcgacggg	ccgaacactc	gtgctggctt	ttgtaaaaac	9240
gtgcgcagta	ctggcagcgg	tgacgaggct	gtacatcctg	cacgaggttg	acctgacgac	9300
cgcgcacaag	gaagcagagt	gggaatttga	gcccctcgcc	tgccgggttt	ggctgggtgg	9360
cttctacttc	ggctgcttgt	ccttgaccgt	ctggctgctc	gaggggagtt	acggtggatc	9420
ggaccaccac	gccgcgcgag	cccaaagtcc	agatgtccgc	gcgcggcggt	cggagcttga	9480
tgacaacatc	gcgcagatgg	gagctgtcca	tggtctggag	ctcccgcggc	gtcaggtcag	9540
gcgggagctc	ctgcaggttt	acctcgcata	gacgggtcag	ggcgcgggct	agatccaggt	9600
gataccta	ttccaggggc	tggttggtgg	cggcgctgat	ggcttgcaag	aggccgcac	9660
cccgcgcgcc	gactacggta	ccgcgcggcg	ggcggtgggc	cgcgggggtg	tccttggtatg	9720
atgcattctaa	aagcggtgac	gcgggcgagc	ccccggaggt	agggggggct	ccggaccgcg	9780
cgggagagg	ggcaggggca	cgctcgccgc	gcgcgcgggc	aggagctggt	gctgcgcgcg	9840
taggttgctg	gcgaacgcga	cgacgcggcg	gttgatctcc	tgaaatctggc	gcctctgcgt	9900
gaagcagacg	ggcccgggtg	gcttgagcct	gaaagagagt	tcgacagaat	caatttcggt	9960
gtcgttgacg	gcggcctggc	gcaaaatctc	ctgcacgtct	cctgagttgt	cttgataggg	10020
gatctcggcc	atgaactgct	cgatctcttc	ctcctggaga	tctccgcgtc	cggtcgcgtc	10080
cacggtggcg	gcgaggtcgt	tggaatgctg	ggccatgagc	tgcgagaagg	cggtgaggcc	10140
tccctcgctt	cagacgcggc	tgtagaccac	gcccccttcg	gcctcgcggg	cgcgcatgac	10200
cacctgcgcg	agattgagct	ccacgtgcgc	ggcggaagacg	gcgtagtttc	gcaggcgctg	10260
aaagaggtag	ttgaggtggg	tgccgggtgtg	ttctgccacg	aagaagtaca	taaccagcgc	10320
tcgcaacgtg	gattcggtga	tatcccccaa	ggcctcaagg	cgctccatgg	cctcgtagaa	10380
gtccacggcg	aaagtga	actgggagtt	gcgcgcggac	acggttaact	cctctccag	10440
aagacggatg	agctcggcga	cagtgtcgcg	cacctcgcg	tcaaaggcta	caggggcctc	10500
ttcttcttct	tcaatctcct	cttcataaag	ggcctcccct	tcttcttctt	ctggcgcgcg	10560
tgggggaggg	gggacacggc	ggcgacgacg	gcgcaccggg	aggcggtcga	caaagcgctc	10620
gatcatctcc	ccgcggcgac	ggcgcatggt	ctcggtgacg	gcgcggccgt	tctcgcgggg	10680
gcgcagttgg	aagacgcgcg	ccgtcatgtc	ccggttatgg	ggtggcgggg	ggctgccatg	10740
cggcagggat	acggcgctaa	cgatgcattc	caacaattgt	tgtgtaggta	ctccgccgcg	10800
gagggacctg	agcgagtcgg	catcgaccgg	atcgga	ctctcgagaa	aggcgctctaa	10860
ccagtcacag	tcgcaaggta	ggctgagcac	cgtggcgggc	ggcagcgggc	ggcggtcggg	10920
ggtgtttctg	gcggaggtgc	tgctgatgat	gtaattaaag	taggcggtct	tgagacggcg	10980
gatgttcgac	agaagcacc	tgctcctggg	tccggcctgc	tgaatgcgca	ggcggtcggc	11040
catgccccag	gcttcgtttt	gacatcggcg	caggtctttg	tagtagtctt	gcattgagcct	11100
ttctacgggc	acttcttctt	ctccttcttc	ttgtcctgca	tctcttgcat	ctatcgctgc	11160
ggcgggcgcg	gagtttgccc	gtaggtggcg	ccctcttctt	cccatgcgtg	tgaccgccga	11220
gccccctc	ggctgaagca	gggctaggtc	ggcgacaacg	cgctcggtct	atatggcctg	11280
ctgcacctgc	gtgaggttag	actggaagtc	atccatgtcc	acaaagcggt	ggtatgcgcc	11340
cgtgttgatg	gtgtaagtgc	agttggccat	aacggaccag	ttaacggtct	ggtgaccggg	11400
ctgcgagagc	tcggtgtacc	tgagacgcga	gtaagccctc	gagtcacaata	cgtagtcgtt	11460
gcaagtccgc	accaggtact	ggatccca	caaaaagtgc	ggcgggcggt	ggcggtagag	11520
gggccagcgt	aggggtggcg	gggctccggg	ggcgagatct	tccaacataa	ggcgatgata	11580
tccgtagatg	tacctggaca	tccaggtgat	gccggcgggc	gtggtggagg	cgcgcgga	11640
gtcgcgagc	cggttcacga	tggtgcgcag	cggcaaaag	tgctccatgg	tcgggacgct	11700
ctggcggtgc	aggcgcgcg	aatcggtgac	gctctagacc	gtgcaaaag	agagcctgta	11760
agcgggcact	cttcctggtt	ctgggtggata	aattcgcaag	ggtatcatgg	cggacgaccg	11820
gggttcgagc	cccgatccg	gccgtccgc	gtgatccatg	cggttaccgc	ccgcgtgctg	11880
aaccacagtg	tgcgacgtca	gacaacgggg	gagtgctcct	tttggttcc	ttccaggcgc	11940
ggcggtcgtc	gcgctagctt	ttttggccac	tgccgcgcgc	cagcgtaagc	ggttaggctg	12000
gaaagcgaaa	gcattaagtg	gctcgctccc	tgtagccgga	gggtattttt	ccaagggttg	12060
agtcggggga	ccccgggttc	gagtcctcga	ccggccggac	tgccggcaac	gggggtttgc	12120
ctccccgtca	tgcaagacc	cgcttgcaaa	ttcctccgga	aacaggagacg	agcccccttt	12180
ttgcttttcc	cagatgcac	cgggtgctgcg	gcagatgcgc	ccccctctc	agcagcgcca	12240
agagcaagag	cagcggcaga	catgcagggc	accctcccct	cctctaccg	cgtcaggagg	12300

ggcgacatcc	gcggttgacg	cggcagcaga	tggtgattac	gaacccccgc	ggcgccgggc	12360
ccggcactac	ctggacttgg	aggagggcga	gggcctggcg	cggctaggag	cgccctctcc	12420
tgagcggtag	ccaaggggtgc	agctgaagcg	tgatacgcgt	gagggctacg	tgccgcggca	12480
gaacctgttt	cgcgaccgcg	aggagagga	gcccaggag	atgcgggac	gaaagtcca	12540
cgcagggcgc	gagctgcggc	atggcctgaa	tcgcgagcgg	ttgctgcgcg	aggaggactt	12600
tgagcccgac	gcgcgaaaccg	ggattagtcc	cgcgcgcgca	cacgtggcgg	ccgccgacct	12660
ggtaaccgca	tacgagcaga	cgggtgaacca	ggagattaac	tttcaaaaaa	gctttaacaa	12720
ccactgctgt	acgcttgtgg	cgcgcgagga	ggtggctata	ggactgatgc	atctgtggga	12780
ctttgttaagc	gcgctggagc	aaaacccaaa	tagcaagccg	ctcatggcgc	agctgttcc	12840
tatagtgcag	cacagcaggg	acaacgaggg	attcagggat	gcgctgctaa	acatagtaga	12900
gcccagaggc	cgtgtggctgc	tcgatttgat	aaacatcctg	cagagcatag	tggtgcagga	12960
gcgagctttg	agcctggctg	acaaggtggc	cgccatcaac	tattccatgc	ttagcctggg	13020
caagttttac	gcccgaaga	tataccatac	cccttacgtt	cccatagaca	aggaggtaaa	13080
gatcgagggg	ttctacatgc	gcatggcgct	gaaggtgctt	accttgagcg	acgacctggg	13140
cgtttatcgc	aacgagcgca	tccacaaggc	cgtgagcgtg	agccggcgcg	gcgagctcag	13200
cgaccgcgag	ctgatgcaca	gcctgcaaa	ggcctggct	ggcacgggca	gcggcgatag	13260
agaggccgag	tcctactttg	acgcggcgcg	tgacctgcgc	tgggcccaa	gccgacgcgc	13320
cctggaggca	gctggggccg	gacctgggct	ggcggtggca	cccgcgcgcg	ctggcaacct	13380
cgggcggtg	gaggaatatg	acgaggacga	tgagtacgag	ccagaggacg	gcgagtacta	13440
agcgggtgatg	tttctgatca	gatgatgcaa	gacgcaacgg	acccggcggt	gcggggcgcg	13500
ctgcagagcc	agccgtccgg	ccttaactcc	acggacgact	ggcgccaggt	catggaccgc	13560
atcatgtcgc	tgactgcgcg	caatcctgac	gcgttcgcgc	agcagccgca	ggccaaccgg	13620
ctctccgcaa	ttctggaagc	ggtggtcccg	gcgcgcgcaa	accccacgca	cgagaagggtg	13680
ctggcgatcg	taaacgcgct	ggccgaaaac	agggccatcc	ggcccgcgca	ggccggcctg	13740
gtctacgacg	cgtgtcttca	gcgcgtggct	cgttacaaca	gcggcaacct	gcagaccaac	13800
ctggaccggc	tggtggggga	ggcgtggcgc	ggcgtggcgc	agcgtgagcg	cgcgacgacg	13860
cagggcaacc	tggtctccat	gggtgcacta	aacgccttcc	tgagtacaca	gcccgcacaac	13920
gtgccgcggg	gacaggagga	ctacaccaac	tttgtgagcg	cactgcggt	aatggtgact	13980
gagacaccgc	aaagtgaggt	gtaccagtct	ggccagact	attttttcca	gaccagtaga	14040
caaggcctgc	agaccgtaaa	cctgagccag	gctttcaaaa	acttgacggg	gctgtggggg	14100
gtgcgggctc	ccacagcgca	ccgcgcgacc	gtgtctagct	tgctgacgcc	caactcgcgc	14160
ctgtgtctgc	tgctaatagc	gcccttcacg	gacagtggca	gcgtgtcccg	ggacacatac	14220
ctaggtcact	tgctgacact	gtaccgcgag	gccataggtc	aggcgcatgt	ggacgagcat	14280
actttccagg	agattacaag	tgctagccgc	gcgtggggc	aggaggacac	gggcagcctg	14340
gaggcaacc	ttaactacct	gctgaccaac	cggcggcaga	agatcccctc	gttgacagt	14400
ttaaacagcg	aggaggagcg	cattttgcgc	tacgtgcagc	agaagcgtgag	ccttaacctg	14460
atgcgcgacg	gggtaacgcc	cagcgtggcg	ctggacatga	ccgcgcgcaa	catggaaccg	14520
ggcatgtatg	cctcaaaccg	gccgtttatc	aacgcctaa	tggaactact	gcatacgcg	14580
gccgccgtga	accccgagta	tttcaaccaat	gccatcttga	acccgcactg	gctaccgccc	14640
cctgggtttct	acacggggg	attecagggtg	cccagaggta	acgatggatt	cctctgggac	14700
gacatagacg	acagcgtggt	ttccccgcaa	ccgcagaccc	tgctagagtt	gcaacagcgc	14760
gagcaggcag	aggcggcgct	gcgaaaggaa	agcttccgca	ggccaagcag	cttgtccgat	14820
ctagggcgctg	cggccccgcg	gtcagatgct	agttagcccat	ttccaagctt	gatagggtct	14880
cttaccagca	ctcgcaccac	ccgccccgcg	ctgctgggcg	aggaggagta	cctaaacaac	14940
tcgctgctgc	agccgcagcg	cgaaaaaaac	ctgcctccgg	catttcccaa	caacgggata	15000
gagagcctag	tggaacaagat	gagtagatgg	aagacgtacg	cgcaggagca	cagggacgtg	15060
ccaggccccgc	gcccgcacc	ccgtcgtcaa	aggcacgacc	gtcagcgggg	tctgggtgtg	15120
gaggacgatg	actcgggcaga	cgacagcagc	gtcctggatt	tgaggaggag	tggaaccccg	15180
tttgcgacc	ttcgccccag	gctggggaga	atgttttaaa	aaaaaaaaag	catgatgcaa	15240
aataaaaaac	tcaccaaggc	catggcaccg	agcgttggtt	ttcttgtatt	ccccttagta	15300
tgccgcgcgc	ggcgatgtat	gaggaaaggtc	ctcctccctc	ctacgagagt	gtggtgagcg	15360
cggcgccagt	ggcgcgggcg	ctgggttctc	ccttcgatgc	tcccctggac	ccgccgtttg	15420
tgcctccgcg	gtacctgcgg	cctaccgggg	ggagaaacag	catccgttac	tctgagttgg	15480
caccctatt	cgacaccacc	cgtgtgtacc	tggtggacaa	caagtcaacg	gatgtggcat	15540
ccctgaacta	ccagaacgac	cacagcaact	ttctgaccac	ggtcattcaa	aacaatgact	15600
acagcccggg	ggaggcaagc	acacagacca	tcaactctga	cgaccggtcg	cactggggcg	15660
gcgacctgaa	aaccatcctg	cataccaaca	tgccaaatgt	gaacgagttc	atgtttacca	15720
ataaatttaa	ggcgcggtg	atggtgtcgc	gcttgccctac	taaggacaat	caggtggagc	15780
tgaaatacga	gtgggtggag	ttcacgctgc	ccgagggcaa	ctactccgag	accatgacca	15840
tagaccttat	gaacaacgcg	atcgtggagc	actacttgaa	agtgggcaga	cagaacgggg	15900
ttctggaaaag	cgacatcggg	gtaaaagttg	acaccgcgaa	cttcagactg	gggtttgacc	15960
ccgtcactgg	tcttgtcatg	cctgggggtat	atacaaacga	agccttccat	ccagacatca	16020

ttttgctgcc	aggatgcggg	gtggacttca	cccacagccg	cctgagcaac	ttgttgggca	16080
tccgcaagcg	gcaacccttc	caggagggtc	ttaggatcac	ctacgatgat	ctggagggtg	16140
gtaacattcc	cgcaactgtt	gatgtggacg	cctaccaggc	gagcttgaaa	gatgacaccg	16200
aacaggggcg	gggtggcgca	ggcggcagca	acagcagtgg	cagcggcgcg	gaagagaact	16260
ccaacgcggc	agccgcggca	atgcagcccg	tggaggacat	gaacgatcat	gccattcgcg	16320
gcgacacott	tgccacacgg	gctgaggaga	agcgcgctga	ggccgaagca	gcggccgaag	16380
ctgccgcccc	cgctgcgcaa	cccagggtcg	agaagcctca	gaagaaaccg	gtgatcaaac	16440
ccctgacaga	ggacagcaag	aaacgcagtt	acaacctaat	aagcaatgac	agcaccttca	16500
cccagtagcg	cagctggtac	cttgcataca	actacggcga	ccctcagacc	ggaatccgct	16560
catggaccct	gctttgcact	cctgacgtaa	cctgcggctc	ggagcaggtc	tactggctcg	16620
tgccagacat	gatgcaagac	cccgtgacct	tccgtccac	gcgccagatc	agcaactttc	16680
cggtgggtgg	cgccgagctg	ttgcccgctg	actccaagag	cttctacaac	gaccaggccg	16740
tctactccca	actcatccgc	cagtttacct	ctctgaccca	cgtgttcaat	cgctttcccc	16800
agaaccagat	tttggcgcg	ccgccagccc	ccaccatcac	caccgtcagt	gaaaacggtc	16860
ctgctctcac	agatcacggg	acgctaccgc	tgcgcaacag	catcgaggga	gtccagcgag	16920
tgaccattac	tgacgccaga	cgccgcacct	tcgctacgt	ttacaaggcc	ctgggcatag	16980
tctcgccg	cgctctatcg	agccgcactt	tttgagcaag	catgtccatc	cttatatcgc	17040
caagcaataa	cacaggctgg	ggcctgcgct	tcccaagcaa	gatgtttggc	ggggccaaga	17100
agcgctccga	ccaacaccca	gtgcgcgtgc	gcgggcacta	ccgcgcgccc	tggggcgcg	17160
acaaagcg	cgcaactggg	cgcaaccacc	catcgacgcg	catcgacgcg	gtgggtggag	17220
aggcgcgcaa	ctacacgccc	acgcgcgcc	cagtgtccac	agtggacgcg	gccattcaga	17280
ccgtggtg	cggagcccgg	cgctatgcta	aaatgaagag	acggcgagg	cgcgtagcac	17340
gtcgccaccg	ccgccgaccc	ggcactgccg	cccaacgcgc	ggcgcgggcc	ctgcttaacc	17400
gcgcacgtcg	caccggccga	cgggcggcca	tgcgggccc	tcgaaggctg	gccgcgggta	17460
ttgtcaactgt	gccccccagg	tccaggcgac	gagcgggcgc	cgacgagcc	gcggccatta	17520
gtgctatgac	tcagggtcgc	aggggcaacg	tgtattgggt	gcgcgactcg	gttagcgcc	17580
tgcgcgtg	cgtgcgcacc	cgccccccgc	gcaactagat	tgcaagaaaa	aactacttag	17640
actcgtaact	ttgtatgtat	ccagcgcg	cggcgcgcaa	cgaagctatg	tccaagcgca	17700
aaatcaaaga	agagatgctc	caggctcatcg	cgccggagat	ctatggcccc	ccgaagaagg	17760
aagagcagga	ttacaagccc	cgaaagctaa	agcgggtcaa	aaagaaaaag	aaagatgatg	17820
atgatgaact	tgacgacgag	gtggaactgc	tgcacgctac	cgcgcccagg	cgacgggtac	17880
agtggaaagg	tcgacgcgta	aaacgtgttt	tgcgacccgg	caccaccgta	gtctttacgc	17940
ccggtgagcg	ctccaccgc	acctacaagc	tgaggtgtac	tgaggtgtac	ggcgacgag	18000
acctgcttga	gcaggccaac	gagcgccctg	gggagtttgc	ctacggaaag	cggcataagg	18060
acatgctggc	gttgccgctg	gacgagggca	acccaacacc	tagcctaagg	cccgtaacac	18120
tgcagcaggt	gctgcccgcg	cttgcaaccgt	ccgaagaaaa	gcgcggccta	aagcgcgagt	18180
ctggtgactt	ggcaccacc	gtgcagctga	tggtaaccaa	gcgccagcga	ctggaagatg	18240
tcttggaata	aaatgaccgtg	gaacctgggc	tgagccccga	ggtccgcgtg	cgcccaatca	18300
agcagggtgg	gcccgggactg	ggcggtcgaga	ccgtggacgt	tcagataccc	actaccagta	18360
gcaccagtat	tgccaccg	acagagggca	tggagacaca	aacgtccccg	gttgccctcag	18420
cggtggcgga	tgccgcgggtg	caggcggtcg	ctgcggccgc	gtccaagacc	tctacggagg	18480
tgcaaacgga	cccgtggatg	tttcgccccg	cagccccccg	gcgcccgcg	ggttcgagga	18540
agtagcgcg	cgccagcgcg	ctactgcccc	aatatgccct	acatccttcc	attgcgccta	18600
cccccggtta	tcgtggctac	acctaccg	ccagaagacg	agcaactacc	cgacgcggaa	18660
ccaccactgg	aaccgcggc	cgccgtcgcc	gtcgccagcc	cgtgctggcc	ccgatttccg	18720
tgcgcagggt	ggctcgcgaa	ggaggcagga	ccctggtgct	gccaacagcg	cgctaccacc	18780
ccagcatcgt	ttaaaaagc	gtctttgtgg	ttcttgca	tatggccctc	acctgccgc	18840
tccgtttccc	ggtgccggga	ttccgaggaa	gaatgcaccg	taggaggggc	atggccggcc	18900
acggcctgac	gggcggcatg	cgctgtgcgc	accaccggcg	gcggcgcgcg	tcgcaccgtc	18960
gcatgcgcg	cggtatcctg	ccccctctta	ttccactgat	cgccgcggcg	attggcgccg	19020
tgccccgaat	tgcatccgtg	gccttgccag	cgcagagaca	ctgattaaaa	acaagttgca	19080
tgtggaataa	tcaaaataaa	aagtctggac	tctcacgctc	gcttggctct	gtaactattt	19140
tgtagaatgg	aagacatcaa	ctttgcgtct	ctggccccgc	gacacggctc	gcgcccgctc	19200
atgggaaact	ggcaagatat	cggcaccagc	aatatgagcg	gtggcgccct	cagctggggc	19260
tcgctgtgga	gcggcattaa	aaatttcggt	tccaccgtta	agaactatgg	cagcaaggcc	19320
tggaaacagca	gcacaggcca	gatctgagg	gataagttga	aagagcaaaa	tttccaacaa	19380
aaggtggtag	atggcctggc	ctctggcatt	agcggggtgg	tggacctggc	caaccaggca	19440
gtgcaaaata	agattaacag	taagcttgat	ccccgccctc	ccgtagagga	gcctccaccg	19500
gccgtggaga	cagtgtctcc	agaggggctg	ggcgaaaagc	gtccgcgccc	cgacagggaa	19560
gaaactctgg	tcacgcaaat	agacgagcct	ccctcgtagc	aggaggcact	aaagcaaggc	19620
ctgccacca	cgcgtcccat	cgcccccag	gctaccggag	tgctgggcca	gcacacacc	19680
gtaacgctgg	acctgcctcc	ccccgcggac	accagcaga	aacctgtgct	gccaggcccc	19740

accgcccgttg ttgtaaccocg tccctagccgc ggcgcgcgcgc cagcgggtccg 19800
cgatccgttgc ggcccgtagc cagtggcaac tggcaaaagca cactgaacag catcggtgggt 19860
ctgggggtgac aatccctgaa gcgccgacga tgcttctgaa tagctaactg gtcgtatgtg 19920
tgtcatgtat gcgtccatgt cgcgcgcaga ggagctgctg agccgcgcgc cgcccgcctt 19980
ccaagatggc taccctctcg atgatgccgc agtggcttta catgcacatc tcggggccagg 20040
acgcctcggg gtacctgagc cccgggttg tgcagtttgc ccgcgccacc gagacgtact 20100
tcagcctgaa taacaagttt agaaaccca ctgcggttca tccctgtgga ccgtgaggat gatgaagctg 20160
accggtccca gcgtttgacg ctgcggttca tccctgtgga ccgtgaggat gatgaagctg 20220
cgtacaaggc gcggttcacc ctgactgtgg gtgataaccg tgtgctggac atggcttcca 20280
cgtactttga catccgcgcg gtgctggaca gggggccctac ttttaagccc tactctggca 20340
ctgctacaa cgccctggct cccaagggtg aggacgatga caacgaagac gaagtagacg 20400
ctactctct ctgaaataaac atagagaag ttgggcaggc gccttattct ggtataaata 20460
agcaagctga gcagcaaaaa actcacgtat ttgggcaggc gccttattct ggtataaata 20520
ttacaaaggg ggggtattcaa ataggtgtcg aaggtcaaac acctaaatat gccgataaaa 20580
catttcaacc tgaacctcaa ataggtgtcg aaggtcaaac acctaaatat gccgataaaa 20640
cagctgggag agtccctaaa aagactaccc caatgaaacc atgttacggt tcatatgcaa 20700
aaccacaaa tgaaatgga gggcaaggca ttcttgtaaa gcaacaaaat ggaaagctag 20760
aaagtcaagt ggaatgcaa ttttctcaa ctactgaggg gaccgcaggc aatgggtgata 20820
acttgactcc taaagtggta ttgtacagt ttgtacagt gtaactcacg agaactaatg ggccaacaa 20880
atatttctta catgcccact attaggaag gtaactcacg agaactaatg ggccaacaa 20940
ctatgcccaa caggcctaata tttagggaaa ttagggacaa ttttattggg ctaatgtatt 21000
acaacagcac gggtaatatg ggtgttctgg cgggccaagc atcgagttg aatgctgttg 21060
tagatttgca agacagaaac acagagcttt ctaccagct tttgcttgat tccattgggt 21120
atagaaccag gtacttttct atgtggaatc aggtgttgga cagctatgat ccagatgtta 21180
gaattattga aatcatgga actgaagatg aacttccaaa ttactgcttt ccactgggag 21240
gtgtgattaa tacagagact cttaccaagg taaaacctaa aacaggtcag gaaaatggat 21300
gggaaaaaga tgctacagaa ttttcagata aaaatgaaat aagagttgga aataattttg 21360
ccatggaaat caatctaaat gccaacctgt ggagaaattt cctgtactcc aacatagcgc 21420
tgtatttgcc cgacaagcta aagtacagtc cttccaacgt aaaaatttct gataacccaa 21480
acacctaaga ctacatgaac aagcgagtg tggtcccggt gttagtggac tgctacatta 21540
accttgagc acgctggtcc cttgactata tggacaacgt caaccattt aaccaacc 21600
gcaatgctgg cctgcgctac cgctcaatgt tgctgggcaa tggctcgctat gtgcccttcc 21660
acatccaggt gcctcagaag ttctttgcca ttaaaaaact ccttctcctg ccgggctcat 21720
acacctaaga ctacatgaac aagcgagtg tggtcccggt gttagtggac tgctacatta 21780
atgacctaa ggttgacgga gccagcatta agtttgatag catttgctt tacgccacct 21840
tcttcccat ggcccacaac accgcctcca cgcttgaggg catgcttaga aacgacacca 21900
acgaccagtc ctttaacgac tatctctccg ccgccaacat gctctacct ataccgcga 21960
acgctacca cgtgcccata tccatccctt ccgcaactg ggcggctttc cgcggctggg 22020
ccttcacgcg ccttaagact aaggaaaacc catcactggg ctcgggctac gacccttatt 22080
acacctaaga ctgctctata cctacctag atggaacctt ttacctcaac cacaccttta 22140
agaaggtggc cattaccttt gactcttctg tcagctggcc tggcaatgac cgcctgctta 22200
cccccaacga gtttgaaatt aagcgctcag ttgacgggga ggggttacaac gttgcccagt 22260
gtaacatgac caaagactgg ttctggtac aaatgctag taactacaac attggctacc 22320
agggttcta tatcccagag agctacaagg cctcttctt ctcttcttt agaaacttcc 22380
agcccatgag ccgtcaggtg gtggatgata cttaaatacaa ggactacca caggtgggca 22440
tccctaccca acacaacaac tctggatttg ttggctacct tgccccacc atgcgcgaag 22500
gacaggccta cctgctaacc tccccctatc cgcttatagg caagacgca gttgacagca 22560
ttaccagaa aaagtttctt tgcatcgca cctttggcg catccattc tccagtaact 22620
ttatgtccat gggcgactc acagacctgg gccaaaacct tctctacgc aactccgccc 22680
acgcgctaga catgactttt gaggtggatc ccatggacga gcccaacctt ctttatgttt 22740
tggttgaaat ctttgacgtg gtcctgtgac accggccgca ccgcggcgct atcgaaaccg 22800
tgtaacctgc cagcccttc tcggccggca acgcacaaac ataaagaagc aagcaacatc 22860
aacaacagct gccgcatggt gctccagtga gcaggaaactg aaagccattg tcaaagatct 22920
tggttggtgg ccatattttt tgggacacta tgacaagcgc tttccaggct ttgtttctcc 22980
acacaagctc gcctgcgcca tagtcaatac ggcggctcgc gagactgggg gcgtacactg 23040
gatggccttt ccttggaaac cgcactcaaa aacatgctac ctctttgagc cctttggctt 23100
ttctgaccag gcactcaagc aggtttacca gtttgagtac gagtcaactc tgcccgtag 23160
cgccattgct tcttcccccg accgctgtat aacgctggaa aagtcacccc aaagcgtaca 23220
ggggcccaac tcggccgcct gtggactatt ctgctgcatg tttctccacg cctttgccc 23280
ctggcccaaa actcccatgg atcacaaccc caccatgaac cttattaccg gggtaaccaa 23340
ctccatgctc aacagtcccc aggtacagcc caccctgcgt cgcaaccagg aacagctcta 23400
cagcttctct gagcgccact cgcctactt cgcagccac agtgccgaga ttaggagcgc 23460

cacttctttt	tgtcacttga	aaaacatgta	aaaataatgt	actagagaca	ctttcaataa	23520
aggcaaatgc	ttttatttgt	acactctcgg	gtgattatgt	acccccaccc	ttgccgtctg	23580
cgccgtttaa	aaatcaaagg	ggttctgccg	cgcatcgcta	tgcgccactg	gcagggaacac	23640
gttgcgatac	tggtgttttag	tgctccactt	aaactcaggg	acaacccatcc	gcggcagctc	23700
ggtgaagttt	tactccaca	ggctgcgcac	catcaccaac	gcgttttagca	ggtcggggcgc	23760
cgatatcttg	aagtcgcagt	tggggcctcc	gccttgcgcg	cgcgagttgc	gatacacagg	23820
gttgccagcac	tggaaacta	tcagcgccgg	gtggtgcacg	ctggccagca	cgctcttgtc	23880
ggagatcaga	tcgcgcgtcca	ggctctccgc	gttgctcagg	gcgaacggag	tcaactttgg	23940
tagctgcctt	cccaaaaagg	gcgcgtgccc	aggcttttag	ttgcactcgc	accgtagtgg	24000
catcaaaaagg	tgaccgtgcc	cggtctgggc	gttaggatac	agcgcctgca	taaaagcctt	24060
gatctgctta	aaagccacct	gagcctttgc	gccttcagag	aagaacatgc	cgcaagactt	24120
gccggaanaac	tgattggccg	gacaggccgc	gtcgtgcacg	cagcaccttg	cgctcgggtgtt	24180
ggagatctgc	accacatttc	ggccccaccg	gttcttccacg	atcttggcct	tgctagactg	24240
ctccttcagc	gcgcgtgcc	cgttttcgcct	cgctcacatcc	atttcaatca	cgctgctcctt	24300
atztatcata	atgcttcctg	gtagacactt	aagctgcctt	tcgatctcag	cgacggcgtg	24360
cagccacaac	gcgcagcccg	tggtctcgtg	atgctttag	gtcacctctg	caaacgactg	24420
caggtacgcc	tgcaggaaac	gccccatcat	cgctcacaag	gtcttgttgc	tggtgaaggt	24480
cagctgaac	ccgcgtgct	cctcgctcag	ccaggctctg	catacggccg	ccagagcttc	24540
cacttggtca	ggcagtagtt	tgaagttcgc	cttagatcg	ttatccacgt	ggtacttgc	24600
catcagcgcg	cgcgagcct	ccatgccctt	ctcccacgca	gacacgatcg	gcacactcag	24660
cggtttcctc	accgtaattt	cactttccgc	ttcgctgggc	tcttctcctt	cctcttgcgt	24720
ccgcatacca	cgcgccactg	ggctcgtctt	attcagccgc	cgactgtgc	gcttacctcc	24780
tttgccatgc	ttgattagca	ccggtgggtt	gctgaaaccc	accattttgt	gcgccacatc	24840
ttctctttct	tcctcgtgt	ccacgattac	ctctgggtgat	ggcgggcgct	cggtctggg	24900
agaagggcgc	ttctttttct	ttctgggcgc	aatggccaaa	tcgcgcgcgc	aggtcgatgg	24960
ccgcgggctg	ggtgtgcgcg	gcaccagcgc	gtcttgtgat	gagtcttctt	cgctctcgga	25020
ctcgatacgc	cgctcatcc	gcttttttgg	ggcgcccgcc	ggaggcgccg	gcgacgggga	25080
cggggacgac	acgtcctcca	tggttggggg	acgtcgccgc	gcaccgcgtc	cgcgctcggg	25140
ggtggtttcg	cgctgctcct	cttcccgact	ggccatttcc	ttctcctata	ggcagaaaaa	25200
gatcatggag	tcagtcgaga	agaaggacag	cctaaccgcc	ccctctgagt	tcgccaccac	25260
cgctccacc	gatgccgcca	acgcgcctac	cacttcccc	gtcgaggcac	ccccgcttga	25320
ggaggaggaa	gtgattatcg	agcaggaccc	aggttttgta	agcgaagacg	acgaggaccg	25380
ctcagtacca	acagaggata	aaaagcaaga	ccaggacaac	gcagaggcaa	acgaggaaac	25440
agtcggggcg	ggggacgaaa	ggcatggcga	ctacctagat	gtgggagacg	acgtgctgtt	25500
gaagcatctg	cagcgccagt	gcgccattat	ctcgacgcg	ttgcaagagc	gcagcgatgt	25560
gccctcgcc	atagcggatg	tcagccttgc	ctacgaacgc	cacctattct	caccgcgcgt	25620
accccccaaa	cgccaagaaa	acggcacatg	cgagcccaac	ccgcgcctca	acttctaccc	25680
cgatatttgc	gtgccagagg	tgcttgccac	ctatcacatc	tttttccaaa	actgcaagat	25740
acccctatcc	tgccgtgcca	accgcagccg	agcggaacaag	cagctggcct	tgccgagggg	25800
cgctgtcata	cctcgctcaa	caaacgctct	cgaagtgcc	aaaatctttg	agggtcttgg	25860
acgcgacgag	aagcgcgcgg	tcgagggtga	gcaacaggaa	aacagcgaaa	atgaaagtca	25920
ctctggagtg	ttggtggaac	tcgagggtga	caacgcgcgc	ctagccgtac	taaaacgcag	25980
catcgaggtc	acccactttg	cctaccgggc	acttaacct	cccccaagg	tcatgagcac	26040
agtcagtgag	gagctgatcg	tgcccggtgc	gcagcccctg	gagagggatg	caaatttgca	26100
agaacaaaca	gaggagggcc	taccgcagtg	tgccgacgag	cagctagcgc	gctggcttca	26160
aacgcgcgag	cctgccgact	tgaggagcgc	acgcaacta	atgatggccg	cagtgcctgt	26220
taccgtggag	cttgagtga	tgacgcggtt	ctttgctgac	ccggagatgc	agcgcaagct	26280
agaggaaaac	ttgcaactaca	cctttcgaca	gggctacgta	cgccaggcct	gcaagatctc	26340
caacgtggag	ctctgcaacc	tggtctccta	ccttggaatt	ttgcacgaaa	accgccttgg	26400
gcaaaacgtg	cttcattcca	cgctcaaggg	cgaggcgccg	cgcgactacg	tcgcgcactg	26460
cgtttactta	tttctatgct	acacctggca	gacggccatg	ggcgtttggc	agcagtgcct	26520
ggaggagtgc	aacctcaagg	agctgcagaa	actgctaaag	caaaacttga	aggacctatg	26580
gacggccttc	aacgagcgct	ccgtggccgc	gcacctggcg	gacatcattt	tccccgaacg	26640
cctgcttaaa	accctgcaac	agggtctgcc	agacttcacc	agtcaaagca	tggtgcagaa	26700
ctttaggaac	tttatcctag	agcgctcagg	aatcttgcgc	gccacctgct	gtgacttcc	26760
tagcgacttt	gtgcccatta	agtaccgcga	atgcctccg	ccgcttggg	gccactgcta	26820
ccttctgcag	ctagccaact	accttgcta	ccactctgac	ataatggaag	acgtgagcgg	26880
tgacggtcta	ctggagtgtc	actgtcgctg	caacctatgc	accccgacc	gctccctggt	26940
ttgcaattcg	cagctgctta	acgaaaagtca	aattatcggt	acctttgagc	tgcaagggtc	27000
ctgcgcctgac	gaaaagtccg	cggtccggg	gttgaactc	actccggggc	tgtggacgtc	27060
ggcttacctt	cgcaaatgtg	tacctgagga	ctaccacgcc	cacgagatta	ggttctacga	27120
agaccaatcc	cgcccgccaa	atgcggagct	taccgcctgc	gtcattaccc	agggccacat	27180

tcttggccaa	ttgcaagcca	tcaacaaagc	ccgccaagag	tttctgctac	gaaagggagc	27240
gggggtttac	ttggaccccc	agtcgggcga	ggagctcaac	ccaatcccc	cgccggccga	27300
gccctatcag	cagcagccgc	gggcccttgc	ttcccaggat	ggcaccctaa	aagaagctgc	27360
agctgccgcc	gccaccacacg	gacgaggagg	aatactggga	cagtcaggca	gaggagggtt	27420
tggacgagga	ggaggaggac	atgatggaag	actgggagag	cctagacgag	gaagcttccg	27480
aggtcgaaga	ggtgtcagac	gaaacaccgt	caccctcggt	cgcttcccc	tcgccggcgc	27540
cccagaaatc	ggcaaccggt	tccagcatgg	ctacaacctc	cgctcctcag	gcgccgccgg	27600
caactgccgt	tcgccgaccc	aaccgtagat	gggacaccac	tggaaaccag	gccggtaagt	27660
ccaagcagcc	gccgccgtta	goccaaagac	aacaacagcg	ccaaggctac	cgctcatggc	27720
gcgggcacaa	gaacgccata	gttgcttgct	tgcaagactg	tgggggcaac	atctccttcg	27780
cccgcgcgtt	tcttctctac	catcacggcg	tggccttccc	ccgtaacatc	ctgcattact	27840
accgtcatct	ctacagccca	tactgcaccg	gcggcagcgg	cagcggcagc	aacagcagcg	27900
gccacacaga	agcaaaggcg	accggatagc	aagactctga	caaagcccaa	gaaatccaca	27960
gcggcgccag	cagcaggagg	aggagcgctg	cgtctggcgc	ccaacgaacc	cgatatcgac	28020
cgcgagctta	gaaacaggat	ttttcccaact	ctgtatgcta	tatttcaaca	gagcaggggc	28080
caagaacaaag	agctgaaaaat	aaaaaacagg	tctctgcgat	ccctcaccgc	cagctgcctg	28140
tatcacaaaa	gcgaagatca	gcttcggcgc	acgctggaag	acgcggaggc	tctcttcagt	28200
aaatactgcg	cgctgactct	taaggactag	tttcgcgccc	tttctcaaat	ttaagcgcg	28260
aaactacgtc	atctccagcg	gccacaccgc	gcggcagcac	ctgtcgtcag	cgccattatg	28320
agcaaggaaa	ttcccacgcc	gtgtcatgtg	agttaccagc	cacaaatggg	acttgccggt	28380
ggagctgccc	aagactactc	aacccgaata	aactacatga	gcgcgggacc	ccacatgata	28440
tcccgggtca	acggaatccg	cgccccaccga	aaccgaattc	tcttggaaaca	ggcgggtatt	28500
accaccacac	ctcgtataaa	ccttaatccc	cgtagtgggc	ccgctgccct	ggtgtaccag	28560
gaaagtcccc	gtcccaccac	tgtggtactt	cccagagacg	cccaggccga	agtctagatg	28620
actaaactcag	ggcgcgagct	tgcgggcggc	tttgcgcaca	gggtgcggtc	gcccgggcag	28680
ggtataactc	acctgacaat	cagagggcga	ggtattcagc	tcaacgacga	gtcgggtgagc	28740
tcctcgcttg	gtctccgtcc	ggacgggaca	tttcagatcg	gcggcgcccg	ccgtccttca	28800
ttcacgcctc	gtcaggcaat	cctaactctg	cagacctcgt	cctctgagcc	gcgctctgga	28860
ggcattggaa	ctctgcaatt	tattgaggag	tttgtgccat	cggtctactt	taacccttcc	28920
tcgggacctc	ccggccacta	tccggatcaa	tttattccta	actttgacgc	ggtaaaggac	28980
tcggcgagcg	gtacgactg	aatgttaagt	ggagaggcag	agcaactgcg	cctgaaacac	29040
ctggtccact	gtcgcccgca	caagtgtctt	gcccgcgact	ccggtgagtt	ttgtactttt	29100
gaattgcccg	aggatcatat	cgaggggccc	gcgcacggcg	tccggcttac	cgcccaggga	29160
gagcttgccc	gtagcctgat	tcgggagttt	acccagcgcc	ccctgctagt	tgagcgggac	29220
aggggaccct	gtgttctcac	tgtgatttgc	aactgtccta	accttggatt	acatcaagat	29280
ttaattaatt	gccacatcct	cttacacttt	ttcatacatt	gcccagaat	aaagaatcgt	29340
ttgtgttatg	tttcaacgtg	tttatttttc	aattgcagaa	aatttcaagt	catttttcat	29400
tcagtatgat	agccccacca	ccacatagct	tatacagatc	accgtacctt	aatcaaaactc	29460
acagaacctt	agtattcaac	ctgccacctc	cctcccaaca	cacagagtac	acagtccttt	29520
ctccccggct	ggccttaaaa	agcatcatat	catgggtaac	agacatatc	ttaggtgtta	29580
tattccacac	ggtttcctgt	cgagccaaac	gctcatcagt	gatattaata	aactccccgg	29640
gcagctcact	taagttcatg	tcgctgtcca	gcgtctgagc	cacaggctgc	tgtccaactt	29700
gcggttgctt	aacgggcggc	gaaggagaag	tccacgccta	catgggggta	gagtcataat	29760
cgtgcatcag	gataggcgcg	tgggtgctga	gcagcgcgcg	aataaaactgc	tgccgccgcc	29820
gctccgtcct	gcaggaatac	aacatggcag	tggctctcctc	agcgatgatt	cgcaccgccc	29880
gcagcataag	gcgccttgct	ctccgggcac	agcagcgcac	cctgatctca	cttaaatcag	29940
cacagtaact	gcagcacagc	accacaatat	tgttcaaaat	cccacagtgc	aaggcgctgt	30000
atccaaagct	catggcgggg	accacagaac	ccacgtggcc	atcataccac	aagcgaggt	30060
agattaagtg	gcgaccocctc	ataaacacgc	tggacataaa	cattacctct	tttggcatgt	30120
tgtaattcac	cacctcccg	taccatataa	acctctgatt	aaacatggcg	ccatccacca	30180
ccatcctaaa	ccagctggcc	aaaacctgcc	cgccggctat	acactgcagg	gaaccgggac	30240
tggacaatg	acagtggaga	gcccaggact	cgtaaccatg	gatcatcatg	ctcgtcatga	30300
tatcaatggt	ggcacaacac	aggcacacgt	gcatacactt	cctcaggatt	acaagctcct	30360
cccgcgttag	aaccatatcc	cagggaaaca	cccattcctg	aatcagcgta	aatcccacac	30420
tgcagggaag	acctcgcacg	taactcacgt	tgtgcattgt	caaagtgtta	cattcgggca	30480
gcagcggtg	atcctccagt	atggtagcgc	gggtttctgt	ctcaaaaagg	ggtagacgat	30540
ccctactgta	cggagtgcgc	cgagacaacc	gagatcgtgt	tggctgtagt	gtcatgcaa	30600
atggaacgcc	ggacgtagtc	atatttctctg	aagcaaaacc	aggtgcgggc	gtgacaaaca	30660
gatctgcgtc	tccggtctcg	ccgcttagat	cgtctgtgt	agtagttgta	gtatatccac	30720
tctctcaaag	catccaggcg	ccccctggct	tcgggttcta	tgtaaaactcc	ttcatgcgcc	30780
gctgcctga	taacatccac	caccgcagaa	taagccacac	ccagccaacc	tacacattcg	30840
ttctgcgagt	cacacacggg	aggagcggga	agagctggaa	gaaccatgtt	ttttttttta	30900

-31-

```

ttccaaaaga ttatccaaaa cctcaaaatg aagatctatt aagtgaacgc gctcccctcc 30960
ggtggcggtg tcaaaactcta cagccaaaaga acagataatg gcatttgtaa gatggtgcac 31020
aatggcttcc aaaaggcaaa cggccctcac gtccaaagtgg acgtaaaggc taaacccttc 31080
aggggtgaatc tcctctataa acattccagc accttcaacc atgccccaaat aattctcatc 31140
tcgccacctt ctcaatatat ctctaagcaa atcccgaata ttaagtccgg ccattgtaaa 31200
aatctgctcc agagcgccct ccaccttcag cctcaagcag cgaatcatga ttgcaaaaat 31260
tcaggttcct cacagacctg tataagattc aaaagcggaa cattaacaaa aataccgcga 31320
tcccgtaggt cccttcgcag ggccagctga acataatcgt gcagggtctgc acggaccagc 31380
gcggccactt ccccgccagg aaccttgaca aaagaaccca cactgattat gacacgcata 31440
ctcggagcta tgctaaccag cgtagccccg atgtaagctt tgttgcatgg gcggcgatat 31500
aaaatgcaag gtgctgctca aaaaatcagg caaagcctcg cgcaaaaaag aaagcacatc 31560
gtagtcatgc tcatgcagat aaaggcaggt aagctccgga accaccacag aaaaagacac 31620
cattttttctc tcaaacatgt ctgcggtttt ctgcataaac acaaaataaa ataacaaaaa 31680
aacatttaaa cattagaagc ctgtcttaca acaggaaaaa caacccttat aagcataaga 31740
cggactacgg ccattgccggc gtgaccgtaa aaaaactggt caccgtgatt aaaaagcacc 31800
accgacagct cctcggtcac gtccggagtc ataattgtaag actcggtaaa cacatcaggt 31860
tgattcatcg gtcagtgtca aaaagcgacc gaaatagccc gggggaatac ataccgcgag 31920
gcgtagagac aacattacag cccccatagg aggtataaca aaattaatag gagagaaaaa 31980
cacataaaca cctgaaaaac cctcctgcct aggcataata gcaccctccc gctccagaac 32040
aacatacagc gcttcacagc ggcagcctaa cagtcagcct taccagtaaa aaagaaaacc 32100
tattaaaaaa acaccaactc acacggcacc agctcaatca gtcacagtgt aaaaaagggc 32160
caagtgcaga gcgagtatat ataggactaa aaaatgacgt aacggttaaa gtccacaaaa 32220
aacaccaga aaaccgcaag cgaacctacg cccagaaaac aaagccaaaa aaccacaac 32280
ttcctcaaat cgtcaattcc gttttccac gttacgtaac ttcccatttt aagaaaacta 32340
caattcccaa cacatacaag ttactccgcc ctaaaaccta cgtcaccgcg cccgttccca 32400
cgccccgcgc cagtcacaa actccacccc ctcattatca tattggcttc aatccaaaat 32460
aaggtatatt attgatgatg                                     32480

```

<210> 28
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 28
 ctcaacaatt gtggatccgt actcc 25

<210> 29
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 29
 gtgctcagca gatcttgca ctgtg 25

<210> 30
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 30

-32-

ggcgcgttcg gatccactct ctcc

25

<210> 31
 <211> 28
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 31
 ctacatgcta ggcagatctc gttcggag

28

<210> 32
 <211> 1240
 <212> DNA
 <213> adenovirus

<400> 32
 ggatccactc tcttccgcat cgctgtctgc gagggccagc tgttggggtg agtactccct 60
 ctgaaaagcg ggcataactt ctgcgcataag attgtcagtt tccaaaaacg agggaggattt 120
 gatattcacc tggcccgcggt tgatgccttt gaggggtggcc gcatccatct ggtcagaaaa 180
 gacaatcttt ttgtttgtcaa gcttggtggc aaacgacccg tagagggcgt tggacagcaa 240
 cttggcgatg gagcgcaggg ttgtgttttt gtcgcgatcg gcgcgctcct tggccgcgat 300
 gtttagctgc acgtattcgc gcgcaacgca ccgccattcg ggaaagacgg tgggtgcgctc 360
 gtcgggcacc aggtgcacgc gccaaaccgcg gttgtgcagg gtgacaaggc caacgctggt 420
 ggctacctct ccgcgtaggc gctcgtttgt ccagcagagg cggccgccct tgcgcgagca 480
 gaatggcggg aggggggtcta gctgcgtctc gtccgggggg tctgcgtcca cggtaaagac 540
 ccggggcagc aggcgcgcgt cgaagtagtc tatcttgcac ccttgcaagt ctagcgccctg 600
 ctgccatgcg cgggcggcaa gcgcgcgctc gtatgggttg agtgggggac cccatggcat 660
 ggggtgggtg agcgcggagg cgtacatgcc gcaaattgtc taaacgtaga ggggctctct 720
 gagtattcca agatatgtag ggtagcatct tccaccgcgg atgctggcgc gcacgtaatc 780
 gtatagttcg tgcgagggag cgaggaggtc gggaccgagg ttgctacggg cgggctgctc 840
 tgctcggaag actatctgcc tgaagatggc atgtgagttg gatgatatgg ttggacgctg 900
 gaagacgttg aagctggcgt ctgtgagacc taccgcgtca cgcacgaagg aggcgtagga 960
 gtcgcgcagc ttgttgacca gctcggcggg gacctgcacg tctagggcgc agtagtccag 1020
 ggtttccttg atgatgtcat acttatcctg tccctttttt ttccacagct cgcggttgag 1080
 gacaaactct tcgcggtctt tccagtactc ttggatcgga aaccgcgcgg cctccgaacg 1140
 agatccgtac tccgcgcggc agggacctga gcgagtcgcg atcgaccgga tcggaaaacc 1200
 tctcgagaaa ggcgtctaac cagtcacagt cgcaagatct 1240

<210> 33
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 33
 ggcgcgttcg gatccactct ctcc

25

<210> 34
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
<400> 34
gggagtagat ctcccaacag 20

<210> 35
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
<400> 35
cccttttttt tggatccctc gcgg 24

<210> 36
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
<400> 36
ctacatgcta ggcagatctc gttcggag 28

<210> 37
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
<400> 37
ctcaacaatt gttggatccg tactcc 26

<210> 38
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
<400> 38
gtgctcagca gatcttgca ctgtg 25

<210> 39
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

-34-

<400> 39
ggcgcgttcg gatccactct ctcc

25

<210> 40
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 40
ctacatgcta ggcagatctc gttcggag

28

<210> 41
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 41
cccttttttt tggatccctc gcgg

24

<210> 42
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 42
gtgctcagca gatcttgcca ctgtg

25

<210> 43
<211> 8383
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: plasmid

<400> 43
gacggatcgg gagatctccc gatccctat ggtcgactct cagtacaatc tgctctgatg 60
ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180
ttagggtttag gcgttttgcg ctgcttcgag atgtacgggc cagatatacg cgttgacatt 240
gattattgac tagttattaa tagtaataca ttacgggggc attagtccat agcccatata 300
tggagtcccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc 360
cccgccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420
attgacgtca atgggtggac tatttacggt aaactgccc cttggcagta catcaagtgt 480
atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540
atgccagta catgacctta tgggactttc ctacttggca gtacatctac gtattagtca 600
tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg 660
actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc 720
aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcy 780

gtaggcgtgt	acgggtgggag	gtctatatataa	gcagagctct	ctggctaact	agagaaccca	840
ctgcttactg	gcttatcgaa	attaatacga	ctcactatag	ggagacccaa	gcttggtacc	900
gagctcggat	ccactctctt	ccgcatcgct	gtctgcgagg	gccagctggt	gggggtgagta	960
ctccctctga	aaagcgggca	tgacttctgc	gctaagattg	tcagtttcca	aaaacgagga	1020
ggatttgata	ttcacctggc	ccgcggtgat	gcctttgagg	gtggccgcat	ccatctggtc	1080
agaaaagaca	atctttttgt	tgtcaagctt	ggtggcaaac	gacccgtaga	gggctgtgga	1140
cagcaacttg	gcgatggagc	gcagggtttg	gtttttgtcg	cgatcgccgc	gctccttggc	1200
cgcgatgttt	agctgcacgt	attcgccgcg	aacgcaccgc	cattcgggaa	agacgggtggt	1260
gcgctcgctg	ggcaccaggt	gcacgcgcca	accgcggttg	tgcagggtga	caaggtcaac	1320
gctggtggct	acctctccgc	gtaggcgctc	gttggtccag	cagaggcggc	cgcccttgcg	1380
cgagcagaat	ggcggtaggg	ggtctagctg	cgctctgctc	ggggggtctg	cgctccacgtt	1440
aaagaccccg	ggcagcaggc	gcgcgtcgaa	gtagtctatc	ttgcatcctt	gcaagtctag	1500
cgcctgctgc	catgcgcggg	cggcaagcgc	gcgctcgat	gggttgagt	ggggacccca	1560
tggcatgggg	tgggtgagcg	cggaggcgta	catgccgcaa	atgtcgtaaa	cgtagagggg	1620
ctctctgagt	attccaagat	atgtagggta	gcacttcca	ccgcggatgc	tggcgcgcac	1680
gtaatcgat	agttcgtag	agggagcgag	gaggtcggga	ccgaggttgc	tacggggcgg	1740
ctgctctgct	cggaagacta	tctgcctgaa	gatggcatgt	gagttggatg	atatggttgg	1800
acgctggaag	acgttgaagc	tggcgtctgt	gagacctacc	gcgtcacgca	cgaaggaggc	1860
gtaggagtcg	cgcagcttgt	tgaccagctc	ggcggtagcc	tgacagtcta	gggcgcagta	1920
gtccagggtt	tccttgatga	tgctactact	atcctgtccc	ttttttttcc	acagctcgcg	1980
gttgaggaca	aaactcttcg	ggtctttcca	gtactcttgg	atcggaaacc	cgctcgccctc	2040
cgaacgagat	ccgtactccg	ccgcgcaggg	acctgagcga	gtccgcatcg	accggatcgg	2100
aaaacctctc	gagaaaggcg	tctaaccagt	cacagtgcga	agatccaaga	tgaagcgcgc	2160
aagaccgtct	gaagatacct	tcaaccccg	gtatccatat	gacacggaaa	ccggctcctcc	2220
aactgtgcct	ttctttactc	ctccctttgt	atcccccaat	gggtttcaag	agagtccccc	2280
tggggtactc	tctttgcgcc	tatccgaacc	tctagttaac	tccaatggca	tgcttgccgt	2340
caaaatgggc	aacggcctct	ctctggacga	ggcgggcaac	cttacctccc	aaaatgtaac	2400
cactgtgagc	ccacctctca	aaaaaaccaa	gtcaaacata	aacctggaaa	tatctgcacc	2460
cctcacagtt	acctcagaag	ccctaactgt	ggctgcgcgc	gcacctctaa	tggtcgccgg	2520
caacacactc	acatgcaat	cacaggcccc	gctaaccgtg	cacgactcca	aacttagcat	2580
tgccacccaa	ggacccctca	cagtgtcaga	aggaaagcta	gccctgcaaa	catcaggccc	2640
cctcaccacc	accgatagca	gtacccttac	tatcactgcc	tcacccctc	taactactgc	2700
cactggtagc	ttgggcattg	acttgaaaaga	gcccatttat	acacaaaatg	gaaaactagg	2760
actaaagtac	ggggctcctt	tgcatgtaac	agacgacctc	aacactttga	ccgtagcaac	2820
tgggtccagg	gtgactatta	ataatacttc	cttgcaaaac	aaagttaact	gagccttggg	2880
ttttgattca	caaggcaata	tgcaacttaa	tgtagcagga	ggactaagga	ttgattctca	2940
aaacagacgc	cttatacttg	atgttagtta	tccgtttgat	gctcaaaacc	aactaaatct	3000
aagactagga	cagggccctc	tttttataaa	ctcagcccac	aacttgga	ttactacaa	3060
caaaaggcct	tacttgttta	cagcttcaaa	caattccaaa	aagcttgagg	ttaacctaag	3120
cactgccaag	gggttgatgt	ttgacgctac	agccatagcc	attaatgcag	gagatgggct	3180
tgaattttgg	tcacctaatg	caccaaacac	aaatccctc	aaaacaaaaa	ttggccatgg	3240
cctagaattt	gattcaaaac	aggctatggt	tcctaaacta	ggaactggcc	ttagttttga	3300
cagcacagg	gccattacag	taggaaaaca	aaataatgat	aagctaaact	tgtggaccac	3360
accagctcca	tctcctaact	gtagactaaa	tgcaagaaaa	gatgctaaac	tcactttggt	3420
cttaacaaaa	tgtggcagtc	aaatacttgc	tacagtttca	gttttggtg	ttaaaggcag	3480
tttggtctca	atatctggaa	cagttcaaa	tgctcatctt	attataagat	ttgacgaaaa	3540
tggagtgtca	ctaaacaatt	ccttcctgga	cccagaatat	tggaacttta	gaaatggaga	3600
tcttactgaa	ggcacagcct	atacaaacgc	tggttgattt	atgcctaacc	tatcagctta	3660
tccaaaatct	cacggtaaaa	ctgccaaaag	taacattgtc	agtcaagttt	acttaaacgg	3720
agacaaaact	aaacctgtaa	cactaaccat	tacactaaac	ggtacacagg	aaacaggaga	3780
cacaactcca	agtgcatact	ctatgtcatt	ttcatgggac	tggtctggcc	acaactacat	3840
taatgaaata	tttgccacat	cctcttacac	tttttcatac	attgcccaag	aataaaaaga	3900
gcggccgctc	gagcatgcat	ctagagggcc	ctattctata	gtgtcaccta	aatgctagag	3960
ctcgctgata	agcctcgact	gtgccttcta	gttgccagcc	atctgttgtt	tgccctctcc	4020
ccgtgccttc	cttgaccctg	gaaggtgcca	ctcccactgt	cctttcctaa	taaaatgagg	4080
aaattgcatc	gcattgtctg	agtaggtgtc	attctattct	gggggggtgg	gtggggcgag	4140
acagcaagg	ggaggattgg	gaagacaata	gcaggcatgc	tggggatgcg	gtgggctcta	4200
tggcttctga	ggcggaagaa	accagctggg	gctctagggg	gtatccccac	gcgccttgta	4260
gcggcgcat	aagcgcggcg	ggtgtggtgg	ttacgcgcag	cgtgaccgct	acacttgcca	4320
gcgccttagc	gcccgtcctt	ttcgctttct	tccttccctt	tctcgccacg	ttcgccggct	4380
ttccccgtca	agctctaaat	cggggcaccc	ctttagggtt	ccgatttagt	gctttacggc	4440
acctcgacc	caaaaaactt	gattaggggtg	atggttcacg	tagtgggcca	tcgccttgat	4500

agacgggtttt	tcgccctttg	acgttgagat	ccacgttctt	taatagtggg	ctcttgttcc	4560
aaactgggaa	aacactcaac	cctatctcgg	tctattcttt	tgattttata	gggattttgg	4620
ggatttcggc	ctattgggta	aaaaatgagc	tgatttaaca	aaaatttaac	gcgaattaat	4680
tctgtggaat	gtgtgtcagt	taggggtgtg	aaagtcccca	ggctccccag	gcaggcagaa	4740
gtatgcaaag	catgcatctc	aattagtcag	caaccagggt	tggaaggtcc	ccaggctccc	4800
cagcaggcag	aagtatgcaa	agcatgcatc	tcaattagtc	agcaaccata	gtcccgcccc	4860
taactccgcc	catcccgccc	ctaactccgc	ccagttccgc	ccattctcgc	ccccatggct	4920
gactaatttt	ttttatttat	gcagaggccg	aggccgcctc	tgctctgag	ctattccaga	4980
agtagtgagg	aggctttttt	ggaggccctag	gcttttgcaa	aaagctcccg	ggagcttgta	5040
tatccatttt	cggatctgat	caagagacag	gatggagatc	gttctgcatg	attgaacaag	5100
atggattgca	cgcaggttct	ccggccgctt	gggtggagag	gctattcggc	tatgactggg	5160
cacaacagac	aatcggctgc	tctgatgccg	ccgtgttccg	gctgtcagcg	caggggcgcc	5220
cggttctttt	tgtcaagacc	gacctgtccg	gtgccctgaa	tgaactgcag	gacgaggcag	5280
cgcggctatc	gtggctggcc	acgacgggcg	ttccttgccg	agctgtgctc	gacgttgcca	5340
ctgaagcggg	aagggaactgg	ctgctattgg	gcggaagtgc	ggggcaggat	ctcctgtcat	5400
ctcaccttgc	tccgtccgag	aaagtatcca	tcatggctga	tgcaatgcgg	cggtgcata	5460
cgttgatcc	ggctacctgc	ccattcgacc	accaagcgaa	acatcgcatc	gagcgagcac	5520
gtactcggat	ggaagccggg	cttgtcgatc	aggatgatct	ggacgaagag	catcaggggc	5580
tcgcgccagc	cgaactgttc	gcccgcgcac	aggcgcgcat	gcccgcgcgc	gaggatctcg	5640
tcgtgaccca	tggtcgatgic	tgcttgccga	atatcatggg	ggaaaatggc	cgcttttctg	5700
gattcatcga	ctgtggccgg	ctgggtgtgg	cggaccgcta	tcaggacata	gcgttggtca	5760
cccgtgatat	tgctgaagag	cttgccggcg	aatgggctga	ccgcttcttc	gtgctttacg	5820
gtatcgccgc	tcccgattcg	cagcgcacgc	ccttctatcg	ccttcttgac	gagttcttct	5880
gagcgggact	ctggggttcg	aaatgaccga	ccaagcgacg	cccaacctgc	catcacgaga	5940
tttcgattcc	accgccgcct	tctatgaaag	gttgggcttc	ggaatcggtt	tccgggacgc	6000
cggctggatg	atcctccage	gccccgatct	catgctggag	ttcttcgccc	accccaactt	6060
gtttattgca	gcttataatg	gttacaataa	aagcaatagc	atcacaaatt	tcacaaataa	6120
agcatttttt	tcactgcatt	ctagtgtgtg	tttgtccaaa	ctcatcaatg	tatcttatca	6180
tgtctgtata	ccgtcgacct	ctagctagag	cttgccgtaa	tcatggtcat	agctgtttcc	6240
tgtgtgaaat	tgttatccgc	tcacaattcc	acacaacata	cgaagccggaa	gcataaagtg	6300
taaagccctg	ggtgcctaata	gagtgagcta	actcacatta	attgcgttgc	gctcactgcc	6360
cgttttccag	tcgggaaacc	tgctgtgcca	gctgcattaa	tgaatcggcc	aacgcgcggg	6420
gagaggcgtt	ttgcgtattg	ggcgctcttc	cgttctctcg	ctcactgact	cgctgcgctc	6480
ggtcgttcgg	ctgcggcgag	cggatcagc	tcactcaaag	gcggtaatac	ggttatccac	6540
agaatcaggg	gataacgcag	gaaagaacat	gtgagcaaaa	ggccagcaaa	aggccaggaa	6600
ccgtaaaaag	gccgcgttgc	tggcgttttt	ccataggctc	cgccccctg	acgagcatca	6660
caaaaatcga	ggactcaagtc	agaggtggcg	aaacccgaca	ggactataaa	gataccaggc	6720
gtttccccct	ggaagctccc	tcgtgcgctc	tcctgttccg	accctgcgcg	ttaccggata	6780
cctgtccgcc	tttctccctt	cgggaagcgt	ggcgctttct	caatgctcac	gctgtaggta	6840
tctcagttcg	gtgtaggteg	ttcgctccaa	gctgggctgt	gtgcacgaac	ccccggttca	6900
gccccaccgc	tgcgcccttat	ccggttaacta	tcgtcttgag	tccaaccccg	taagacacga	6960
cttatcgcca	ctggcagcag	cactggtaaa	caggattagc	agagcgaggt	atgtaggcgg	7020
tgctacagag	ttcttgaaagt	ggtggcctaa	ctacggctac	actagaagga	cagtatttgg	7080
tatctgcgct	ctgctgaagc	cagttacctt	cggaaaaaga	gttggtagct	cttgatccgg	7140
caaaacaaacc	accgctggta	gcggtgggtt	ttttgtttgc	aagcagcaga	ttacgcgcag	7200
aaaaaaagga	tctcaagaag	atcctttgat	cttttctacg	gggtctgacg	ctcagtggaa	7260
cgaaaactca	cggttaaggga	ttttggtcat	gagattatca	aaaaggatct	tcacctagat	7320
ccttttaaat	taaaaatgaa	gttttaaatc	aatctaaagt	atatatgagt	aaacttggtc	7380
tgacagttac	caatgcttaa	tcagtgaggc	acctatctca	gcgatctgtc	tatttcgttc	7440
atccatagtt	gcctgactcc	ccgtcgtgta	gataactacg	atacgggagg	gcttaccatc	7500
tggccccagt	gctgcaatga	taccgcgaga	cccacgctca	ccggctccag	atttatcagc	7560
aataaaccag	ccagccggaa	gggcccagcg	cagaagtggg	cctgcaactt	tatccgcctc	7620
catccagttc	attaattggt	gccgggaagc	tagagtaagt	agttcgccag	ttaatagttt	7680
gcgcaacggt	gttgccattg	ctacaggcat	cgtgggtgca	cgctcgtcgt	ttggtatggc	7740
ttcattcagc	tcgggttccc	aacgatcaag	tgatccccc	tgatccccc	tggtgtgcaa	7800
aaaagcgggt	agctccttcg	gtcctccgat	cggtgtcaga	agtaagttgg	ccgcagtggt	7860
atcactcatg	gttatggcag	cactgcataa	ttctcttact	gtcatgccat	ccgtaagatg	7920
cttttctgtg	actggtgagt	actcaaccaa	gtcattctga	gaatagtgtg	tcggcgacc	7980
gagttgctct	tgccccggcg	caatacggga	taataccgcg	ccacatagca	gaactttaaa	8040
agtgtcatc	attggaaaac	gttcttcggg	gcgaaaaactc	tcaaggatct	taccgctgtt	8100
gagatccagt	tcgatgtaac	ccactcgtgc	acccaactga	tcttcagcat	cttttacttt	8160
caccagcgtt	tctgggtgag	caaaaacagg	aaggcaaaat	gccgcaaaaa	aggggaataag	8220

-37-

```

ggcgacacgg aaatgttgaa tactcatact cttccttttt caatattatt gaagcattta 8280
tcagggttat tgtctcatga ggggatacat atttgaatgt atttagaaaa ataaacaaat 8340
aggggttccg cgcacatttc cccgaaaagt gccacctgac gtc 8383

```

<210> 44
 <211> 7960
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: plasmid

```

<400> 44
gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg 60
ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gtagtagtgcg 120
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180
ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt 240
gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata 300
tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc 360
cccgccatt gacgtcaata atgacgtatg ttcccatagt aacgccaaata gggactttcc 420
attgacgtca atgggtggac tatttacggt aaactgcccc ctgggcagta catcaagtgt 480
atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540
atgcccagta atgcacctta tgggactttc ctacttggca gtacatctac gtattagtca 600
tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcgttttg 660
actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc 720
aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg 780
gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaaccga 840
ctgcttactg gcttatcgaa attaatacga ctactatag ggagacccaa gctggctagc 900
gtttaaaactt aagcttggtg cccgagctcg atccactctc ttccgcatcg ctgtctgcga 960
gggccagctg ttgggttgag tactccctct gaaaagcggg catgacttct gcgctaagat 1020
tgtcagtttc caaaaacgag gaggatttga tattcacctg gcccgcggtg atgcctttga 1080
gggtggccgc atccatctgg tcagaaaaga caatcttttt gttgtcaagc ttggtggcaa 1140
acgacccgta gagggcggtg gacagcaact tggcgatgga gcgcaggggt tggtttttgt 1200
cgcgatcggc gcgctccttg gccgcgatgt tttagctgac gtattcgcgc gcaacgcacc 1260
gccattcggg aaagacgggt gtgcgctcgt cgggcaccag gtgcacgcgc caaccgcgcg 1320
tgtgcagggg gacaaggtca acgctggttg ctacctctcc gcgtaggcgc tcgttgggtc 1380
agcagaggcg gccgcccttg cgcgagcaga atggcggtag ggggtctagc tgcgtctcgt 1440
ccgggggggtc tgcgtccacg gtaaaagacc cgggcagcag gccatgcgcg ggcggaagc gcgcgctcgt 1500
tcttgcaccc ttgcaagtct agcgcctgct gctgagtgag ggtgggtgag cgcggaggcg tacatgccgc 1560
atgggttgag tgggggaccc catggcatgg gtgtgggtgag atatgtaggg tagcatcttc 1620
aaatgtcgta aacgtagagg ggctctctga gctattccaag atagtctgtg cgagggagcg aggaggtcgg 1680
caccgcggat gctggcgcg cgtgctctg acgtaatcgt ctcggaagac tatctgcctg aagatggcat 1740
gaccgaggtt gctacggcg ggctgctct ggacgctgga agacgttgaa gctggcgtct gtgagacctc 1800
gtgagttgga tgatatggtt ggcgtaggag cgcgcagctt gttgaccagc tcggcgggtg 1860
ccgcgtcacg cacgaaggag gcgttagagt ttctcttgat gatgtcatac ttatcctgtc 1920
cctgcacgtc tagggcgag tagtccagg tttccttgat gatgtcatac ttatcctgtc 1980
cctttttttt ccacagctcg cggttgagga caaactcttc gcggtctttc cagtactctt 2040
ggatcggaaa cccgtcggcc tccgaacgag atccgtactc cgcgcgcgag ggacctgagc 2100
gagtcgcgat cgaccggatc ggaaaacctc tcgagaaagg cgtctaacca gtcacagtgc 2160
caagatccaa gatgaagcgc gcaagaccgt ctgaagatac cttcaacccc gtgtatccat 2220
atgacacgga aaccggtcct ccaactgtgc cttttcttac tctcccttt gtatcccca 2280
atgggtttca agagagtccc cctggggtac tctctttgag cctatccgaa cctctagtta 2340
cctccaatgg catgcttgcg ctcaaatgg gcaacggcct ctctctggac gaggccggca 2400
accctacctc ccaaatgta accactgtga gcccacctc caaaaaaacc aagtcaaaac 2460
taaacctgga aatatctgca cccctcacag ttacctcaga agccctaact gtggctgccg 2520
ccgcacctct aatggtcgcg ggcaacacac tcacctgca atcacaggcc ccgctaaccg 2580
tgcacgactc caaacttagc attgccaccc aaggacccct cacagtgtca gaaggaaagc 2640
tagccctgca aacatcaggc cccctcacca ccaccgatag cagtacctt actatcactg 2700
cctcaccccc tctaactact gccactggta gcttggcat tgacttgaaa gagccattt 2760
atacacaaaa tgaaaaacta ggactaaaag acggggctcc tttgcatgta acagacgacc 2820
taaacacttt gaccgtagca actggtccag gtgtgactat taataatact tccttgcaaa 2880

```

ctaaagttac	tggagccttg	ggttttgatt	cacaaggcaa	tatgcaactt	aatgtagcag	2940
gaggactaag	gattgattct	caaaacagac	gccttatact	tgatgttagt	tatccgtttg	3000
atgctcaaaa	ccaactaaat	ctaagactag	gacaggcccc	tctttttata	aactcagccc	3060
acaacttgga	tattaactac	aacaaaggcc	tttacttggt	tacagcttca	aacaattcca	3120
aaaagcttga	ggttaaccta	agcactgcca	aggggttgat	gtttgacgct	acagccatag	3180
ccattaatgc	aggagatggg	cttgaatttg	gttcaccta	tgacacaaac	acaaatcccc	3240
tcaaaacaaa	aattggccat	ggcctagaat	ttgattcaaa	caaggctatg	gttcctaaac	3300
taggaactgg	ccttagtttt	gacagcacag	gtgccattac	agtaggaaac	aaaaataatg	3360
ataagctaac	tttgtggacc	acaccagctc	catctcctaa	ctgtagacta	aatgcagaga	3420
aagatgctaa	actcactttg	gtcttaacaa	aatgtggcag	tcaaataactt	gctacagttt	3480
cagttttggc	tgttaaaggc	agtttggctc	caatatctgg	aacagttcaa	agtgtctatc	3540
ttattataag	atgtgacgaa	aatggagtg	tactaaacaa	ttccttcctg	gaccagaat	3600
attggaactt	tagaaatgga	gatcttactg	aaggcacagc	ctatacaaac	gctgttggat	3660
ttatgcctaa	cctatcagct	tatccaaaat	ctcacggtaa	aactgccaaa	agtaacattg	3720
tcagtcaagt	ttacttaaac	ggagacaaaa	ctaaacctgt	aacactaacc	attacactaa	3780
acggtacaca	ggaaacagga	gacacaactc	caagtgcata	ctctatgtca	ttttcatggg	3840
actggctctg	ccacaactac	attaatgaaa	tatttgccac	atcctcttac	actttttcat	3900
acattgcccc	agaataaaa	agcggccgc	tcgagtctag	agggcccgtt	taaaccgctg	3960
gatcagcctc	gactgtgect	tctagtggcc	agccatctgt	tgtttgcccc	tccccgctgc	4020
cttccctgac	cctggaaggt	gccactccca	ctgtcccttc	ctaataaaat	gaggaaattg	4080
catcgctatt	tctgagtagg	tgctattcta	ttctgggggg	tggggtgggg	caggacagca	4140
agggggagga	ttgggaagac	aatagcaggc	atgctgggga	tgcggtgggc	tctatggctt	4200
ctgaggcgga	aagaaccagc	tggggctcta	gggggtatcc	ccacgcgccc	tgtagcgctg	4260
cattaagcgc	ggcgggtgtg	gtggttacgc	gcagcgtgac	cgctacactt	gccagcgccc	4320
tagcgccccg	tcctttcgct	ttcttccctt	cctttctcgc	cacgttcgcc	ggctttcccc	4380
gtcaagctct	aaatcggggc	atccctttag	ggttccgatt	tagtgcttta	cggcacctcg	4440
acccccaaaa	acttgattag	ggtgatgggt	cacgtagtgg	gccatcgccc	tgatagacgg	4500
tttttcgccc	tttgacgttg	gagtcacagt	tctttaatag	tggaactctt	ttccaaactg	4560
gaacaacact	caaccctatc	tcggtctatt	cttttgattt	ataagggtat	ttggggattt	4620
cggcctattg	gttaaaaaat	gagctgattt	aacaaaaatt	taacgcgaat	taattctgtg	4680
gaatgtgtgt	cagttagggt	gtggaaagtc	cccaggctcc	ccaggcaggc	agaagtatgc	4740
aaagcatgca	tctcaattag	tcagcaacca	ggtgtggaaa	gtccccaggc	tccccagcag	4800
gcagaagtat	gcaaagcatg	catctcaatt	agtcagcaac	catagtcccc	cccctaactc	4860
cgccccatcc	gcccctaact	ccgccaggtt	ccgccattc	tccgccccat	ggctgactaa	4920
ttttttttat	ttatgcagag	gccgaggccg	cctctgcctc	tgagctattc	cagaagtagt	4980
gaggaggctt	ttttggaggc	ctaggctttt	gcaaaaagct	cccgggagct	tgtatatcca	5040
ttttcggtat	tgatcagcac	gtgttgacaa	ttaatcatcg	gcatagtata	tcggcatagt	5100
ataatacgac	aaggtgagga	actaaacct	ggccaagtgt	accagtgccg	ttccggtgct	5160
caccgcgcgc	gacgtcgccg	gagcggctcg	gttctggacc	gaccggctcg	ggttctcccg	5220
ggacttcgtg	gaggacgact	tcgccggtgt	ggtccgggac	gacgtgaccc	tggtcatcag	5280
cgcggtccag	gaccagggtg	tgccggacaa	caccctggcc	tggtgtggg	tgccggccct	5340
ggacgagctg	tacgccaggt	ggtcggaggt	cggtgccacg	aacttcgggg	acgcctccgg	5400
gccggccatg	accgagatcg	gcgagcagcc	gtggggcgcg	gagttcgccc	tgccgcaccc	5460
ggccggcaac	tgctgcaact	tcgtggccga	ggagcaggac	tgacacgtgc	tacgagattt	5520
cgattccacc	gccgccttct	atgaaaggtt	gggcttcgga	atcgttttcc	gggacgcggg	5580
ctggatgatc	ctccagcgcg	gggatctcat	gctggagttc	ttcgccccacc	ccaacttgtt	5640
tattgcagct	tataatgggt	acaaataaag	caatagcatc	acaaatttca	caaataaagc	5700
atttttttca	ctgcattcta	gttgtgtgtt	gtccaaactc	atcaatgtat	cttatcatgt	5760
ctgtataccg	tcgacctcta	gctagagctt	ggcgtaatca	tggtcatagc	tgtttccgtg	5820
gtgaaattgt	tatccgctca	caattccaca	caacatacga	gccggaagca	taaagtgtaa	5880
agcctggggt	gcctaattgag	tgagctaact	cacattaatt	gcgttgcgct	cactgcccgc	5940
tttccagtcg	ggaaacctgt	cggtgccagt	gcattaatga	atcgccaac	gcgcggggag	6000
aggcggtttg	cgtattgggc	gctcttcggc	ttcctcgctc	actgactcgc	tgcgctcggt	6060
cgttcggctg	cggcgagcgg	tatcagctca	ctcaaaggcg	gtaatacggg	tatccacaga	6120
atcaggggat	aacgcaggaa	agaacatgtg	agcaaaaagg	cagcaaaaagg	ccaggaaccg	6180
taaaaaggcc	gcgttgctgg	cggttttcca	taggctccgc	ccccctgacg	agcatcacia	6240
aaatcgacgc	tcaagtcaga	ggtggcgaaa	cccgacagga	ctataaagat	accaggcggt	6300
ccccctgga	agctccctcg	tgcgctctcc	tgttccgacc	ctgcccgtta	ccggatacct	6360
gtccgccttt	ctcccttcgg	gaagcgtggc	gctttctcaa	tgctcacgct	gtaggtatct	6420
cagttcggtg	taggtcgctc	gctccaaagt	gggctgtgtg	cacgaacccc	cggttcagcc	6480
cgaccgctgc	gccttatccg	gtaactatcg	tcttgagtc	aaccgggtaa	gacacgactt	6540
atcgccactg	gcagcagcca	ctggtaacag	gattagcaga	gcgaggtatg	taggcgggtg	6600

-39-

tacagagttc	ttgaagtgg	ggcctaacta	cggtacact	agaaggacag	tatttggtat	6660
ctgcgctctg	ctgaagccag	ttaccttcgg	aaaaagagtt	ggtagctctt	gatccggcaa	6720
acaaaccacc	gctggtagcg	gtggtttttt	tggttgcaag	cagcagatta	cgcgagaaa	6780
aaaaggatct	caagaagatc	ctttgatctt	ttctacgggg	tctgacgctc	agtggaaacga	6840
aaactcacgt	taagggattt	tggtcatgag	attatcaaaa	aggatcttca	cctagatcct	6900
tttaaattaa	aaatgaagtt	ttaaatcaat	ctaaagtata	tatgagtaaa	cttgggtctga	6960
cagttacca	tgcttaata	gtgaggcacc	tatctcagcg	atctgtctat	ttcgttcac	7020
catagttgcc	tgactccccg	tcgtgtagat	aactacgata	cgaggagggt	taccatctgg	7080
ccccagtgt	gcaatgatac	cgcgagaccc	acgtccaccg	gctccagatt	tatcagcaat	7140
aaaccagcca	gccggaagg	ccgagcgag	aagtggctct	gcaactttat	ccgcctccat	7200
ccagtctatt	aattgttgcc	gggaagctag	agtaagtagt	tcgccagtta	atagtttgcg	7260
caacgttggt	gccattgcta	caggcatcgt	gggtgcacgc	tcgtcgtttg	gtatggcttc	7320
attcagctcc	gggtcccaac	gatcaaggcg	agttacatga	tcccccatgt	tgtgcaaaaa	7380
agcggttagc	tccttcggtc	ctccgatcgt	tgtcagaagt	aagttggccg	cagtgttatc	7440
actcatgggt	atggcagcac	tgcataatc	tcttactgtc	atgccatccg	taagatgctt	7500
ttctgtgact	ggtgagtact	caaccaagtc	attctgagaa	tagtgtatgc	ggcgaccgag	7560
ttgctcttgc	ccggcgtaaa	tacgggataa	taccgcgcca	catagcagaa	ctttaaaggt	7620
gtcatcatt	ggaaaacgtt	cttcggggcg	aaaactctca	aggatcttac	cgctgttgag	7680
atccagttcg	atgtaaccca	ctcgtgcacc	caactgatct	tcagcatctt	ttactttcac	7740
cagcgtttct	gggtgagcaa	aaacaggaag	gcaaaaatgcc	gcaaaaagg	gaataagggc	7800
gacacggaaa	tgttgaatac	tcatactctt	octttttcaa	tattattgaa	gcatttatca	7860
gggttattgt	ctcatgagcg	gatacatatt	tgaatgtatt	tagaaaaata	aacaaatagg	7920
ggttccgcgc	acatttcccc	gaaaagtgcc	acctgacgtc			7960

<210> 45
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 45
 atgggatcca agatgaagcg cgcaagaccg 30

<210> 46
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 46
 cactatagcg gccgcattct cagtcattct 30

<210> 47
 <211> 7989
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: plasmid

<400> 47
 gacggatcgg gagatctccc gateccctat ggtcgactct cagtacaatc tgctctgatg 60
 ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120
 cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180
 ttagggttag gcgttttgcg ctgcttcgag atgtacgggc cagatatacg cgttgacatt 240

gattattgac	tagttattaa	tagtaatacaa	ttacgggggtc	attagttcat	agcccatata	300
tggagttccg	cggtacataa	cttacggtaa	atggcccgc	tggctgaccg	cccaacgacc	360
cccgccatt	gacgtcaata	atgacgtatg	ttcccatagt	aacgccata	gggactttcc	420
attgacgtca	atgggtggac	tatttacgggt	aaactgcccc	cttggcagta	catcaagtgt	480
atcatatgcc	aagtacgcc	cctattgacg	tcaatgacgg	taaattggccc	gcctggcatt	540
atgcccagta	catgacctta	tgggacttcc	ctacttggca	gtacatctac	gtattagtca	600
tcgctattac	catgggtgatg	cggttttggc	agtacatcaa	tgggcgtgga	tagcggtttg	660
actcacgggg	atttccaagt	ctccacccca	ttgacgtcaa	tgggagtttg	ttttggcacc	720
aaaatcaacg	ggactttcca	aaatgtcgta	acaactccgc	cccatgacg	caaatgggcg	780
gtaggcgtgt	acgggtgggag	gtctatataa	gcagagctct	ctggctaact	agagaacca	840
ctgcttactg	gcttatcgaa	attaatacga	ctcactatag	ggagaccxaa	gctggctagc	900
gtttaaactt	aagcttggta	ccgagctcgg	atccactctc	ttccgcctcg	ctgtctgcga	960
gggccagctg	ttgggtgag	tactccctct	gaaaagcggg	catgacttct	gcgctaagat	1020
tgtagtttct	caaaaacgag	gaggatttga	tattcacctg	gcccgcgggtg	atgcctttga	1080
gggtggccgc	atccatctgg	tcagaaaaga	caactctttt	gttgcaagc	ttgggtggcaa	1140
acgacccgta	gagggcgttg	gacagcaact	tgccgatgga	gcgcagggtt	tggtttttgt	1200
cgcgatcggc	gcgctccttg	gccgcgatgt	ttagctgcac	gtattcgcgc	gcaacgcacc	1260
gccattcggg	aaagacggtg	gtgcgctcgt	cgggcaccag	gtgcacgcgc	caaccgcggg	1320
tgtagcagggt	gacaaggtca	acgctggtgg	ctacctctcc	gcgtaggcgc	tcgttggtcc	1380
agcagaggcg	gcccgccttg	cgcgagcaga	atggcggtag	ggggtctagc	tgcgctctcg	1440
ccgggggggtc	tgcgctccacg	gtaaagaccc	cgggcagcag	gcgcgcgtcg	aagtagtcta	1500
tcttgcatcc	ttgcaagtct	agcgccctgct	gccatgcgcg	ggcggcaagc	gcgcgcctcg	1560
atgggttgag	tgggggaccc	catggcatgg	ggtgggtgag	cgcgaggcg	tacatgccgc	1620
aaatgtcgta	aacgtagagg	ggctctctga	gtattccaag	atatgtaggg	tagcatcttc	1680
caccgcggat	gctggcgcgc	acgtaatcgt	atagttcgtg	cgaggagcgc	aggaggtcgg	1740
gaccgaggtt	gctacggggc	ggctgctctg	ctcggaagac	tatctgcctg	aagatggcat	1800
gtgagttgga	tgatatggtt	ggacgctgga	agacgttgaa	gctggcgtct	gtgagacctt	1860
ccgcgtcacg	cacgaaggag	gcgtaggagt	cgccagcctt	gttgaccagc	tcggcgggtga	1920
cctgcacgtc	tagggcgtag	tttccctgat	gatgtcatac	gtgtcatac	ttatcctgtc	1980
cctttttttt	ccacagctcg	cggttgagga	caaactcttc	gcggtctttc	cagtactctt	2040
ggatcgga	cccgtcggcc	tccgaacgag	atccgtactc	cgccgcggag	ggacctgagc	2100
gagtcgcgat	cgaccggatc	ggaaaacctc	tcgagaaagg	cgtctaacca	gtcacagctg	2160
caagatccaa	gatgaagcgc	gcaagaccgt	ctgaagatac	cttcaacccc	gtgtatccat	2220
atgacacgga	aaccggtcct	ccaactgtgc	cttttcttac	tcctcccttt	gtatccccc	2280
atgggtttca	agagagtccc	cctgggggtac	tctcttttgc	cctatccgaa	cctctagtta	2340
cctccaatgg	catgcttgcg	ctcaaatgg	gcaacggcct	ctctctggac	gaggccggga	2400
accttacctc	ccaaaatgta	accactgtga	gcccacctct	caaaaaaacc	aagtcaaa	2460
taaacctgga	aatatctgca	cccctcacag	ttacctcaga	agccctaact	gtggctgccc	2520
ccgcacctct	aatggtcgcg	ggcaacacac	tcacatgca	atcacaggcc	ccgctaaccg	2580
tgacgactc	caaaacttagc	attgccaccc	aaggacccct	cacagtgtca	gaaggaaagc	2640
tagccctgca	aacatcaggc	cccctcacca	ccaccgatag	cagtaccctt	actatcactt	2700
cctcaccccc	tctaactact	gccactggtt	gcttgggcct	tgacttgaaa	gagccattt	2760
atacacaaaa	tggaaaacta	ggactaaagt	acggggctcc	tttgcatgta	acagacgacc	2820
taaacacttt	gaccgtagca	actggtccag	gtgtgactat	taataatact	tccttgcaaa	2880
ctaaagttac	tggagccttg	ggttttgatt	cacaaggcaa	tatgcaactt	aatgtagcag	2940
gaggactaag	gattgattct	caaaacagac	gccttatact	tgatgttagt	tatccgtttg	3000
atgctcaaaa	ccaactaaat	ctaagactag	gacaggcccc	tctttttata	aactcagccc	3060
acaacttgga	tattaactac	aacaaaggcc	tttacttgtt	tacagcttca	aacaattcca	3120
aaaagcttga	ggttaacctt	agcactgcca	aggggttgat	gtttgacgct	acagccatag	3180
ccattaatgc	aggagatggg	cttgaatttg	gttcacctaa	tgcaccaa	acaaatcccc	3240
tcaaaaacaa	aattggccat	ggcctagaat	ttgattcaaa	caaggctatg	gttccctaaa	3300
taggaactgg	ccttagtttt	gacagcacag	gtgccattac	agtaggaaac	aaaaataatg	3360
ataagcta	tttggtggacc	ggtccaaaac	cagaagccaa	ctgcataatt	gaatacggga	3420
aacaaaaccc	agatagcaaa	ctaactttaa	tccttgtaaa	aatggaggga	attgttaatg	3480
gatagttaac	gctaattggga	gcctcagact	acgttaaac	cttattttaa	aacaaaaatg	3540
tctccactaa	tgtagaacta	tactttgatg	ccactggcca	tatattacca	gactcatctt	3600
ctcttaaaac	agacttagaa	ctaaaataca	agcaaaccgc	tgactttagt	gcaagaggtt	3660
ttatgccaa	tactacagcg	tatccatttg	tccttcctaa	tgcgggaaca	cataatgaaa	3720
atttatattt	tggtcaaatgc	tactacaaag	caagcgatgg	tgcccttttt	ccgttggaag	3780
ttactgttat	gcttaataaa	cgctgcccag	atagtcgcac	atcctatgtt	atgacttttt	3840
tatggtcctt	gaatgctggg	ctagctccag	aaactactca	ggcaaccctc	ataacctccc	3900
catttacctt	ttcctatatt	agagaagatg	actgattttt	aagaagcggc	cgctcgagtc	3960

tagagggccc	gtttaaaccc	gctgatcagc	ctcgactgtg	ccttctagtt	gccagccatc	4020
tgttgtttgc	ccctcccccg	tgccttcctt	gaccctggaa	ggtgccactc	ccactgtcct	4080
ttcctaataa	aatgaggaaa	ttgcatcgca	ttgtctgagt	aggtgtcatt	ctattctggg	4140
gggtggggtg	gggcaggaca	gcaaggggga	ggattgggaa	gacaatagca	ggcatgctgg	4200
ggatgcggtg	ggctctatgg	cttctgaggg	ggaaagaacc	snccntagct	ggggctctag	4260
ggggatatccc	cacgcgcctt	gtagcggcgc	attaagcgcg	gcgggtgtgg	tggttacgcg	4320
cagcgtgacc	gtacacattg	ccagcgccct	agcgcccgct	cctttcgctt	tcttcccttc	4380
ctttctcgcc	acgttcgccc	gctttccccg	tcaagctcta	aatcggggca	tccctttaag	4440
gttccgattt	agtgtcttac	ggcacctcga	ccccaaaaaa	cttgattagg	gtgatggttc	4500
acgtagtggg	ccatcgccct	gatagacggt	ttttcgccct	ttgacgttgg	agtcacagtt	4560
ctttaatagt	ggactcttgt	tccaaaactg	aacaacactc	aacctatct	cggtctattc	4620
ttttgattta	taagggattt	tggggatttc	ggcctattgg	ttaaaaaatg	agctgattta	4680
acaaaaattt	aacgcgaatt	aattctgtgg	aatgtgtgtc	agttaggggt	tggaaagtcc	4740
ccaggctccc	caggcaggca	gaagtatgca	aagcatgcat	ctcaattagt	cagcaaccag	4800
gtgtggaaag	tccccagggt	ccccagcagg	gcaatgatg	caaagcatgc	atctcaatta	4860
gtcagcaacc	atagtcccg	ccctaactcc	gcccattccc	cccctaactc	cgccagtttc	4920
cgccattctt	cgcccccatg	gctgactaat	tttttttatt	tatgcagagg	ccgaggccgc	4980
ctctgcctct	gagctattcc	agaagtatgt	aggaggcttt	tttggaggcc	taggcttttg	5040
caaaaagctc	ccgggagctt	gtatatccat	tttcggatct	gatcagcacg	tgttgacaat	5100
taatctcgg	catagtatat	cggcatagta	taatacgaca	aggtgaggaa	ctaaacctatg	5160
gccaaagtga	ccagtgcctg	tccggtgctc	accgcgcgcg	acgtcgccgg	agcggctcag	5220
ttctggaccg	accggctcgg	gttctcccg	gacttcgtgg	aggacgactt	cgccgggtgtg	5280
gtccgggacg	acgtgaccct	gttcatcagc	gcggtccagg	accagggtgg	gccggacaac	5340
accctggcct	gggtgtgggt	gcgcggcctg	gacgagctgt	acgccgagtg	gtcggaggtc	5400
gtgtccacga	acttccggga	cgctccggga	ccggccatga	ccgagatcgg	cgagcagccg	5460
tgggggcccc	agttcgccct	gcgcgacccg	gccggcaact	gcgtgcactt	cgtagccag	5520
gagcaggact	gacacgtgct	acgagatttc	gattccaccg	ccgccttcta	tgaaggttg	5580
ggcttcggaa	tgcgttttcg	ggacgcgggc	tggatgatcc	tccagcgccg	ggatctcatg	5640
ctggagtctt	tcgcccaccc	caacttgttt	attgcagctt	ataatgggta	caaataaagc	5700
aatagcatca	caaatttcac	aaataaagca	tttttttcac	tgcatcttag	ttgtggtttg	5760
tccaaactca	tcaatgtatc	ttatcatgtc	tgtataccgt	cgacctctag	ctagagcttg	5820
gcgtaatcat	ggtcatagct	gtttcctgtg	tgaatttgtt	atccgctcac	aattccacac	5880
aacatacgag	ccggaagcat	aaagtgtaaa	gcctgggggtg	cctaatagag	gagctaactc	5940
acattaattg	cggtgcgctc	actgcccgtc	ttccagtcgg	gaaacctgtc	gtgccagctg	6000
cattaatgaa	tcggccaacg	cgccggggaga	ggcggtttgc	gtattgggcg	ctcttccgct	6060
tcctcgctca	ctgactcgct	gcgctcggtc	gttcggctgc	ggcgagcggt	atcagctcac	6120
tcaaaggcgg	taatacgggt	atccacagaa	tcaggggata	acgcaggaaa	gaacatgtga	6180
gcaaaaggcc	agcaaaaggc	caggaaccgt	aaaaaggccg	cgttgctggc	gtttttccat	6240
aggctccgcc	ccccgacga	gcatacaaaa	aatcgacgct	caagtcagag	gtggcgaaac	6300
ccgacaggac	tataaagata	ccaggcggtt	ccccctggaa	gctccctcgt	gcgctctcct	6360
gttccgaccc	tgcgcgttac	cgataacctg	tccgccttcc	tcccttcggg	aagcgtggcg	6420
ctttctcaat	gctcacgctg	taggtatctc	aggtcgttgc	aggtcgttgc	ctccaagctg	6480
ggctgtgtgc	acgaaccccc	cgttcagccc	gaccgctgcg	ccttatccgg	taactatcgt	6540
cttgagtcca	acccggtaag	acacgactta	tcgccactgg	cagcagccac	tggtaacagg	6600
attagcagag	cgaggatagt	aggcggtgct	acagagttct	tgaagtgggt	gcctaactac	6660
ggctacacta	gaaggacagt	atttggatcc	tgcgctctgc	tgaagccagt	taccttcgga	6720
aaaagagttg	gtagctcttg	atccggcaaa	caaaccaccg	ctggtagcgg	tggttttttt	6780
gtttgcaagc	agcagattac	gcgcagaaaa	aaaggatctc	aagaagatcc	tttgatcttt	6840
tctacggggt	ctgacgctca	gtggaacgaa	aactcacggt	aagggatttt	ggtcatgaga	6900
ttatcaaaaa	ggatcttcac	ctagatccct	ttaaattaaa	aatgaagttt	taaatcaatc	6960
taaagtatat	atgagtaaac	ttggtctgac	agttaccaat	gcttaatcag	tgaggccact	7020
atctcagcga	tctgtctatt	tcgttcattc	atagttgcct	gactccccgt	cgtgtagata	7080
actacgatac	gggagggctt	accatctggc	cccagtgtgc	caatgatacc	gcgagacca	7140
cgctcaccgg	ctocagattt	atcagcaata	aaccagccag	ccggaagggc	cgagcgaga	7200
agtgggtcctg	caactttatc	cgctccatc	cagctctatta	attgttgccg	ggaagctaga	7260
gtaagtagtt	cgccagttaa	tagtttgccg	aacgttggtg	ccattgctac	aggcatcgtg	7320
gtgtcacgct	cgctggtttg	tatggcttca	ttcagctccg	gttcccaacg	atcaaggcga	7380
gttacatgat	cccccatggt	gtgcaaaaaa	gcgggttagct	ccttcgggtcc	tccgatcgtt	7440
gtcagaagta	agttggccgc	agtggtatca	ctcatgggta	tggcagcact	gcataattct	7500
cttactgtca	tgccatccgt	aagatgcttt	tctgtgactg	gtgagtactc	aaccaagtca	7560
ttctgagaat	agtgatgcg	gcgaccgagt	tgtcttggcc	cgcggtcaat	acgggataat	7620
accgcgccac	atagcagaac	tttaaaagtg	ctcatcattg	gaaaacgttc	ttcggggcga	7680

-42-

aaactctcaa	ggatcttacc	gctgttgaga	tccagttcga	tgtaaccac	tcgtgcaccc	7740
aactgatctt	cagcatcttt	tactttcacc	agcgtttctg	ggtgagcaaa	aacaggaagg	7800
caaaatgccg	caaaaaagg	aataagggcg	acacggaaat	gttgaatact	catactcttc	7860
ctttttcaat	attattgaag	catttatcag	ggttattgtc	tcatgagcgg	atacatatct	7920
gaatgtatct	agaaaaataa	acaaatagg	gttccgcgca	catttccccg	aaaagtgcc	7980
cctgacgtc						7989

<210> 48

<211> 7607

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 48

tctagaagat	ccgctgtaca	ggatgttcta	gctactttat	tagatccgct	gtacaggatg	60
ttctagctac	tttattagat	ccgctgtaca	ggatgttcta	gctactttat	tagatccgct	120
gtacaggatg	ttctagctac	tttattagat	ccgctgtacag	gatgttctag	ctactttatt	180
agatcgatct	cctggccggt	cggggtcaaa	aaccagggtt	ggctataaaa	gggggtgggg	240
gcgcgttcgt	cctcactctc	ttccgcacgc	ctgtctgcga	gggccaggat	cgatcctgag	300
aacttcagg	tgagtttggg	gacccttgat	tgttctttct	ttttcgctat	tgtaaaattc	360
atgttatatg	gagggggcaa	agttttcagg	gtgttggtta	gaatgggaag	atgtcccttg	420
tatcaccatg	gaccctcatg	ataattttgt	ttctttcact	ttctactctg	ttgacaacca	480
ttgtctcctc	ttattttctt	ttcattttct	gtaacttttt	cgtaaaactt	tagcttgcat	540
ttgtaacgaa	tttttaaat	cacttttggt	tatttgcag	attgtaagta	ctttctctaa	600
tcactttttt	ttcaaggcaa	tcagggtata	ttatattgta	cttcagcaca	gttttagaga	660
acaattgtta	taattaaatg	ataaggtaga	atatttctgc	atataaatc	tggtggcgt	720
ggaaatattc	ttattggtag	aaacaactac	atcctgggtc	tcactcctgc	tttctcttta	780
tggttacaat	gatatacact	gtttgagatg	aggataaaat	actctgagtc	caaaccgggc	840
ccctctgcta	accatgttca	tgccctcttc	ttttcctac	agctcctggg	caacgtgctg	900
gttattgtgc	tgtctcatca	ttttggcaaa	gaattagatc	taagcttctg	cagctcgagg	960
actcggctga	ctgaaaatga	gacatattat	ctgccacgga	ggtgttatta	ccgaagaagt	1020
ggccggccagt	cttttggacc	agctgatcga	agagggtactg	gctgataatc	ttccacctcc	1080
tagccatttt	gaaccaccta	cccttcacga	actgtatgat	ttagacgtga	cgcccccgga	1140
agatcccaac	gaggaggcgg	tttcgcagat	ttttcccgac	tctgtaatgt	tgccgggtga	1200
ggaagggatt	gacttactca	cttttccgcc	ggcgcccggt	tctccggagc	cgcttccact	1260
ttcccgccag	cccgagcagc	cggagcagag	agccttgggt	ccggtttcta	tgccaaacct	1320
tgtaaccgag	gtgatcgatc	ttacctgcca	cgaggctggc	tttccaccga	gtgacgacga	1380
ggatgaagag	ggtgaggagt	ttgtgttaga	ttatgtggag	caccccgggc	acggttgcat	1440
gtcttgcctc	tatcaccgga	ggaatacggg	ggaccagat	attatgtgtt	cgcttgccta	1500
tatgaggacc	tgtggcatgt	ttgtctacag	taagtgaata	ttatgggcag	tggtgtatag	1560
agtgtgtggg	ttgtgtgtgt	aatttttttt	ttatttttta	cagtttttgt	gtttaaagaa	1620
ttttgtattg	tgattttttt	aaaaggctct	gtgtctgaac	ctgagcctga	gcccagagcca	1680
gaaccggagc	ctgcaagacc	taccgcgcgt	cctaaaatgg	cgctgtctat	cctgagacgc	1740
ccgacatcac	ctgtgtctag	agaatgcaat	agtagtacgg	atagctgtga	ctccggtcct	1800
tctaacacac	ctcctgagat	acaccgggtg	gtcccgctgt	gccccattaa	accagttgcc	1860
gtgagagttg	gtgggcgtcg	ccaggctgtg	gaatgtatcg	aggacttgct	taacgagcct	1920
gggcaacctt	tggacttgag	ctgtaaacgc	cccaggccat	aagggtgaaa	cctgtgattg	1980
cggtgtgtgt	taacgccttt	gtttgctgaa	tgagttgatg	taagtttaat	aaagggtag	2040
ataatgttta	acttgcattg	cgtgttaaat	ggggcggggc	ttaaaagggt	tataatgcgc	2100
cgtgggctaa	tcttggttac	atctgacctc	atggaggctt	gggagtgttt	ggaagatttt	2160
tctgctgtgc	gtaacttgct	ggaacagagc	tctaacagta	cctcttggtt	ttggaggttt	2220
ctgtggggct	catcccaggc	aaagttagtc	tgcaagaatta	aggaggatta	caagtgggaa	2280
tttgaagagc	ttttgaaatc	ctgtggtgag	ctgtttgatt	ctttgaatct	gggtcaccag	2340
gcgcttttcc	aagagaagg	catcaagact	ttggattttt	ccacaccggg	gcgcgctgcg	2400
gctgctgttg	tttttttgag	ttttataaag	gataaatgga	gcgaagaaac	ccatctgagc	2460
ggggggtacc	tgctggattt	tctggccatg	catctgtgga	gagcgggtgt	gagacacaag	2520
aatcgccctg	tactgttgct	ttccgtccgc	ccggcgataa	taccgacgga	ggagcagcag	2580
cagcagcagg	aggaagccag	gcggcgccgg	caggagcaga	gcccattgaa	cccagagacc	2640
ggcctggacc	ctcgggaatg	aatgttgtag	aggtggctga	actgtatcca	gaactgagac	2700

gcattttgac aattacagag gatgggcagg ggctaaaggg ggtaaagagg gagcgggggg 2760
cttgtgaggc tacagaggag gctaggaatc tagcttttag cttaatgacc agacaccgtc 2820
ctgagtgtat tacttttcaa cagatcaagg ataattgcgc taatgagctt gatctgctgg 2880
cgcagaagta ttccatagag cagctgacca cttactggct gcagccaggg gatgattttg 2940
aggaggctat taggggtatat gcaaagggtg cacttaggcc agattgcaag tacaagatca 3000
gcaaacttgt aaatatcagg aattgttgct acatttctgg gaacggggcc gaggtggaga 3060
tagatacggg ggatagggtg gccttttagat gtagcatgat aaatatgtgg ccgggggtgc 3120
ttggcatgga cgggggtggt attatgaatg taagggtttac tggcccaat tttagcggta 3180
cggttttccct ggccaatacc aaccttatcc tacacgggtg aagcttctat ggggtttaaca 3240
atacctgtgt ggaagcctgg accgatgtaa ggggtcgggg ctgtgccttt tactgctgct 3300
ggaagggggg ggtgtgtcgc cccaaaagca gggcttcaat taagaaatgc ctctttgaaa 3360
ggtgtacctt ggggtatcctg tctgagggtg actccagggt gcgccacaat gtggcctcgc 3420
actgtggttg cttcatgcta gtgaaaagcg tggctgtgat taagcataac atgggtatgtg 3480
gcaactgcga ggacagggcc tctcagatgc tgacctgctc ggacggcaac tgtcacctgc 3540
tgaagaccat tcacgtagcc agccactctc gcaaggcctg gccagtgttt gagcataaca 3600
tactgacccg ctgttccctg catttggtga agcccgagag catgtccaag ccttaccat 3660
gcaatttgag tcacactaag atattgcttg agcccgagag catgtccaag gtgaacctga 3720
acggggtgtt tgacatgacc atgaagatct ggaagggtgct gaggtacgat gagacccgca 3780
ccagggtgcag accctgcgag tgtggcggta aacatattag gaaccagcct gtgatgctgg 3840
atgtgaccga ggaagataca gattgaggtg tgggtgctggc ctgcacccgc gtgagtttg 3900
gctctagcga tgaagataca gattgaggtg tgggtgctggc ctgcacccgc gtgagtttg 3960
gaaagaatat ataagggtgg ggtcttatgt agttttgtat tgggctggc ttaagggtgg 4020
ccgccatgag caccaactcg tttgatggaa gcatgtgtgag ctcatatttg qcacccgcg 4080
tgcccccatg ggccgggggtg cgtcagaatg tgatgggctc cagcattgat ggtcgccccg 4140
tctgccccgc aaactctact accttgacct acgagaccgt gtctggaacg ccgttgagg 4200
ctgcagcctc cgcgcgcgct tcagccgctg cagccaccgc ccgcgggatt gtgactgact 4260
ttgtcttccct gagcccgctt gcaagcagtg cagcttcccg ttcacccgc ccgcgatgaca 4320
agttgacggc tcttttgcca caattggatt ctttgaccgg ggaacttaat gtcgtttctc 4380
agcagctggt ggatctgcgc cagcaggttt ctgcccga ggcttccctc cctcccaatg 4440
cgggttaaaa cataaataaa aaaccagact ctgcttggat ttggatcaag caagtgtctt 4500
gctgtctcag ctgactgctt aagtcgcaag ccgaattgga tccaattcgg atcgatctta 4560
ttaaagcaga acttgtttat tgcagcttat aatgggtaca aataaagcaa tagcatcaca 4620
aatttcacaa ataaagcatt tttttcactg cattctagtt gtggtttgtc caaactcatc 4680
aatgtatctt atcatgtctg gtcgactcta gactcttccg cttcctcgct cactgactcg 4740
ctgcgctcgg tcgttcggct gggcgagcgc gtatcagctc actcaaaggc ggtaatacgg 4800
ttatccacag aatcagggga taacgcagga aagaacatgt gagcaaaagg ccagcaaaag 4860
gccaggaacc gtaaaaaggg cgcttttctc gcgtttttcc ataggctccg ccccccgtac 4920
gagcatcaca aaaatcgacg ctcaagtcag aggtggcgaa acccgacagg actataaaga 4980
taccaggcgt ttccccctgg aagctccctc gtgcgctctc ctgttccgac cctgccgctt 5040
accggatacc tgtccgcctt tctcccttcc ggaagcgtgg cgctttctca tagctcacgc 5100
tgtaggatcc tcagttcggg gtaggtcggt cgctccaagg tgggctgtgt gcacgaacc 5160
cccgttcagc ccgaccgctg cgccttatcc ggttaactat gtcttgagtc caaccggta 5220
agacacgact tatcgccact ggcagcagcc actggttaaca ggattagcag agcgaggtat 5280
gtaggcgggt ctacagagtt cttgaagtgg tggcctaact acggtacac tagaaggaca 5340
gtatttggtg tctgcgctct gctgaagcca gttaccctcg gaaaaagagt tggtagctct 5400
tgatccggca aacaaaccac cgctggtagc ggtggttttt ttggttgcaa gcagcagatt 5460
acgcgcagaa aaaaaggatc tcaagaagat cctttgatct tttctacggg gctctgacgt 5520
cagtggaacg aaaaactcac ttaagggtatt ttggtcatga gattatcaaa aaggatcttc 5580
acctagatcc ttttaaatga aaaatgaagt tttaaatcaa tctaaagtat atatgagtaa 5640
acttggtctg acagttacca atgcttaatc agtgaggcac ctatctcagc gatctgtcta 5700
tttcgttcat ccatagttgc ctgactcccc gtcgtgtaga taactacgat acgggagggc 5760
ttaccatctg gccccagtcg tgcaatgata ccgcgagacc cacgctcacc ggctccagat 5820
ttatcagcaa taaaccagcc agccggaagg gccgagcgca gaagtggctc tgcaacttta 5880
tccgctcca tccagttctat taattgttgc cggaagcta gagtaagtag ttcgccagtt 5940
aatagtttgc gcaacgttgt tgccattgct acaggcatcg tgggtgtcacg ctgcgctgtt 6000
ggtatgctt cattcagctc cggttcccaa cgatcaaggc gagttacatg atccccatg 6060
ttgtgcaaaa aagcgggttag ctccttcggg cctccgatcg ttgtcagaag taagttggcc 6120
gcaggttat cactcatggt tatggcagca ctgcataatt ctcttactgt catgccatcc 6180
gtaagatgct tttctgtgac tggtagtac tcaaccaagt cattctgaga atagtgtatg 6240
cggcgaccga gttgctcttg cccggcgta ataccgggata ataccgcgc aatagcaga 6300
actttaaaag tgctcatcat tggaaaacgt tcttcggggc aaaaactctc aaggatctta 6360
ccgctgttga gatccagttc gatgtaaccc actcgtgcac ccaactgate ttcagcatct 6420

-44-

```

tttacttttca ccagcgtttc tgggtgagca aaaacaggaa ggcaaaatgc cgcaaaaaag 6480
ggaataaggg cgacacggaa atgttgaata ctcatactct tcctttttca atattattga 6540
agcattttatc aggggttattg tctcatgagc ggatacatat ttgaatgat ttagaaaaat 6600
aaacaaatag ggggtccgcg cacatttccc cgaaaagtgc cacttgacgt ctaagaaacc 6660
attattatca tgacattaac ctataaaaat aggcgtatca cgaggccct ttcgtctcgc 6720
gcgtttcggt gatgacggg aaaaacctctg acacatgcag ctcccgga cggtcacagc 6780
ttgtctgtaa gcggatgccg ggagcagaca agcccgtcag ggcgcgtcag cgggtgttgg 6840
cgggtgtcgg ggctggctta actatgcggc atcagagcag attgtactga gagtgcacca 6900
tatgcgggtgt gaaataccgc acagatgcgt aaggagaaaa taccgcatca ggaaattgta 6960
agcgttaata ttttgttaaa attcgcgtta aatttttgtt aaatcagctc attttttaac 7020
caataggccg aaatcggcaa aatcccttat aaatcaaaag aatagaccga gatagggttg 7080
agtgttgttc cagtttggaa caagagtcca ctattaaaga acgtggactc caacgtcaaa 7140
gggcgaaaaa ccgtctatca gggcgatggc ccactacgtg aaccatcacc ctaatcaagt 7200
tttttggggt cgaggtgccg taaagcacta aatcggaacc cttaaaggag cccccgattt 7260
agagcttgac ggggaaagcc ggcgaacgtg gcgagaaagg aaggggaagaa agcgaaagga 7320
gcgggcgcta gcgcgctggc aagtgtagcg gtcacgctgc gcgtaaccac cacaccgcc 7380
gcgcttaatg gcgcgctaca gggcgctcc cattcgccat tcaggtcgcg caactgttgg 7440
gaagggcgat cgggtcgggc ctcttcgcta ttacgccagc tggcgaaagg gggatgtgct 7500
gcaaggcgat taagttgggt aacgccaggg ttttcccagt cacgacgttg taaaacgacg 7560
gccagtgaat tgtaatacga ctactatag ggcgaattaa ttcgggg 7607

```

<210> 49

<211> 11600

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 49

```

gaattccgca ttgcagagat attgtattta agtgccctagc tcgatacaat aaacgccatt 60
tgaccattca ccacattggt gtgcacctcc aagcttgggc agaaatggtt gaactcccga 120
gagtgtccta cacctagggg agaagcagcc aaggggttgt ttcccaccaa ggacgacccg 180
tctgcgcaca aacggatgag cccatcagac aaagacatat tcatttctctg ctgcaaaactt 240
ggcatagctc tgctttgcct. ggggctattg ggggaagtgt cggttcgtgc tcgcagggct 300
ctcacccttg actcttttaa tagctcttct gtgcaagatt acaatctaaa caattcggag 360
aactcgacct tctcctgag gcaaggacca cagccaactt cctcttaciaa gccgcattcga 420
ttttgtcctt cagaaataga aataagaatg cttgctaaaa atttatattt taccataaag 480
accaatccaa taggtagatt attagttact atgttaaaga atgaatcatt atcttttagt 540
actattttta ctcaaattca gaagttagaa atgggaatag aaaatagaaa gagacgctca 600
acctcaattg aagaacaggt gcaaggacta ttgaccacag gcctagaagt aaaaaaggga 660
aaaaagagtg tttttgtcaa aataggagac aggtggtggc aaccagggac ttatagggga 720
ccttacatct acagaccaac agatgcccc ttaccatata caggaagata tgacttaaat 780
tgggataggt ggggttacagt caatggctat aaagtgttat atagatccct cctttttcgt 840
gaaagactcg ccagagctag acctccttgg tgtatgttgt ctcaagaaga aaaagacgac 900
atgaaacaac aggtacatga ttatatattt ctggaacag gaatgcactt ttggggaaag 960
attttccata ccaaggaggg gacagtggct ggactaatag aacattattc tgcaaaaact 1020
catggcatga gttattatga atagccttta ttggcccaac cttgcggttc ccagggttca 1080
agtaagtttt tggttacaaa ctgttcttaa aacgaggatg tgagacaagt ggtttcctga 1140
cttggtttgg tatcaaagg tctgatctga gctctgagtg ttctattttc ctatgttctt 1200
ttggaattta tccaaatctt atgtaaatgc ttatgtaaac caagatataa aagagtgtctg 1260
attttttgag taaacttgca acagtcctaa cattcacctc ttgtgtgttt gtgtctgttc 1320
gccatcccgt ctccgctcgt cacttatcct tcactttcca gaggggtccc ccgcagacc 1380
cggcgacccct caggtcggcc gactgcggca gctggcgccc gaacagggac cctcgataa 1440
gtgacccttg tctctatttc tactatttgg tgtttgtctt gtattgtctc tttcttgtct 1500
ggctatcatc acaagagcgg aacggactca ccatagggac caagctagcg cttctcgtcg 1560
cgtccaagac cctcaaagat ttttggcact tcgttgagcg aggcgatatc aggtatgaca 1620
gcgccttgc gcaaggccag ctgcttgcgc gctcggtgc ggttggcacg gcaggatagg 1680
ggatctcttc agttttggaa aaagatgtga taggtggcaa gcacctctgg cacggcaaat 1740
acggggtaga agttgaggcg cgggttgggc tcgcatgtgc cgttttcttg gcgtttgggg 1800
ggtacgcgcg gtgagaatag gtggcgctcg taggcaaggc tgacatccgc tatggcgagg 1860

```

ggcacatcgc	tgcgctcttg	caacgcgctcg	cagataatgg	cgcactggcg	ctgcagatgc	1920
ttcaacagca	cgctcgtctcc	cacatctagg	tagtcgccat	gcctttcgtc	ccccgcgccg	1980
acttgctcct	cgtttgectc	tgcgttgctcc	tggtcttget	ttttatcctc	tggtgggtact	2040
gagcggctct	cgctcgtcttc	gcttacaaaa	cctgggtcct	gctcgataat	cacttccctcc	2100
tcctcaagcg	ggggtgcctc	gacgggggaag	gtggtagggc	cggtggcggc	atcgggtggag	2160
gcgggtggtg	cgaactcaga	ggggggcggtt	aggctgtcct	tcttctcgac	tgactccatg	2220
atctttttct	gcctatagga	gaaggaaatg	gccagtcggg	aagaggagca	gcgcgaaacc	2280
acccccgagc	gcggacgcgg	tgcggcgcg	cgcccccaa	ccatggagga	cggtgcgtcc	2340
ccgtccccgt	cgccgcgcgc	tccccggcg	cccccaaaaa	agcggatgag	gcggcggtatc	2400
gagtcgcagg	acgaggaaga	ctcatcacaa	gacgcgctgg	tgccgcgcac	accagcccg	2460
cgcccatcga	cctcggcggc	ggatttgccc	attgcgcca	agaagaaaaa	gaagcgccct	2520
tctcccaagc	ccgagcgccc	gccatcacca	gaggtaatcg	tggaacagca	ggaagaaaga	2580
gaagatgtgg	cgctacaaat	ggtgggtttc	agcaaccac	cggtgcta	caagcatggc	2640
aaaggaggtg	agcgcacagt	gcggcggtcg	aatgaagacg	accagtggc	gcgtgggtatg	2700
cggacgcaag	aggaagagga	agagcccagc	gaagcgga	gtgaaattac	ggtgatgaac	2760
ccgctgagtg	tgccgatcgt	gtctgcgtgg	gagaagggca	tggaaggctg	gcgcgcgctg	2820
atggacaagt	accacgtgga	taacgatcta	aaggcgaa	tcaaaactact	gcctgaccaa	2880
gtggaagctc	tggcgccgt	atgcaagacc	tggtgaa	aggagcaccg	cggttgtag	2940
ctgaccttca	ccagcaacaa	gacctttgtg	acgatgatgg	ggcgattcct	gcaggcgtag	3000
ctgcacgcgt	ttgcagaggt	gacctacaag	catcacgagc	ccacgggctg	cgctgtgtgg	3060
aataaggagc	acgtgattga	aatggatgtg	cttaagtgtc	tacacggaag	cattatgata	3120
gagcagctca	gcaaggccaa	gatcgtgaag	acgagcgaaa	acgggcagcg	cgcgctgaag	3180
tccaacaccg	acgcaagggtg	ctgcgtgcac	aaccggtggg	gccgaaatgt	ggtgcagatc	3240
ggcaagtctt	gcggcatggt	cttctctgaa	gacgcggcct	gtccggccaa	tcagttttcc	3300
atcaaggctt	ttatgcaggc	gctgtatcct	gacgcgcaag	ctcaggtggc	ttttaagcag	3360
atgccactac	ggtgcgagtg	caactcaaa	cctgggcacg	cgcccttttt	gggaaggcag	3420
ctaccaaaagt	tgactccgtt	cgccctgagc	aacgcggagg	acctggacgc	ggatctgac	3480
tccgacaaga	gcgtgctggc	cagcgtgcac	caccggcgcg	tgatagtgtt	ccagtgtctg	3540
aaacctgtgt	atcgcaactc	gcgcgcgcag	ggcgagggcc	ccaactgcga	cttcaagata	3600
tcggcgcccc	acctgctaaa	cgcttggtg	atggtgcgca	gcctgtggag	tgaaaacttc	3660
accgagctgc	cgcggtgggt	tgtgcctgag	tttaagtggg	gcactaaaca	ccagtatcgc	3720
aacgtgtccc	tgccagtggc	gcatagcgat	gcgcggcaga	acccctttga	tttttaaagc	3780
gcgcagacgg	caagggtggg	ggtaataaat	cacccgagag	tgtacaaata	aaagcatttg	3840
cctttattga	aagtgtctct	agtaacattat	ttttacatgt	ttttcaagtg	acaaaaagaa	3900
gtggcgctcc	taatctgcgc	actgtggctg	cggaagtagg	gcgagtggcg	ctccaggaag	3960
ctgtagagct	gttccctggt	gcgacgcagg	gtgggctgta	cctggggact	gttgagcatg	4020
gagttgggta	ccccggta	aaggttcag	gtggggtgt	gatccatggg	agtttggggc	4080
cagttggcaa	aggcgtggag	aaacatgcag	cagaatagtc	cacaggcggc	cgagttgggc	4140
ccctgtacgc	tttggtgga	cttttccagc	gttatacagc	ggtcggggga	agaagcaatg	4200
gcgctacggc	gcaggagtga	ctcgtactca	aactggtaaa	cctgcttgag	tcgctggtca	4260
gaaaagccaa	agggtcaaa	gaggtagcat	gtttttgagt	gcgggttcca	ggcaaaggcc	4320
atccagtgtg	cgccccag	cgcgtagc	gcgtagtga	ctatggcgca	ggcgagcttg	4380
tgtggagaaa	caaagcctgg	aaagcgcttg	tcataggtgc	ccaaaaata	tggtccacaa	4440
ccaagatctt	tgacaatggc	tttcagttcc	tgctcactgg	agcccatggc	ggcagctggt	4500
gttgatgttg	cttgcttctt	tatgttggtg	cgttgccggc	cgagaagggc	gtgcgcaggt	4560
acacggtttc	gatgacgccg	cggtgcggcc	ggtgcacacg	gaccacgtca	aagacttcaa	4620
acaaaacata	aagaagggtg	ggctcgtcca	tggtatccat	atatagggcc	cggtgtataa	4680
ttacctcagg	tcgacctcga	gggatctttg	tgaaggaa	ttacttctgt	ggtgtgacat	4740
aattggacaa	actacctaca	gagatttaaa	gctctaaggt	aaatataaaa	tttttaagtg	4800
tataatgtgt	taaactactg	attctaattg	tttgtgtatt	ttagattcca	acctatggaa	4860
ctgatgaatg	ggagcagtg	tggaatgcct	ttaatgagga	aaacctgttt	tgctcagaag	4920
aaatgccatc	tagtgatgat	gaggctactg	ctgactctca	acattctact	cctccaaaaa	4980
agaagagaaa	ggtagaagac	cccaaggact	ttccttcaga	attgctaagt	tttttgagtc	5040
atgctgtgtt	tagtaataga	actcttgctt	gctttgctat	ttacaccaca	aaggaaaaag	5100
ctgcactgct	atacaagaaa	attatggaaa	aatattctgt	aacctttata	agtaggcata	5160
acagttataa	tcataacata	ctgttttttc	ttactccaca	caggcataga	gtgtctgcta	5220
ttaataacta	tgctcaaaaa	ttgtgtacct	ttagcttttt	aatttgtaaa	gggtgtataa	5280
aggaatat	gatgtatagt	gccttgacta	gagatcataa	tcagccatac	cacatttgta	5340
gaggttttac	ttgcttttaa	aaacctccca	cacctcccc	tgaacctgaa	acataaaatg	5400
aatgcaattg	ttgtgttaa	ctgtgttatt	gcagcttata	atggttataa	ataaagcaat	5460
agcatcacia	atttcacaaa	taaagcattt	ttttcactgc	attctagttg	tggtttgtcc	5520

aaactcatca	atgtatctta	tcatgtctgg	atccggctgt	ggaatgtgtg	tcagttaggg	5640
tgtggaaaagt	ccccaggctc	cccagcaggc	agaagtatgc	aaagcatgca	tctcaattag	5700
tcagcaacca	ggtgtggaaa	gtccccaggc	tccccagcag	gcagaagtat	gcaaagcatg	5760
catctcaatt	agtcagcaac	catagtcctc	cccctaactc	cgcccatccc	gcccctaact	5820
ccgcccagtt	ccgcccattc	tccgcccctc	ggctgactaa	ttttttttat	ttatgcagag	5880
gccgaggccg	cctcggcctc	tgagctatct	cagaagtagt	gaggaggcct	ttttggaggc	5940
ctaggctttt	gcaaaaagct	tcacgctgcc	gcaagcactc	agggcgcaag	ggctgctaaa	6000
ggaagcggaa	cacgtagaaa	gccagtcctc	agaaacggtg	ctgaccccg	atgaatgtca	6060
gctactgggc	tatctggaca	agggaaaacg	caagcgcaaa	gagaaagcag	gtagcttgca	6120
gtgggcttac	atggcgatag	ctagactggg	cggttttatg	gacagcaagc	gaaccggaat	6180
tgccagctgg	ggcgccctct	ggtaagggtg	ggaagccctg	caaagtaaac	tggatggcct	6240
tcttgccgct	aaggatctga	tggcgagggg	gatcaagatc	tgatcaagag	acaggatgag	6300
gatcgtttcg	catgattgaa	caagatggat	tgacgcagag	ttctccggcc	gcttgggtgg	6360
agaggctat	cggctatgac	tgggcacaac	agacaatcgg	ctgctctgat	gccgcctgtg	6420
tccggctgtc	agcgaggggg	cgcccggttc	ttttgtcaa	gaccgacctg	tccggtgcc	6480
tgaatgaact	gcaggacgag	gcagcgcgcc	tatcgtggct	ggccacgacg	ggcgttcctt	6540
gcgcagctgt	gctcgacgtt	gtcactgaag	cgggaaggga	ctggctgcta	ttgggcgaag	6600
tgcgggggca	ggatctcctg	tcatctcacc	ttgctcctgc	cgagaaagta	tccatcatgg	6660
ctgatgcaat	gcggcggtct	catacgcttg	atccggctac	ctgcccattc	gaccaccaag	6720
ogaaacatcg	catcgagcga	gcacgtactc	ggatggaaag	cggctctgtc	gatcaggatg	6780
atctggacga	agagcatcag	gggctcgcgc	cagccgaact	gttcgccagg	ctcaaggcgc	6840
gcatgcccg	cggcgaggat	ctcgtctgta	cccatggcga	tgcctgcttg	ccgaatatca	6900
tgggtgaaaa	tggccgcttt	tctggattca	tgcactgtgg	cgggctgggt	gtggcgagcc	6960
gctatcagga	catagcggtg	gctaccggtg	atattgtgta	agagcttgcc	ggcgaatggg	7020
ctgaccgctt	cctcgtgctt	tacggtatcg	ccgctcccga	ttcgcagcgc	atcgcttctt	7080
atcgcttctt	tgacgagttc	ttctgagcgg	gactctgggg	ttcgaaatga	ccgaccaagc	7140
gacgcccac	ctgccatcac	gagatttcga	ttccaccgcc	gccttctatg	aaaggttggg	7200
cctcggaatc	gttttccggg	acgcgcgctg	gatgatcctc	cagcgcgggg	atctcatgct	7260
ggagtctctt	gcccaccccg	ggctcgatcc	cctcgcgagt	tggttcagct	gctgcctgag	7320
gctggacgac	ctcgcggagt	tctaccggca	gtgcaaatcc	gtcggcatcc	aggaaaccag	7380
cagcggtctat	ccgcgcaccc	atgccccgga	actgcaggag	tggggaggca	cgatggccgc	7440
tttgggtccc	gatctttgtg	aaggaaacct	acttctgtgg	tgtgacataa	ttggacaaa	7500
tacctacaga	gatttaaagc	tctaaggtaa	atataaaatt	tttaagtgtg	taatgtgtta	7560
aactactgat	tctaattgtt	tgtgtatttt	agattccaac	ctatggaact	gatgaatggg	7620
agcagtgggt	gaatgccttt	aatgaggaaa	acctgttttg	ctcagaagaa	atgccatcta	7680
gtgatgatga	ggctactgct	gactctcaac	attctactcc	tccaaaaaag	aagagaaagg	7740
tagaagaccc	caaggacttt	ccttcagaat	tgctaagttt	tttgagtcat	gctgtgttta	7800
gtaatagaac	tcttgcttgc	atataaaatt	acaccacaaa	ggaaaaagct	gcactgctat	7860
acaagaaaat	tatggaaaaa	tattctgtaa	cctttataag	taggcataac	agttataatc	7920
ataacatact	gttttttctt	actccacaca	ggcatagagt	gtctgctatt	aataactatg	7980
ctcaaaaatt	gtgtaccttt	agctttttta	ttgttaaagg	ggttaataag	gaatatttga	8040
tgtatagtgc	cttgactaga	gatcataate	agccatacca	catttgtaga	ggttttactt	8100
gctttaaaaa	acctcccaca	cctccccctg	aacctgaac	ataaaatgaa	tgcaattgtt	8160
gttggttaact	tgttttattg	agcttataat	ggttacaaat	aaagcaatag	catcacaaat	8220
ttcacaaaata	aagcattttt	ttcactgcat	tctagtgtg	gtttgtccaa	actcatcaat	8280
gtatcttatc	atgtctggat	ccccaggaag	ctcctctgtg	tctcatataa	ccctaaccct	8340
ctctacttga	gaggacattc	caatcatagg	gtgcccaccc	accctctgtg	tctcctgttt	8400
aattaggtca	cttaacaaaa	aggaaattgg	gtaggggttt	ttcacagacc	gctttctaag	8460
ggtaattttt	aaatatctgg	gaagtccctt	ccactgctgt	gttccagaag	tgttggttaa	8520
cagcccacaa	atgtcaacag	cagaaacata	caagctgtca	gctttgcaca	agggcccaac	8580
accctgctca	tcaagaagca	ctgtggttgc	tgtgttagta	atgtgcaaaa	caggaggcac	8640
attttcccca	cctgtgtagg	ttccaaaata	tctagtgttt	tcatttttac	ttggatcagg	8700
aaccagcac	tccactggat	aagcattatc	cttatccaaa	acagccttgt	ggtcagtgtt	8760
catctgctga	ctgtcaactg	tagcattttt	tggggttaca	gtttgagcag	gatatttggg	8820
cctgtagttt	gctaacacac	cctgcagctc	caaaagttcc	ccaccaacag	caaaaaaatg	8880
aaaattttgc	ccttgaatgg	gttttccagc	accattttca	tgagtttttt	gtgtccctga	8940
atgcaagttt	aacatagcag	ttaccccaat	aacctcagtt	ttaacagtaa	cagcttccca	9000
catcaaaaata	tttccacagg	tttaagtctc	atttaaatta	ggcaaaaggaa	ttcttgaaag	9060
cgaaagggcc	tctgtgatac	cctattttta	taggttaatg	tcatgataat	aatggtttct	9120
tagacgtcag	gtggcacttt	tccgggaaat	gtgcgcggaa	ccctattttg	tttatttttc	9180
taaatatcatt	caaatatgta	tccgctcatg	agacaataac	cctgataaat	gcttcaataa	9240
tattgaaaaa	ggaagagtat	gagtattcaa	catttccgtg	tccgcttat	tccctttttt	9300

```

gcggcatttt gccttcctgt ttttgctcac ccagaaacgc tggtgaaagt aaaagatgct 9360
gaagatcagt tgggtgcacg agtgggttac atcgaactgg atctcaacag cggtaagatc 9420
cttgagagtt ttgcgcccga agaacgtttt ccaatgatga gcacttttaa agttctgcta 9480
tgtggcgcggt tattatcccg tgttgacgcc gggcaagagc aactcgggtcg ccgcatacac 9540
tattctcaga atgacttggt tgagtactca ccagtcacag aaaagcatct tacggatggc 9600
atgacagtaa gagaattatg cagtgcctgc ataaccatga gtgataacac tgcggccaac 9660
ttacttctga caacgatcgg aggaccgaag gagctaaccg cttttttgca caacatgggg 9720
gatcatgtaa ctgcgcctga tcgttgggaa ccggagctga atgaagccat accaaacgac 9780
gagcgtgaca ccacgatgcc tgcagcaatg gcaacaacgt tgcgcaaac attaatggc 9840
gaactactta ctctagcttc ccggcaacaa ttaatagact ggatggaggc ggataaagt 9900
gcaggaccac ttctgcgctc ggcccttcgg gctggctggg ttattgctga taaatctgga 9960
gccggtgagc gtgggtctcg cgggtatcatt gcagcactgg ggccagatgg taagccctcc 10020
cgtatcgtag ttatctacac gacggggagt caggcaacta tggatgaacg aaatagacag 10080
atcgtcgaga taggtgcctc actgattaag cattggtaac tgtcagacca agtttactca 10140
tatatacttt agattgattt aaaacttcac ttttaattta aaaggatcta ggtgaagatc 10200
ctttttgata atctcatgac caaaatccct taacgtgagt tttcgttcca ctgagcgtca 10260
gaccccgtag aaaagatcaa aggatcttct tgagatcctt tttttctgcg cgtaatctgc 10320
tgcttgcaaa caaaaaaacc accgctacca gcggtgggtt gtttgccgga tcaagagcta 10380
ccaactcttt ttccgaaggt aactggcttc agcagagcgc agataccaaa tactgtcctt 10440
ctagtgtagc ctgagttagg ccaccacttc aagaactctg tagcacgcc tacatacctc 10500
gctctgctaa tcctgttacc agtggctgct gccagtggcg ataagtcgtg tcttaccggg 10560
ttggactcaa gacgatagtt accggataag gcgcagcggg cgggctgaac pgggggttcg 10620
tgcacacagc ccagcttgga gcgaacgacc tacaccgaac tgagatacct acagcgtgag 10680
ctatgagaaa gcgccacgct tcccgaaggc agaaaggcgg acaggatcc ggtaagcggc 10740
agggtcggaa caggagagcg caccagggag cttccagggg gaaacgcctg gtatctttat 10800
agtcctgtcg ggtttcgcca cctctgactt gagcgtcgat ttttgtgatg ctctgcaggg 10860
gggcggagcc tatggaaaaa cgccagcaac gcggcctttt tacggttcct ggccttttgc 10920
tggccttttg ctacatggtt ctttctctcg ttatccctg attctgtgga taaccgtatt 10980
accgcctttg agtgagctga taccgctcgc cgcagccgaa cgaccgagcg cagcagagtc 11040
gtgagcgagg aagcggaaga gcgcctgatg cggatttttc tccttacgca tctgtgcggt 11100
atttcacacc gcatatggtg cactctcagt acaatctgct ctgatgccgc atagttaagc 11160
cagtatctgc tcctgcttg tgtgttgag gtcgctgagt agtgcgcgag caaaatttaa 11220
gtacaacaa ggcaaggctt gaccgacaat tgcatgaaga atctgcttag ggttaggcgt 11280
tttgcgctgc ttgcgcatgt acgggccaga tatacgcgta tctgagggga ctagggtgtg 11340
tttaggcgaa aagcggggct tcggttgtag gcggttagga gtccctcag gatatagtag 11400
tttcgctttt gcatagggag ggggaaatgt agtcttatgc aatacacttg tagtcttgca 11460
acatggtaac gatgagttag caacatgcct tacaaggaga gaaaaagcac cgtgcatgcc 11520
gattggtgga agtaagggtg tacgatcgtg ccttattagg aaggcaacag acgggtctga 11580
catggattgg acgaaccact

```

<220>

<223> Description of Artificial Sequence: plasmid

<400> 49

<210> 50

<211> 8238

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 50

```

gcggccgcca tcatcaataa tataccttat tttggattga agccaatatg ataatgaggg 60
ggtggagttt gtgacgtggc gcggggcggt ggaacggggc ggggtgacgta gtagtgtggc 120
ggaagtgtga gtgttgaagt gtggcggaac acatgtaagc gacggatgtg gcaaaagtga 180
cgtttttggt gtgcgcgggt gtacacagga agtgacaatt ttgcgcgggt tttaggcgga 240

```

tgttgtagta	aatttgggcg	taaccgagta	agatttgggc	atcttcgagg	gaaaactgaa	300
taagaggaag	tgaaatctga	ataatcttga	gttactcata	gcgcgtaata	tttgtctagg	360
gccgcgggga	ctttgaccgt	ttacgtggag	actcgccag	ggcgcgcccc	gatgtacggg	420
ccagatatac	gcgtatctga	ggggactagg	gtgtgtttag	gcgaaaagcg	gggcttcggt	480
tgtacgcggt	taggagtecc	ctcaggatat	agtagtttcg	cttttgcata	gggaggggga	540
aatgtagtct	tatgcaatac	tcttgtagtc	ttgcaacatg	gtaacgatga	gttagcaaca	600
tgccctacaa	ggagagaaaa	agcaccgtgc	atgccgattg	gtggaagtaa	gggtgtacga	660
tcgtgcctta	ttaggaaggc	aacagacggg	tctgacatgg	attggacgaa	ccactgaatt	720
ccgcattgca	gagatattgt	atttaagtgc	ctagctcgat	acaataaacg	ccatttgacc	780
attcaccaca	ttgggtgtgca	cctccggccc	atatggccac	tctcttcgct	atcgctgtct	840
gcgggggcca	gctgttgggc	tcgcggttga	ggacaaaactc	ttcgcggtct	ttccagtact	900
cttggtatcg	aaaccogtgc	gcctccgaac	ggactccgc	cgccgaggga	cctgagcgag	960
tcgcgatcga	ccggatcgga	aaacctctcg	agaaaggcgt	gtaaccagtc	acagtcgctc	1020
tagaactagt	ggatcccccg	ggctgcagga	attcgatgat	cttggtggcg	tgaaactccc	1080
gcacctcttt	ggcaagcgcc	ttgtagaagc	gcgtatggct	tcgtaccct	gccatcaaca	1140
cgcgctctgc	ttcgaccagg	ctgcgcgttc	tcgcggccat	agcaaccgac	gtacggcggt	1200
gcgcctctgc	cggcagcaag	aagccacgga	agtccgcctg	gagcagaaaa	tgcccacgct	1260
actgcgggtt	tatatagaag	gtcctcacgg	gatggggaaa	accaccacca	cgcaactgct	1320
ggtggccctg	ggttcgcgcg	acgatatact	ctacgtaccc	gagccgatga	cttactggca	1380
ggtgctgggg	gcttcgcgga	caatcgcgaa	catctacacc	acacaacacc	gcctcgacca	1440
gggtgagata	tcggccgggg	acgcggcggt	ggtaatgaca	agcgcccaga	taacaatggg	1500
catgccttat	gccgtgacgg	acgcggttct	ggctcctcat	gtcggggggg	aggctgggag	1560
ttcacatgcc	ccgcccccg	ccctcacctc	catcttcgac	cgccatccca	tcgcccgcct	1620
cctgtgtctac	ccggccgcgc	gataccttat	gggcagcatg	acccccagg	ccgtgctggc	1680
gttcgtggcc	ctcatcccg	cgaccttgcc	cggcacaaac	atcgtgttgg	gggccccttc	1740
ggaggacaga	cacatcgacc	gcctggccaa	acgccagcgc	cccgccgagc	ggcttgacct	1800
ggctatgctg	gccgcgattc	gccgcgttta	cgggctgctt	gccaaatagg	tgcggtatct	1860
gcagggcggc	gggtcggtgt	gggaggattg	gggacagctt	tcggggagcg	ccgtgcccgc	1920
ccaggggtgc	gagccccaga	gcaacgcggg	cccacgaccc	catatcgggg	acacgttatt	1980
tacctgtttt	cgggcccccg	agttgtctgg	ccccaacggc	gacctgtata	acgtgtttgc	2040
ctgggccttg	gacgtcttgg	ccaaacgcct	ccgtcccatg	cacgtcttta	tcctggatta	2100
cgaccaatcg	cccgcgggct	gccgggagcg	cctgctgcaa	cttacctccg	ggatggtcca	2160
gacccacgtc	accaccccag	gctccatacc	gacgatctgc	gacctggcgc	gcacgtttgc	2220
ccggagagtg	ggggaggcta	actgactcga	gaagcttggg	cccatcgatc	aagcttatcg	2280
ataccgtcga	aacttgttta	ttgcagctta	taatggttac	aaataaagca	atagcatcac	2340
aaatttcaca	aataaagcat	ttttttcact	gcattctagt	tgtggtttgt	ccaaactcat	2400
caatgtatct	tatcatgtct	ggatccgacc	tcggatctgg	aaggtgctga	ggtacgatga	2460
gaccgcgacc	aggtgcagac	cctgcgagtg	tgccggtaaa	catattagga	accagcctgt	2520
gatctggat	gtgaccgagg	agctgaggcc	cgatcacttg	gtgctggcct	gcaccgcgcg	2580
tgagtttggc	tctagcgatg	aagatacaga	ttgaggtact	gaaatgtgtg	ggcggtggctt	2640
aagggtggga	aagaatatat	aagggtgggg	tcttatgtag	ttttgtatct	gttttgacg	2700
agccgcgcgc	gccatgagca	ccaactcggt	tgatggaagc	attgtgagct	catatttgac	2760
aacgcgcgat	cccccatggg	ccggggtgcg	tcagaatgtg	atgggctcca	gcattgatgg	2820
tcgcccgcgc	ctgcccgcga	actctactac	cttgacctac	gagaccgtgt	ctggaacgcc	2880
gttgagagact	gcagcctccg	ccgcgccttc	agccgctgca	gccaccgccc	gcgggattgt	2940
gactgacttt	gctttcctga	gcccgccttg	aagcagtgc	gcttcccgtt	catccgcccg	3000
cgatgacaag	ttgacggctc	ttttggcaca	attggattct	ttgaccgggg	aacttaattgt	3060
cgtttctcag	catctgttgg	atctgcgcca	gcaggtttct	gccctgaagg	cttccctccc	3120
tcccaatgcg	gtttaaaaca	taaataaaaa	accagactct	gtttggattt	ggatcaagca	3180
agtgtcttgc	tgtctttatt	taggggtttt	gcgcgcgcgg	taggcccggg	accagcggtc	3240
tcggtcgttg	agggctcctg	gtattttttc	caggacgtgg	taaagggtgac	tctggatgtt	3300
cagatacatg	ggcataagcc	cgtctctggg	gtggaggtag	caccactgca	gagcttcatg	3360
ctgcgggggtg	gtgttgtaga	tgatccagtc	gtagcaggag	cgctggcggt	ggtgcctaaa	3420
aatgtctttc	agtagcaagc	tgattgccag	gggcaggccc	ttggtgtaag	tgtttacaaa	3480
gcggttaagc	tgggatgggt	gcatacgtgg	ggatattgaga	tgcatcttgg	actgtatttt	3540
taggttggtc	atgttcccag	ccatatccct	ccggggattc	atgttttgca	gaaccaccag	3600
cacagtgtat	ccggtgcact	tgggaaattt	gtcatgtagc	ttagaaggaa	atgcgtggaa	3660
gaacttgag	acgcccttgc	gacctccaag	atcttccatg	cattcgctca	taatgatggc	3720
aatgggcccc	cgggcgcgcg	cctgggcgaa	gatattttctg	ggatcactaa	cgatcatagt	3780
gtgttccagg	atgagatcgt	cataggccat	ttttacaaa	cgcgggcgga	gggtgcgaga	3840
ctgcgggtata	atggttccat	ccggcccagg	ggcgtagtta	ccctcacaga	tttgcatctc	3900
ccacgccttg	agttcagatg	gggggatcat	gtctacctgc	ggggcgatga	agaaaacggt	3960

ttccgggggta	ggggagatca	gctgggaaga	aagcagggttc	ctgagcagct	gcgacttacc	4020
gcagccgggtg	ggcccgtaaa	tcacacctat	taccgggtgc	aactggtagt	taagagagct	4080
gcagctgccg	tcacccctga	gcaggggggc	cacttcgtta	agcatgtccc	tgactcgcag	4140
gttttccctg	accaaataccg	ccagaaggcg	ctcgccgccc	agcgatagca	gttcttgcaa	4200
ggaagcaaa	tttttcaacg	gtttgagacc	gtccgccgta	ggcatgcttt	tgagcgtttg	4260
accaagcagt	tccaggcggt	cccacagctc	gttcacactgc	tctacggcat	ctcgatccag	4320
catatctcct	cgtttcgagg	gttggggcgg	ctttcgctgt	acggcagtag	tcggtgctcg	4380
tccagacggg	ccagggtcat	gtctttccac	gggcgaggg	tcctcgtcag	cgtagtctgg	4440
gtcacgggtga	aggggtgcgc	tccgggctgc	gcgctggcca	gggtgcgctt	gaggctggtc	4500
ctgctgggtgc	tgaagcgctg	ccggtcttcg	ccctgcgctg	cggccaggta	gcatttgacc	4560
atggtgtcat	agtcagccc	ctccgaggcg	tggcccttgg	cgcgagctt	gcccttggag	4620
gaggcgccgc	acgaggggca	gtgcagactt	ttgagggcgt	agagcttggg	cgcgagaaat	4680
accgattccg	gggagtaggc	atccgcgcgc	caggccccgc	agacggtctc	gcattccacg	4740
agccagggtga	gctctggccg	ttcgggggtca	aaaaccagggt	ttccccatg	ctttttgatg	4800
cgtttcttac	ctctggtttc	catgagccgg	tgccacgct	cggtgacgaa	aaggctgtcc	4860
gtgtccccgt	atacagactt	gagaggcctg	tcctcgagcg	gtgttcgctg	gtcctcctcg	4920
tatagaaact	cggaccactc	tgagacaaa	gctcgcgctc	aggccagcac	gaaggagggt	4980
aagtgggagg	ggtagcggtc	gttgtccact	aggggggtcca	ctcgctccag	ggtgtgaaga	5040
cacatgtcgc	ctcttcggc	atcaaggaa	gtgattgggt	tgtaggtgta	ggccacgtga	5100
ccgggtgttc	ctgaaggggg	gctataaaa	gggggtgggg	cgcttcgctc	ctcactctct	5160
tccgcatcgc	tgtctgcgag	ggccagctgt	tgggggtgagt	actccctctg	aaaagcgggc	5220
atgacttctg	cgctaagatt	gtcagtttcc	aaaaacgagg	aggatttgat	attcacctgg	5280
cccgcggtga	tgcttttgag	ggtggccgca	tcctctggtt	cagaaaagac	aatctttttg	5340
ttgtcaagct	tcgagggggg	gcccgttacc	cagcttttgt	tccttttagt	gagggttaat	5400
tgcgcgcttg	gcgtaatcat	ggtcatagct	gtttcctgtg	tgaaattggt	atccgctcac	5460
aattccacac	aacatacgag	ccggaagcat	aaagtgtaaa	gcctgggggtg	cctaagtagt	5520
gagctaactc	acattaattg	cgttgcgctc	actgcccgtc	ttccagtcgg	gaaacctgtc	5580
gtgccagctg	cattaatgaa	tcggccaacg	cgcggggaga	ggcggtttgc	gtattgggag	5640
ctcttcgctg	tcctcgctca	ctgactcgct	gcgctcggtc	gttcggctgc	ggcgagcggt	5700
atcagctcac	tcaaaggcgg	taatacgttt	atccacagaa	tcaggggata	acgcaggaaa	5760
gaacatgtga	gcaaaaggcc	agcaaaaggc	caggaaccgt	aaaaaggccg	cgttgctggc	5820
gtttttccat	aggctccgcc	ccctgacga	gcatacacia	aatcgacgt	caagtacag	5880
ttggcgaaac	ccgacaggac	tataaagata	ccaggcggtt	ccccctggaa	gctccctcgt	5940
gcgctctcct	gttccgaccc	tgcgcttac	cggatacctg	tcgccttttc	tccttcggg	6000
aagcgtggcg	ctttctcata	gctcacgctg	taggtatctc	agttcggtgt	aggtcggtcg	6060
tcceaagctg	ggctgtgtgc	acgaaccccc	cgttcagccc	gaccgctgcg	ccttatccgg	6120
taactatcgt	cttgagtcca	acacgactta	acacgactta	tcgccaactg	cagcagccac	6180
tggtaacagg	attagcagag	cgagggtatgt	aggcggtgct	acagagttct	tgaagtgggtg	6240
gcctaactac	ggctacacta	gaaggacagt	atttggtatc	tgcgctctgc	tgaagccagt	6300
taccttcgga	aaaagagttg	gtagctcttg	atccggcaaa	caaaccaccg	ctggtagcgg	6360
tgggtttttt	gtttgcaagc	agcagattac	gcgcagaaaa	aaaggatctc	aagaagattc	6420
tttgatcttt	tctacggggt	ctgacgctca	gtggaacgaa	aactcacgtt	aagggatttt	6480
ggtcatgaga	ttatcaaaaa	ggatcttcac	ctagatcctt	ttaaattaaa	aatgaagttt	6540
taaataaatc	taaagtatat	atgagtaaac	ttggtctgac	agttaccaat	gcttaatacag	6600
tgaggcacct	atctcagcga	tctgtctatt	tcgttcaccc	atagttgcct	gactccccgt	6660
cgtgtagata	actacgatac	gggagggctt	accatctggc	cccagtgctg	caatgatacc	6720
gcgagaccca	cgctcaccgg	ctccagattt	atcagcaata	aaccagccag	ccggaagggc	6780
cgagcgcaga	agtggctcctg	caactttatc	cgccctccatc	cagtctatta	attggtgccc	6840
ggaagctaga	gtaagtgttt	cgccagttaa	tagtttgccg	aacgttggtg	ccattgctac	6900
aggcatcggtg	gtgtcacgct	cgctggtttg	tatggcttca	ttcagctccg	gttcccaacg	6960
atcaaggcga	gttacatgat	ccccatggt	gtgcaaaaaa	gcggttagct	ccttcgggtcc	7020
tccgatcggt	gtcagaagta	agttggccgc	agtggtatca	ctcatgggtta	tggcagcact	7080
gcataattct	cttactgtca	tgccatccgt	aagatgcttt	tctgtgactg	gtgagtactc	7140
aaccaagtca	ttctgagaat	agtgtatgcg	gcgaccgagt	tgctcttgcc	cggcgctcaat	7200
atcgggataat	accgcgccac	atagcagaac	tttaaaagtg	ctcatcattg	gaaaacgttc	7260
tcggggcgga	aaactctcaa	ggatcttacc	gctgttgaga	tccagttcga	tgtaacccac	7320
tcgtgcaccc	aactgatctt	cagcatcttt	tactttcacc	agcgtttctg	ggtgagcaaa	7380
aacaggaagg	caaaatgccg	caaaaaaggg	aataagggcg	acacggaaat	gttgaaatact	7440
catactcttc	ctttttcaat	attattgaag	catttatcag	ggttattgtc	tcatgagcgg	7500
atacatattt	gaatgtattt	agaaaaataa	acaaataggg	gttccgcgca	catttccccg	7560
aaaagtgcca	cctgacgcgc	cctgtagcgg	cgcatataagc	gcggcggggtg	tgggtggttac	7620
gcgcagcgtg	accgctacac	ttgccagcgc	cctagcgcgc	gctcctttcg	ctttcttccc	7680

-50-

```

ttcttttctc gccacgttcg ccggttttcc cegtcaagct cttaatcggg ggctcccttt 7740
agggttccga tttagtgtt tacggcacct cgaccccaaa aaacttgatt agggatgatg 7800
ttcacgtagt gggccatcgc cctgatagac ggtttttcgc cctttgacgt tggagtccac 7860
gttctttaat agtggactct tgttccaaac tggaacaaca ctcaacccta tctcgggtcta 7920
ttcttttgat ttataaggga ttttgcgatt tcggcctatt ggttaaaaaa tgagctgatt 7980
taacaaaaat ttaacgcgaa ttttaacaaa atattaacgc ttacaatttc cattcgccat 8040
tcaggctgcg caactgttgg gaagggcgat cgggtgcgggc ctcttcgcta ttacgccagc 8100
tgggcgaagg gggatgtgct gcaaggcgat taagttgggt aacgccaggg ttttcccagt 8160
cacgacgttg taaaacgacg gccagtgagc gcgcgtaata cgactcacta tagggcgaat 8220
tggagctcca ccgcggtg

```

<210> 51
 <211> 11
 <212> DNA
 <213> adenovirus

<400> 51
 cgcgatccc g 11

<210> 52
 <211> 26
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 52
 ctgacaaact cagatcttgt ttattg 26

<210> 53
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 53
 gtcgactcta gaggatccag a 21

<210> 54
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 54
 ccggactcta gatggcaacc atggcgctac 30

<210> 55
 <211> 31
 <212> DNA
 <213> Artificial Sequence

-51-

<220>

<223> Description of Artificial Sequence: primer

<400> 55

ggaggggaag cttggccctc agccagcctc t

31

<210> 56

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 56

tgtcttggaat ccaagatgaa gcgcgcccgc cccagcgaag atgacttc

48

<210> 57

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 57

aaacacggcg gccgctcttt cattcttg

28

<210> 58

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 58

cgcgctgact cttaggacta gtttc

25

<210> 59

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 59

gcgcttaatt aacatcatca ataataacc ttatttt

37

<210> 60

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

-52-

<400> 60
tgaagcgcgc aagaccgtct gaag

24

<210> 61
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 61
cataacactg cagattcttt attcttgg

28

<210> 62
<211> 47
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 62
ggtacacagg aaacaggagg ttccggaggt ggaggagaca caactcc

47

<210> 63
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic peptide

<400> 63
Gly Gly Ser Gly Gly Gly
1 5

<210> 64
<211> 7231
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: plasmid

<400> 64
ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg cgagcaaaat ttaagctaca 60
acaaggcaag gcttgaccga caattgcatg aagaatctgc ttagggttag gcgttttgcg 120
ctgcttcgcg atgtacgggc cagatatagc cgttgacatt gattattgac tagttattaa 180
tagtaatcaa ttacggggtc attagttcat agcccatata tggagttccg cgttacataa 240
cttacggtaa atggcccgcc tggctgaccg cccaacgacc ccgcccatt gacgtcaata 300
atgacgtatg ttcccatagt aacgccaata gggactttcc attgacgtca atgggtggac 360
tatttacggt aaactgcca cttggcagta catcaagtgt atcatatgcc aagtagcccc 420
cctattgacg tcaatgacgg taaatggccc gcctggcatt atgcccagta catgacctta 480
tgggactttc ctacttggca gtacatctac gtattagtca tcgctattac catggtgatg 540
cggttttggc agtacatcaa tgggcgtgga tagcggtttg actcacgggg atttccaagt 600
ctccaccca ttgacgtcaa tgggagtttg ttttggcacc aaaatcaacg ggactttcca 660
aaatgtcgtg acaactccgc cccattgacg caaatgggag gtaggcgtgt acggtgggag 720

gtctatataa	gcagagctct	ctggctaact	agagaaccca	ctgcttactg	gcttatcgaa	780
attaatacga	ctcactatag	ggagacccaa	gctggctagc	gtttaaactt	aagcttggtg	840
ccgagctcgg	atccactctc	ttccgcatcg	ctgtctgcga	gggccagctg	ttgggggtgag	900
tactccctct	gaaaagcggg	catgaactct	gcgctaagat	tgtcagtttc	caaaaacgag	960
gaggatttga	tattcacctg	gcccgcgggtg	atgcctttga	gggtggccgc	atccatctgg	1020
tcagaaaaga	caatcttttt	gttgtaagc	ttggtggcaa	acgacccgta	gagggcgttg	1080
gacagcaact	tggcgatgga	gcgcaggggtt	tggtttttgt	cgcgatcggc	gcgctccttg	1140
gccgcgatgt	ttagctgcac	gtattcgcgc	gcaacgcacc	gccattcggg	aaagacgggtg	1200
gtgcgctcgt	cgggcaccag	gtgcacgcgc	caaccgcggt	tgtgcagggg	gacaagggtca	1260
acgctgggtg	ctacctctcc	gcgtaggcgc	tcgttggtcc	agcagaggcg	gccgcccttg	1320
cgcgagcaga	atggcggtag	ggggcttagc	tgctctcgt	ccgggggggtc	tgcgctccacg	1380
gtaaagaccc	cgggcagcag	gcgcgcgtcg	aagtagtcta	tcttgcatcc	ttgcaagtct	1440
agcgcctgct	gccatgcgcg	ggcggcaagc	gcgcgctcgt	atgggttgag	ttgggggaccc	1500
catggcatgg	ggtgggtgag	cgcgaggcgc	tacatgccgc	aaatgtcgta	aacgtagagg	1560
ggctctctga	gtattccaag	atatgtaggc	tgcatcttc	caccgcggat	gctggcgcg	1620
acgtaatcgt	atagttcgtg	cgagggagcg	aggaggtcgg	gaccgaggtt	gctacgggcg	1680
ggctgctctg	ctcggaagac	tatctgcctg	aagatggcat	gtgagttgga	tgatatggtt	1740
ggacgctgga	agacgttgaa	gctggcgctc	gtgagaccta	ccgcgtcacg	cacgaaggag	1800
gcgtaggagt	cgcgcagctt	gttgaccagc	ctggcgggtg	cctgcacgtc	tagggccttg	1860
tagtccaggg	tttcttgat	gatgtcatac	ttatcctgtc	cctttttttt	ccacagctcg	1920
cggttgagga	caaactcttc	gcggctcttc	cagtaactct	ggatcggaaa	cccgtcggcc	1980
tccgaacgag	atccgtactc	cgccgcgcgag	ggacctgagc	gagtcgcgat	cgaccgggac	2040
ggaaaacctc	tcgagaaaag	cgtctaacca	gtcacagtcg	caagatccaa	gatgaagcgc	2100
gccgcgccca	gcgaagatga	cttcaacccc	gtctacccct	atggctacgc	gcggaatcag	2160
aatatccccc	tcctcactcc	cccccttgct	tcctccgatg	gattcaaaaa	cttccccctt	2220
ggggtaactg	cactcaaaact	ggctgatcca	atcaccatta	ccaatgggga	tgtatccctc	2280
aaggtgggag	gtggtctcac	tttgcaagat	ggaagccata	ctgtaaaccc	taaggctcca	2340
ctgcaagtta	atactgataa	aaaacttgag	cttgcatatg	ataatccatt	tgaaaagtgt	2400
gctaataaac	ttagtttaaa	agtaggacat	ggattaaaaa	tattagatga	aaaaagtgtt	2460
gcgggggttaa	aagatttaat	tggaacaaact	gtgggtttta	caggaaaagg	aataggcact	2520
gaaaatttag	aaaatacaga	tggtagcagc	agaggaattg	gtataaatgt	aagagcaaga	2580
gaagggttga	catttgacaa	tgatggatac	ttggtagcat	ggaacccaaa	gtatgacacg	2640
cgcacacttt	ggacaacacc	agacacatct	ccaaactgca	caattgctca	agataaggag	2700
tctaaactca	ctttggtact	tacaaagtgt	ggaagtcaaa	tattagctaa	tgtgtctttg	2760
attgtggctg	caggaaagta	ccacatcata	aataataaga	caaatccaaa	ataaaaaagt	2820
tttactatta	aactgctatt	taataagaac	ggagtgtttt	tagacaactc	aaatcttgga	2880
aaagcttatt	gaagctttag	aagtggaat	tccaatgttt	cgacagctta	tgaaaaagca	2940
attgggttta	tgccctaatt	ggtagcgtat	ccaaaaccca	gtaattctaa	aaaatatgca	3000
agagacatag	tttatggaac	tatatatctt	ggtaggaac	ctgatcagcc	agcagtcatt	3060
aaaactacct	ttaaccaaga	aactggatgt	gaataactta	tcacatttaa	cttttagttg	3120
tccaaaacct	atgaaaatgt	tgaatttgaa	accacctctt	ttacctcttc	ctatatggcc	3180
caagaatgaa	agagcggcgc	ctcgagtcta	gagggcccg	ttaaaccgcg	tgatcagcct	3240
cgactgtgcc	ttctagttgc	cagccatctg	ttgtttgccc	ctcccccg	ccttccttga	3300
ccctggaagg	tgccactccc	actgtccttt	cctaataaaa	tgaggaaatt	gcatacgcat	3360
gtctgagtag	gtgtcattct	attctggggg	gtgggggtgg	gcaggacagc	aagggggagg	3420
attgggaaga	caatagcagg	catgctggg	atgcgggtgg	ctctatggct	tctgagccgg	3480
aaagaaccag	ctggggctct	agggggtatc	cccacgcgcc	ctgtagcggc	gcattaagcg	3540
cggcgggtgt	ggtggttacg	cgcagcgtga	ccgctacact	tgccagcgcc	ctagcgcccc	3600
ctcctttcgc	tttcttccct	tcctttctcg	ccacgttcgc	cggtttcccc	cgtaacagtc	3660
taaactcggg	catcccttta	gggttccgat	ttagtgtttt	acggcacctc	gaccccaaaa	3720
aacttgatta	gggtgatggt	tcacgtagt	ggccatcgcc	ctgatagacg	gtttttcgcc	3780
ctttgacgtt	ggagtccacg	ttctttaata	gtggactctt	gttccaaact	ggaacaacac	3840
tcaaccctat	ctcggctctat	tcttttgatt	tataagggat	tttggggatt	tcggccctatt	3900
ggttaaaaaa	tgagctgatt	taacaaaaat	ttaacgcgaa	ttattctgt	ggaatgtgtg	3960
tcagttaggg	tgtggaaagt	ccccaggctc	ccaggcgagg	cagaagtatg	caaagcatgc	4020
atctcaatta	gtcagcaacc	aggtgtggaa	agtcgccagg	ctccccagca	ggcagaagta	4080
tgcaaaagcat	gcatctcaat	tagtcagcaa	ccatagtcct	gcccctaact	ccgcccattc	4140
cgccccctaac	tcgccccagt	tcgcgccatt	ctccgcccc	tggtgacta	atTTTTTTT	4200
tttatgcaga	ggccgaggcc	gcctctgcct	ctgagctatt	ccagaagttag	tgaggaggct	4260
tttttgagg	cctaggcttt	tgcaaaaagc	tcgggggagc	ttgtatatcc	atTTTcggt	4320
ctgatcagca	cgtgttgaca	attaatcatc	ggcatagtat	atcggcatag	tataatacga	4380
caaggtgagg	aactaaacca	tggccaagtt	gaccagtgcc	gttccgggtc	tcaccgcgcg	4440

-54-

```

cgacgtcgcc ggagcgggac agttctggac cgaccgggtc ggggtctccc gggacttcgt 4500
ggaggacgac ttccgcggtg tggctcggga cgacgtgacc ctgttcacga gcgcgggtcca 4560
ggaccagggtg gtgcccggaca acacctgggc ctgggtgtgg gtgcgcggcc tggacgagct 4620
gtacgcccag tggctggagg tcgtgtccac gaacttccgg gacgcctccg ggcgggcat 4680
gaccgagatc ggcgagcagc cgtgggggcg ggagttcgcc ctgcgcgacc cggccggcaa 4740
ctgcgtgcac ttctgtggcg agggagcagga ctgacacgtg ctacgagatt tcgattccac 4800
cgccgccttc tatgaaaggt tgggcttcgg aatcggtttc cgggacgccg gctggatgat 4860
cctccagcgc ggggatctca tgctggagtt ctctgcccac cccaacttgt ttattgcagc 4920
ttataatggt tacaaataaa gcaatagcat cacaaatttc acaaataaag catttttttc 4980
actgcattct agttgtggtt tgtccaaact catcaatgta tcttatcatg tctgtatacc 5040
gtcgacctct agctagagct tggcgtaatc agccggaagc ataaagtgtg aagcctgggg 5100
ttatccgctc acaattccac tgcattaatg aatcggtccg tcaactgccg ctttccagtc 5220
tgccaatga gtgagctaac tgcattaatg aatcggtccg cgcgcgggga gaggcgggtt 5280
gggaaacctg tcgtgccagc cttcctcgct cactgactcg ctgcgctcgg tcgttcgggt 5340
gcgtattggg cgtctctccg actcaaaggc gagcaaaagg ccagcaaaag gccaggaaac gtaaaaaggc 5400
gcggcgagcg gtatcagctc gagcaaaagg cccccctgac gagcatcaca aaaatcgagc 5460
taacgcagga aagaacatgt ataggtccg acccgacagg actataaaga taccaggcgt tccccctgg 5520
cgctgtgctg gcgtttttcc cttcctcgct ctgttccgac cctgccgctt acccgatacc tgccgcctt 5580
ctcaagtcag aggtggcgaa cgttccgctc atgctcacgc tgtaggtatc tcaagtcggt 5640
aagctccctc gtgcgctctc ctgttccgac gacgaacccc cccgttcagc gcgacgctg 5700
tctcccttcg ggaagcgtgg cgcttctca atgctcacgc cccgttcagc gcgacgctg 5760
gtaggtcggt cgctccaagc gctcttagtc caaccgggtg agacacgact tatcgccact 5820
cgcttatcc ggtaactatc ggattagcag agcgagggtat gtaggcggtg ctacagagtt 5880
ggcagcagcc actggttaaca acggctacac tagaaggaca gtatttggtg tctgcgctct 5940
cttgaagtgg tggcctaact gaaaaagagt tggtagctct tgatccggca aacaaaccac 6000
gctgaagcca gttaccttcg ttgtttgcaa gcagcagatt acgcgcagaa aaaaaggatc 6060
cgctggtagc ggtggttttt tttctacggg gtctgacgct cagtggaaagc aaactcacg 6120
tcaagaagat cctttgatct tttatcaaaa acctagatcc ttttaaatga 6180
ttaagggtatt ttggtcatga gattatcaaa atatgagtaa acttggtctg acagttacca 6240
aaaatgaagt tttaaatcaa tctaaagtat gatctgtcta tttcgttcat ccatagttgc 6300
atgcttaatc agtgaggcac ctatctcagc gatctgtcta tttcgttcat ccatagttgc 6360
ctgactcccc gtctgttaga taactacgat acgggagggc ttaccatctg gcccagtg 6420
tgcaatgata ccgcgagacc cagctcacc ggtccagat ttatcagcaa taaaccagcc 6480
agccggaagg gccgagcgca gaagtgggtc tgcaacttta tccgctcca tccagttat 6540
taattgttgc cgggaagcta gagtaagtag ttcgccagtt aatagtttgc gcaacggtgt 6600
tgcaattgct acaggcatcg tgggtgtcag ctcgtcggtt ggtatggctt cattcagctc 6660
cggttcccaa cgatcaaggc gagttacatg atccccatg ttgtgcaaaa aagcggttag 6720
ctccttcggt cctccgatcg ttgtcagaag taagttggcc gcagtggtat cactcatggt 6780
tatggcagca ctgcataatt ctcttactgt catgccatcc gtaagatgct tttctgtgac 6840
tggtgagtag tcaaccaagt cattctgaga atagtgtag cggcgaccga gttgctcttg 6900
cccgcgctca atacgggata ataccgcgcc acatagcaga actttaaaag tgctcatcat 6960
tgaaaaacgt tcttcggggc gaaaactctc aaggatctta ccgctgttga gatccagttc 7020
gatgtaaccc actcgtgcac ccaactgatc ttcagcatct tttactttca ccagcgtttc 7080
tggtgagca aaaacaggaa ggcaaaatgc cgcaaaaag ggaataaggg cgacacggaa 7140
atgttgaata ctcatactct tcctttttca atattattga agcatttatc aggggtattg 7200
tctcatgagc ggatacatat ttgaatgtat ttagaaaaat aaacaaatag gggttccgcg 7231
cacatttccc cgaaaagtgc cacctgacgt c

```

<210> 65

<211> 8484

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 65

```

ctgctccctg cttgtgtggt ggaggtcgct gtagtagtgc cgagcaaaat ttaagctaca 60
acaaggcaag gcttgaccga caattgcatg aagaatctgc ttagggtag gcgttttgcg 120
ctgcttcgcg atgtacgggc cagatatagc cgttgacatt gattattgac tagttattaa 180
tagtaataca ttacgggggc attagttcat agcccatata tggagttccg cgttacataa 240

```

cttacggtaa	atggcccgcc	tggctgaccg	cccaacgacc	cccgcgccatt	gacgtcaata	300
atgacgtatg	ttcccatagt	aacgccaaata	gggactttcc	attgacgtca	atgggtggac	360
tattttacggt	aaactgccc	cttggcagta	catcaagtgt	atcatatgcc	aagtacgcc	420
cctattgacg	tcaatgacgg	taaattggccc	gcctggcatt	atgccagta	catgacctta	480
tgggactttc	ctacttggca	gtacatctac	gtattagtca	tcgctattac	catggtgatg	540
cggttttggc	agtacatcaa	tgggcgtgga	tagcggtttg	actcacgggg	atttccaagt	600
ctccacccca	ttgacgtcaa	tgggagtttg	ttttggcacc	aaaatcaacg	ggactttcca	660
aaatgtcgta	acaactccgc	cccatgacg	caaattggcg	gtaggcgtgt	acggtgggag	720
gtctatataa	gcagagctct	ctggctaact	agagaaccca	ctgcttactg	gcttatcgaa	780
attaatacga	ctcactatag	ggagacccaa	gctggctagc	gtttaaactt	aagcttggtg	840
ccgagctcgg	atccactctc	ttccgcatcg	ctgtctgcga	gggccagctg	ttggggtgag	900
tactccctct	gaaaagcggg	catgacttct	gcgctaagat	tgtagtttc	caaaaacgag	960
gaggatttga	tattcacctg	gcccgcggtg	atgcctttga	gggtggccgc	atccatctgg	1020
tcagaaaaga	caatcttttt	gtttgtcaagc	ttggtggcaa	acgacccgta	gagggcggtg	1080
gacagcaact	tggcgatgga	gcgcagggtt	tggtttttgt	cgcgatcggc	gcgctccttg	1140
gcccgcgtgt	ttagctgcac	gtattcgcgc	gcaacgcacc	gccattcggg	aaagacggtg	1200
gtgcgctcgt	cgggcaccag	gtgcacgcgc	caaccgcggt	tgtgcagggt	gacaagggtca	1260
acgctggtgg	ctacctctcc	gcgtaggcgc	tcggttggtcc	agcagaggcg	gccgcccttg	1320
cgcgagcaga	atggcggtag	ggggtctagc	tgcgtctcgt	ccgggggggtc	tgcgtccacg	1380
gtaaagaccc	cgggcagcag	gcgcgcgtcg	aagttagtcta	tcttgcatcc	ttgcaagtct	1440
agccgctgct	gccatgcgcg	ggcggcaagc	gcgcgctcgt	atgggttgag	tgggggaccc	1500
catggcatgg	ggtgggtgag	cgcgaggcg	tacatgccgc	aaatgtcgta	aacgtagagg	1560
ggctctctga	gtattccaag	atatgtaggg	tagcatcttc	caccgcggat	gctggcgcg	1620
acgtaatcgt	atagttcgtg	cgagggagcg	aggaggtcgg	gaccgaggtt	gctacgggcg	1680
ggctgctctg	ctcggaagac	tatctgcctg	aagatggcat	gtgagttgga	tgatatggtt	1740
ggacgctgga	agacgttgaa	gctggcgtct	gtgagacctt	ccgcgtcacg	cacgaaggag	1800
gcgtaggagt	cgcgacgctt	gttgaccagc	tcggcggtga	cctgcacgtc	tagggcgag	1860
tagtccaggg	tttcttctgt	gatgtcatat	ttatctctgc	cctttttttt	ccacagctcg	1920
cggttgagga	caaactcttc	gcggtctttc	cgactactct	ggatcgga	cccgctggcc	1980
tcggaacgag	atccgtactc	gcgcgcgag	ggacctgagc	gagtcgcgat	cgaccggatc	2040
ggaaaacctc	tcgagaaagg	cgtctaacca	gtcacagtcg	caagatccaa	gatgaagcgc	2100
gcaagaccgt	ctgaagatac	cttcaacccc	gtgtatccat	atgacacgga	aaccgggtcct	2160
ccaactgtgc	cttttcttac	tctccctttt	atgccccca	atgggtttca	agagagtcct	2220
cctgggggtac	tctctttgcg	tactctcgaa	cctctagtta	cctccaatgg	catgcttgcg	2280
ctcaaaatgg	gcaacggcct	ctctctggac	gaggccggca	accttacctc	ccaaaatgta	2340
accactgtga	gcccacctct	caaaaaaacc	aagtcaaa	taaaacctgga	aatatctgca	2400
ccccctcacg	ttacctcaga	agccctaact	gtggctgccg	ccgcacctct	aatggtcgag	2460
ggcaacacac	tcaccatgca	atcacaggcc	ccgctaaaccg	tgcacgactc	caaaacttagc	2520
attgccaccc	aaggaccctt	cacagtgtca	gaaggaaagc	tagccctgca	aacatcaggc	2580
ccccctacca	ccaccgatag	cagtaccctt	actatactg	cctcaccccc	tctaactact	2640
gccactggta	gcttgggcat	tgacttgaaa	gagccattt	atacaca	tggaaaacta	2700
ggactaaagt	acggggctcc	tttgcatgta	acagacgacc	taaacacttt	gaccgtagca	2760
actgggtccag	gtgtgactat	taataatact	tccttgcaaa	ctaaagtta	tggagccttg	2820
ggttttgatt	cacaaggcaa	tatgcaactt	aatgtagcag	gaggactaag	gattgattct	2880
caaaacagac	gccttatact	tgatgttagt	tatccgtttg	atgctcaaaa	ccaactaaat	2940
ctaagactag	gacagggccc	tctttttata	aactcagccc	acaacttgga	tattaactac	3000
aacaaaggcc	tttacttggt	tacagcttca	aacaattcca	aaaagcttga	ggttaacctt	3060
agcactgcca	aggggtgat	gtttgacgct	acagccatag	ccattaatgc	aggagatggg	3120
cttgaatttg	gttcacctaa	tgcaccaa	acaaatcccc	tcaaaacaaa	aattggccat	3180
ggcctagaat	ttgattcaaa	caaggctatg	gttccctaa	taggaactgg	ccttagtttt	3240
gacagcacag	gtgccattac	agtagga	aaaaataatg	ataagcta	tttgtggacc	3300
acacagctc	catctcctaa	ctgtagacta	aatgcagaga	aagatgctaa	actcactttg	3360
gtcttaacaa	aatgtggcag	tcaaatactt	gctacagttt	cagttttggc	tgtaaaggc	3420
agtttggtct	caatatctgg	aacagttcaa	agtgtcatc	ttattataag	atttgacgaa	3480
aatggagtgc	tactaaacaa	ttccttctctg	gacccagaat	attggaactt	tagaaatgga	3540
gatcttactg	aaggcacagc	ctatacaaac	gctgttggtt	ttatgcctaa	cctatcagct	3600
tatccaaaat	ctcacggtaa	aactgccaaa	agtaacattg	tcagtcaagt	ttacttaaac	3660
ggagacaaaa	ctaaacctgt	aacactaacc	attacactaa	acggtacaca	ggaaacagga	3720
gacacaactc	caagtgcata	ctctatgtca	ttttcatggg	actggtctgg	ccacaactac	3780
attaatgaaa	tatttgccac	atcctcttac	cctttttcat	acattgcccc	agaataaaa	3840
aagcggccgc	tcgagtctag	cgataatcaa	actctggatt	acaaaatttg	tgaaagattg	3900
actggtattc	ttaactatgt	tgctcctttt	acgctatgtg	gatacgctgc	tttaatgcct	3960

ttgtatcatg	ctattgcttc	ccgtatggct	ttcattttct	cctccttgta	taaactcctgg	4020
ttgctgtctc	tttatgagga	gttgtggccc	gttgtcaggc	aacgtggcgt	ggtgtgcaact	4080
gtgtttgctg	acgcaacccc	cactgggttg	ggcattgcca	ccacctgtca	gctcctttcc	4140
gggactttcg	ctttccccc	ccctattgcc	acggcggaac	tcacgcgcgc	ctgccttgcc	4200
cgctgctgga	caggggctcg	gctgttgggc	actgacaatt	ccgtggtgtt	gtcggggaag	4260
ctgacgtcct	ttccatggct	gctcgccgtg	gttgccacct	ggattctgcg	cgggacgtcc	4320
ttctgctacg	tccttccggc	cctcaatcca	gcggaccttc	cttcccgcgg	cctgctgccg	4380
gctctgcggc	ctcttcgcgc	tcttcgcctt	cgccctcaga	cgagtccgat	ctccctttgg	4440
gccgcctccc	cgccctgatcg	ctagaggggc	cgtttaaacc	cgctgatcag	cctcgactgt	4500
gccttctagt	tgccagccat	ctgttgtttg	ccccccccc	gtgccttcc	tgacctgga	4560
aggtgccact	cccactgtcc	tttcttaata	aaatgaggaa	attgcatcgc	attgtctgag	4620
taggtgtcat	tctattctgg	ggggtggggg	ggggcaggac	agcaaggggg	aggattggga	4680
agacaataga	aggcatgtcg	gggatgcggg	gggctctatg	gcttctgagg	cggaaagaac	4740
cagctggggc	tctagggggg	atccccacgc	gccctgtagc	ggcgcattaa	gcgcggcggg	4800
tgtggtggtt	acgcgcagcg	tgaccgctac	acttgccagc	gccctagcgc	ccgctccttt	4860
cgctttcttc	ccttctcttc	tcgccaagtt	cgccgctttt	ccccgtcaag	ctctaaactg	4920
gggcatccct	ttagggttcc	gatttagtgc	tttacggcac	ctcgacccca	aaaaacttga	4980
ttagggtgat	ggttcacgta	gtgggccatc	gccctgatag	acggtttttc	gccctttgac	5040
gttgaggtcc	acgttcttta	atagtggaact	cttggttcaa	actggaacaa	cactcaaccc	5100
tatctcggtc	tattcttttg	atttataagg	gattttgggg	atttcggcct	attggtgga	5160
aaatgactcg	atttaacaaa	aatttaacgc	gaattaattc	tgtggaatgt	gtgtcagtta	5220
gggtgtggaa	agtccccagg	ctccccaggc	aggcagaagt	atgcaaagca	tgcatctcaa	5280
ttagtacgca	accaggtgtg	gaaagtcccc	aggctcccca	gcaggcagaa	gtatgcaaag	5340
catgcatctc	aattagtcag	caaccatagt	cccgcacctc	actccgccca	tcccgccctc	5400
aactccgcgc	agttccgcgc	attctccgc	ccatggctga	ctaatttttt	ttatttatgc	5460
agaggccgag	gccgcctctg	cctctgagct	attccagaag	tagtgaggag	gcttttttgg	5520
aggcctaggg	ttttgcaaaa	agctccccgg	agcttgtata	tccatttttc	gatctgatca	5580
gcacgtgttg	acaattaatc	atcggcatag	tatatcgcca	tagtataata	cgacaaggtg	5640
aggaactaaa	ccatggccaa	gttgaccagt	gccgttccgg	tgctcaccgc	gcgcgacgtc	5700
gccggagcgg	tcgagttctg	gaccgaccgg	ctcgggttct	cccgggactt	cgtaggaggc	5760
gacttcgcgc	gtgtggtccg	ggacgacgtg	accctgttca	tcagcgcggg	ccaggaccag	5820
gtggtgcgcg	acaacaccct	ggcctgggtg	tgggtgcgcg	gcctggacga	gctgtacgcc	5880
gagtgtcgcg	aggctcgtgc	cacgaacttc	cgggacgcct	ccgggcccgc	catgaccgag	5940
atcggcgagc	agccgtgggg	gcgggagttc	gcctgcgcgc	acccggcccg	caactgcgtg	6000
cacttcgtgg	ccgaggagca	ggactgacac	gtgctacgag	atttcgatcc	caccgcccgc	6060
ttctatgaaa	ggttgggctt	cggaatcggt	ttccgggacg	ccggttggtg	gatctccag	6120
cgcggggata	tcattgctga	gttcttcgcc	caccccaact	tgtttattgc	agcttataat	6180
ggttacaaat	aaagcaatag	catcacaat	ttcacaata	aagcattttt	ttcactgcat	6240
tctagtgtg	gtttgtccaa	actcatcaat	gtatcttatc	atgtctgtat	accgtcgacc	6300
ttcagctaga	gcttggcgta	atcatggtca	tagctgtttc	ctgtgtgaaa	ttgttatccg	6360
ctcaacaatt	cacacaacat	acgagccgga	agcataaagt	gtaaagcctg	gggtgcctaa	6420
tgagtgcgct	aactcacatt	aattgcgttg	cgctcactgc	ccgctttcca	gtcgggaaac	6480
ctgtcgtgcc	agctgcatta	atgaatcggc	caacgcgcgc	ggagaggcgc	tttgcgtatt	6540
gggcgctctt	ccgcttcttc	gctcactgac	tcgctgcgct	cggctcgttc	gctgcggcga	6600
gcggtatcag	ctcactcaaa	ggcggttaata	cggttatcca	cagaatcagg	ggataacgca	6660
ggaaagaaca	tgtgagcaaa	aggccagcaa	aaggccagga	accgtaaaaa	ggccgcgttg	6720
ctggcgtttt	tccataggct	ccgccccccc	gacgagcatc	acaaaaatcg	acgctcaagt	6780
cagagggtgg	gaaacccgac	aggactataa	agataccagg	cgtttccccc	tggaagctcc	6840
ctcgtgcgct	ctcctgttcc	gacctgcgc	cttacgggat	acctgtccgc	ctttctccct	6900
tcgggaagcg	tggcgctttc	tcaatgctca	cgctgtaggt	atctcagttc	ggtgtaggtc	6960
gttcgctcca	agctgggctg	tgtgcacgaa	ccccccgttc	agccccgacc	ctgcgcctta	7020
tccggttaact	atcgtcttga	gtccaaccgc	gtaagacacg	acttatcgcc	actggcagca	7080
gccactggta	acaggattag	cagagcagg	tatgtaggcg	gtgctacaga	gttcttgaag	7140
tggtggccta	actacggcta	cactagaagg	acagtatttg	gtatctgcgc	tctgctgaag	7200
ccagttacct	tcggaaaaag	agttggtagc	tcttgatccg	gcaaacaaac	caccgctggt	7260
agcgggtggt	tttttgtttg	caagcagcag	attacgcgca	gaaaaaaagg	atctcaagaa	7320
gatcctttga	tcttttctac	ggggtctgac	gctcagtgga	acgaaaactc	acgttaaggg	7380
atthttggtc	tgagattatc	aaaaaggatc	ttcacctaga	tcctttttaa	ttaaaaatga	7440
agttttaaat	caatctaaag	tatatatgag	taaacttggt	ctgacagtta	ccaatgctta	7500
atcagtgcgg	cacctatctc	agcgatctgt	ctatttcggt	catccatagt	tgctgactc	7560
cccgtcgtgt	agataactac	gatacgggag	ggcttaccat	ctggccccag	tgctgcaatg	7620
ataccgcgag	accacgcctc	accggctcca	gatttatcag	caataaacca	gccagccgga	7680

-57-

```

agggccgagc gcagaagtgg tcctgcaact ttatccgcct ccatccagtc tattaattgt 7740
tgccgggaag ctagagtaag tagttcgcca gttaatatgt tgcgcaacgt tgttgccatt 7800
gctacaggca tcgtggtgtc acgctcgctg ttgggtatgg cttcattcag ctccggttcc 7860
caacgatcaa ggcgagttac atgatcccc atgttggtgca aaaaagcggg tagtccttc 7920
ggtcctccga tcgttggtcag aagtaagttg gccgcagtg taccactcat ggttatggca 7980
gcactgcata attctcttac tgtcatgcca tccgtaagat gcttttctgt gactggtgag 8040
tactcaacca agtcattctg agaatagtg atgcggcgac cgagttgctc ttgcccggcg 8100
tcaatacggg ataataccgc gccacatagc agaactttaa aagtgtcat cattggaaaa 8160
cgttcttcgg ggcgaaaact ctcaaggatc ttaccgctgt tgagatccag ttcatgtaa 8220
cccactcggt cacccaactg atcttcagca tcttttactt tcaccagcgt ttctgggtga 8280
gcaaaaacag gaaggcaaaa tgccgcaaaa aagggaataa gggcgacacg gaaatgttga 8340
atactcatat tcttcctttt tcaatattat tgaagcattt atcagggtta ttgtctcatg 8400
agcggataca tatttgaatg tatttagaaa aataaaciaa taggggttcc gcgcacattt 8460
ccccgaaaag tgccacctga cgtc                                     8484

```

<210> 66
 <211> 53
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 66
 gtcactcgag gactcggctg actgaaaatg agacatatta tctgccacgg acc 53

<210> 67
 <211> 36
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 67
 cgagatcgat cacctccggt acaagggttg gcatag 36

<210> 68
 <211> 37
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 68
 catgaagatc tggaaggtgc tgaggtacga tgagacc 37

<210> 69
 <211> 51
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer

<400> 69
 gcgacttaag cagtcagctg agacagcaag acacttgctt gatccaaatc c 51

-58-

<210> 70
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 70
cacgaattcg tcagcgcttc tcgtcgcgtc caagaccc 38

<210> 71
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 71
caccgccggg aggcggcggc gacggggacg gg 32

<210> 72
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: oligonucleotide

<400> 72
atgggatcca agatgaagcg cgcaagaccg 30

<210> 73
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: oligonucleotide

<400> 73
cataacctgc aggattcttt attcttgggc 30

<210> 74
<211> 47
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: oligonucleotide

<400> 74
ggtacacagg aaacaggagg ttccggaggt ggaggagaca caactcc 47

<210> 75

-59-

<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 75
atgggatcca agatgaagcg cgcaagaccg

30

<210> 76
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 76
cactatagcg gccgcattct cagtcattct

30

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 00/00265

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/85 C07K14/075 C12N5/10 C12N15/34 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 13499 A (CIBA GEIGY AG ;SCRIPPS RESEARCH INST (US); MEMEROW GLEN R (US); VO) 2 April 1998 (1998-04-02) the whole document	1-6, 9-14, 21-24, 38, 39, 46, 47, 49-52, 59
X	WO 97 37220 A (CHUGAI BIOPHARMACEUTICALS INC) 9 October 1997 (1997-10-09) page 44-49 -/-	10

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

22 May 2000

Date of mailing of the international search report

06/06/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Mateo Rosell, A.M.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 00/00265

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 17783 A (UNIV MICHIGAN) 30 April 1998 (1998-04-30) page 16, line 14 -page 21, line 14; examples 1-8	1-5, 11, 24, 30, 36, 72, 76-78, 90-93
A	WO 95 00655 A (UNIV MCMASTER) 5 January 1995 (1995-01-05) cited in the application examples 1-3	24-26
X	STEVENSON S C ET AL: "Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein" JOURNAL OF VIROLOGY, US, THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 71, no. 6, June 1997 (1997-06), pages 4782-4790, XP002121965 ISSN: 0022-538X the whole document	7, 8
X	VON SEGGERN DAN J ET AL., : "Complementation of a fibre mutant adenovirus by packaging cell lines stably expressing the adenovirus type 5 fibre protein" JOURNAL OF GENERAL VIROLOGY, vol. 79, June 1998 (1998-06), page 1461-1468 XP002138278 cited in the application the whole document	1-4, 6, 11-13, 15, 20-24, 31, 38-53, 59-63, 65-75
X	WO 96 39530 A (UNIV PENNSYLVANIA ; WILSON JAMES M (US); FISHER KRISHNA J (US); GAO) 12 December 1996 (1996-12-12) page 3, line 21 -page 5, line 9 examples 1, 5-7, 9, 14, 17, 18, 20 page 73-101	1, 11, 34, 36
X	VON SEGGERN DAN ET AL., : "An adenoviral gene therapy vector deleted for E1, E3 and fiber: Structure and infectivity of fiberless particles" CANCER GENE THERAPY, vol. 5, no. 6, December 1998 (1998-12), page s14 XP000909076 abstract: P-39D	24-26, 31-33, 36, 40-45, 50-58, 60-63, 65-78

-/--

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 00/00265

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HARDY S ET AL: "CONSTRUCTION OF ADENOVIRUS VECTORS THROUGH CRE-LOX RECOMBINATION" JOURNAL OF VIROLOGY, US, THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 71, no. 3, 1 March 1997 (1997-03-01), pages 1842-1849, XP000670223 ISSN: 0022-538X the whole document	76-85
X	FALGOUT B AND KETNER G: "Characterization of adenovirus particles made by deletion mutants lacking the fiber gene " JOURNAL OF VIROLOGY, vol. 62, XP000909209 the whole document	31, 38, 42, 44
A	STEVENSON S C ET AL: "HUMAN ADENOVIRUS SEROTYPES 3 AND 5 BIND TO TWO DIFFERENT CELLULAR RECEPTORS VIA THE FIBER HEAD DOMAIN" JOURNAL OF VIROLOGY, US, THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 69, no. 5, May 1995 (1995-05), pages 2850-2857, XP002911347 ISSN: 0022-538X the whole document	6-8, 16, 17
A	PARKS R J ET AL: "A HELPER-DEPENDENT ADENOVIRUS VECTOR SYSTEM: REMOVAL OF HELPER VIRUS BY CRE-MEDIATED EXCISION OF THE VIRAL PACKAGING SIGNAL" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, US, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 93, no. 24, 26 November 1996 (1996-11-26), pages 13565-13570, XP000617948 ISSN: 0027-8424 the whole document	80-82
P, X	ZUFFEREY R ET AL.: "Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors" JOURNAL OF VIROLOGY, vol. 73, no. 4, April 1999 (1999-04), pages 2886-2892, XP000906913 cited in the application abstract	9, 10
P, X	EP 0 892 047 A (HOECHST MARION ROUSSEL DE GMBH) 20 January 1999 (1999-01-20) SEQ.ID.N.36	10
	-/--	

INTERNATIONAL SEARCH REPORT

In International Application No
PCT/EP 00/00265

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	VON SEGGERN DAN J ET AL., : " A helper-independent adenovirus vector with E1, E3, and fiber deleted: Structure and infectivity of fiberless particles." JOURNAL OF VIROLOGY, vol. 73, no. 2, February 1999 (1999-02), pages 1601-1608, XP000906914 cited in the application the whole document	1-53, 59-75
T	VON SEGGERN DAN J ET AL., : "Adenovirus vector pseudotyping in fiber-expressing cell lines: Improved transduction of Epstein-Barr virus-transformed B cells." JOURNAL OF VIROLOGY, vol. 74, no. 1, January 2000 (2000-01), page 354-362 XP000906911 the whole document	1,9-13, 16-19, 25-29, 50-75,90

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 00/00265

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 56-58 and 72
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/00265

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9813499 A	02-04-1998	AU 4624197 A EP 0937150 A	17-04-1998 25-08-1999
WO 9737220 A	09-10-1997	US 5866341 A AU 717289 B AU 2661997 A EP 0801307 A	02-02-1999 23-03-2000 22-10-1997 15-10-1997
WO 9817783 A	30-04-1998	US 5994132 A AU 5152998 A EP 0935648 A	30-11-1999 15-05-1998 18-08-1999
WO 9500655 A	05-01-1995	AU 687829 B AU 7118494 A CA 2166118 A EP 0705344 A US 5919676 A	05-03-1998 17-01-1995 05-01-1995 10-04-1996 06-07-1999
WO 9639530 A	12-12-1996	US 5756283 A AU 715533 B AU 6277996 A CA 2222880 A EP 0835321 A JP 11507240 T	26-05-1998 03-02-2000 24-12-1996 12-12-1996 15-04-1998 29-06-1999
EP 0892047 A	20-01-1999	DE 19729211 A DE 19805371 A AU 7507698 A BR 9802360 A CA 2237158 A CN 1209436 A CZ 9802149 A HU 9801511 A JP 11235189 A PL 327385 A	14-01-1999 12-08-1999 21-01-1999 05-10-1999 09-01-1999 03-03-1999 13-01-1999 28-05-1999 31-08-1999 18-01-1999

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.